A	O
syndrome	O
of	O
brachydactyly	S-Phenotype
(	O
absence	B-Phenotype
of	I-Phenotype
some	I-Phenotype
middle	I-Phenotype
or	I-Phenotype
distal	I-Phenotype
phalanges	E-Phenotype
)	O
,	O
aplastic	B-Phenotype
or	I-Phenotype
hypoplastic	I-Phenotype
nails	E-Phenotype
,	O
symphalangism	S-Phenotype
(	O
ankylois	B-Phenotype
of	I-Phenotype
proximal	I-Phenotype
interphalangeal	I-Phenotype
joints	E-Phenotype
)	O
,	O
synostosis	B-Phenotype
of	I-Phenotype
some	I-Phenotype
carpal	I-Phenotype
and	I-Phenotype
tarsal	I-Phenotype
bones	E-Phenotype
,	O
craniosynostosis	S-Phenotype
,	O
and	O
dysplastic	B-Phenotype
hip	I-Phenotype
joints	E-Phenotype
is	O
reported	O
in	O
five	O
members	O
of	O
an	O
Italian	O
family	O
.	O

It	O
may	O
represent	O
a	O
previously	O
undescribed	O
autosomal	O
dominant	O
trait	O
.	O

Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
with	O
multiple	O
malformations	O
and	O
variable	O
expression	O
.	O

Major	O
findings	O
include	O
external	B-Phenotype
ear	I-Phenotype
anomalies	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
preaxial	B-Phenotype
polydactyly	E-Phenotype
and	O
triphalangeal	B-Phenotype
thumbs	E-Phenotype
,	O
imperforate	B-Phenotype
anus	E-Phenotype
,	O
and	O
renal	B-Phenotype
malformations	E-Phenotype
.	O

Most	O
patients	O
with	O
Townes	O
-	O
Brocks	O
syndrome	O
have	O
normal	O
intelligence	O
,	O
although	O
mental	B-Phenotype
retardation	E-Phenotype
has	O
been	O
noted	O
in	O
a	O
few	O
.	O

Nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
is	O
a	O
hereditary	O
condition	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
complete	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

The	O
syndrome	O
is	O
characterised	O
by	O
numerous	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
BCCs	S-Phenotype
)	O
,	O
odontogenic	O
keratocysts	B-Phenotype
of	I-Phenotype
the	I-Phenotype
jaws	E-Phenotype
,	O
palmar	B-Phenotype
and	I-Phenotype
/	I-Phenotype
or	I-Phenotype
plantar	I-Phenotype
pits	E-Phenotype
,	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
and	O
intracranial	B-Phenotype
calcifications	E-Phenotype
.	O

In	O
this	O
paper	O
,	O
the	O
clinical	O
features	O
of	O
37	O
Italian	O
patients	O
are	O
reviewed	O
.	O

Jaw	B-Phenotype
cysts	E-Phenotype
and	O
calcification	B-Phenotype
of	I-Phenotype
falx	I-Phenotype
cerebri	E-Phenotype
were	O
the	O
most	O
frequently	O
observed	O
anomalies	O
,	O
followed	O
by	O
BCCs	S-Phenotype
and	O
palmar	B-Phenotype
/	I-Phenotype
plantar	I-Phenotype
pits	E-Phenotype
.	O

Similar	O
to	O
the	O
case	O
of	O
African	O
Americans	O
,	O
the	O
relatively	O
low	O
frequency	O
of	O
BCCs	S-Phenotype
in	O
the	O
Italian	O
population	O
is	O
probably	O
due	O
to	O
protective	O
skin	O
pigmentation	O
.	O

A	O
future	O
search	O
based	O
on	O
mutation	O
screening	O
might	O
establish	O
a	O
possible	O
genotype	O
phenotype	O
correlation	O
in	O
Italian	O
patients	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
neurodevelopmental	B-Phenotype
disorder	E-Phenotype
caused	O
by	O
the	O
absence	O
of	O
a	O
maternal	O
contribution	O
to	O
chromosome	O
15q11	O
-	O
q13	O
.	O

There	O
are	O
four	O
classes	O
of	O
AS	O
according	O
to	O
molecular	O
or	O
cytogenetic	O
status	O
:	O
maternal	O
microdeletion	O
of	O
15q11	O
-	O
q13	O
(	O
approximately	O
70	O
%	O
of	O
AS	O
patients	O
)	O
;	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
;	O
defects	O
in	O
a	O
putative	O
imprinting	O
centre	O
(	O
IM	O
)	O
;	O
the	O
fourth	O
includes	O
20	O
-	O
30	O
%	O
of	O
AS	O
individuals	O
with	O
biparental	O
inheritance	O
and	O
a	O
normal	O
pattern	O
of	O
allelic	O
methylation	O
in	O
15q11	O
-	O
q13	O
.	O

Mutations	O
of	O
UBE3A	O
have	O
recently	O
been	O
identified	O
as	O
causing	O
AS	O
in	O
the	O
latter	O
group	O
.	O

Few	O
studies	O
have	O
investigated	O
the	O
phenotypic	O
differences	O
between	O
these	O
classes	O
.	O

We	O
compared	O
20	O
non	O
-	O
deletion	O
to	O
20	O
age	O
-	O
matched	O
deletion	O
patients	O
and	O
found	O
significant	O
phenotypic	O
differences	O
between	O
the	O
two	O
groups	O
.	O

The	O
more	O
severe	O
phenotype	O
in	O
the	O
deletion	O
group	O
may	O
suggest	O
a	O
contiguous	O
gene	O
syndrome	O
.	O

Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
and	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
are	O
distinct	O
neurobehavioral	B-Phenotype
disorders	E-Phenotype
that	O
most	O
often	O
arise	O
from	O
a	O
4	O
-	O
Mb	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
q13	O
during	O
paternal	O
or	O
maternal	O
gametogenesis	O
,	O
respectively	O
.	O

At	O
a	O
de	O
novo	O
frequency	O
of	O
approximately.67	O
-	O
1	O
/	O
10,000	O
births	O
,	O
these	O
deletions	O
represent	O
a	O
common	O
structural	O
chromosome	O
change	O
in	O
the	O
human	O
genome	O
.	O

To	O
elucidate	O
the	O
mechanism	O
underlying	O
these	O
events	O
,	O
we	O
characterized	O
the	O
regions	O
that	O
contain	O
two	O
proximal	O
breakpoint	O
clusters	O
and	O
a	O
distal	O
cluster	O
.	O

Novel	O
DNA	O
sequences	O
potentially	O
associated	O
with	O
the	O
breakpoints	O
were	O
positionally	O
cloned	O
from	O
YACs	O
within	O
or	O
near	O
these	O
regions	O
.	O

Analyses	O
of	O
rodent	O
-	O
human	O
somatic	O
-	O
cell	O
hybrids	O
,	O
YAC	O
contigs	O
,	O
and	O
FISH	O
of	O
normal	O
or	O
rearranged	O
chromosomes	O
15	O
identified	O
duplicated	O
sequences	O
(	O
the	O
END	O
repeats	O
)	O
at	O
or	O
near	O
the	O
breakpoints	O
.	O

The	O
END	O
-	O
repeat	O
units	O
are	O
derived	O
from	O
large	O
genomic	O
duplications	O
of	O
a	O
novel	O
gene	O
(	O
HERC2	O
)	O
,	O
many	O
copies	O
of	O
which	O
are	O
transcriptionally	O
active	O
in	O
germline	O
tissues	O
.	O

One	O
of	O
five	O
PWS	O
/	O
AS	O
patients	O
analyzed	O
to	O
date	O
has	O
an	O
identifiable	O
,	O
rearranged	O
HERC2	O
transcript	O
derived	O
from	O
the	O
deletion	O
event	O
.	O

We	O
postulate	O
that	O
the	O
END	O
repeats	O
flanking	O
15q11	O
-	O
q13	O
mediate	O
homologous	O
recombination	O
resulting	O
in	O
deletion	O
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
active	O
transcription	O
of	O
these	O
repeats	O
in	O
male	O
and	O
female	O
germ	O
cells	O
may	O
facilitate	O
the	O
homologous	O
recombination	O
process	O
.	O

We	O
describe	O
a	O
14	O
-	O
month	O
-	O
old	O
girl	O
with	O
unilateral	O
congenital	O
cholesteatoma	S-Phenotype
and	O
anomalies	B-Phenotype
of	I-Phenotype
the	I-Phenotype
facial	I-Phenotype
nerve	E-Phenotype
in	O
addition	O
to	O
the	O
more	O
common	O
branchial	B-Phenotype
arch	I-Phenotype
,	I-Phenotype
otic	I-Phenotype
,	I-Phenotype
and	I-Phenotype
renal	I-Phenotype
malformations	E-Phenotype
comprising	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
.	O

Her	O
mother	O
also	O
has	O
the	O
BOR	O
syndrome	O
and	O
unilateral	B-Phenotype
duplication	I-Phenotype
of	I-Phenotype
the	I-Phenotype
facial	I-Phenotype
nerve	E-Phenotype
.	O

This	O
is	O
the	O
first	O
study	O
of	O
a	O
BOR	O
patient	O
with	O
congenital	O
cholesteatoma	S-Phenotype
and	O
the	O
second	O
family	O
in	O
which	O
cholesteatoma	O
and	O
anomalies	B-Phenotype
of	I-Phenotype
the	I-Phenotype
facial	I-Phenotype
nerve	E-Phenotype
are	O
described	O
in	O
patients	O
with	O
the	O
BO	O
/	O
BOR	O
syndrome	O
.	O

We	O
review	O
the	O
congenital	O
cholesteatoma	S-Phenotype
literature	O
and	O
discuss	O
hypotheses	O
for	O
the	O
pathogenesis	O
of	O
this	O
entity	O
in	O
light	O
of	O
this	O
new	O
report	O
.	O

The	O
clinical	O
features	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
comprise	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
postnatal	B-Phenotype
microcephaly	E-Phenotype
,	O
macrostomia	S-Phenotype
and	O
prognathia	S-Phenotype
,	O
absence	B-Phenotype
of	I-Phenotype
speech	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
a	O
happy	B-Phenotype
disposition	E-Phenotype
.	O

We	O
report	O
on	O
seven	O
patients	O
who	O
lack	O
most	O
of	O
these	O
features	O
,	O
but	O
presented	O
with	O
obesity	S-Phenotype
,	O
muscular	B-Phenotype
hypotonia	E-Phenotype
and	O
mild	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
.	O

Based	O
on	O
the	O
latter	O
findings	O
,	O
the	O
patients	O
were	O
initially	O
suspected	O
of	O
having	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

DNA	O
methylation	O
analysis	O
of	O
SNRPN	O
and	O
D15S63	O
,	O
however	O
,	O
revealed	O
an	O
AS	O
pattern	O
,	O
ie	O
the	O
maternal	O
band	O
was	O
faint	O
or	O
absent	O
.	O

Cytogenetic	O
studies	O
and	O
microsatellite	O
analysis	O
demonstrated	O
apparently	O
normal	O
chromosomes	O
15	O
of	O
biparental	O
inheritance	O
.	O

We	O
conclude	O
that	O
these	O
patients	O
have	O
an	O
imprinting	O
defect	O
and	O
a	O
previously	O
unrecognised	O
form	O
of	O
AS	O
.	O

The	O
mild	O
phenotype	O
may	O
be	O
explained	O
by	O
an	O
incomplete	O
imprinting	O
defect	O
or	O
by	O
cellular	O
mosaicism	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
is	O
a	O
highly	O
penetrant	O
autosomal	O
dominant	O
condition	O
predisposing	O
affected	O
individuals	O
to	O
schwannomas	S-Phenotype
and	O
meningiomas	S-Phenotype
.	O

The	O
proportion	O
of	O
children	O
presenting	O
with	O
meningioma	S-Phenotype
or	O
schwannoma	S-Phenotype
who	O
have	O
NF2	O
is	O
not	O
well	O
described	O
,	O
and	O
neither	O
is	O
the	O
mode	O
of	O
presentation	O
in	O
most	O
children	O
with	O
the	O
inherited	O
disease	O
.	O

To	O
determine	O
the	O
frequency	O
of	O
childhood	O
meningioma	S-Phenotype
and	O
schwannoma	S-Phenotype
cases	O
caused	O
by	O
NF2	O
and	O
the	O
mode	O
of	O
presentation	O
.	O

The	O
records	O
of	O
the	O
Manchester	O
Children	O
's	O
Tumour	S-Phenotype
Registry	O
from	O
1954	O
were	O
searched	O
for	O
cases	O
of	O
meningioma	S-Phenotype
and	O
schwannoma	S-Phenotype
.	O

Paediatric	O
presentation	O
in	O
a	O
large	O
UK	O
series	O
of	O
NF2	O
was	O
also	O
studied	O
.	O

18	O
%	O
(	O
61	O
/	O
334	O
)	O
of	O
patients	O
with	O
NF2	O
on	O
the	O
UK	O
database	O
presented	O
in	O
the	O
paediatric	O
age	O
group	O
(	O
0	O
-	O
15	O
years	O
)	O
,	O
frequently	O
with	O
the	O
symptoms	O
of	O
an	O
isolated	O
tumour	S-Phenotype
.	O

More	O
than	O
half	O
had	O
no	O
family	O
history	O
to	O
alert	O
the	O
clinician	O
to	O
their	O
susceptibility	O
.	O

Three	O
of	O
22	O
children	O
presenting	O
with	O
a	O
meningioma	S-Phenotype
on	O
the	O
Manchester	O
Children	O
's	O
Tumour	S-Phenotype
Registry	O
have	O
gone	O
on	O
to	O
develop	O
classic	O
features	O
of	O
NF2	O
.	O

Clinicians	O
should	O
suspect	O
NF2	O
in	O
children	O
presenting	O
with	O
meningioma	S-Phenotype
,	O
schwannoma	S-Phenotype
,	O
and	O
skin	B-Phenotype
features	E-Phenotype
,	O
such	O
as	O
neurofibromas	S-Phenotype
/	O
schwannomas	S-Phenotype
,	O
but	O
fewer	O
than	O
6	O
caf√©	B-Phenotype
au	I-Phenotype
lait	I-Phenotype
patches	E-Phenotype
,	O
who	O
thus	O
fall	O
short	O
of	O
a	O
diagnosis	O
of	O
neurofibromatosis	S-Phenotype
type	O
1	O
.	O

Popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
(	O
PPS	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
,	O
thought	O
to	O
occur	O
with	O
an	O
incidence	O
of	O
approximately	O
1	O
in	O
300	O
000	O
live	O
births	O
.	O

The	O
main	O
clinical	O
manifestations	O
are	O
popliteal	B-Phenotype
webbing	E-Phenotype
,	O
cleft	B-Phenotype
lip	I-Phenotype
,	I-Phenotype
cleft	I-Phenotype
palate	E-Phenotype
,	O
lower	B-Phenotype
lip	I-Phenotype
pits	E-Phenotype
,	O
syndactyly	S-Phenotype
,	O
and	O
genital	B-Phenotype
and	I-Phenotype
nail	I-Phenotype
anomalies	E-Phenotype
.	O

This	O
report	O
describes	O
the	O
clinical	O
features	O
in	O
two	O
families	O
with	O
PPS	O
and	O
one	O
isolated	O
case	O
,	O
showing	O
the	O
range	O
of	O
anomalies	O
found	O
both	O
within	O
and	O
between	O
the	O
families	O
.	O

PPS	O
has	O
some	O
features	O
in	O
common	O
with	O
Van	O
der	O
Woude	O
syndrome	O
(	O
VWS	O
)	O
,	O
also	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
condition	O
,	O
with	O
cleft	B-Phenotype
lip	I-Phenotype
/	I-Phenotype
palate	E-Phenotype
and	O
,	O
more	O
distinctively	O
,	O
lower	B-Phenotype
lip	I-Phenotype
pits	E-Phenotype
.	O

Although	O
the	O
gene	O
for	O
VWS	O
has	O
not	O
yet	O
been	O
identified	O
,	O
it	O
has	O
been	O
localised	O
to	O
within	O
1.6	O
cM	O
in	O
the	O
region	O
1q32	O
-	O
41	O
.	O

To	O
determine	O
whether	O
PPS	O
and	O
VWS	O
represent	O
allelic	O
forms	O
of	O
the	O
same	O
gene	O
,	O
three	O
families	O
were	O
genotyped	O
for	O
markers	O
flanking	O
and	O
within	O
the	O
critical	O
region	O
.	O

A	O
multipoint	O
lod	O
score	O
of	O
2.7	O
was	O
obtained	O
,	O
with	O
no	O
evidence	O
of	O
recombination	O
,	O
supporting	O
the	O
hypothesis	O
that	O
these	O
two	O
disorders	O
are	O
allelic	O
.	O

Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
)	O
has	O
been	O
recognized	O
as	O
a	O
dominant	O
inherited	O
syndrome	O
.	O

We	O
report	O
2	O
cases	O
of	O
TBS	O
.	O

Case	O
1	O
was	O
operated	O
on	O
for	O
imperforate	B-Phenotype
anus	E-Phenotype
.	O

Triphalangeal	B-Phenotype
thumb	E-Phenotype
and	O
ear	B-Phenotype
anomalies	E-Phenotype
were	O
remarkable	O
.	O

Deafness	S-Phenotype
was	O
diagnosed	O
when	O
the	O
patient	O
was	O
6	O
months	O
old	O
.	O

Anomalies	B-Phenotype
of	I-Phenotype
the	I-Phenotype
semicircular	I-Phenotype
canals	E-Phenotype
and	O
the	O
incus	O
with	O
inculomalleolar	B-Phenotype
fusion	E-Phenotype
were	O
shown	O
when	O
the	O
patient	O
was	O
3.5	O
years	O
old	O
.	O

During	O
childhood	O
,	O
recurrent	O
episodes	B-Phenotype
of	I-Phenotype
abdominal	I-Phenotype
pain	E-Phenotype
appeared	O
.	O

The	O
diagnosis	O
of	O
hereditary	O
angioneurotic	O
edema	S-Phenotype
(	O
HANE	O
)	O
was	O
made	O
.	O

HANE	O
was	O
familial	O
as	O
the	O
father	O
,	O
the	O
father	O
's	O
brother	O
and	O
the	O
paternal	O
grand	O
mother	O
were	O
also	O
affected	O
.	O

The	O
parents	O
of	O
case	O
2	O
,	O
a	O
female	O
,	O
are	O
both	O
mildly	B-Phenotype
mentally	I-Phenotype
retarded	E-Phenotype
.	O

This	O
was	O
the	O
first	O
pregnancy	O
of	O
the	O
mother	O
who	O
had	O
short	B-Phenotype
stature	E-Phenotype
.	O

The	O
child	O
had	O
an	O
antepositioned	B-Phenotype
anus	E-Phenotype
,	O
bifid	B-Phenotype
right	I-Phenotype
thumb	E-Phenotype
,	O
large	B-Phenotype
toes	E-Phenotype
,	O
low	B-Phenotype
set	I-Phenotype
ears	E-Phenotype
,	O
microretrognathia	S-Phenotype
and	O
deafness	S-Phenotype
.	O

A	O
(	O
5	O
,	O
16	O
)	O
translocation	O
was	O
observed	O
in	O
a	O
child	O
with	O
TBS	O
.	O

At	O
the	O
breakpoint	O
in	O
16q21.1	O
,	O
a	O
gene	O
coding	O
for	O
a	O
transcription	O
factor	O
SALL1	O
has	O
been	O
identified	O
and	O
it	O
was	O
shown	O
that	O
mutations	O
in	O
the	O
putative	O
zinc	O
finger	O
of	O
SALL1	O
cause	O
TBS	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
A	I-Phenotype
-	I-Phenotype
1	E-Phenotype
(	O
BDA1	S-Phenotype
)	O
was	O
,	O
in	O
1903	O
,	O
the	O
first	O
recorded	O
example	O
of	O
a	O
human	O
anomaly	O
with	O
Mendelian	O
autosomal	O
dominant	O
inheritance	O
.	O

Two	O
large	O
families	O
,	O
the	O
affected	O
members	O
of	O
which	O
were	O
radiographed	O
,	O
were	O
recruited	O
in	O
the	O
study	O
we	O
describe	O
here	O
.	O

Two	O
-	O
point	O
linkage	O
analysis	O
for	O
pedigree	O
1	O
(	O
maximum	O
LOD	O
score	O
[	O
Zmax	O
]	O
6.59	O
at	O
recombination	O
fraction	O
[	O
theta	O
]	O
0.00	O
)	O
and	O
for	O
pedigree	O
2	O
(	O
Zmax=5.53	O
at	O
straight	O
theta=0.00	O
)	O
mapped	O
the	O
locus	O
for	O
BDA1	S-Phenotype
in	O
the	O
two	O
families	O
to	O
chromosome	O
2q	O
.	O

Haplotype	O
analysis	O
of	O
pedigree	O
1	O
confined	O
the	O
locus	O
for	O
family	O
1	O
within	O
an	O
interval	O
of	O
<	O
8.1	O
cM	O
flanked	O
by	O
markers	O
D2S2248	O
and	O
D2S360	O
,	O
which	O
was	O
mapped	O
to	O
chromosome	O
2q35	O
-	O
q36	O
on	O
the	O
cytogenetic	O
map	O
.	O

Haplotype	O
analysis	O
of	O
pedigree	O
2	O
confined	O
the	O
locus	O
for	O
family	O
2	O
within	O
an	O
interval	O
of	O
<	O
28	O
.	O

8	O
cM	O
flanked	O
by	O
markers	O
GATA30E06	O
and	O
D2S427	O
,	O
which	O
was	O
localized	O
to	O
chromosome	O
2q35	O
-	O
q37	O
.	O

The	O
two	O
families	O
had	O
no	O
identical	O
haplotype	O
within	O
the	O
defined	O
region	O
,	O
which	O
suggests	O
that	O
the	O
two	O
families	O
were	O
not	O
related	O
.	O

In	O
addition	O
to	O
craniofacial	B-Phenotype
,	I-Phenotype
auricular	I-Phenotype
,	I-Phenotype
ophthalmologic	I-Phenotype
,	I-Phenotype
and	I-Phenotype
oral	I-Phenotype
anomalies	E-Phenotype
,	O
the	O
distinctive	O
phenotype	O
of	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
(	O
BOF	O
)	O
syndrome	O
(	O
MIM	O
113620	O
)	O
includes	O
skin	B-Phenotype
defects	I-Phenotype
in	I-Phenotype
the	I-Phenotype
neck	E-Phenotype
or	O
infra	B-Phenotype
/	I-Phenotype
supra	I-Phenotype
-	I-Phenotype
auricular	I-Phenotype
region	E-Phenotype
.	O

These	O
unusual	B-Phenotype
areas	I-Phenotype
of	I-Phenotype
thin	I-Phenotype
,	I-Phenotype
erythematous	I-Phenotype
wrinkled	I-Phenotype
skin	E-Phenotype
differ	O
from	O
the	O
discrete	O
cervical	B-Phenotype
pits	I-Phenotype
,	I-Phenotype
cysts	I-Phenotype
,	I-Phenotype
and	I-Phenotype
fistulas	E-Phenotype
of	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
(	O
MIM	O
113650	O
)	O
.	O

Although	O
the	O
BOF	O
and	O
BOR	O
syndromes	O
are	O
sufficiently	O
distinctive	O
that	O
they	O
should	O
not	O
be	O
confused	O
,	O
both	O
can	O
be	O
associated	O
with	O
nasolacrimal	B-Phenotype
duct	I-Phenotype
stenosis	E-Phenotype
,	O
deafness	S-Phenotype
,	O
prehelical	B-Phenotype
pits	E-Phenotype
,	O
malformed	B-Phenotype
pinna	E-Phenotype
,	O
and	O
renal	B-Phenotype
anomalies	E-Phenotype
.	O

Furthermore	O
,	O
a	O
reported	O
father	O
and	O
son	O
[	O
Legius	O
et	O
al.	O
,	O
1990	O
,	O
Clin	O
Genet	O
37:347	O
-	O
500	O
]	O
had	O
features	O
of	O
both	O
conditions	O
.	O

It	O
was	O
not	O
clear	O
whether	O
they	O
had	O
an	O
atypical	O
presentation	O
of	O
either	O
BOR	O
or	O
BOF	O
syndrome	O
,	O
or	O
represented	O
a	O
private	O
syndrome	O
.	O

In	O
light	O
of	O
these	O
issues	O
,	O
we	O
selected	O
the	O
BOR	O
locus	O
(	O
EYA1	O
)	O
as	O
a	O
possible	O
gene	O
mutation	O
for	O
the	O
BOF	O
syndrome	O
.	O

In	O
five	O
BOF	O
patients	O
,	O
there	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
EYA1	O
gene	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
allelic	O
to	O
the	O
BOR	O
syndrome	O
.	O

Schwannomas	S-Phenotype
in	O
the	O
skin	O
are	O
frequently	O
observed	O
in	O
neurofibromatosis	S-Phenotype
2	O
patients	O
.	O

In	O
about	O
one	O
-	O
quarter	O
of	O
the	O
cases	O
,	O
skin	B-Phenotype
tumors	E-Phenotype
are	O
the	O
first	O
clinical	O
symptoms	O
of	O
this	O
disease	O
.	O

Recognizing	O
neurofibromatosis	S-Phenotype
-	O
2	O
-	O
related	O
skin	B-Phenotype
tumors	E-Phenotype
is	O
therefore	O
important	O
for	O
early	O
diagnosis	O
of	O
neurofibromatosis	O
2	O
,	O
especially	O
in	O
pediatric	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
40	O
skin	B-Phenotype
tumors	E-Phenotype
(	O
36	O
schwannomas	S-Phenotype
and	O
four	O
neurofibromas	S-Phenotype
)	O
from	O
20	O
neurofibromatosis	S-Phenotype
2	O
patients	O
for	O
NF2	O
mutations	O
and	O
allelic	O
loss	O
.	O

NF2	O
mutations	O
have	O
been	O
identified	O
in	O
blood	O
from	O
15	O
(	O
75	O
%	O
)	O
of	O
the	O
20	O
patients	O
.	O

We	O
found	O
NF2	O
mutations	O
in	O
five	O
(	O
13	O
%	O
)	O
and	O
NF2	O
allelic	O
loss	O
in	O
18	O
(	O
45	O
%	O
)	O
of	O
the	O
40	O
analyzed	O
tumors	S-Phenotype
.	O

Genetic	O
alterations	O
(	O
allelic	O
loss	O
or	O
mutation	O
)	O
were	O
thus	O
found	O
in	O
50	O
(	O
63	O
%	O
)	O
out	O
of	O
the	O
total	O
of	O
80	O
examined	O
alleles	O
.	O

In	O
17	O
(	O
43	O
%	O
)	O
tumors	S-Phenotype
,	O
alterations	O
were	O
found	O
on	O
both	O
NF2	O
alleles	O
.	O

These	O
results	O
suggest	O
that	O
,	O
as	O
in	O
the	O
case	O
of	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
and	O
meningiomas	S-Phenotype
,	O
loss	O
of	O
functional	O
NF2	O
gene	O
product	O
is	O
also	O
the	O
critical	O
event	O
in	O
the	O
development	O
of	O
skin	B-Phenotype
schwannomas	E-Phenotype
.	O

Identification	O
of	O
genetic	O
alterations	O
of	O
the	O
NF2	O
gene	O
in	O
skin	B-Phenotype
tumors	E-Phenotype
may	O
help	O
to	O
identify	O
neurofibromatosis	S-Phenotype
-	O
2	O
-	O
associated	O
skin	O
tumors	O
,	O
thus	O
assisting	O
in	O
the	O
diagnosis	O
of	O
neurofibromatosis	O
2	O
in	O
ambiguous	O
cases	O
,	O
and	O
excluding	O
neurofibromatosis	O
1	O
in	O
unclear	O
cases	O
.	O

We	O
also	O
report	O
that	O
the	O
detection	O
rate	O
of	O
constitutional	O
mutations	O
was	O
higher	O
in	O
patients	O
with	O
skin	B-Phenotype
tumors	E-Phenotype
(	O
65	O
%	O
)	O
than	O
in	O
patients	O
without	O
skin	O
tumors	O
(	O
40	O
%	O
)	O
.	O

Among	O
25	O
patients	O
diagnosed	O
with	O
Angelman	O
syndrome	O
,	O
we	O
detected	O
21	O
with	O
deletion	O
and	O
4	O
with	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
,	O
2	O
isodisomies	O
originating	O
by	O
postzygotic	O
error	O
,	O
and	O
1	O
MII	O
nondisjunction	O
event	O
.	O

The	O
diagnosis	O
was	O
obtained	O
by	O
molecular	O
techniques	O
,	O
including	O
methylation	O
pattern	O
analysis	O
of	O
exon	O
1	O
of	O
SNRPN	O
and	O
microsatellite	O
analysis	O
of	O
loci	O
within	O
and	O
outside	O
the	O
15q11	O
-	O
q13	O
region	O
.	O

Most	O
manifestations	O
present	O
in	O
deletion	O
patients	O
are	O
those	O
previously	O
reported	O
.	O

Comparing	O
the	O
clinical	O
data	O
from	O
our	O
and	O
published	O
UPD	O
patients	O
with	O
those	O
with	O
deletions	O
we	O
observed	O
the	O
following	O
:	O
the	O
age	O
of	O
diagnosis	O
is	O
higher	O
in	O
UPD	O
group	O
(	O
average	O
7	O
3	O
/	O
12	O
years	O
)	O
,	O
microcephaly	S-Phenotype
is	O
more	O
frequent	O
among	O
deletion	O
patients	O
,	O
UPD	O
children	O
start	O
walking	O
earlier	O
(	O
average	O
age	O
2	O
9	O
/	O
12	O
years	O
)	O
,	O
whereas	O
in	O
deletion	O
patients	O
the	O
average	O
is	O
4	O
(	O
1	O
/	O
2	O
)	O
years	O
,	O
epilepsy	S-Phenotype
started	O
later	O
in	O
UPD	O
patients	O
(	O
average	O
5	O
10	O
/	O
12	O
years	O
)	O
than	O
in	O
deletion	O
patients	O
(	O
average	O
1	O
11	O
/	O
12	O
years	O
)	O
,	O
weight	O
above	O
the	O
75th	O
centile	O
is	O
reported	O
mainly	O
in	O
UPD	O
patients	O
,	O
complete	O
absence	B-Phenotype
of	I-Phenotype
speech	E-Phenotype
is	O
more	O
common	O
in	O
the	O
deleted	O
(	O
88.9	O
%	O
)	O
than	O
in	O
the	O
UPD	O
patients	O
because	O
half	O
of	O
the	O
children	O
are	O
able	O
to	O
say	O
few	O
words	O
.	O

Thus	O
,	O
besides	O
the	O
abnormalities	O
already	O
described	O
,	O
the	O
UPD	O
patients	O
have	O
somewhat	O
better	O
verbal	O
development	O
,	O
a	O
weight	O
above	O
the	O
75th	O
centile	O
,	O
and	O
OFC	O
in	O
the	O
upper	O
normal	O
range	O
.	O

Angelman	O
syndrome	O
is	O
a	O
neuro	B-Phenotype
-	I-Phenotype
developmental	I-Phenotype
disorder	E-Phenotype
caused	O
by	O
genetic	O
abnormalities	O
affecting	O
the	O
maternal	O
gene	O
expression	O
in	O
the	O
chromosome	O
region	O
15q11	O
-	O
q13	O
.	O

In	O
a	O
study	O
group	O
of	O
45	O
Finnish	O
Angelman	O
patients	O
,	O
a	O
recurrence	O
of	O
a	O
del	O
(	O
15	O
)	O
(	O
q11q13	O
)	O
was	O
detected	O
in	O
one	O
family	O
.	O

The	O
mother	O
's	O
chromosomes	O
15	O
were	O
structurally	O
normal	O
,	O
whereas	O
the	O
patients	O
and	O
their	O
unaffected	O
brother	O
shared	O
an	O
identical	O
maternally	O
derived	O
haplotype	O
outside	O
the	O
deletion	O
region	O
.	O

These	O
findings	O
are	O
suggestive	O
of	O
maternal	O
germ	O
-	O
line	O
mosaicism	O
of	O
del	O
(	O
15	O
)	O
(	O
q11q13	O
)	O
.	O

We	O
present	O
a	O
child	O
with	O
mild	B-Phenotype
to	I-Phenotype
moderate	I-Phenotype
global	I-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
including	O
severe	O
speech	B-Phenotype
impairment	E-Phenotype
,	O
inappropriate	B-Phenotype
happy	I-Phenotype
demeanor	E-Phenotype
,	O
wide	B-Phenotype
-	I-Phenotype
based	I-Phenotype
gait	E-Phenotype
,	O
frequent	B-Phenotype
ear	I-Phenotype
infections	E-Phenotype
with	O
mild	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
deep	B-Phenotype
-	I-Phenotype
set	I-Phenotype
eyes	E-Phenotype
,	O
a	O
wide	B-Phenotype
mouth	E-Phenotype
,	O
widely	B-Phenotype
-	I-Phenotype
spaced	I-Phenotype
teeth	E-Phenotype
,	O
normal	O
head	O
circumference	O
,	O
and	O
no	O
seizures	S-Phenotype
.	O

Results	O
of	O
peripheral	O
blood	O
lymphocyte	O
chromosomal	O
analysis	O
with	O
GTG	O
banding	O
were	O
normal	O
.	O

However	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
studies	O
showed	O
mosaicism	O
for	O
a	O
deletion	O
of	O
probes	O
(	O
D15S10	O
and	O
SNRPN	O
)	O
from	O
the	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
critical	O
region	O
with	O
approximately	O
40	O
%	O
of	O
peripheral	O
lymphocytes	O
having	O
the	O
deletion	O
.	O

The	O
deleted	O
chromosome	O
15	O
also	O
showed	O
centromeric	O
duplication	O
,	O
which	O
was	O
detected	O
with	O
a	O
D15Z1	O
probe	O
[	O
46	O
,	O
XX	O
,	O
dic	O
(	O
15	O
)	O
(	O
pter	O
-	O
-	O
>	O
q11.1	O
:	O
:p11.2	O
-	O
-	O
>	O
q11	O
.	O

1	O
:	O
:q13	O
-	O
-	O
>	O
qter	O
)	O
]	O
.	O

The	O
same	O
duplication	O
pattern	O
was	O
observed	O
in	O
30	O
%	O
of	O
the	O
nuclei	O
obtained	O
from	O
a	O
buccal	O
smear	O
.	O

Methylation	O
studies	O
using	O
polymerase	O
chain	O
reaction	O
with	O
sodium	O
bisulfite	O
-	O
treated	O
DNA	O
demonstrated	O
a	O
normal	O
biparental	O
methylation	O
pattern	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
with	O
AS	O
and	O
a	O
FISH	O
detectable	O
deletion	O
in	O
a	O
mosaic	O
pattern	O
.	O

We	O
recommend	O
FISH	O
studies	O
for	O
the	O
detection	O
of	O
mosaicism	O
in	O
the	O
patients	O
with	O
AS	O
clinical	O
findings	O
even	O
if	O
results	O
of	O
the	O
methylation	O
studies	O
are	O
normal	O
.	O

Older	O
paternal	O
age	O
has	O
previously	O
been	O
documented	O
as	O
a	O
factor	O
in	O
sporadic	O
fresh	O
mutational	O
cases	O
of	O
several	O
autosomal	O
dominant	O
disorders	O
.	O

In	O
this	O
collaborative	O
study	O
,	O
an	O
older	O
mean	O
paternal	O
age	O
has	O
been	O
documented	O
in	O
sporadic	O
cases	O
of	O
at	O
least	O
five	O
additional	O
dominantly	O
inheritable	O
disorders	O
;	O
the	O
basal	B-Phenotype
cell	I-Phenotype
nevus	I-Phenotype
syndrome	E-Phenotype
,	O
the	O
Waardenburg	O
syndrome	O
,	O
the	O
Crouzon	O
syndrome	O
,	O
the	O
oculo	O
-	O
dental	O
-	O
digital	O
sysdrome	O
,	O
and	O
the	O
Treacher	O
-	O
Collins	O
syndrome	O
.	O

It	O
was	O
also	O
found	O
to	O
be	O
a	O
factor	O
in	O
acrodysostosis	O
and	O
progeria	O
,	O
suggesting	O
a	O
fresh	O
mutant	O
gene	O
etiology	O
for	O
these	O
two	O
conditions	O
in	O
which	O
virtually	O
all	O
cases	O
have	O
been	O
sporadic	O
and	O
the	O
mode	O
of	O
genetic	O
etiology	O
has	O
been	O
unknown	O
.	O

A	O
1	O
-	O
year	O
-	O
old	O
male	O
with	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
together	O
with	O
preaxial	B-Phenotype
polydatyly	E-Phenotype
and	O
a	O
white	B-Phenotype
forelock	E-Phenotype
at	O
birth	O
is	O
described	O
.	O

This	O
is	O
only	O
the	O
second	O
case	O
where	O
preaxial	B-Phenotype
polydactyly	E-Phenotype
has	O
been	O
described	O
in	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
.	O

In	O
both	O
cases	O
a	O
diagnosis	O
of	O
Waardenburg	O
syndrome	O
had	O
been	O
considered	O
.	O

Hereditary	O
isolated	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
(	O
OMIM	O
113100	O
)	O
mostly	O
follows	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
with	O
a	O
marked	O
variability	O
in	O
expression	O
.	O

This	O
phenotype	O
has	O
been	O
mapped	O
to	O
two	O
different	O
loci	O
on	O
chromosomes	O
12q24	O
and	O
20q11.2	O
.	O

The	O
latter	O
locus	O
contains	O
the	O
cartilage	O
-	O
derived	O
morphogenetic	O
protein	O
(	O
CDMP	O
)	O
1	O
gene	O
,	O
in	O
which	O
a	O
null	O
mutation	O
has	O
been	O
found	O
in	O
patients	O
with	O
malformations	B-Phenotype
restricted	I-Phenotype
to	I-Phenotype
the	I-Phenotype
upper	I-Phenotype
limbs	E-Phenotype
.	O

A	O
more	O
complex	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
phenotype	O
has	O
been	O
mapped	O
to	O
chromosome	O
12q24	O
.	O

Differences	O
in	O
complexity	O
of	O
these	O
phenotypes	O
have	O
been	O
attributed	O
to	O
locus	O
heterogeneity	O
.	O

Clinical	O
subclassification	O
based	O
on	O
the	O
degree	O
of	O
complexity	O
of	O
the	O
phenotype	O
has	O
therefore	O
been	O
suggested	O
.	O

We	O
present	O
patients	O
with	O
a	O
complex	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
phenotype	O
in	O
whom	O
there	O
is	O
considerable	O
intra	O
-	O
and	O
interfamilial	O
variability	O
in	O
expression	O
.	O

We	O
show	O
that	O
clinical	O
subclassification	O
based	O
on	O
the	O
complexity	O
of	O
the	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
phenotype	O
related	O
to	O
the	O
genetic	O
defect	O
is	O
not	O
feasible	O
.	O

We	O
present	O
evidence	O
that	O
differences	O
in	O
complexity	O
are	O
not	O
only	O
due	O
to	O
locus	O
heterogeneity	O
,	O
but	O
that	O
genetic	O
modifiers	O
and	O
/	O
or	O
environmental	O
factors	O
must	O
also	O
play	O
a	O
role	O
.	O

A	O
retrospective	O
review	O
of	O
29	O
consecutive	O
unselected	O
patients	O
referred	O
for	O
neuro	O
-	O
ophthalmic	O
evaluation	O
after	O
the	O
diagnosis	O
of	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
showed	O
that	O
four	O
of	O
them	O
had	O
a	O
monocular	B-Phenotype
elevator	I-Phenotype
paresis	E-Phenotype
.	O

In	O
two	O
of	O
the	O
four	O
MRI	O
demonstrated	O
lesions	O
,	O
presumed	O
to	O
be	O
schwannomas	S-Phenotype
,	O
of	O
the	O
third	O
nerve	O
.	O

These	O
findings	O
indicate	O
that	O
monocular	B-Phenotype
elevator	I-Phenotype
paresis	E-Phenotype
is	O
a	O
common	O
neuro	O
-	O
ophthalmic	O
finding	O
in	O
NF2	O
,	O
which	O
the	O
authors	O
suspect	O
is	O
probably	O
a	O
sign	O
of	O
third	O
nerve	O
infiltration	O
or	O
compression	O
by	O
a	O
schwannoma	S-Phenotype
.	O

The	O
diagnosis	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
can	O
be	O
confirmed	O
by	O
genetic	O
laboratory	O
in	O
about	O
80	O
%	O
of	O
cases	O
.	O

In	O
20	O
%	O
,	O
the	O
diagnosis	O
remains	O
clinical	O
,	O
but	O
often	O
there	O
is	O
uncertainty	O
about	O
the	O
correctness	O
of	O
the	O
clinical	O
diagnosis	O
and	O
alternative	O
diagnoses	O
may	O
be	O
investigated	O
.	O

In	O
evaluating	O
individuals	O
for	O
AS	O
in	O
our	O
center	O
since	O
1989	O
,	O
we	O
have	O
encountered	O
several	O
mimicking	O
conditions	O
,	O
and	O
additional	O
ones	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Mimicking	O
conditions	O
can	O
be	O
grouped	O
into	O
the	O
areas	O
of	O
chromosome	O
,	O
single	O
gene	O
,	O
and	O
symptom	O
complex	O
anomalies	O
.	O

Microdeletions	O
or	O
microduplications	O
include	O
chromosome	O
regions	O
2,4,17	O
,	O
22	O
,	O
and	O
15	O
.	O

Single	O
gene	O
conditions	O
include	O
methylene	O
tetrahydrofolate	O
reductase	O
deficiency	O
(	O
MTHFR	O
)	O
,	O
Rett	O
syndrome	O
,	O
alpha	O
-	O
thalassemia	O
retardation	S-Phenotype
syndrome	O
(	O
ATR	O
-	O
X	O
)	O
,	O
and	O
Gurrieri	O
syndrome	O
.	O

Symptom	O
complexes	O
include	O
cerebral	B-Phenotype
palsy	E-Phenotype
,	O
static	O
encephalopathy	S-Phenotype
,	O
Lennox	O
-	O
Gastaut	O
syndrome	O
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
,	O
pervasive	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
(	O
PDD	O
)	O
,	O
and	O
mitochondrial	O
disorders	O
.	O

We	O
present	O
a	O
review	O
of	O
these	O
mimicking	O
disorders	O
to	O
increase	O
the	O
awareness	O
about	O
conditions	O
that	O
can	O
lead	O
to	O
an	O
incorrect	O
clinical	O
diagnosis	O
of	O
AS	O
.	O

To	O
describe	O
the	O
ophthalmic	O
and	O
systemic	O
features	O
in	O
a	O
series	O
of	O
patients	O
initially	O
seen	O
with	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
associated	O
with	O
Gorlin	O
-	O
Goltz	O
syndrome	O
.	O

Retrospective	O
noncomparative	O
case	O
series	O
.	O

Of	O
105	O
consecutive	O
patients	O
with	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
managed	O
at	O
an	O
Ocular	O
Oncology	O
Center	O
between	O
January	O
1973	O
and	O
December	O
1999	O
,	O
four	O
patients	O
with	O
Gorlin	O
-	O
Goltz	O
syndrome	O
were	O
identified	O
.	O

The	O
ophthalmic	O
and	O
systemic	O
features	O
,	O
management	O
,	O
and	O
outcome	O
of	O
patients	O
with	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
associated	O
with	O
Gorlin	O
-	O
Goltz	O
syndrome	O
were	O
analyzed	O
.	O

The	O
published	O
literature	O
on	O
Gorlin	O
-	O
Goltz	O
syndrome	O
,	O
specifically	O
related	O
to	O
genetics	O
,	O
systemic	O
features	O
,	O
ophthalmic	O
associations	O
,	O
and	O
prophylactic	O
management	O
strategies	O
,	O
was	O
reviewed	O
.	O

Response	O
of	O
the	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
to	O
treatment	O
and	O
the	O
final	O
systemic	O
condition	O
were	O
the	O
main	O
outcome	O
measures	O
.	O

All	O
four	O
patients	O
had	O
a	O
family	O
history	O
of	O
Gorlin	O
-	O
Goltz	O
syndrome	O
.	O

The	O
systemic	O
manifestations	O
included	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
in	O
all	O
the	O
patients	O
,	O
frontal	B-Phenotype
bossing	E-Phenotype
or	O
increased	B-Phenotype
occipitofrontal	I-Phenotype
circumference	E-Phenotype
in	O
three	O
patients	O
,	O
palmar	B-Phenotype
pits	E-Phenotype
in	O
two	O
patients	O
,	O
odontogenic	B-Phenotype
keratocyst	E-Phenotype
in	O
one	O
patient	O
,	O
ectopic	B-Phenotype
calcification	E-Phenotype
in	O
one	O
patient	O
,	O
and	O
bifid	B-Phenotype
rib	E-Phenotype
in	O
one	O
patient	O
.	O

The	O
mean	O
age	O
at	O
the	O
detection	O
of	O
the	O
first	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
was	O
30	O
years	O
(	O
range	O
,	O
16	O
-	O
38	O
years	O
)	O
.	O

All	O
four	O
patients	O
had	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
on	O
the	O
face	O
and	O
elsewhere	O
.	O

The	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
was	O
advanced	O
with	O
orbital	O
infiltration	O
in	O
three	O
patients	O
,	O
one	O
of	O
whom	O
opted	O
for	O
palliative	O
radiotherapy	O
,	O
whereas	O
the	O
other	O
two	O
underwent	O
orbital	O
exenteration	O
.	O

The	O
fourth	O
patient	O
,	O
who	O
had	O
localized	O
recurrent	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
in	O
the	O
upper	O
eyelid	O
,	O
was	O
treated	O
with	O
excision	O
and	O
eyelid	O
reconstruction	O
.	O

At	O
the	O
final	O
follow	O
-	O
up	O
(	O
mean	O
,	O
41	O
months	O
)	O
,	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
was	O
cured	O
in	O
three	O
patients	O
and	O
stable	O
in	O
one	O
patient	O
.	O

No	O
patient	O
had	O
life	O
-	O
threatening	O
sequelae	O
of	O
Gorlin	O
-	O
Goltz	O
syndrome	O
.	O

Gorlin	O
-	O
Goltz	O
syndrome	O
is	O
a	O
rare	O
autosomal	O
dominant	O
cancer	S-Phenotype
predisposition	O
syndrome	O
that	O
may	O
be	O
associated	O
with	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

The	O
associated	O
systemic	O
findings	O
may	O
be	O
a	O
clue	O
to	O
the	O
diagnosis	O
of	O
this	O
condition	O
.	O

It	O
is	O
important	O
to	O
recognize	O
Gorlin	O
-	O
Goltz	O
syndrome	O
when	O
a	O
patient	O
has	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
or	O
when	O
a	O
young	O
patient	O
with	O
eyelid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
is	O
seen	O
by	O
an	O
ophthalmologist	O
,	O
because	O
lifelong	O
monitoring	O
is	O
essential	O
for	O
patient	O
management	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
A	I-Phenotype
-	I-Phenotype
1	E-Phenotype
(	O
BDA	B-Phenotype
-	I-Phenotype
1	E-Phenotype
;	O
MIM	O
112500	O
)	O
is	O
characterized	O
by	O
shortening	B-Phenotype
or	I-Phenotype
missing	I-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
phalanges	E-Phenotype
(	O
Fig	O
.	O

1a	O
)	O
.	O

It	O
was	O
first	O
identified	O
by	O
Farabee	O
in	O
1903	O
(	O
ref	O
.	O

2	O
)	O
,	O
is	O
the	O
first	O
recorded	O
example	O
of	O
a	O
human	O
anomaly	O
with	O
Mendelian	O
autosomal	O
-	O
dominant	O
inheritance	O
and	O
,	O
as	O
such	O
,	O
is	O
cited	O
in	O
most	O
genetic	O
and	O
biological	O
textbooks	O
.	O

Here	O
we	O
show	O
that	O
mutations	O
in	O
IHH	O
,	O
which	O
encodes	O
Indian	O
hedgehog	O
,	O
cause	O
BDA	B-Phenotype
-	I-Phenotype
1	E-Phenotype
.	O

We	O
have	O
identified	O
three	O
heterozygous	O
missense	O
mutations	O
in	O
the	O
region	O
encoding	O
the	O
amino	O
-	O
terminal	O
signaling	O
domain	O
in	O
all	O
affected	O
members	O
of	O
three	O
large	O
,	O
unrelated	O
families	O
.	O

The	O
three	O
mutant	O
amino	O
acids	O
,	O
which	O
are	O
conserved	O
across	O
all	O
vertebrates	O
and	O
invertebrates	O
studied	O
so	O
far	O
,	O
are	O
predicted	O
to	O
be	O
adjacent	O
on	O
the	O
surface	O
of	O
IHH	O
.	O

Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
)	O
is	O
a	O
condition	O
with	O
imperforate	B-Phenotype
anus	E-Phenotype
,	O
hand	B-Phenotype
anomalies	E-Phenotype
,	O
and	O
ear	B-Phenotype
malformations	E-Phenotype
with	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Many	O
cases	O
are	O
sporadic	O
.	O

Within	O
and	O
between	O
families	O
,	O
the	O
phenotype	O
displays	O
striking	O
variability	O
.	O

Recently	O
,	O
the	O
disease	O
-	O
causing	O
gene	O
for	O
TBS	O
was	O
identified	O
as	O
SALL1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

Here	O
,	O
we	O
report	O
a	O
three	O
-	O
generation	O
family	O
with	O
seven	O
affected	O
individuals	O
who	O
have	O
a	O
novel	O
SALL1	O
mutation	O
.	O

Unique	O
cardiac	B-Phenotype
anomalies	E-Phenotype
seen	O
in	O
this	O
family	O
include	O
lethal	O
truncus	B-Phenotype
arteriosus	E-Phenotype
in	O
one	O
patient	O
and	O
a	O
lethal	O
complicated	O
defect	O
,	O
including	O
pulmonary	B-Phenotype
valve	I-Phenotype
atresia	E-Phenotype
,	O
in	O
a	O
second	O
patient	O
.	O

These	O
severe	O
cardiac	B-Phenotype
anomalies	E-Phenotype
have	O
not	O
previously	O
been	O
reported	O
in	O
a	O
familial	O
case	O
of	O
TBS	O
.	O

This	O
family	O
and	O
a	O
review	O
of	O
the	O
literature	O
indicate	O
that	O
cardiac	O
evaluation	O
is	O
warranted	O
in	O
all	O
individuals	O
with	O
this	O
disorder	O
.	O

In	O
addition	O
,	O
hypoplastic	B-Phenotype
thumbs	E-Phenotype
were	O
seen	O
in	O
two	O
individuals	O
in	O
this	O
family	O
and	O
should	O
,	O
therefore	O
,	O
be	O
considered	O
a	O
true	O
feature	O
of	O
TBS	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
severe	O
neurobehavioural	B-Phenotype
disorder	E-Phenotype
caused	O
by	O
defects	O
in	O
the	O
maternally	O
derived	O
imprinted	O
domain	O
located	O
on	O
15q11	O
-	O
q13	O
.	O

Most	O
patients	O
acquire	O
AS	O
by	O
one	O
of	O
five	O
mechanisms	O
:	O
(	O
1	O
)	O
a	O
large	O
interstitial	O
deletion	O
of	O
15q11	O
-	O
q13	O
;	O
(	O
2	O
)	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
of	O
chromosome	O
15	O
;	O
(	O
3	O
)	O
an	O
imprinting	O
defect	O
(	O
ID	O
)	O
;	O
(	O
4	O
)	O
a	O
mutation	O
in	O
the	O
E3	O
ubiquitin	O
protein	O
ligase	O
gene	O
(	O
UBE3A	O
)	O
;	O
or	O
(	O
5	O
)	O
unidentified	O
mechanism	O
(	O
s	O
)	O
.	O

All	O
classical	O
patients	O
from	O
these	O
classes	O
exhibit	O
four	O
cardinal	O
features	O
,	O
including	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
/	O
or	O
mental	B-Phenotype
retardation	I-Phenotype
,	I-Phenotype
profound	E-Phenotype
speech	O
impairment	O
,	O
a	O
movement	B-Phenotype
and	I-Phenotype
balance	I-Phenotype
disorder	E-Phenotype
,	O
and	O
AS	O
specific	O
behaviour	O
typified	O
by	O
an	O
easily	O
excitable	O
personality	O
with	O
an	O
inappropriately	B-Phenotype
happy	I-Phenotype
affect	E-Phenotype
.	O

In	O
addition	O
,	O
patients	O
can	O
display	O
other	O
characteristics	O
,	O
including	O
microcephaly	S-Phenotype
,	O
hypopigmentation	S-Phenotype
,	O
and	O
seizures	S-Phenotype
.	O

We	O
restricted	O
the	O
present	O
study	O
to	O
104	O
patients	O
(	O
93	O
families	O
)	O
with	O
a	O
classical	O
AS	O
phenotype	O
.	O

All	O
of	O
our	O
patients	O
were	O
evaluated	O
for	O
22	O
clinical	O
variables	O
including	O
growth	O
parameters	O
,	O
acquisition	O
of	O
motor	O
skills	O
,	O
and	O
history	O
of	O
seizures	S-Phenotype
.	O

In	O
addition	O
,	O
molecular	O
and	O
cytogenetic	O
analyses	O
were	O
used	O
to	O
assign	O
a	O
molecular	O
class	O
(	O
I	O
-	O
V	O
)	O
to	O
each	O
patient	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

In	O
our	O
patient	O
repository	O
,	O
22	O
%	O
of	O
our	O
families	O
had	O
normal	O
DNA	O
methylation	O
analyses	O
along	O
15q11	O
-	O
q13	O
.	O

Of	O
these	O
,	O
44	O
%	O
of	O
sporadic	O
patients	O
had	O
mutations	O
within	O
UBE3A	O
,	O
the	O
largest	O
percentage	O
found	O
to	O
date	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
five	O
molecular	O
classes	O
can	O
be	O
divided	O
into	O
four	O
phenotypic	O
groups	O
:	O
deletions	O
,	O
UPD	O
and	O
ID	O
patients	O
,	O
UBE3A	O
mutation	O
patients	O
,	O
and	O
subjects	O
with	O
unknown	O
aetiology	O
.	O

Deletion	O
patients	O
are	O
the	O
most	O
severely	O
affected	O
,	O
while	O
UPD	O
and	O
ID	O
patients	O
are	O
the	O
least	O
.	O

Differences	O
in	O
body	O
mass	O
index	O
,	O
head	O
circumference	O
,	O
and	O
seizure	S-Phenotype
activity	O
are	O
the	O
most	O
pronounced	O
among	O
the	O
classes	O
.	O

Clinically	O
,	O
we	O
were	O
unable	O
to	O
distinguish	O
between	O
UPD	O
and	O
ID	O
patients	O
,	O
suggesting	O
that	O
15q11	O
-	O
q13	O
contains	O
the	O
only	O
significant	O
maternally	O
expressed	O
imprinted	O
genes	O
on	O
chromosome	O
15	O
.	O

Intrafamilial	O
clinical	O
variability	O
in	O
type	B-Phenotype
C	E-Phenotype
brachydactyly	S-Phenotype
:	O
In	O
this	O
report	O
we	O
describe	O
a	O
4	O
-	O
generation	O
family	O
in	O
which	O
three	O
members	O
present	O
variable	O
clinical	O
and	O
radiological	O
manifestations	O
of	O
brachydactyly	O
type	O
C.	O
The	O
observation	O
of	O
'skipped	O
generations	O
'	O
in	O
the	O
present	O
family	O
and	O
in	O
a	O
few	O
other	O
families	O
reported	O
previously	O
,	O
may	O
indicate	O
that	O
brachydactyly	O
type	O
C	O
is	O
not	O
a	O
true	O
autosomal	O
dominant	O
condition	O
due	O
to	O
mutations	O
in	O
a	O
single	O
gene	O
.	O

Six	O
breakpoint	O
regions	O
for	O
rearrangements	O
of	O
human	O
chromosome	O
15q11	O
-	O
q14	O
have	O
been	O
described	O
.	O

These	O
rearrangements	O
involve	O
deletions	O
found	O
in	O
approximately	O
70	O
%	O
of	O
Prader	O
-	O
Willi	O
or	O
Angelman	O
's	O
syndrome	O
patients	O
(	O
PWS	O
,	O
AS	O
)	O
,	O
duplications	O
detected	O
in	O
some	O
cases	O
of	O
autism	S-Phenotype
,	O
triplications	O
and	O
inverted	O
duplications	O
.	O

HERC2	O
-	O
containing	O
(	O
HEct	O
domain	O
and	O
RCc1	O
domain	O
protein	O
2	O
)	O
segmental	O
duplications	O
or	O
duplicons	O
are	O
present	O
at	O
two	O
of	O
these	O
breakpoints	O
(	O
BP2	O
and	O
BP3	O
)	O
mainly	O
associated	O
with	O
deletions	O
.	O

We	O
show	O
here	O
that	O
clusters	O
containing	O
several	O
copies	O
of	O
the	O
human	O
chromosome	O
15	O
low	O
-	O
copy	O
repeat	O
(	O
LCR15	O
)	O
duplicon	O
are	O
located	O
at	O
each	O
of	O
the	O
six	O
described	O
15q11	O
-	O
q14	O
BPs	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
the	O
existence	O
of	O
breakpoints	O
for	O
large	O
15q11	O
-	O
q13	O
deletions	O
in	O
a	O
proximal	O
duplicon	O
-	O
containing	O
clone	O
.	O

The	O
study	O
reveals	O
that	O
HERC2	O
-	O
containing	O
duplicons	O
(	O
estimated	O
on	O
50	O
-	O
400	O
kb	O
)	O
and	O
LCR15	O
duplicons	O
(	O
approximately	O
15	O
kb	O
on	O
15q11	O
-	O
q14	O
)	O
share	O
the	O
golgin	O
-	O
like	O
protein	O
(	O
GLP	O
)	O
genomic	O
sequence	O
.	O

Through	O
the	O
analysis	O
of	O
a	O
human	O
BAC	O
library	O
and	O
public	O
databases	O
we	O
have	O
identified	O
36	O
LCR15	O
related	O
sequences	O
in	O
the	O
human	O
genome	O
,	O
most	O
(	O
27	O
)	O
mapping	O
to	O
chromosome	O
15q	O
and	O
being	O
transcribed	O
.	O

LCR15	O
analysis	O
in	O
non	O
-	O
human	O
primates	O
and	O
age	O
-	O
sequence	O
divergences	O
support	O
a	O
recent	O
origin	O
of	O
this	O
family	O
of	O
segmental	O
duplications	O
through	O
human	O
speciation	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
must	O
be	O
suspected	O
in	O
patients	O
presenting	O
with	O
a	O
unilateral	S-Phenotype
vestibular	B-Phenotype
schwannoma	E-Phenotype
at	O
a	O
young	O
age	O
who	O
are	O
therefore	O
at	O
theoretical	O
risk	O
of	O
developing	O
bilateral	B-Phenotype
disease	E-Phenotype
.	O

We	O
identified	O
45	O
patients	O
aged	O
30	O
years	O
or	O
less	O
at	O
the	O
onset	O
of	O
symptoms	O
of	O
a	O
unilateral	S-Phenotype
vestibular	B-Phenotype
schwannoma	E-Phenotype
.	O

Molecular	O
genetic	O
analysis	O
of	O
the	O
NF2	O
gene	O
was	O
completed	O
on	O
peripheral	O
blood	O
samples	O
in	O
all	O
45	O
and	O
on	O
28	O
tumour	S-Phenotype
samples	O
.	O

No	O
pathogenic	O
NF2	O
mutations	O
were	O
identified	O
in	O
any	O
of	O
the	O
blood	O
samples	O
.	O

NF2	O
point	O
mutations	O
were	O
identified	O
in	O
21	O
/	O
28	O
(	O
75	O
%	O
)	O
tumour	S-Phenotype
samples	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
21	O
/	O
28	O
(	O
75	O
%	O
)	O
tumour	O
samples	O
.	O

Both	O
mutational	O
hits	O
were	O
identified	O
in	O
18	O
/	O
28	O
(	O
65	O
%	O
)	O
tumour	S-Phenotype
samples	O
.	O

In	O
one	O
multilobular	O
tumour	S-Phenotype
,	O
one	O
(	O
presumably	O
first	O
hit	O
)	O
mutation	O
was	O
confirmed	O
which	O
was	O
common	O
to	O
different	O
foci	O
of	O
the	O
tumour	O
,	O
while	O
the	O
second	O
mutational	O
event	O
differed	O
between	O
foci	O
.	O

The	O
molecular	O
findings	O
in	O
this	O
patient	O
were	O
consistent	O
with	O
somatic	O
mosaicism	O
for	O
NF2	O
and	O
the	O
clinical	O
diagnosis	O
was	O
confirmed	O
with	O
the	O
presence	O
of	O
two	O
meningiomas	S-Phenotype
on	O
a	O
follow	O
up	O
MRI	O
scan	O
.	O

A	O
further	O
patient	O
developed	O
a	O
contralateral	S-Phenotype
vestibular	B-Phenotype
schwannoma	E-Phenotype
on	O
a	O
follow	O
up	O
MRI	O
scan	O
in	O
whom	O
neither	O
of	O
the	O
truncating	O
mutations	O
in	O
the	O
vestibular	O
schwannoma	O
were	O
present	O
in	O
blood	O
.	O

It	O
is	O
important	O
when	O
counselling	O
patients	O
with	O
unilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
to	O
identify	O
(	O
1	O
)	O
those	O
at	O
risk	O
of	O
bilateral	B-Phenotype
disease	E-Phenotype
,	O
(	O
2	O
)	O
those	O
at	O
risk	O
of	O
developing	O
other	O
tumours	S-Phenotype
,	O
and	O
(	O
3	O
)	O
other	O
family	O
members	O
at	O
risk	O
of	O
developing	O
NF2	O
.	O

Comparing	O
tumour	S-Phenotype
and	O
blood	O
DNA	O
can	O
not	O
exclude	O
mosaicism	O
in	O
the	O
index	O
case	O
and	O
can	O
not	O
,	O
therefore	O
,	O
be	O
used	O
to	O
predict	O
those	O
at	O
risk	O
of	O
developing	O
further	O
tumours	S-Phenotype
.	O

However	O
,	O
identification	O
of	O
both	O
mutations	O
or	O
one	O
mutation	O
plus	O
LOH	O
in	O
the	O
tumour	S-Phenotype
and	O
exclusion	O
of	O
those	O
mutations	O
in	O
the	O
blood	O
samples	O
of	O
the	O
sibs	O
or	O
offspring	O
of	O
the	O
affected	O
case	O
may	O
be	O
sufficient	O
to	O
render	O
further	O
screening	O
unnecessary	O
in	O
these	O
relatives	O
.	O

Mutations	O
of	O
the	O
neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
tumor	S-Phenotype
suppressor	O
gene	O
cause	O
the	O
inherited	O
disorder	O
NF2	O
and	O
are	O
also	O
common	O
in	O
malignant	S-Phenotype
mesothelioma	S-Phenotype
,	O
which	O
is	O
not	O
a	O
characteristic	O
feature	O
of	O
NF2	O
.	O

The	O
authors	O
report	O
an	O
asbestos	O
-	O
exposed	O
person	O
with	O
NF2	O
and	O
malignant	S-Phenotype
mesothelioma	S-Phenotype
.	O

Immunohistochemical	O
analysis	O
of	O
the	O
mesothelioma	S-Phenotype
confirmed	O
loss	O
of	O
expression	O
of	O
the	O
NF2	O
protein	O
,	O
and	O
comparative	O
genomic	O
hybridization	O
revealed	O
losses	O
of	O
chromosomes	O
14	O
,	O
15	O
,	O
and	O
22	O
,	O
and	O
gain	O
of	O
7	O
.	O

The	O
authors	O
propose	O
that	O
a	O
person	O
with	O
a	O
constitutional	O
mutation	O
of	O
an	O
NF2	O
allele	O
is	O
more	O
susceptible	B-Phenotype
to	I-Phenotype
mesothelioma	E-Phenotype
.	O

Interferon	O
regulatory	O
factor	O
6	O
(	O
IRF6	O
)	O
belongs	O
to	O
a	O
family	O
of	O
nine	O
transcription	O
factors	O
that	O
share	O
a	O
highly	O
conserved	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
domain	O
and	O
a	O
less	O
conserved	O
protein	O
-	O
binding	O
domain	O
.	O

Most	O
IRFs	O
regulate	O
the	O
expression	O
of	O
interferon	O
-	O
alpha	O
and	O
-	O
beta	O
after	O
viral	O
infection	O
,	O
but	O
the	O
function	O
of	O
IRF6	O
is	O
unknown	O
.	O

The	O
gene	O
encoding	O
IRF6	O
is	O
located	O
in	O
the	O
critical	O
region	O
for	O
the	O
Van	O
der	O
Woude	O
syndrome	O
(	O
VWS	O
;	O
OMIM	O
119300	O
)	O
locus	O
at	O
chromosome	O
1q32	O
-	O
q41	O
(	O
refs	O
2,3	O
)	O
.	O

The	O
disorder	O
is	O
an	O
autosomal	O
dominant	O
form	O
of	O
cleft	B-Phenotype
lip	E-Phenotype
and	O
palate	O
with	O
lip	B-Phenotype
pits	E-Phenotype
,	O
and	O
is	O
the	O
most	O
common	O
syndromic	O
form	O
of	O
cleft	B-Phenotype
lip	I-Phenotype
or	I-Phenotype
palate	E-Phenotype
.	O

Popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
(	O
PPS	O
;	O
OMIM	O
119500	O
)	O
is	O
a	O
disorder	O
with	O
a	O
similar	O
orofacial	O
phenotype	O
that	O
also	O
includes	O
skin	B-Phenotype
and	I-Phenotype
genital	I-Phenotype
anomalies	E-Phenotype
.	O

Phenotypic	O
overlap	O
and	O
linkage	O
data	O
suggest	O
that	O
these	O
two	O
disorders	O
are	O
allelic	O
.	O

We	O
found	O
a	O
nonsense	O
mutation	O
in	O
IRF6	O
in	O
the	O
affected	O
twin	O
of	O
a	O
pair	O
of	O
monozygotic	O
twins	O
who	O
were	O
discordant	O
for	O
VWS	O
.	O

Subsequently	O
,	O
we	O
identified	O
mutations	O
in	O
IRF6	O
in	O
45	O
additional	O
unrelated	O
families	O
affected	O
with	O
VWS	O
and	O
distinct	O
mutations	O
in	O
13	O
families	O
affected	O
with	O
PPS	O
.	O

Expression	O
analyses	O
showed	O
high	O
levels	O
of	O
Irf6	O
mRNA	O
along	O
the	O
medial	O
edge	O
of	O
the	O
fusing	O
palate	O
,	O
tooth	O
buds	O
,	O
hair	O
follicles	O
,	O
genitalia	O
and	O
skin	O
.	O

Our	O
observations	O
demonstrate	O
that	O
haploinsufficiency	O
of	O
IRF6	O
disrupts	O
orofacial	O
development	O
and	O
are	O
consistent	O
with	O
dominant	O
-	O
negative	O
mutations	O
disturbing	O
development	O
of	O
the	O
skin	O
and	O
genitalia	O
.	O

To	O
evaluate	O
clinical	O
and	O
molecular	O
predictors	O
of	O
the	O
risk	O
of	O
mortality	O
in	O
people	O
with	O
neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
,	O
we	O
analyzed	O
the	O
mortality	O
experience	O
of	O
368	O
patients	O
from	O
261	O
families	O
in	O
the	O
United	O
Kingdom	O
NF2	O
registry	O
,	O
using	O
the	O
Cox	O
proportional	O
-	O
hazards	O
model	O
and	O
the	O
jackknife	O
method	O
.	O

Age	O
at	O
diagnosis	O
,	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
,	O
and	O
type	O
of	O
treatment	O
center	O
were	O
informative	O
predictors	O
of	O
the	O
risk	O
of	O
mortality	O
.	O

In	O
Cox	O
models	O
,	O
the	O
relative	O
risk	O
of	O
mortality	O
increased	O
1.13	O
-	O
fold	O
per	O
year	O
decrease	O
in	O
age	O
at	O
diagnosis	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.08	O
-	O
1.18	O
)	O
and	O
was	O
2.51	O
-	O
fold	O
greater	O
in	O
people	O
with	O
meningiomas	S-Phenotype
compared	O
with	O
those	O
without	O
meningiomas	O
(	O
95	O
%	O
CI	O
1.38	O
-	O
4.57	O
)	O
.	O

The	O
relative	O
risk	O
of	O
mortality	O
in	O
patients	O
treated	O
at	O
specialty	O
centers	O
was	O
0.34	O
compared	O
with	O
those	O
treated	O
at	O
nonspecialty	O
centers	O
(	O
95	O
%	O
CI	O
0.12	O
-	O
0.98	O
)	O
.	O

In	O
a	O
separate	O
model	O
,	O
the	O
relative	O
risk	O
of	O
mortality	O
in	O
people	O
with	O
constitutional	O
NF2	O
missense	O
mutations	O
was	O
very	O
low	O
compared	O
with	O
those	O
with	O
other	O
types	O
of	O
mutations	O
(	O
nonsense	O
or	O
frameshift	O
mutations	O
,	O
splice	O
-	O
site	O
mutations	O
,	O
and	O
large	O
deletions	O
)	O
,	O
but	O
the	O
CI	O
could	O
not	O
be	O
well	O
quantified	O
because	O
there	O
was	O
only	O
one	O
death	O
among	O
people	O
with	O
missense	O
mutations	O
.	O

We	O
conclude	O
that	O
age	O
at	O
diagnosis	O
,	O
the	O
strongest	O
single	O
predictor	O
of	O
the	O
risk	O
of	O
mortality	O
,	O
is	O
a	O
useful	O
index	O
for	O
patient	O
counseling	O
and	O
clinical	O
management	O
(	O
as	O
are	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
)	O
.	O

To	O
ensure	O
optimal	O
care	O
,	O
we	O
recommend	O
that	O
people	O
with	O
NF2	O
be	O
referred	O
to	O
specialty	O
treatment	O
centers	O
.	O

Growth	O
/	O
differentiation	O
factor	O
-	O
5	O
(	O
GDF5	O
)	O
,	O
also	O
known	O
as	O
cartilage	O
-	O
derived	O
morphogenetic	O
protein	O
-	O
1	O
(	O
CDMP	O
-	O
1	O
)	O
,	O
is	O
a	O
secreted	O
signaling	O
molecule	O
that	O
participates	O
in	O
skeletal	O
morphogenesis	O
.	O

Heterozygous	O
mutations	O
in	O
GDF5	O
,	O
which	O
maps	O
to	O
human	O
chromosome	O
20	O
,	O
occur	O
in	O
individuals	O
with	O
autosomal	O
dominant	O
brachydactyly	S-Phenotype
type	O
C	O
(	O
BDC	S-Phenotype
)	O
.	O

Here	O
we	O
show	O
that	O
BDC	S-Phenotype
is	O
locus	O
homogeneous	O
by	O
reporting	O
a	O
GDF5	O
frameshift	O
mutation	O
segregating	O
with	O
the	O
phenotype	O
in	O
a	O
family	O
whose	O
trait	O
was	O
initially	O
thought	O
to	O
map	O
to	O
human	O
chromosome	O
12	O
.	O

We	O
also	O
describe	O
heterozygous	O
mutations	O
in	O
nine	O
additional	O
probands	O
/	O
families	O
with	O
BDC	S-Phenotype
and	O
show	O
nonpenetrance	O
in	O
a	O
mutation	O
carrier	O
.	O

Finally	O
,	O
we	O
show	O
that	O
mutant	O
GDF5	O
polypeptides	O
containing	O
missense	O
mutations	O
in	O
their	O
active	O
domains	O
do	O
not	O
efficiently	O
form	O
disulfide	O
-	O
linked	O
dimers	O
when	O
expressed	O
in	O
vitro	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
BDC	S-Phenotype
results	O
from	O
functional	O
haploinsufficiency	O
for	O
GDF5	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
A1	E-Phenotype
(	O
BDA1	S-Phenotype
)	O
was	O
the	O
first	O
disorder	O
described	O
in	O
terms	O
of	O
autosomal	O
dominant	O
Mendelian	O
inheritance	O
.	O

Early	O
in	O
the	O
1900s	O
Farabee	O
and	O
Drinkwater	O
described	O
a	O
number	O
of	O
families	O
with	O
BDA1	S-Phenotype
.	O

Examination	O
of	O
two	O
of	O
Drinkwater	O
's	O
families	O
has	O
revealed	O
that	O
,	O
although	O
they	O
are	O
not	O
known	O
to	O
be	O
related	O
,	O
both	O
share	O
a	O
common	O
mutation	O
within	O
the	O
Indian	O
hedgehog	O
gene	O
(	O
IHH	O
)	O
.	O

This	O
novel	O
mutation	O
is	O
a	O
guanine	O
to	O
adenine	O
transition	O
at	O
nucleotide	O
298	O
,	O
resulting	O
in	O
an	O
Asn100Asp	O
amino	O
acid	O
substitution	O
.	O

Both	O
families	O
demonstrate	O
significant	O
intrafamilial	O
phenotypic	O
heterogeneity	O
among	O
the	O
affected	O
individuals	O
.	O

Examination	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
has	O
shown	O
that	O
the	O
affected	O
individuals	O
in	O
both	O
families	O
share	O
SNPs	O
within	O
IHH	O
consistent	O
with	O
that	O
of	O
a	O
common	O
founder	O
.	O

The	O
identification	O
of	O
the	O
same	O
mutation	O
in	O
these	O
families	O
has	O
answered	O
a	O
question	O
that	O
is	O
nearly	O
a	O
century	O
old	O
about	O
the	O
genetic	O
cause	O
of	O
their	O
disease	O
and	O
supports	O
the	O
hypothesis	O
that	O
IHH	O
plays	O
a	O
pivotal	O
role	O
in	O
normal	O
human	O
skeletogenesis	O
.	O

Branchio	O
-	O
Oto	O
-	O
Renal	O
(	O
BOR	O
)	O
syndrome	O
is	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
disorder	O
,	O
affects	O
an	O
estimated	O
2	O
%	O
of	O
profoundly	B-Phenotype
deaf	E-Phenotype
children	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
human	O
EYA1	O
gene	O
.	O

However	O
,	O
in	O
up	O
to	O
half	O
of	O
the	O
reported	O
cases	O
,	O
EYA1	O
mutation	O
screening	O
is	O
negative	O
.	O

This	O
finding	O
has	O
been	O
taken	O
as	O
evidence	O
of	O
genetic	O
heterogeneity	O
.	O

Mutation	O
screening	O
of	O
the	O
coding	O
region	O
of	O
EYA1	O
in	O
a	O
panel	O
of	O
families	O
linked	O
to	O
chromosome	O
8	O
was	O
conducted	O
using	O
SSCP	O
and	O
direct	O
sequencing	O
.	O

Only	O
one	O
point	O
mutation	O
in	O
five	O
probands	O
was	O
detected	O
.	O

However	O
,	O
complex	O
rearrangements	O
,	O
such	O
as	O
inversions	O
or	O
large	O
deletions	O
,	O
were	O
discovered	O
in	O
the	O
other	O
four	O
patients	O
using	O
Southern	O
blot	O
analysis	O
.	O

These	O
data	O
suggest	O
that	O
more	O
complex	O
rearrangements	O
may	O
remain	O
undetected	O
in	O
EYA1	O
since	O
SSCP	O
and	O
sequencing	O
were	O
commonly	O
used	O
to	O
detect	O
mutations	O
in	O
this	O
gene	O
.	O

Four	O
sets	O
of	O
clinical	O
diagnostic	O
criteria	O
for	O
neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
have	O
been	O
developed	O
by	O
groups	O
of	O
expert	O
clinicians	O
,	O
but	O
sensitivity	O
has	O
never	O
been	O
formally	O
assessed	O
.	O

The	O
sets	O
of	O
criteria	O
differ	O
for	O
people	O
without	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
,	O
which	O
are	O
pathognomonic	O
for	O
NF2	O
.	O

To	O
empirically	O
evaluate	O
the	O
four	O
existing	O
sets	O
of	O
clinical	O
diagnostic	O
criteria	O
for	O
NF2	O
.	O

The	O
study	O
was	O
based	O
on	O
163	O
of	O
403	O
people	O
in	O
the	O
United	O
Kingdom	O
NF2	O
registry	O
(	O
41	O
%	O
)	O
who	O
presented	O
without	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
.	O

The	O
authors	O
applied	O
the	O
sets	O
of	O
criteria	O
to	O
each	O
person	O
at	O
initial	O
assessment	O
and	O
at	O
the	O
most	O
recent	O
clinical	O
evaluation	O
(	O
mean	O
+	O
/	O
-	O
SE	O
length	O
of	O
follow	O
-	O
up	O
,	O
13	O
+	O
/	O
-	O
1	O
years	O
)	O
.	O

In	O
people	O
with	O
``	O
definite	O
NF2	O
''	O
and	O
a	O
negative	O
family	O
history	O
of	O
NF2	O
,	O
the	O
1987	O
US	O
NIH	O
and	O
1991	O
NIH	O
criteria	O
each	O
identify	O
78	O
%	O
of	O
people	O
at	O
the	O
most	O
recent	O
clinical	O
evaluation	O
but	O
0	O
%	O
at	O
initial	O
assessment	O
.	O

The	O
National	O
Neurofibromatosis	O
Foundation	O
(	O
NNFF	O
)	O
criteria	O
and	O
the	O
Manchester	O
criteria	O
each	O
identify	O
higher	O
proportions	O
at	O
both	O
time	O
points	O
(	O
NNFF	O
criteria	O
,	O
91	O
%	O
and	O
10	O
%	O
;	O
Manchester	O
criteria	O
,	O
93	O
%	O
and	O
14	O
%	O
)	O
,	O
but	O
the	O
proportions	O
at	O
initial	O
assessment	O
are	O
still	O
low	O
.	O

None	O
of	O
the	O
existing	O
sets	O
of	O
criteria	O
are	O
adequate	O
at	O
initial	O
assessment	O
for	O
diagnosing	O
people	O
who	O
present	O
without	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
as	O
having	O
NF2	O
,	O
particularly	O
people	O
with	O
a	O
negative	O
family	O
history	O
of	O
NF2	O
.	O

The	O
authors	O
recommend	O
that	O
a	O
single	O
,	O
revised	O
set	O
of	O
diagnostic	O
criteria	O
be	O
devised	O
to	O
replace	O
all	O
of	O
the	O
existing	O
sets	O
of	O
criteria	O
.	O

The	O
present	O
report	O
concerns	O
a	O
two	O
-	O
generation	O
family	O
of	O
nine	O
individuals	O
in	O
which	O
the	O
father	O
and	O
three	O
of	O
the	O
six	O
living	O
children	O
all	O
had	O
:	O
(	O
1	O
)	O
a	O
mixed	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
with	O
a	O
Mondini	B-Phenotype
type	I-Phenotype
cochlear	I-Phenotype
malformation	E-Phenotype
and	O
stapes	B-Phenotype
fixation	E-Phenotype
;	O
(	O
2	O
)	O
cup	B-Phenotype
-	I-Phenotype
shaped	I-Phenotype
,	I-Phenotype
anteverted	I-Phenotype
pinnae	E-Phenotype
with	O
bilateral	O
prehelical	B-Phenotype
pits	E-Phenotype
:	O
(	O
3	O
)	O
bilateral	O
branchial	B-Phenotype
cleft	I-Phenotype
fistulas	E-Phenotype
;	O
and	O
(	O
4	O
)	O
bilateral	B-Phenotype
renal	I-Phenotype
dysplasia	E-Phenotype
and	O
anomalies	B-Phenotype
of	I-Phenotype
the	I-Phenotype
collecting	I-Phenotype
system	E-Phenotype
.	O

The	O
father	O
and	O
one	O
affected	O
son	O
also	O
had	O
aplasia	B-Phenotype
of	I-Phenotype
the	I-Phenotype
lacrimal	I-Phenotype
ducts	E-Phenotype
.	O

A	O
fourth	O
child	O
who	O
died	O
at	O
5	O
months	O
of	O
age	O
was	O
reported	O
to	O
have	O
branchial	B-Phenotype
cleft	I-Phenotype
fistulas	E-Phenotype
and	O
bilateral	B-Phenotype
polycystic	I-Phenotype
kidneys	E-Phenotype
at	O
autopsy	O
.	O

In	O
addition	O
,	O
the	O
concept	O
of	O
noso	O
-	O
embryologic	O
communities	O
is	O
presented	O
.	O

Such	O
groups	O
are	O
composed	O
of	O
syndromes	O
whose	O
total	O
phenotypic	O
spectra	O
not	O
only	O
overlap	O
but	O
also	O
share	O
common	O
elements	O
in	O
embryogenesis	O
.	O

This	O
concept	O
is	O
illustrated	O
with	O
a	O
group	O
of	O
branchial	B-Phenotype
arch	I-Phenotype
syndromes	E-Phenotype
that	O
are	O
related	O
in	O
this	O
way	O
.	O

CDMP	O
-	O
1	O
,	O
a	O
cartilage	O
-	O
specific	O
member	O
of	O
the	O
TGFss	O
superfamily	O
of	O
secreted	O
signaling	O
molecules	O
,	O
plays	O
a	O
key	O
role	O
in	O
chondrogenesis	O
,	O
growth	O
and	O
patterning	O
of	O
the	O
developing	O
vertebrate	O
skeleton	O
.	O

Homozygous	O
CDMP	O
-	O
1	O
mutations	O
cause	O
Hunter	O
-	O
Thompson	O
and	O
Grebe	O
types	O
of	O
acromesomelic	O
chondrodysplasia	O
and	O
DuPan	O
syndrome	O
in	O
humans	O
,	O
as	O
well	O
as	O
brachypodism	O
in	O
mice	O
,	O
while	O
heterozygous	O
mutations	O
cause	O
brachydactyly	S-Phenotype
type	O
C	O
(	O
BDC	O
)	O
.	O

We	O
present	O
clinical	O
and	O
radiographic	O
data	O
from	O
three	O
unrelated	O
families	O
in	O
which	O
12	O
members	O
share	O
the	O
same	O
heterozygous	O
CDMP	O
-	O
1	O
mutation	O
,	O
an	O
insertion	O
(	O
insG206	O
)	O
,	O
resulting	O
in	O
a	O
frameshift	O
predicted	O
to	O
cause	O
functional	O
haploinsufficiency	O
.	O

Although	O
eight	O
mutation	O
carriers	O
display	O
BDC	O
,	O
four	O
have	O
normal	O
hands	O
and	O
feet	O
,	O
confirming	O
nonpenetrance	O
of	O
BDC	O
with	O
CDMP	O
-	O
1	O
mutations	O
.	O

In	O
addition	O
,	O
several	O
carriers	O
have	O
other	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
,	O
including	O
severe	O
bilateral	O
vertical	B-Phenotype
talus	E-Phenotype
(	O
in	O
two	O
)	O
,	O
developmental	B-Phenotype
hip	I-Phenotype
dysplasia	E-Phenotype
(	O
in	O
one	O
)	O
,	O
and	O
short	B-Phenotype
stature	E-Phenotype
(	O
in	O
two	O
,	O
who	O
are	O
otherwise	O
unaffected	O
)	O
.	O

Premature	B-Phenotype
vertebral	I-Phenotype
end	I-Phenotype
-	I-Phenotype
plate	I-Phenotype
disease	E-Phenotype
was	O
observed	O
in	O
four	O
mutation	O
carriers	O
and	O
was	O
associated	O
with	O
spondylolysis	S-Phenotype
and	O
spondylolisthesis	S-Phenotype
in	O
three	O
of	O
these	O
.	O

Axial	B-Phenotype
skeletal	I-Phenotype
involvement	E-Phenotype
has	O
not	O
been	O
previously	O
reported	O
in	O
association	O
with	O
CDMP	O
-	O
1	O
mutations	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
CDMP	O
-	O
1	O
expression	O
in	O
human	O
hypertrophic	O
chondrocytes	O
,	O
which	O
are	O
present	O
in	O
the	O
ring	O
epiphyses	O
of	O
vertebral	O
end	O
plates	O
.	O

Phenotypic	O
variation	O
in	O
BDC	O
has	O
previously	O
been	O
attributed	O
either	O
to	O
locus	O
heterogeneity	O
or	O
to	O
the	O
varied	O
functional	O
effects	O
of	O
different	O
CDMP	O
-	O
1	O
mutations	O
.	O

The	O
remarkable	O
range	O
of	O
phenotypes	O
caused	O
by	O
this	O
identical	O
CDMP	O
-	O
1	O
mutation	O
in	O
these	O
families	O
emphasizes	O
the	O
crucial	O
role	O
of	O
genetic	O
background	O
,	O
stochastic	O
variation	O
and	O
/	O
or	O
environmental	O
factors	O
in	O
modifying	O
the	O
observed	O
phenotype	O
.	O

Our	O
findings	O
illustrate	O
that	O
nonpenetrance	O
for	O
the	O
typical	O
features	O
of	O
BDC	O
can	O
be	O
appreciable	O
and	O
that	O
atypical	O
skeletal	O
features	O
that	O
have	O
been	O
reported	O
in	O
some	O
patients	O
with	O
BDC	O
(	O
i.e.	O
,	O
clubfoot	S-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
spondylolysis	S-Phenotype
)	O
may	O
also	O
result	O
from	O
CDMP	O
-	O
1	O
mutation	O
.	O

The	O
distal	B-Phenotype
arthrogryposes	E-Phenotype
(	O
DAs	O
)	O
are	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
multiple	B-Phenotype
congenital	I-Phenotype
contractures	E-Phenotype
of	O
the	O
limbs	O
.	O

We	O
previously	O
mapped	O
a	O
locus	O
for	O
DA	O
type	O
2B	O
(	O
DA2B	O
)	O
,	O
the	O
most	O
common	O
of	O
the	O
DAs	O
,	O
to	O
chromosome	O
11	O
.	O

We	O
now	O
report	O
that	O
DA2B	O
is	O
caused	O
by	O
mutations	O
in	O
TNNI2	O
that	O
are	O
predicted	O
to	O
disrupt	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
an	O
isoform	O
of	O
troponin	O
I	O
(	O
TnI	O
)	O
specific	O
to	O
the	O
troponin	O
-	O
tropomyosin	O
(	O
Tc	O
-	O
Tm	O
)	O
complex	O
of	O
fast	O
-	O
twitch	O
myofibers	O
.	O

Because	O
the	O
DAs	O
are	O
genetically	O
heterogeneous	O
,	O
we	O
sought	O
additional	O
candidate	O
genes	O
by	O
examining	O
modifiers	O
of	O
mutant	O
Drosophila	O
isoforms	O
of	O
TnI	O
.	O

One	O
of	O
these	O
modifiers	O
,	O
Tm2	O
,	O
encodes	O
tropomyosin	O
,	O
another	O
component	O
of	O
the	O
Tc	O
-	O
Tm	O
complex	O
.	O

A	O
human	O
homologue	O
of	O
Tm2	O
,	O
TPM2	O
,	O
encodes	O
beta	O
-	O
tropomyosin	O
and	O
maps	O
to	O
the	O
critical	O
interval	O
of	O
DA	O
type	O
1	O
(	O
DA1	O
)	O
.	O

We	O
discovered	O
that	O
DA1	O
is	O
caused	O
by	O
substitution	O
of	O
a	O
highly	O
conserved	O
amino	O
acid	O
residue	O
in	O
beta	O
-	O
tropomyosin	O
.	O

These	O
findings	O
suggest	O
that	O
DAs	O
,	O
in	O
general	O
,	O
may	O
be	O
caused	O
by	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
of	O
the	O
contractile	O
apparatus	O
specific	O
to	O
fast	O
-	O
twitch	O
myofibers	O
.	O

This	O
provides	O
a	O
new	O
opportunity	O
to	O
directly	O
study	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
multiple	B-Phenotype
-	I-Phenotype
congenital	I-Phenotype
-	I-Phenotype
contracture	E-Phenotype
syndromes	O
.	O

A	O
mother	O
and	O
daughter	O
with	O
Gorlin	O
syndrome	O
with	O
similar	O
neuroradiological	O
findings	O
are	O
reported	O
.	O

These	O
include	O
calcification	B-Phenotype
of	I-Phenotype
the	I-Phenotype
falx	I-Phenotype
cerebri	I-Phenotype
and	I-Phenotype
tentorium	I-Phenotype
cerebelli	E-Phenotype
and	O
dysgenesis	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	I-Phenotype
and	I-Phenotype
vermis	E-Phenotype
.	O

Vermian	B-Phenotype
dysgenesis	E-Phenotype
was	O
detected	O
in	O
both	O
mother	O
and	O
daughter	O
suggesting	O
a	O
previously	O
unrecognized	O
finding	O
associated	O
with	O
Gorlin	O
syndrome	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	O
syndrome	O
(	O
BOR	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
with	O
variable	O
clinical	O
manifestations	B-Phenotype
affecting	I-Phenotype
branchial	I-Phenotype
,	I-Phenotype
renal	E-Phenotype
and	O
auditory	O
development	O
.	O

Varying	O
clinical	O
expression	O
of	O
the	O
disease	O
between	O
different	O
families	O
suggests	O
that	O
multiple	O
loci	O
may	O
be	O
involved	O
.	O

However	O
,	O
the	O
possibility	O
of	O
genetic	O
heterogeneity	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
can	O
not	O
be	O
resolved	O
until	O
the	O
gene	O
(	O
s	O
)	O
causing	O
BOR	O
syndrome	O
are	O
mapped	O
.	O

DNA	O
from	O
four	O
generations	O
of	O
a	O
family	O
with	O
autosomal	O
dominant	O
BOR	O
syndrome	O
have	O
been	O
typed	O
with	O
a	O
series	O
of	O
genetic	O
markers	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
8	O
.	O

Using	O
two	O
point	O
linkage	O
analysis	O
,	O
a	O
significant	O
lod	O
score	O
of	O
Z	O
=	O
4.0	O
at	O
theta	O
=	O
0.05	O
was	O
obtained	O
with	O
the	O
D8S165	O
microsatellite	O
marker	O
.	O

Multipoint	O
analyses	O
with	O
8q	O
markers	O
place	O
the	O
gene	O
for	O
BOR	O
between	O
the	O
markers	O
D8S87	O
and	O
D8S165	O
.	O

The	O
Gorlin	O
(	O
naevoid	O
-	O
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
-	I-Phenotype
carcinoma	E-Phenotype
)	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterised	O
by	O
multiple	B-Phenotype
naevoid	E-Phenotype
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
recurrent	O
odontogenic	B-Phenotype
keratocysts	E-Phenotype
,	O
skeletal	B-Phenotype
anomalies	E-Phenotype
,	O
intracranial	B-Phenotype
calcification	E-Phenotype
,	O
and	O
developmental	B-Phenotype
malformations	E-Phenotype
.	O

Characterisation	O
of	O
the	O
gene	O
that	O
causes	O
the	O
syndrome	O
may	O
improve	O
our	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
other	O
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
.	O

By	O
linkage	O
analysis	O
,	O
we	O
have	O
shown	O
that	O
the	O
gene	O
is	O
located	O
on	O
chromosome	O
9q22.3	O
-	O
q31	O
;	O
the	O
most	O
likely	O
position	O
is	O
between	O
DNA	O
markers	O
D9S12	O
and	O
D9S53	O
.	O

Location	O
of	O
the	O
gene	O
for	O
Gorlin	O
syndrome	O
offers	O
the	O
possibility	O
that	O
DNA	O
markers	O
can	O
be	O
used	O
in	O
risk	O
estimation	O
and	O
presymptomatic	O
identification	O
of	O
patients	O
for	O
surveillance	O
.	O

Gorlin	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
predisposes	O
to	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	I-Phenotype
of	I-Phenotype
the	I-Phenotype
skin	E-Phenotype
,	O
ovarian	B-Phenotype
fibromas	E-Phenotype
,	O
and	O
medulloblastomas	S-Phenotype
.	O

Unlike	O
other	O
hereditary	O
disorders	O
associated	O
with	O
cancer	S-Phenotype
,	O
it	O
features	O
widespread	O
developmental	B-Phenotype
defects	E-Phenotype
.	O

To	O
investigate	O
the	O
possibility	O
that	O
the	O
syndrome	O
is	O
caused	O
by	O
mutation	O
in	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
we	O
searched	O
for	O
loss	O
of	O
heterozygosity	O
in	O
16	O
sporadic	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
2	O
hereditary	O
basal	O
cell	O
carcinomas	O
,	O
and	O
1	O
hereditary	O
ovarian	B-Phenotype
fibroma	E-Phenotype
and	O
performed	O
genetic	O
linkage	O
studies	O
in	O
five	O
Gorlin	O
syndrome	O
kindreds	O
.	O

Eleven	O
sporadic	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
all	O
3	O
hereditary	O
tumors	S-Phenotype
had	O
allelic	O
loss	O
of	O
chromosome	O
9q31	O
,	O
and	O
all	O
informative	O
kindreds	O
showed	O
tight	O
linkage	O
between	O
the	O
Gorlin	O
syndrome	O
gene	O
and	O
a	O
genetic	O
marker	O
in	O
this	O
region	O
.	O

Loss	O
of	O
heterozygosity	O
at	O
this	O
chromosomal	O
location	O
,	O
particularly	O
in	O
hereditary	O
tumors	S-Phenotype
,	O
implies	O
that	O
the	O
gene	O
is	O
homozygously	O
inactivated	O
and	O
normally	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
.	O

In	O
contrast	O
,	O
hemizygous	O
germline	O
mutations	O
lead	O
to	O
multiple	O
congenital	O
anomalies	O
.	O

Uniparental	O
disomy	O
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	O
disomy	O
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	O
disomy	O
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	O
15	O
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O

Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O

The	O
child	O
was	O
hypotonic	B-Phenotype
at	I-Phenotype
birth	E-Phenotype
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-	O
70	O
%	O
of	O
patients	O
with	O
PWS	O
.	O

Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	O
developed	O
.	O

Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	O
disomy	O
in	O
this	O
case	O
of	O
PWS	O
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
.	O

Eleven	O
patients	O
with	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
and	O
their	O
parents	O
from	O
5	O
families	O
have	O
been	O
studied	O
with	O
high	O
resolution	O
chromosome	O
analysis	O
and	O
molecular	O
probes	O
from	O
region	O
15q11	O
-	O
13	O
in	O
an	O
attempt	O
to	O
elucidate	O
the	O
mode	O
of	O
inheritance	O
in	O
familial	O
AS	O
.	O

No	O
deletions	O
were	O
detected	O
.	O

All	O
families	O
were	O
informative	O
with	O
a	O
combination	O
of	O
different	O
short	O
arm	O
cytogenetic	O
markers	O
.	O

All	O
sets	O
of	O
sibs	O
inherited	O
the	O
same	O
maternal	O
chromosome	O
15	O
,	O
but	O
in	O
3	O
families	O
sibs	O
inherited	O
different	O
paternal	O
15s	O
.	O

Analysis	O
of	O
6	O
polymorphic	O
DNA	O
markers	O
supported	O
the	O
conclusion	O
that	O
AS	O
sibs	O
inherit	O
the	O
same	O
maternal	O
15	O
,	O
but	O
often	O
different	O
paternal	O
15s	O
.	O

These	O
data	O
make	O
autosomal	O
recessive	O
inheritance	O
at	O
a	O
15q11	O
-	O
13	O
locus	O
very	O
unlikely	O
and	O
support	O
the	O
hypothesis	O
that	O
familial	O
AS	O
is	O
due	O
to	O
maternal	O
transmission	O
of	O
a	O
mutation	O
within	O
15q11	O
-	O
13	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
and	O
Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
have	O
become	O
the	O
classical	O
examples	O
of	O
genomic	O
imprinting	O
in	O
man	O
,	O
as	O
completely	O
different	O
phenotypes	O
are	O
generated	O
by	O
the	O
absence	O
of	O
maternal	O
(	O
AS	O
)	O
or	O
paternal	O
(	O
PWS	O
)	O
contributions	O
to	O
the	O
q11	O
-	O
13	O
region	O
of	O
chromosome	O
15	O
as	O
a	O
result	O
of	O
deletion	O
or	O
uniparental	O
disomy	O
.	O

Apparently	O
,	O
most	O
patients	O
are	O
sporadic	O
cases	O
.	O

The	O
genetic	O
mechanism	O
underlying	O
familial	O
AS	O
has	O
remained	O
enigmatic	O
for	O
a	O
long	O
time	O
.	O

Recently	O
,	O
evidence	O
has	O
been	O
emerging	O
suggesting	O
autosomal	O
dominant	O
inheritance	O
of	O
a	O
detectable	O
or	O
undetectable	O
defect	O
in	O
a	O
gene	O
or	O
genes	O
at	O
15q11	O
-	O
13	O
,	O
subject	O
to	O
genomic	O
imprinting	O
.	O

The	O
present	O
report	O
describes	O
an	O
unusually	O
large	O
pedigree	O
with	O
segregation	O
of	O
AS	O
through	O
maternal	O
inheritance	O
and	O
apparent	O
asymptomatic	O
transmission	O
through	O
several	O
male	O
ancestors	O
.	O

Deletion	O
and	O
paternal	O
disomy	O
at	O
15q11	O
-	O
13	O
were	O
excluded	O
.	O

However	O
,	O
the	O
genetic	O
defect	O
is	O
still	O
located	O
in	O
this	O
region	O
,	O
as	O
we	O
obtained	O
a	O
maximum	O
lod	O
score	O
of	O
5.40	O
for	O
linkage	O
to	O
the	O
GABA	O
receptor	O
locus	O
GABRB3	O
and	O
the	O
anonymous	O
DNA	O
marker	O
D15S10	O
,	O
which	O
have	O
been	O
mapped	O
within	O
or	O
adjacent	O
to	O
the	O
AS	O
critical	O
region	O
at	O
15q11	O
-	O
13	O
.	O

The	O
size	O
of	O
the	O
pedigree	O
allowed	O
calculation	O
of	O
an	O
odds	O
ratio	O
in	O
favour	O
of	O
genomic	O
imprinting	O
of	O
9.25	O
x	O
10	O
(	O
5	O
)	O
.	O

This	O
family	O
illustrates	O
the	O
necessity	O
of	O
extensive	O
pedigree	O
analysis	O
when	O
considering	O
recurrence	O
risks	O
for	O
relatives	O
of	O
AS	O
patients	O
,	O
those	O
without	O
detectable	O
deletion	O
or	O
disomy	O
in	O
particular	O
.	O

Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
and	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
are	O
distinct	O
mental	B-Phenotype
retardation	E-Phenotype
disorders	O
associated	O
with	O
deletions	O
of	O
proximal	O
15q	O
(	O
q11	O
-	O
q13	O
)	O
of	O
different	O
parental	O
origin	O
.	O

Yeast	O
artificial	O
chromosome	O
(	O
YAC	O
)	O
clones	O
were	O
isolated	O
for	O
9	O
previously	O
mapped	O
DNA	O
probes	O
from	O
this	O
region	O
,	O
and	O
for	O
one	O
newly	O
derived	O
marker	O
,	O
LS6	O
-	O
1	O
(	O
D15S113	O
)	O
.	O

A	O
YAC	O
contig	O
of	O
1	O
-	O
1.5	O
Mb	O
encompassing	O
four	O
markers	O
(	O
ML34	O
,	O
IR4	O
-	O
3R	O
,	O
PW71	O
,	O
and	O
TD189	O
-	O
1	O
)	O
was	O
constructed	O
.	O

Multi	O
-	O
color	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
of	O
interphase	O
nuclei	O
was	O
combined	O
with	O
YAC	O
contig	O
information	O
to	O
provide	O
the	O
following	O
order	O
of	O
markers	O
:	O
cen	O
-	O
IR39	O
-	O
ML34	O
-	O
IR4	O
-	O
3R	O
-	O
PW71	O
-	O
TD189	O
-	O
1	O
-	O
LS6++	O
+	O
-	O
1	O
-	O
TD3	O
-	O
21	O
-	O
GABRB3	O
-	O
IR10	O
-	O
1	O
-	O
CMW1	O
-	O
tel	O
.	O

FISH	O
analysis	O
was	O
performed	O
on	O
8	O
cases	O
of	O
PWS	O
and	O
3	O
cases	O
of	O
AS	O
,	O
including	O
5	O
patients	O
with	O
normal	O
karyotypes	O
.	O

All	O
eleven	O
patients	O
were	O
deleted	O
for	O
YACs	O
in	O
the	O
interval	O
from	O
IR4	O
-	O
3R	O
to	O
GABRB3	O
.	O

On	O
the	O
proximal	O
side	O
of	O
the	O
deletion	O
interval	O
,	O
10	O
/	O
10	O
breakpoints	O
fell	O
within	O
a	O
single	O
ML34	O
YAC	O
of	O
370	O
kb	O
.	O

On	O
the	O
distal	O
side	O
,	O
8	O
/	O
9	O
breakpoints	O
fell	O
within	O
a	O
single	O
IR10	O
-	O
1	O
YAC	O
of	O
200	O
kb	O
.	O

These	O
results	O
indicate	O
a	O
striking	O
consistency	O
in	O
the	O
location	O
of	O
the	O
proximal	O
and	O
distal	O
breakpoints	O
in	O
PWS	O
and	O
AS	O
patients	O
.	O

FISH	O
analysis	O
on	O
a	O
previously	O
reported	O
case	O
of	O
familial	O
AS	O
confirmed	O
a	O
submicroscopic	O
deletion	O
including	O
YACs	O
corresponding	O
to	O
LS6	O
-	O
1	O
,	O
TD3	O
-	O
21	O
and	O
GABRB3	O
and	O
supports	O
the	O
separation	O
of	O
the	O
PWS	O
and	O
AS	O
critical	O
regions	O
.	O

Since	O
these	O
three	O
YACs	O
do	O
not	O
overlap	O
each	O
other	O
,	O
the	O
minimum	O
size	O
of	O
the	O
AS	O
critical	O
region	O
is	O
>	O
or	O
=	O
650	O
kb	O
.	O

We	O
report	O
on	O
a	O
woman	O
who	O
was	O
diagnosed	O
with	O
branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
after	O
2	O
pregnancies	O
complicated	O
by	O
oligohydramnios	S-Phenotype
due	O
to	O
renal	B-Phenotype
hypoplasia	E-Phenotype
and	O
agenesis	O
.	O

Both	O
babies	O
died	O
neonatally	O
of	O
pulmonary	B-Phenotype
hypoplasia	E-Phenotype
.	O

Histopathology	O
of	O
the	O
temporal	O
bones	O
of	O
the	O
second	O
child	O
showed	O
marked	O
immaturity	B-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
ear	I-Phenotype
cleft	I-Phenotype
,	I-Phenotype
ossicles	I-Phenotype
,	I-Phenotype
facial	I-Phenotype
nerve	E-Phenotype
and	O
canal	O
,	O
and	O
cochlear	O
nerve	O
.	O

Maternal	O
renal	O
ultrasound	O
study	O
was	O
normal	O
although	O
intravenous	O
pyelography	O
indicated	O
renal	B-Phenotype
hypoplasia	E-Phenotype
.	O

The	O
frequency	O
of	O
BOR	O
syndrome	O
among	O
cases	O
of	O
recurrent	O
fetal	O
renal	B-Phenotype
hypoplasia	I-Phenotype
/	I-Phenotype
dysplasia	E-Phenotype
or	O
agenesis	O
is	O
unknown	O
,	O
and	O
parental	O
renal	O
ultrasonography	O
may	O
not	O
identify	O
a	O
heritable	O
renal	B-Phenotype
defect	E-Phenotype
.	O

Investigations	O
should	O
include	O
a	O
family	O
history	O
,	O
and	O
examination	O
of	O
relatives	O
to	O
look	O
for	O
preauricular	B-Phenotype
pits	E-Phenotype
,	O
lacrimal	B-Phenotype
duct	I-Phenotype
stenosis	E-Phenotype
,	O
and	O
branchial	B-Phenotype
fistulae	E-Phenotype
and	O
/	O
or	O
cysts	O
.	O

Hearing	B-Phenotype
studies	E-Phenotype
and	O
IVP	O
may	O
be	O
indicated	O
.	O

We	O
report	O
on	O
a	O
female	O
patient	O
with	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neurinomas	E-Phenotype
and	O
other	B-Phenotype
tumors	E-Phenotype
in	O
the	O
central	O
nervous	O
system	O
(	O
neurofibromatosis	S-Phenotype
type	O
2	O
:	O
NF2	O
)	O
and	O
the	O
constitutional	O
translocation	O
,	O
t	O
(	O
4	O
;	O
22	O
)	O
(	O
q12	O
;	O
q12.2	O
)	O
.	O

The	O
precise	O
identification	O
of	O
the	O
translocation	O
breakpoint	O
(	O
q12.2	O
)	O
on	O
chromosome	O
22	O
implies	O
the	O
refined	O
localization	O
of	O
a	O
gene	O
responsible	O
for	O
NF2	O
,	O
and	O
would	O
provide	O
a	O
clue	O
to	O
its	O
molecular	O
characterization	O
and	O
to	O
the	O
isolation	O
of	O
the	O
gene	O
.	O

Chromosomes	O
of	O
a	O
paraspinal	B-Phenotype
neurinoma	E-Phenotype
from	O
the	O
patient	O
were	O
also	O
analyzed	O
,	O
and	O
the	O
same	O
karyotype	O
as	O
seen	O
in	O
cultured	O
peripheral	O
lymphocytes	O
was	O
found	O
.	O

The	O
patient	O
's	O
father	O
was	O
also	O
a	O
carrier	O
of	O
the	O
translocation	O
,	O
but	O
he	O
had	O
no	O
clinical	O
symptoms	O
of	O
NF2	O
,	O
nor	O
did	O
other	O
relatives	O
.	O

Several	O
explanations	O
are	O
offered	O
for	O
the	O
different	O
expression	O
of	O
the	O
translocation	O
between	O
the	O
patient	O
and	O
her	O
father	O
.	O

We	O
report	O
on	O
the	O
12	O
-	O
year	O
development	O
of	O
a	O
child	O
with	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
who	O
was	O
initially	O
referred	O
at	O
age	O
5	O
months	O
.	O

Of	O
note	O
is	O
his	O
normal	O
intelligence	O
,	O
regular	O
class	O
placement	O
,	O
hypernasal	B-Phenotype
speech	E-Phenotype
,	O
and	O
continued	B-Phenotype
growth	I-Phenotype
along	I-Phenotype
the	I-Phenotype
third	I-Phenotype
centile	E-Phenotype
.	O

The	O
importance	O
of	O
serial	O
observations	O
of	O
patients	O
with	O
rare	O
genetic	O
disorders	O
is	O
emphasized	O
.	O

The	O
association	O
between	O
ear	B-Phenotype
and	I-Phenotype
kidney	I-Phenotype
anomalies	E-Phenotype
is	O
not	O
usually	O
due	O
to	O
an	O
insult	O
to	O
the	O
embryo	O
.	O

In	O
recent	O
years	O
,	O
many	O
essential	O
development	O
control	O
genes	O
that	O
coordinate	O
the	O
assembly	O
and	O
function	O
of	O
kidney	O
and	O
ear	O
have	O
been	O
discovered	O
through	O
the	O
generation	O
of	O
animal	O
mutants	O
and	O
have	O
increased	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
human	O
oto	O
-	O
renal	O
diseases	O
.	O

Here	O
,	O
we	O
describe	O
ear	B-Phenotype
and	I-Phenotype
kidney	I-Phenotype
clinical	I-Phenotype
syndromes	E-Phenotype
and	O
their	O
molecular	O
expression	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
(	O
BDC	S-Phenotype
)	O
is	O
characterized	O
by	O
shortening	B-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
phalanges	I-Phenotype
of	I-Phenotype
the	I-Phenotype
index	I-Phenotype
,	I-Phenotype
middle	I-Phenotype
,	I-Phenotype
and	I-Phenotype
little	I-Phenotype
finger	E-Phenotype
with	O
hyperphalangy	B-Phenotype
,	I-Phenotype
usually	I-Phenotype
of	I-Phenotype
the	I-Phenotype
index	I-Phenotype
and	I-Phenotype
middle	I-Phenotype
finger	E-Phenotype
.	O

Heterozygous	O
mutations	O
of	O
the	O
cartilage	O
derived	O
morphogenetic	O
protein	O
-	O
1	O
(	O
CDMP1	O
)	O
resulting	O
in	O
a	O
loss	O
of	O
function	O
have	O
been	O
reported	O
in	O
BDC	S-Phenotype
.	O

We	O
here	O
describe	O
a	O
large	O
kindred	O
with	O
a	O
semi	O
-	O
dominant	O
form	O
of	O
BDC	S-Phenotype
and	O
pronounced	O
ulnar	B-Phenotype
deviation	I-Phenotype
of	I-Phenotype
the	I-Phenotype
second	I-Phenotype
and	I-Phenotype
third	I-Phenotype
digits	E-Phenotype
.	O

In	O
this	O
family	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
was	O
identified	O
(	O
517A	O
>	O
G	O
)	O
changing	O
methionine	O
to	O
valine	O
at	O
amino	O
acid	O
position	O
173	O
.	O

The	O
mutation	O
is	O
located	O
within	O
a	O
highly	O
conserved	O
seven	O
amino	O
acid	O
region	O
of	O
the	O
prodomain	O
of	O
CDMP1	O
.	O

Hand	O
radiographs	O
of	O
heterozygous	O
mutation	O
carriers	O
showed	O
mild	O
shortening	B-Phenotype
of	I-Phenotype
the	I-Phenotype
metacarpals	I-Phenotype
IV	I-Phenotype
and	I-Phenotype
V	E-Phenotype
;	O
a	O
finding	O
confirmed	O
by	O
the	O
analysis	O
of	O
their	O
metacarpophalangeal	O
profiles	O
(	O
MCPPs	O
)	O
.	O

The	O
mutation	O
described	O
here	O
points	O
toward	O
an	O
important	O
function	O
of	O
the	O
prodomain	O
for	O
the	O
folding	O
,	O
secretion	O
,	O
and	O
availability	O
of	O
biologically	O
active	O
CDMP1	O
.	O

Branchiootorenal	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
affects	O
an	O
estimated	O
2	O
%	O
of	O
profoundly	B-Phenotype
deaf	E-Phenotype
children	O
.	O

In	O
addition	O
to	O
hearing	B-Phenotype
impairment	E-Phenotype
,	O
it	O
is	O
characterized	O
by	O
a	O
lop	B-Phenotype
-	I-Phenotype
ear	I-Phenotype
deformity	E-Phenotype
,	O
preauricular	B-Phenotype
pits	E-Phenotype
,	O
branchial	B-Phenotype
cleft	E-Phenotype
sinus	O
tracts	O
,	O
and	O
renal	B-Phenotype
anomalies	E-Phenotype
.	O

The	O
pathogenesis	O
of	O
the	O
disease	O
remains	O
unknown	O
;	O
however	O
,	O
the	O
defective	O
gene	O
has	O
been	O
localized	O
to	O
chromosome	O
8q	O
by	O
family	O
linkage	O
studies	O
.	O

A	O
clinical	O
and	O
genetic	O
study	O
of	O
type	O
2	O
neurofibromatosis	S-Phenotype
(	O
NF2	O
)	O
has	O
been	O
carried	O
out	O
in	O
the	O
United	O
Kingdom	O
.	O

Virtually	O
complete	O
ascertainment	O
of	O
cases	O
in	O
the	O
north	O
-	O
west	O
of	O
England	O
was	O
achieved	O
and	O
suggests	O
a	O
population	O
incidence	O
of	O
1	O
in	O
33,000	O
to	O
40,000	O
.	O

In	O
the	O
UK	O
as	O
a	O
whole	O
,	O
150	O
cases	O
have	O
been	O
identified	O
and	O
been	O
used	O
to	O
study	O
the	O
clinical	O
and	O
genetic	O
features	O
of	O
NF2	O
.	O

The	O
autosomal	O
dominant	O
inheritance	O
of	O
NF2	O
was	O
confirmed	O
,	O
49	O
%	O
of	O
cases	O
were	O
assessed	O
as	O
representing	O
new	O
mutations	O
,	O
and	O
the	O
mutation	O
rate	O
was	O
estimated	O
to	O
be	O
6.5	O
x	O
10	O
(	O
-	O
6	O
)	O
.	O

Evidence	O
to	O
support	O
a	O
maternal	O
gene	O
effect	O
was	O
found	O
in	O
that	O
age	O
at	O
onset	O
was	O
18.17	O
years	O
in	O
36	O
maternally	O
inherited	O
cases	O
and	O
24.5	O
in	O
20	O
paternally	O
inherited	O
cases	O
(	O
p	O
=	O
0.027	O
)	O
.	O

The	O
preponderance	O
of	O
maternally	O
inherited	O
cases	O
was	O
also	O
significant	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Data	O
are	O
presented	O
which	O
suggest	O
that	O
there	O
are	O
two	O
types	O
of	O
NF2	O
,	O
one	O
with	O
later	O
onset	O
and	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
as	O
the	O
only	O
usual	O
feature	O
,	O
and	O
the	O
other	O
with	O
earlier	O
onset	O
and	O
multiple	O
other	O
tumours	S-Phenotype
.	O

A	O
considerable	O
number	O
of	O
cases	O
did	O
not	O
fall	O
easily	O
into	O
one	O
or	O
other	O
group	O
and	O
other	O
factors	O
such	O
as	O
maternal	O
effect	O
on	O
severity	O
and	O
anticipation	O
need	O
to	O
be	O
considered	O
.	O

The	O
major	O
defining	O
features	O
,	O
age	O
at	O
onset	O
of	O
symptoms	O
,	O
and	O
survival	O
in	O
150	O
patients	O
with	O
type	O
2	O
neurofibromatosis	S-Phenotype
(	O
NF2	O
)	O
have	O
been	O
studied	O
.	O

The	O
mean	O
age	O
at	O
onset	O
was	O
21.57	O
years	O
(	O
n	O
=	O
110	O
)	O
and	O
no	O
cases	O
presented	O
after	O
55	O
years	O
of	O
age	O
.	O

Patients	O
presented	O
with	O
symptoms	O
attributable	O
to	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
(	O
acoustic	B-Phenotype
neuroma	E-Phenotype
)	O
,	O
cranial	B-Phenotype
meningiomas	E-Phenotype
,	O
and	O
spinal	B-Phenotype
tumours	E-Phenotype
.	O

In	O
97	O
cases	O
studied	O
personally	O
by	O
the	O
authors	O
,	O
skin	O
and	O
eye	O
examination	O
were	O
found	O
to	O
be	O
useful	O
to	O
detect	O
early	O
signs	O
of	O
the	O
condition	O
.	O

Examination	O
of	O
the	O
skin	O
is	O
likely	O
to	O
assist	O
in	O
early	O
diagnosis	O
in	O
at	O
least	O
10	O
%	O
of	O
cases	O
and	O
examination	O
of	O
the	O
eye	O
for	O
a	O
lens	B-Phenotype
opacity	E-Phenotype
or	O
cataract	S-Phenotype
in	O
at	O
least	O
as	O
many	O
again	O
.	O

There	O
are	O
marked	O
interfamilial	O
differences	O
in	O
disease	O
severity	O
and	O
tumour	S-Phenotype
susceptibility	O
.	O

Vestibular	B-Phenotype
schwannomas	E-Phenotype
are	O
not	O
fully	O
penetrant	O
,	O
but	O
the	O
condition	O
is	O
usually	O
expressed	O
in	O
another	O
way	O
.	O

Alteration	O
to	O
the	O
current	O
diagnostic	O
criteria	O
is	O
advocated	O
to	O
cover	O
the	O
lack	O
of	O
provision	O
for	O
new	O
mutations	O
.	O

A	O
screening	O
protocol	O
is	O
proposed	O
and	O
the	O
effect	O
of	O
disease	O
heterogeneity	O
on	O
management	O
is	O
discussed	O
.	O

The	O
clinical	O
features	O
,	O
age	O
at	O
onset	O
of	O
symptoms	O
and	O
survival	O
of	O
150	O
patients	O
with	O
type	O
2	O
neurofibromatosis	S-Phenotype
were	O
studied	O
.	O

The	O
mean	O
age	O
at	O
onset	O
was	O
21.57	O
years	O
(	O
n	O
=	O
110	O
)	O
and	O
no	O
patients	O
presented	O
after	O
55	O
years	O
of	O
age	O
.	O

Patients	O
presented	O
with	O
symptoms	O
attributable	O
to	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
(	O
acoustic	B-Phenotype
neuroma	E-Phenotype
)	O
,	O
cranial	B-Phenotype
meningiomas	E-Phenotype
and	O
spinal	B-Phenotype
tumours	E-Phenotype
.	O

In	O
100	O
patients	O
studied	O
personally	O
by	O
the	O
authors	O
44	O
per	O
cent	O
presented	O
with	O
deafness	S-Phenotype
and	O
this	O
was	O
unilateral	O
in	O
the	O
majority	O
(	O
35	O
/	O
44	O
)	O
.	O

Deafness	S-Phenotype
was	O
accompanied	O
by	O
tinnitus	S-Phenotype
in	O
a	O
further	O
10	O
per	O
cent	O
and	O
muscle	B-Phenotype
weakness	E-Phenotype
or	O
wasting	O
was	O
the	O
first	O
symptom	O
in	O
12	O
per	O
cent	O
.	O

Less	O
common	O
presenting	O
symptoms	O
were	O
seizures	S-Phenotype
(	O
8	O
per	O
cent	O
)	O
,	O
vertigo	S-Phenotype
(	O
8	O
per	O
cent	O
)	O
numbness	O
and	O
tingling	O
(	O
2	O
per	O
cent	O
)	O
and	O
blindness	S-Phenotype
(	O
1	O
per	O
cent	O
)	O
.	O

Eleven	O
patients	O
were	O
diagnosed	O
asymptomatically	O
through	O
screening	O
.	O

Caf√©	B-Phenotype
au	I-Phenotype
lait	I-Phenotype
spots	E-Phenotype
occurred	O
in	O
43	O
per	O
cent	O
(	O
n	O
=	O
43	O
)	O
but	O
only	O
one	O
case	O
had	O
six	O
.	O

Skin	B-Phenotype
tumours	E-Phenotype
were	O
detected	O
in	O
68	O
per	O
cent	O
(	O
68	O
/	O
100	O
)	O
and	O
38	O
per	O
cent	O
(	O
34	O
/	O
90	O
)	O
had	O
an	O
identifiable	O
lens	B-Phenotype
opacity	E-Phenotype
or	O
cataract	S-Phenotype
.	O

The	O
mean	O
age	O
at	O
death	O
in	O
40	O
cases	O
was	O
36.25	O
years	O
and	O
all	O
but	O
one	O
death	O
was	O
a	O
result	O
of	O
a	O
complication	O
of	O
neurofibromatosis	S-Phenotype
.	O

There	O
are	O
marked	O
inter	O
-	O
family	O
differences	O
in	O
disease	O
severity	O
and	O
tumour	S-Phenotype
susceptibility	O
.	O

The	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
gene	O
has	O
been	O
hypothesized	O
to	O
be	O
a	O
recessive	O
tumor	S-Phenotype
suppressor	O
,	O
with	O
mutations	O
at	O
the	O
same	O
locus	O
on	O
chromosome	O
22	O
that	O
lead	O
to	O
NF2	O
also	O
leading	O
to	O
sporadic	O
tumors	S-Phenotype
of	O
the	O
types	O
seen	O
in	O
NF2	O
.	O

Flanking	O
markers	O
for	O
this	O
gene	O
have	O
previously	O
been	O
defined	O
as	O
D22S1	O
centromeric	O
and	O
D22S28	O
telomeric	O
.	O

Identification	O
of	O
subregions	O
of	O
this	O
interval	O
that	O
are	O
consistently	O
rearranged	O
in	O
the	O
NF2	O
-	O
related	O
tumors	S-Phenotype
would	O
aid	O
in	O
better	O
defining	O
the	O
disease	O
locus	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
compared	O
tumor	S-Phenotype
and	O
constitutional	O
DNAs	O
,	O
isolated	O
from	O
39	O
unrelated	O
patients	O
with	O
sporadic	O
and	O
NF2	O
-	O
associated	O
acoustic	B-Phenotype
neuromas	E-Phenotype
,	O
meningiomas	S-Phenotype
,	O
schwannomas	S-Phenotype
,	O
and	O
ependymomas	S-Phenotype
,	O
at	O
eight	O
polymorphic	O
loci	O
on	O
chromosome	O
22	O
.	O

Two	O
of	O
the	O
tumors	S-Phenotype
studied	O
revealed	O
loss	O
-	O
of	O
-	O
heterozygosity	O
patterns	O
,	O
which	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
chromosome	O
22	O
terminal	O
deletions	O
.	O

By	O
using	O
additional	O
polymorphic	O
markers	O
,	O
the	O
terminal	O
deletion	O
breakpoint	O
found	O
in	O
one	O
of	O
the	O
tumors	S-Phenotype
,	O
an	O
acoustic	B-Phenotype
neuroma	E-Phenotype
from	O
an	O
NF2	O
patient	O
,	O
was	O
mapped	O
within	O
the	O
previously	O
defined	O
NF2	O
region	O
.	O

The	O
breakpoint	O
occurred	O
between	O
the	O
haplotyped	O
markers	O
D22S41	O
/	O
D22S46	O
and	O
D22S56	O
.	O

This	O
finding	O
redefines	O
the	O
proximal	O
flanking	O
marker	O
and	O
localizes	O
the	O
NF2	O
gene	O
between	O
markers	O
D22S41	O
/	O
D22S46	O
and	O
D22S28	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
sporadic	O
acoustic	B-Phenotype
neuroma	E-Phenotype
that	O
reveals	O
a	O
loss	O
-	O
of	O
-	O
heterozygosity	O
pattern	O
consistent	O
with	O
mitotic	O
recombination	O
or	O
deletion	O
and	O
reduplication	O
,	O
which	O
are	O
mechanisms	O
not	O
previously	O
seen	O
in	O
studies	O
of	O
these	O
tumors	S-Phenotype
.	O

This	O
finding	O
,	O
while	O
inconsistent	O
with	O
models	O
of	O
tumorigenesis	O
that	O
invoke	O
single	O
deletions	O
and	O
their	O
gene	O
-	O
dosage	O
effects	O
,	O
lends	O
further	O
support	O
to	O
the	O
recessive	O
tumor	S-Phenotype
-	O
suppressor	O
model	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
is	O
an	O
autosomal	O
dominant	O
syndrome	O
characterized	O
by	O
the	O
development	O
of	O
vestibular	S-Phenotype
schwannomas	S-Phenotype
and	O
other	B-Phenotype
tumors	E-Phenotype
of	O
the	O
nervous	O
system	O
,	O
including	O
cranial	B-Phenotype
and	I-Phenotype
spinal	I-Phenotype
meningiomas	E-Phenotype
,	O
schwannomas	O
,	O
and	O
ependymomas	S-Phenotype
.	O

The	O
presence	O
of	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
is	O
sufficient	O
for	O
the	O
diagnosis	O
.	O

Skin	B-Phenotype
manifestations	E-Phenotype
are	O
less	O
common	O
than	O
in	O
neurofibromatosis	S-Phenotype
type	O
1	O
(	O
NF1	O
;	O
von	O
Recklinghausen	O
disease	O
)	O
.	O

The	O
apparent	O
clinical	O
distinction	O
between	O
NF1	O
and	O
NF2	O
has	O
been	O
confirmed	O
at	O
the	O
level	O
of	O
the	O
gene	O
locus	O
by	O
linkage	O
studies	O
;	O
the	O
gene	O
for	O
NF1	O
maps	O
to	O
chromosome	O
17	O
,	O
whereas	O
the	O
gene	O
for	O
NF2	O
has	O
been	O
assigned	O
(	O
in	O
a	O
single	O
family	O
)	O
to	O
chromosome	O
22	O
.	O

To	O
increase	O
the	O
precision	O
of	O
the	O
genetic	O
mapping	O
of	O
NF2	O
and	O
to	O
determine	O
whether	O
additional	O
susceptibility	O
loci	O
exist	O
,	O
we	O
have	O
performed	O
linkage	O
analysis	O
on	O
12	O
families	O
with	O
NF2	O
by	O
using	O
four	O
polymorphic	O
markers	O
from	O
chromosome	O
22	O
and	O
a	O
marker	O
at	O
the	O
NF1	O
locus	O
on	O
chromosome	O
17	O
.	O

Our	O
results	O
confirm	O
the	O
assignment	O
of	O
the	O
gene	O
for	O
NF2	O
to	O
chromosome	O
22	O
and	O
do	O
not	O
support	O
the	O
hypothesis	O
of	O
genetic	O
heterogeneity	O
.	O

We	O
believe	O
that	O
chromosome	O
22	O
markers	O
can	O
now	O
be	O
used	O
for	O
presymptomatic	O
diagnosis	O
in	O
selected	O
families	O
.	O

The	O
NF2	O
gene	O
is	O
tightly	O
linked	O
to	O
the	O
D22S32	O
locus	O
(	O
maximum	O
lod	O
score	O
4.12	O
;	O
recombination	O
fraction	O
0	O
)	O
.	O

A	O
CA	O
-	O
repeat	O
polymorphism	O
at	O
the	O
CRYB2	O
locus	O
was	O
the	O
most	O
informative	O
marker	O
in	O
our	O
families	O
(	O
lod	O
score	O
5.99	O
)	O
,	O
but	O
because	O
the	O
observed	O
recombination	O
fraction	O
between	O
NF2	O
and	O
CRYB2	O
was	O
10	O
cM	O
,	O
predictions	O
using	O
this	O
marker	O
will	O
need	O
to	O
be	O
interpreted	O
with	O
caution	O
.	O

Mutations	O
have	O
been	O
found	O
in	O
the	O
UBE3A	O
gene	O
(	O
E6	O
-	O
AP	O
ubiquitin	O
protein	O
ligase	O
gene	O
)	O
in	O
many	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
patients	O
with	O
no	O
deletion	O
,	O
no	O
uniparental	O
disomy	O
,	O
and	O
no	O
imprinting	O
defect	O
.	O

UBE3A	O
mutations	O
are	O
more	O
frequent	O
in	O
familial	O
than	O
in	O
sporadic	O
patients	O
and	O
the	O
mutations	O
described	O
so	O
far	O
seem	O
to	O
cause	O
similar	O
phenotypes	O
in	O
the	O
familial	O
affected	O
cases	O
.	O

Here	O
we	O
describe	O
two	O
first	O
cousins	O
who	O
have	O
inherited	O
the	O
same	O
UBE3A	O
frameshift	O
mutation	O
(	O
duplication	O
of	O
GAGG	O
in	O
exon	O
10	O
)	O
from	O
their	O
asymptomatic	O
mothers	O
but	O
present	O
discordant	O
phenotypes	O
.	O

The	O
proband	O
shows	O
typical	O
AS	O
features	O
.	O

Her	O
affected	O
cousin	O
shows	O
a	O
more	O
severe	O
phenotype	O
,	O
with	O
asymmetric	O
spasticity	S-Phenotype
that	O
led	O
originally	O
to	O
a	O
diagnosis	O
of	O
cerebral	B-Phenotype
palsy	E-Phenotype
.	O

Proband	O
's	O
brain	O
MRI	O
shows	O
mild	O
cerebral	B-Phenotype
atrophy	E-Phenotype
while	O
her	O
cousin	O
's	O
brain	O
MRI	O
shows	O
severe	O
brain	B-Phenotype
malformation	E-Phenotype
.	O

This	O
family	O
demonstrates	O
that	O
,	O
although	O
brain	B-Phenotype
malformation	E-Phenotype
is	O
unusual	O
in	O
AS	O
,	O
presence	O
of	O
a	O
brain	O
malformation	O
does	O
not	O
exclude	O
the	O
diagnosis	O
of	O
AS	O
.	O

Also	O
,	O
this	O
UBE3A	O
mutation	O
was	O
transmitted	O
from	O
the	O
cousin	O
's	O
grandfather	O
to	O
only	O
two	O
sisters	O
among	O
eight	O
full	O
siblings	O
,	O
raising	O
the	O
hypothesis	O
of	O
mosaicism	O
for	O
this	O
mutation	O
.	O

Neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
that	O
is	O
characterized	O
by	O
tumors	S-Phenotype
on	O
the	O
vestibular	O
branch	O
of	O
the	O
VIII	O
cranial	O
nerve	O
,	O
but	O
other	O
types	O
of	O
nervous	B-Phenotype
system	I-Phenotype
tumors	E-Phenotype
usually	O
occur	O
as	O
well	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
are	O
well	O
documented	O
for	O
overall	O
NF2	O
disease	O
severity	O
but	O
have	O
not	O
been	O
definitively	O
evaluated	O
for	O
specific	O
types	O
of	O
non	O
-	O
VIII	O
nerve	S-Phenotype
tumors	S-Phenotype
.	O

We	O
evaluated	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
various	O
types	O
of	O
non	O
-	O
VIII	O
nerve	S-Phenotype
tumors	S-Phenotype
in	O
406	O
patients	O
from	O
the	O
population	O
-	O
based	O
United	O
Kingdom	O
NF2	O
registry	O
,	O
using	O
regression	O
models	O
with	O
the	O
additional	O
covariates	O
of	O
current	O
age	O
and	O
type	O
of	O
treatment	O
center	O
(	O
specialty	O
or	O
nonspecialty	O
)	O
.	O

The	O
models	O
also	O
permitted	O
consideration	O
of	O
intrafamilial	O
correlation	O
.	O

We	O
found	O
statistically	O
significant	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
,	O
spinal	B-Phenotype
tumors	E-Phenotype
,	O
and	O
peripheral	B-Phenotype
nerve	I-Phenotype
tumors	E-Phenotype
.	O

People	O
with	O
constitutional	O
NF2	O
missense	O
mutations	O
,	O
splice	O
-	O
site	O
mutations	O
,	O
large	O
deletions	O
,	O
or	O
somatic	O
mosaicism	O
had	O
significantly	O
fewer	O
tumors	S-Phenotype
than	O
did	O
people	O
with	O
constitutional	O
nonsense	O
or	O
frameshift	O
NF2	O
mutations	O
.	O

In	O
addition	O
,	O
there	O
were	O
significant	O
intrafamilial	O
correlations	O
for	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
and	O
spinal	B-Phenotype
tumors	E-Phenotype
,	O
after	O
adjustment	O
for	O
the	O
type	O
of	O
constitutional	O
NF2	O
mutation	O
.	O

The	O
type	O
of	O
constitutional	O
NF2	O
mutation	O
is	O
an	O
important	O
determinant	O
of	O
the	O
number	O
of	O
NF2	O
-	O
associated	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
,	O
spinal	B-Phenotype
tumors	E-Phenotype
,	O
and	O
peripheral	B-Phenotype
nerve	I-Phenotype
tumors	E-Phenotype
.	O

Angelman	O
syndrome	O
is	O
a	O
neurogenetic	O
disorder	O
caused	O
by	O
the	O
loss	O
of	O
function	O
of	O
the	O
imprinted	O
UBE3A	O
gene	O
in	O
15q11	O
-	O
q13	O
.	O

In	O
a	O
small	O
group	O
of	O
patients	O
,	O
the	O
disease	O
is	O
due	O
to	O
an	O
imprinting	O
defect	O
(	O
ID	O
)	O
that	O
silences	O
the	O
maternal	O
UBE3A	O
allele	O
.	O

The	O
presence	O
of	O
a	O
faint	O
maternal	O
band	O
detected	O
by	O
methylation	O
-	O
specific	O
PCR	O
analysis	O
of	O
the	O
SNURF	O
-	O
SNRPN	O
locus	O
in	O
approximately	O
one	O
-	O
third	O
of	O
patients	O
who	O
have	O
an	O
ID	O
but	O
no	O
imprinting	O
center	O
deletion	O
suggested	O
that	O
these	O
patients	O
are	O
mosaics	O
of	O
ID	O
cells	O
and	O
normal	O
cells	O
.	O

In	O
two	O
patients	O
studied	O
,	O
somatic	O
mosaicism	O
was	O
proven	O
by	O
molecular	O
and	O
cellular	O
cloning	O
,	O
respectively	O
.	O

X	O
inactivation	O
studies	O
of	O
cloned	O
fibroblasts	O
from	O
one	O
patient	O
suggest	O
that	O
ID	O
occurred	O
before	O
the	O
blastocyst	O
stage	O
.	O

To	O
quantify	O
the	O
degree	O
of	O
mosaicism	O
,	O
we	O
developed	O
a	O
novel	O
quantitative	O
methylation	O
assay	O
based	O
on	O
real	O
-	O
time	O
PCR	O
.	O

In	O
24	O
patients	O
tested	O
,	O
the	O
percentage	O
of	O
normal	O
cells	O
ranged	O
from	O
<	O
1	O
%	O
to	O
40	O
%	O
.	O

Regression	O
analysis	O
suggests	O
that	O
patients	O
with	O
a	O
higher	O
percentage	O
of	O
normally	O
methylated	O
cells	O
tend	O
to	O
have	O
milder	O
clinical	O
symptoms	O
than	O
patients	O
with	O
a	O
lower	O
percentage	O
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
mosaic	O
imprinting	O
defects	O
in	O
mental	B-Phenotype
retardation	E-Phenotype
is	O
underestimated	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
can	O
result	O
from	O
either	O
a	O
15q11	O
-	O
q13	O
deletion	O
(	O
del	O
)	O
,	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
,	O
imprinting	O
,	O
or	O
UBE3A	O
mutations	O
.	O

Here	O
,	O
we	O
describe	O
the	O
phenotypic	O
and	O
behavioral	O
variability	O
detected	O
in	O
49	O
patients	O
with	O
different	O
classes	O
of	O
deletions	O
and	O
nine	O
patients	O
with	O
UPD	O
.	O

Diagnosis	O
was	O
made	O
by	O
methylation	O
pattern	O
analysis	O
of	O
exon	O
1	O
of	O
the	O
SNRPN	O
-	O
SNURF	O
gene	O
and	O
by	O
microsatellite	O
profiling	O
of	O
loci	O
within	O
and	O
outside	O
the	O
15q11	O
-	O
q13	O
region	O
.	O

There	O
were	O
no	O
major	O
phenotypic	O
differences	O
between	O
the	O
two	O
main	O
classes	O
(	O
BP1	O
-	O
BP3	O
;	O
BP2	O
-	O
BP3	O
)	O
of	O
AS	O
deletion	O
patients	O
,	O
except	O
for	O
the	O
absence	B-Phenotype
of	I-Phenotype
vocalization	E-Phenotype
,	O
more	O
prevalent	O
in	O
patients	O
with	O
BP1	O
-	O
BP3	O
deletions	O
,	O
and	O
for	O
the	O
age	O
of	O
sitting	O
without	O
support	O
,	O
which	O
was	O
lower	O
in	O
patients	O
with	O
BP2	O
-	O
BP3	O
deletions	O
.	O

Our	O
data	O
suggest	O
that	O
gene	O
deletions	O
(	O
NIPA1	O
,	O
NIPA2	O
,	O
CYF1P1	O
,	O
GCP5	O
)	O
mapped	O
to	O
the	O
region	O
between	O
breakpoints	O
BP1	O
and	O
BP2	O
may	O
be	O
involved	O
in	O
the	O
severity	O
of	O
speech	B-Phenotype
impairment	E-Phenotype
,	O
since	O
all	O
BP1	O
-	O
BP3	O
deletion	O
patients	O
showed	O
complete	O
absence	B-Phenotype
of	I-Phenotype
vocalization	E-Phenotype
,	O
while	O
38.1	O
%	O
of	O
the	O
BP2	O
-	O
BP3	O
deletion	O
patients	O
were	O
able	O
to	O
pronounce	O
syllabic	O
sounds	O
,	O
with	O
doubtful	O
meaning	O
.	O

Compared	O
to	O
UPD	O
patients	O
,	O
deletion	O
patients	O
presented	O
a	O
higher	O
incidence	O
of	O
swallowing	B-Phenotype
disorders	E-Phenotype
(	O
73.9	O
%	O
del	O
x	O
22.2	O
%	O
UPD	O
)	O
and	O
hypotonia	S-Phenotype
(	O
73.3	O
%	O
del	O
x	O
28.57	O
%	O
UPD	O
)	O
.	O

In	O
addition	O
,	O
children	O
with	O
UPD	O
showed	O
better	O
physical	O
growth	O
,	O
fewer	O
or	O
no	O
seizures	S-Phenotype
,	O
a	O
lower	O
incidence	O
of	O
microcephaly	S-Phenotype
,	O
less	O
ataxia	S-Phenotype
and	O
higher	O
cognitive	O
skills	O
.	O

As	O
a	O
consequence	O
of	O
their	O
milder	O
or	O
less	O
typical	O
phenotype	O
,	O
AS	O
may	O
remain	O
undiagnosed	O
,	O
leading	O
to	O
an	O
overall	O
underdiagnosis	O
of	O
the	O
disease	O
.	O

To	O
report	O
new	O
ocular	B-Phenotype
manifestations	E-Phenotype
of	O
branchio	O
-	O
oculo	O
-	O
facial	O
(	O
BOF	O
)	O
syndrome	O
.	O

Case	O
report	O
.	O

A	O
10	O
-	O
year	O
-	O
old	O
girl	O
with	O
known	O
BOF	O
syndrome	O
was	O
referred	O
because	O
of	O
a	O
fundus	B-Phenotype
lesion	E-Phenotype
in	O
her	O
left	O
eye	O
.	O

She	O
had	O
undergone	O
excision	O
of	O
a	O
left	S-Phenotype
orbital	B-Phenotype
dermoid	I-Phenotype
cyst	E-Phenotype
at	O
age	O
18	O
months	O
and	O
a	O
branchial	B-Phenotype
cleft	E-Phenotype
fistula	O
from	O
the	O
right	O
side	O
of	O
neck	O
at	O
age	O
4	O
years	O
.	O

Examination	O
disclosed	O
openings	O
of	O
sinus	O
tracts	O
on	O
each	O
side	O
of	O
the	O
nose	O
connecting	O
the	O
lacrimal	O
sac	O
to	O
skin	O
.	O

In	O
the	O
right	O
eye	O
,	O
an	O
iris	B-Phenotype
pigment	I-Phenotype
epithelial	I-Phenotype
cyst	E-Phenotype
was	O
confirmed	O
with	O
ultrasound	O
biomicroscopy	O
.	O

In	O
the	O
left	O
eye	O
,	O
there	O
was	O
a	O
combined	O
hamartoma	B-Phenotype
of	I-Phenotype
the	I-Phenotype
retina	E-Phenotype
and	O
retina	B-Phenotype
pigment	I-Phenotype
epithelium	E-Phenotype
.	O

BOF	O
syndrome	O
can	O
display	O
mild	O
to	O
severe	O
craniofacial	B-Phenotype
,	I-Phenotype
auricular	I-Phenotype
,	I-Phenotype
oral	I-Phenotype
,	I-Phenotype
and	I-Phenotype
ophthalmic	I-Phenotype
anomalies	E-Phenotype
.	O

In	O
this	O
case	O
,	O
the	O
ophthalmic	O
manifestations	O
included	O
lacrimal	B-Phenotype
sac	I-Phenotype
fistula	E-Phenotype
,	O
orbital	B-Phenotype
dermoid	I-Phenotype
cyst	E-Phenotype
,	O
iris	B-Phenotype
pigment	I-Phenotype
epithelial	I-Phenotype
cyst	E-Phenotype
,	O
and	O
combined	O
hamartoma	B-Phenotype
of	I-Phenotype
the	I-Phenotype
retina	E-Phenotype
and	O
retinal	B-Phenotype
pigment	I-Phenotype
epithelium	E-Phenotype
.	O

A	O
four	O
generation	O
autosomal	O
dominant	O
pedigree	O
of	O
brachydactyly	S-Phenotype
type	O
C	O
is	O
presented	O
with	O
its	O
radiological	O
features	O
.	O

The	O
hands	O
and	O
feet	O
were	O
similarly	O
affected	O
.	O

All	O
the	O
subjects	O
showing	O
these	O
changes	O
had	O
shortening	B-Phenotype
of	I-Phenotype
the	I-Phenotype
big	I-Phenotype
toes	E-Phenotype
and	O
,	O
in	O
addition	O
,	O
had	O
cupped	B-Phenotype
ears	E-Phenotype
.	O

Neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
patients	O
with	O
constitutional	O
splice	O
site	O
NF2	O
mutations	O
have	O
greater	O
variability	O
in	O
disease	O
severity	O
than	O
NF2	O
patients	O
with	O
other	O
types	O
of	O
mutations	O
;	O
the	O
cause	O
of	O
this	O
variability	O
is	O
unknown	O
.	O

We	O
evaluated	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
with	O
particular	O
focus	O
on	O
the	O
location	O
of	O
splice	O
site	O
mutations	O
,	O
using	O
mutation	O
and	O
clinical	O
information	O
on	O
831	O
patients	O
from	O
528	O
NF2	O
families	O
with	O
identified	O
constitutional	O
NF2	O
mutations	O
.	O

The	O
clinical	O
characteristics	O
examined	O
were	O
age	O
at	O
onset	O
of	O
symptoms	O
of	O
NF2	O
and	O
number	O
of	O
intracranial	B-Phenotype
meningiomas	E-Phenotype
,	O
which	O
are	O
the	O
primary	O
indices	O
of	O
the	O
severity	O
of	O
NF2	O
.	O

Two	O
regression	O
models	O
were	O
used	O
to	O
analyse	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

People	O
with	O
splice	O
site	O
mutations	O
in	O
exons	O
1	O
-	O
5	O
had	O
more	O
severe	O
disease	O
than	O
those	O
with	O
splice	O
site	O
mutations	O
in	O
exons	O
11	O
-	O
15	O
.	O

This	O
result	O
is	O
compatible	O
with	O
studies	O
showing	O
that	O
exons	O
2	O
and	O
3	O
are	O
required	O
for	O
self	O
-	O
association	O
of	O
the	O
amino	O
terminal	O
of	O
the	O
NF2	O
protein	O
in	O
vitro	O
,	O
and	O
that	O
deletions	O
of	O
exons	O
2	O
and	O
3	O
in	O
transgenic	O
and	O
knockout	O
mouse	O
models	O
of	O
NF2	O
cause	O
a	O
high	O
prevalence	O
of	O
Schwann	B-Phenotype
cell	I-Phenotype
derived	I-Phenotype
tumours	E-Phenotype
.	O

Two	O
sibs	O
with	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
are	O
reported	O
.	O

They	O
both	O
have	O
orbital	B-Phenotype
haemangiomatous	I-Phenotype
cysts	E-Phenotype
,	O
which	O
is	O
a	O
previously	O
unreported	O
feature	O
.	O

Both	O
parents	O
are	O
clinically	O
normal	O
and	O
unrelated	O
.	O

This	O
disorder	O
has	O
been	O
reported	O
showing	O
autosomal	O
dominant	O
transmission	O
so	O
this	O
family	O
could	O
represent	O
either	O
an	O
autosomal	O
recessive	O
form	O
or	O
germline	O
mosaicism	O
for	O
the	O
dominant	O
gene	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
neurogenetic	O
disorder	O
characterized	O
by	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
speech	B-Phenotype
disorder	E-Phenotype
,	O
stereotyped	B-Phenotype
jerky	I-Phenotype
movements	E-Phenotype
,	O
and	O
a	O
peculiar	O
behavioral	B-Phenotype
profile	E-Phenotype
,	O
with	O
a	O
happy	B-Phenotype
disposition	E-Phenotype
and	O
outbursts	B-Phenotype
of	I-Phenotype
laughter	E-Phenotype
.	O

Most	O
patients	O
with	O
AS	O
present	O
with	O
epilepsy	S-Phenotype
and	O
suggestive	O
electroencephalographic	B-Phenotype
patterns	E-Phenotype
,	O
which	O
may	O
be	O
used	O
as	O
diagnostic	O
criteria	O
.	O

To	O
study	O
epilepsy	S-Phenotype
and	O
response	O
to	O
treatment	O
in	O
a	O
series	O
of	O
patients	O
with	O
AS	O
determined	O
by	O
deletion	O
.	O

Parent	O
and	O
caregiver	O
interview	O
and	O
medical	O
record	O
review	O
.	O

Epilepsy	S-Phenotype
Center	O
at	O
the	O
University	O
of	O
S√£o	O
Paulo	O
.	O

Nineteen	O
patients	O
with	O
AS	O
determined	O
by	O
deletion	O
of	O
chromosome	O
15q11	O
-	O
13	O
.	O

Epilepsy	S-Phenotype
severity	O
,	O
epilepsy	S-Phenotype
evolution	O
,	O
and	O
response	O
to	O
antiepileptic	O
drug	O
treatment	O
.	O

All	O
patients	O
with	O
AS	O
in	O
this	O
group	O
had	O
generalized	O
epilepsy	S-Phenotype
,	O
and	O
10	O
(	O
53	O
%	O
)	O
also	O
had	O
partial	O
epilepsy	O
.	O

Main	O
seizure	S-Phenotype
types	O
were	O
atypical	B-Phenotype
absences	E-Phenotype
and	O
myoclonic	B-Phenotype
and	I-Phenotype
tonic	I-Phenotype
-	I-Phenotype
clonic	E-Phenotype
seizures	S-Phenotype
.	O

Mean	O
age	O
at	O
onset	O
was	O
1	O
year	O
1	O
month	O
.	O

Epilepsy	S-Phenotype
aggravated	O
by	O
fever	S-Phenotype
occurred	O
in	O
10	O
patients	O
(	O
53	O
%	O
)	O
and	O
status	B-Phenotype
epilepticus	E-Phenotype
in	O
16	O
(	O
84	O
%	O
)	O
.	O

Eighteen	O
patients	O
(	O
95	O
%	O
)	O
had	O
previous	O
or	O
current	O
history	O
of	O
daily	O
seizures	S-Phenotype
,	O
of	O
which	O
14	O
(	O
64	O
%	O
)	O
had	O
disabling	O
seizures	O
.	O

Multiple	O
seizure	S-Phenotype
types	O
were	O
observed	O
in	O
13	O
patients	O
(	O
53	O
%	O
)	O
.	O

History	O
of	O
refractory	O
epilepsy	S-Phenotype
was	O
reported	O
in	O
16	O
patients	O
(	O
84	O
%	O
)	O
.	O

Parents	O
reported	O
improvement	O
,	O
characterized	O
by	O
decrease	O
in	O
seizure	S-Phenotype
frequency	O
or	O
seizure	O
control	O
,	O
at	O
the	O
mean	O
age	O
of	O
5.3	O
years	O
.	O

Therefore	O
,	O
most	O
of	O
these	O
patients	O
had	O
a	O
period	O
of	O
refractory	O
epilepsy	S-Phenotype
;	O
however	O
,	O
improvement	O
occurred	O
during	O
late	O
childhood	O
and	O
puberty	O
.	O

The	O
best	O
therapeutic	O
response	O
was	O
obtained	O
with	O
valproic	O
acid	O
alone	O
or	O
in	O
association	O
with	O
phenobarbital	O
or	O
clonazepam	O
.	O

Epilepsy	S-Phenotype
was	O
aggravated	O
by	O
carbamazepine	O
,	O
oxcarbazepine	O
,	O
and	O
vigabatrin	O
.	O

Patients	O
with	O
AS	O
with	O
deletion	O
have	O
epilepsy	S-Phenotype
with	O
early	O
onset	O
and	O
stereotyped	O
electroclinical	B-Phenotype
profile	E-Phenotype
regarding	O
seizure	S-Phenotype
type	O
,	O
severity	O
,	O
and	O
response	O
to	O
antiepileptic	O
drug	O
treatment	O
.	O

Another	O
feature	O
of	O
AS	O
is	O
the	O
age	O
-	O
related	O
improvement	O
,	O
even	O
in	O
refractory	O
cases	O
,	O
during	O
late	O
childhood	O
and	O
puberty	O
.	O

These	O
characteristics	O
are	O
not	O
specific	O
to	O
this	O
syndrome	O
but	O
,	O
when	O
inserted	O
in	O
the	O
proper	O
clinical	O
context	O
,	O
may	O
anticipate	O
diagnosis	O
.	O

We	O
believe	O
that	O
AS	O
should	O
be	O
considered	O
a	O
differential	O
diagnosis	O
in	O
developmentally	B-Phenotype
delayed	E-Phenotype
infants	O
with	O
severe	O
,	O
generalized	O
,	O
cryptogenic	O
epilepsy	S-Phenotype
;	O
however	O
,	O
a	O
proper	O
electroclinical	O
delineation	O
of	O
each	O
genetic	O
group	O
is	O
mandatory	O
.	O

Angelman	O
's	O
syndrome	O
and	O
Prader	O
-	O
Willi	O
syndrome	O
are	O
both	O
causes	O
of	O
mental	B-Phenotype
retardation	E-Phenotype
with	O
recognisable	O
,	O
but	O
quite	O
different	O
,	O
clinical	O
phenotypes	O
.	O

Both	O
are	O
associated	O
with	O
deletions	O
of	O
chromosome	O
15q11	O
-	O
13	O
,	O
of	O
maternal	O
origin	O
in	O
Angelman	O
's	O
and	O
paternal	O
in	O
Prader	O
-	O
Willi	O
.	O

Prader	O
-	O
Willi	O
can	O
arise	O
by	O
inheritance	O
of	O
two	O
chromosomes	O
15	O
from	O
the	O
mother	O
and	O
none	O
from	O
the	O
father	O
(	O
uniparental	O
maternal	O
disomy	O
)	O
.	O

In	O
2	O
patients	O
with	O
Angelman	O
's	O
syndrome	O
we	O
found	O
evidence	O
of	O
uniparental	O
paternal	O
disomy	O
.	O

The	O
phenotypic	O
effects	O
of	O
maternal	O
and	O
paternal	O
disomy	O
of	O
chromosome	O
15	O
are	O
very	O
different	O
and	O
inheritance	O
of	O
two	O
normal	O
15s	O
from	O
one	O
parent	O
does	O
not	O
lead	O
to	O
normal	O
development	O
-	O
-	O
strong	O
evidence	O
in	O
man	O
for	O
genomic	O
imprinting	O
,	O
in	O
which	O
the	O
same	O
gene	O
has	O
different	O
effects	O
dependent	O
upon	O
its	O
parental	O
origin	O
.	O

DNA	O
deletion	O
studies	O
using	O
5	O
DNA	O
markers	O
localized	O
at	O
15q11	O
-	O
q12	O
were	O
performed	O
in	O
14	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
patients	O
(	O
9	O
sporadic	O
and	O
5	O
familial	O
cases	O
)	O
.	O

A	O
one	O
-	O
copy	O
density	O
for	O
one	O
or	O
more	O
of	O
the	O
5	O
loci	O
was	O
detected	O
in	O
8	O
(	O
57.1	O
%	O
)	O
of	O
the	O
14	O
patients	O
.	O

A	O
deletion	O
of	O
only	O
the	O
D15S11	O
locus	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	O
,	O
that	O
involving	O
only	O
the	O
D15S10	O
in	O
3	O
familial	O
patients	O
(	O
sibs	O
in	O
a	O
family	O
)	O
,	O
that	O
spanning	O
3	O
loci	O
(	O
D15S11	O
,	O
D15S10	O
,	O
D15S12	O
)	O
in	O
one	O
sporadic	O
patient	O
,	O
and	O
that	O
spanning	O
4	O
loci	O
(	O
D15S9	O
,	O
D15S11	O
,	O
D15S10	O
,	O
D15S12	O
)	O
in	O
the	O
other	O
3	O
sporadic	O
patients	O
.	O

The	O
deletion	O
common	O
to	O
our	O
patients	O
as	O
well	O
as	O
to	O
the	O
reported	O
patients	O
may	O
be	O
confined	O
to	O
a	O
segment	O
between	O
D15S11	O
and	O
D15S10	O
,	O
if	O
the	O
5	O
loci	O
are	O
ordered	O
as	O
cen	O
-	O
D15S18	O
-	O
(	O
D15S9	O
-	O
D15S11	O
-	O
D15S10	O
)	O
-	O
D15S12	O
-	O
qt	O
er	O
.	O

This	O
site	O
overlaps	O
but	O
is	O
more	O
distal	O
to	O
the	O
common	O
deletion	O
site	O
in	O
Prader	O
-	O
Willi	O
syndrome	O
(	O
PWS	O
)	O
patients	O
.	O

In	O
the	O
family	O
of	O
the	O
3	O
sibs	O
,	O
both	O
of	O
the	O
phenotypically	O
normal	O
mother	O
and	O
maternal	O
grandfather	O
also	O
have	O
deletions	O
of	O
the	O
D15S10	O
locus	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
genomic	O
imprinting	O
hypothesis	O
for	O
the	O
occurrence	O
of	O
AS	O
,	O
i.e.	O
,	O
the	O
lack	O
of	O
a	O
maternally	O
derived	O
locus	O
leads	O
to	O
AS	O
,	O
but	O
may	O
not	O
support	O
a	O
model	O
that	O
AS	O
is	O
the	O
alternative	O
phenotype	O
of	O
PWS	O
at	O
the	O
identical	O
locus	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
A1	E-Phenotype
(	O
BDA1	S-Phenotype
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Indian	O
hedgehog	O
gene	O
,	O
IHH	O
,	O
on	O
chromosome	O
2q35	O
-	O
36	O
.	O

In	O
this	O
study	O
,	O
a	O
large	O
five	O
-	O
generation	O
Chinese	O
family	O
with	O
BDA1	S-Phenotype
was	O
identified	O
and	O
characterized	O
.	O

All	O
affected	O
family	O
members	O
demonstrated	O
significant	O
homogeneous	O
phenotype	O
and	O
some	O
unique	O
clinical	O
features	O
different	O
from	O
those	O
associated	O
with	O
the	O
reported	O
BDA1	S-Phenotype
mutations	O
in	O
IHH	O
.	O

Linkage	O
analysis	O
showed	O
that	O
the	O
BDA1	S-Phenotype
gene	O
in	O
the	O
family	O
was	O
linked	O
to	O
marker	O
D2S126	O
close	O
to	O
IHH	O
with	O
a	O
LOD	O
score	O
of	O
4.74	O
at	O
a	O
recombination	O
fraction	O
of	O
0	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
a	O
heterozygous	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
461	O
of	O
IHH	O
,	O
resulting	O
in	O
a	O
novel	O
T154I	O
substitution	O
.	O

The	O
T154I	O
mutation	O
co	O
-	O
segregated	O
with	O
all	O
affected	O
individuals	O
in	O
the	O
family	O
,	O
and	O
was	O
not	O
present	O
in	O
normal	O
family	O
members	O
or	O
200	O
normal	O
controls	O
.	O

These	O
results	O
expand	O
the	O
spectrum	O
of	O
clinical	O
phenotype	O
associated	O
with	O
IHH	O
mutations	O
.	O

Heterozygous	O
missense	O
mutations	O
in	O
the	O
serine	O
-	O
threonine	O
kinase	O
receptor	O
BMPR1B	O
result	O
typically	O
in	O
brachydactyly	B-Phenotype
type	I-Phenotype
A2	I-Phenotype
(	E-Phenotype
BDA2	B-Phenotype
)	E-Phenotype
,	O
whereas	O
mutations	O
in	O
the	O
corresponding	O
ligand	O
GDF5	O
cause	O
brachydactyly	O
type	O
C	O
(	O
BDC	S-Phenotype
)	O
.	O

Mutations	O
in	O
the	O
GDF	O
inhibitor	O
Noggin	O
(	O
NOG	O
)	O
or	O
activating	O
mutations	O
in	O
GDF5	O
cause	O
proximal	B-Phenotype
symphalangism	E-Phenotype
(	O
SYM1	S-Phenotype
)	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
mutation	O
in	O
BMPR1B	O
(	O
R486Q	O
)	O
that	O
is	O
associated	O
with	O
either	O
BDA2	S-Phenotype
or	O
a	O
BDC	S-Phenotype
/	O
SYM1	B-Phenotype
-	I-Phenotype
like	E-Phenotype
phenotype	O
.	O

Functional	O
investigations	O
of	O
the	O
R486Q	O
mutation	O
were	O
performed	O
and	O
compared	O
with	O
the	O
previously	O
reported	O
BDA2	S-Phenotype
-	O
causing	O
mutation	O
R486W	O
and	O
WT	O
BMPR1B	O
.	O

Overexpression	O
of	O
the	O
mutant	O
receptors	O
in	O
chicken	O
micromass	O
cultures	O
resulted	O
in	O
a	O
strong	O
inhibition	O
of	O
chondrogenesis	O
with	O
the	O
R486Q	O
mutant	O
,	O
showing	O
a	O
stronger	O
effect	O
than	O
the	O
R486W	O
mutant	O
.	O

To	O
investigate	O
the	O
consequences	O
of	O
the	O
BMPR1B	O
mutations	O
on	O
the	O
intracellular	O
signal	O
transduction	O
,	O
we	O
used	O
stably	O
transfected	O
C2C12	O
cells	O
and	O
measured	O
the	O
activity	O
of	O
SMAD	O
-	O
dependent	O
and	O
SMAD	O
-	O
independent	O
pathways	O
.	O

SMAD	O
activation	O
after	O
stimulation	O
with	O
GDF5	O
was	O
suppressed	O
in	O
both	O
mutants	O
.	O

Alkaline	O
phosphatase	O
induction	O
showed	O
an	O
almost	O
complete	O
loss	O
of	O
activation	O
by	O
both	O
mutants	O
.	O

Our	O
data	O
extend	O
the	O
previously	O
known	O
mutational	O
and	O
phenotypic	O
spectrum	O
associated	O
with	O
mutations	O
in	O
BMPR1B	O
.	O

Disturbances	O
of	O
NOG	O
-	O
GDF5	O
-	O
BMPR1B	O
signaling	O
cascade	O
can	O
result	O
in	O
similar	O
clinical	O
manifestations	O
depending	O
on	O
the	O
quantitative	O
effect	O
and	O
mode	O
of	O
action	O
of	O
the	O
specific	O
mutations	O
within	O
the	O
same	O
functional	O
pathway	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
is	O
almost	O
unique	O
among	O
inherited	O
disorders	O
in	O
the	O
frequency	O
of	O
mosaicism	O
in	O
the	O
first	O
affected	O
generation	O
.	O

However	O
,	O
the	O
implications	O
of	O
this	O
on	O
transmission	O
risks	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

The	O
expanded	O
database	O
of	O
460	O
families	O
with	O
NF2	O
and	O
704	O
affected	O
individuals	O
was	O
analysed	O
for	O
mosaicism	O
and	O
transmission	O
risks	O
to	O
offspring	O
.	O

64	O
mosaic	O
patients	O
,	O
with	O
a	O
projected	O
mosaicism	O
rate	O
of	O
33	O
%	O
for	O
sporadic	O
classical	O
NF2	O
with	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannoma	E-Phenotype
at	O
presentation	O
and	O
60	O
%	O
for	O
those	O
presenting	O
unilaterally	O
,	O
were	O
identified	O
.	O

Offspring	O
risks	O
can	O
be	O
radically	O
reduced	O
on	O
the	O
basis	O
of	O
a	O
sensitive	O
mutation	O
analysis	O
of	O
blood	O
DNA	O
including	O
multiple	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
,	O
which	O
detects	O
15	O
%	O
of	O
all	O
mutations	O
)	O
,	O
but	O
even	O
MLPA	O
can	O
not	O
detect	O
high	O
levels	O
of	O
mosaicism	O
.	O

The	O
chances	O
of	O
mosaicism	O
in	O
NF2	O
and	O
the	O
resultant	O
risks	O
of	O
transmission	O
of	O
the	O
mutation	O
to	O
offspring	O
in	O
a	O
number	O
of	O
different	O
clinical	O
situations	O
have	O
been	O
further	O
delineated	O
.	O

The	O
use	O
of	O
MLPA	O
in	O
this	O
large	O
NF2	O
series	O
is	O
also	O
reported	O
for	O
the	O
first	O
time	O
.	O

To	O
gain	O
insight	O
into	O
the	O
pathogenesis	O
of	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
by	O
investigating	O
the	O
ocular	B-Phenotype
manifestations	E-Phenotype
of	O
this	O
disease	O
.	O

Using	O
standard	O
histologic	O
techniques	O
,	O
immunohistochemistry	O
,	O
and	O
electron	O
microscopy	O
,	O
we	O
described	O
the	O
ocular	B-Phenotype
pathologic	I-Phenotype
findings	E-Phenotype
of	O
a	O
34	O
-	O
year	O
-	O
old	O
woman	O
who	O
died	O
from	O
complications	O
of	O
NF2	O
.	O

We	O
identified	O
3	O
types	O
of	O
NF2	O
-	O
associated	O
lesions	O
:	O
juvenile	O
posterior	B-Phenotype
subcapsular	I-Phenotype
cataracts	E-Phenotype
,	O
epiretinal	B-Phenotype
membranes	E-Phenotype
,	O
and	O
an	O
intrascleral	B-Phenotype
schwannoma	E-Phenotype
.	O

Our	O
analysis	O
indicated	O
that	O
dysplastic	O
lens	O
cells	O
accumulate	O
just	O
anterior	O
to	O
the	O
posterior	O
lens	O
capsule	O
in	O
juvenile	O
posterior	B-Phenotype
subcapsular	I-Phenotype
cataracts	E-Phenotype
and	O
that	O
dysplastic	O
M√ºller	O
cells	O
may	O
be	O
a	O
major	O
component	O
of	O
NF2	O
-	O
associated	O
epiretinal	B-Phenotype
membranes	E-Phenotype
.	O

Clinical	O
Relevance	O
Our	O
findings	O
suggest	O
that	O
a	O
subset	O
of	O
glial	O
cells	O
with	O
epithelial	O
features	O
(	O
Schwann	O
cells	O
,	O
ependymal	O
cells	O
,	O
and	O
M√ºller	O
cells	O
)	O
may	O
be	O
particularly	O
sensitive	O
to	O
loss	O
of	O
the	O
NF2	O
gene	O
.	O

Understanding	O
the	O
molecular	O
basis	O
for	O
this	O
sensitivity	O
may	O
lead	O
to	O
novel	O
strategies	O
for	O
treating	O
NF2	O
.	O

We	O
report	O
on	O
wide	O
phenotypic	O
variations	O
within	O
a	O
family	O
with	O
SALL1	O
mutations	O
;	O
the	O
elder	O
sister	O
presented	O
with	O
a	O
Townes	O
-	O
Brocks	O
syndrome	O
phenotype	O
including	O
external	B-Phenotype
ear	I-Phenotype
anomalies	E-Phenotype
,	O
preaxial	B-Phenotype
polydactyly	E-Phenotype
,	O
and	O
anteriorly	B-Phenotype
placed	I-Phenotype
anus	E-Phenotype
,	O
whereas	O
the	O
younger	O
sister	O
presented	O
with	O
a	O
phenotype	O
resembling	O
Goldenhar	O
syndrome	O
,	O
including	O
atretic	B-Phenotype
ear	I-Phenotype
canals	E-Phenotype
,	O
mandibular	B-Phenotype
hypoplasia	E-Phenotype
,	O
and	O
right	O
preaxial	O
polydactyly	O
as	O
well	O
as	O
an	O
epibulbar	B-Phenotype
dermoid	E-Phenotype
.	O

The	O
mother	O
had	O
abnormal	O
external	O
ears	O
but	O
was	O
otherwise	O
structurally	O
normal	O
,	O
and	O
the	O
father	O
was	O
asymptomatic	O
.	O

Analysis	O
of	O
the	O
SALL1	O
gene	O
revealed	O
that	O
both	O
daughters	O
were	O
heterozygous	O
for	O
nonsense	O
mutation	O
1256T	O
>	O
A	O
(	O
L419X	O
)	O
,	O
that	O
is	O
present	O
5	O
'	O
to	O
the	O
region	O
encoding	O
the	O
first	O
double	O
zinc	O
finger	O
.	O

The	O
mother	O
was	O
heterozygous	O
for	O
the	O
L419X	O
mutation	O
.	O

The	O
younger	O
daughter	O
is	O
the	O
first	O
patient	O
with	O
a	O
SALL1	O
mutation	O
to	O
exhibit	O
a	O
classic	O
Goldenhar	O
syndrome	O
-	O
like	O
phenotype	O
with	O
an	O
epibulbar	B-Phenotype
dermoid	E-Phenotype
.	O

The	O
observation	O
lends	O
further	O
support	O
to	O
the	O
concept	O
that	O
Goldenhar	O
syndrome	O
is	O
an	O
etiologically	O
heterogeneous	O
disorder	O
that	O
may	O
have	O
a	O
genetic	O
basis	O
in	O
some	O
cases	O
.	O

We	O
studied	O
two	O
families	O
with	O
an	O
unusual	O
variant	O
of	O
neurofibromatosis	S-Phenotype
(	O
NF	O
)	O
.	O

The	O
first	O
family	O
had	O
spinal	B-Phenotype
neurofibromas	E-Phenotype
and	O
caf√©	B-Phenotype
au	I-Phenotype
lait	I-Phenotype
spots	I-Phenotype
(	I-Phenotype
CLS	I-Phenotype
)	E-Phenotype
,	O
the	O
second	O
spinal	O
neurofibromas	O
without	O
CLS	O
.	O

Other	O
signs	O
of	O
NF1	O
or	O
NF2	O
,	O
such	O
as	O
cutaneous	B-Phenotype
tumors	E-Phenotype
,	O
Lisch	B-Phenotype
nodules	E-Phenotype
,	O
or	O
acoustic	B-Phenotype
tumors	E-Phenotype
,	O
were	O
absent	O
.	O

The	O
inheritance	O
pattern	O
in	O
both	O
pedigrees	O
was	O
consistent	O
with	O
autosomal	O
dominant	O
inheritance	O
.	O

Using	O
genetic	O
linkage	O
analysis	O
with	O
DNA	O
markers	O
tightly	O
linked	O
to	O
the	O
NF1	O
and	O
NF2	O
loci	O
,	O
we	O
determined	O
that	O
the	O
likely	O
location	O
for	O
the	O
mutation	O
in	O
the	O
first	O
family	O
was	O
in	O
the	O
NF1	O
gene	O
with	O
odds	O
of	O
97:1	O
,	O
whereas	O
the	O
mutation	O
in	O
the	O
second	O
family	O
was	O
excluded	O
from	O
the	O
NF1	O
locus	O
with	O
odds	O
greater	O
than	O
100,000:1	O
.	O

Families	O
such	O
as	O
these	O
,	O
in	O
which	O
a	O
defined	O
subset	O
of	O
the	O
NF	O
phenotype	O
is	O
passed	O
on	O
,	O
are	O
important	O
for	O
understanding	O
the	O
functional	O
consequences	O
of	O
particular	O
mutations	O
in	O
the	O
NF	O
genes	O
.	O

Mutations	O
in	O
SALL1	O
and	O
GLI3	O
are	O
responsible	O
for	O
human	O
limb	B-Phenotype
malformation	E-Phenotype
syndromes	O
.	O

The	O
molecular	O
pathophysiology	O
of	O
these	O
mutations	O
is	O
incompletely	O
understood	O
,	O
and	O
many	O
conclusions	O
have	O
been	O
drawn	O
from	O
studies	O
performed	O
in	O
the	O
mouse	O
.	O

We	O
identified	O
truncating	O
mutations	O
in	O
SALL1	O
and	O
GLI3	O
in	O
patients	O
with	O
limb	B-Phenotype
malformation	E-Phenotype
and	O
studied	O
the	O
contribution	O
of	O
nonsense	O
-	O
mediated	O
decay	O
(	O
NMD	O
)	O
to	O
the	O
expression	O
of	O
mutant	O
mRNA	O
in	O
patient	O
-	O
derived	O
fibroblasts	O
.	O

Quantification	O
of	O
the	O
relative	O
proportions	O
of	O
mutant	O
and	O
wild	O
-	O
type	O
alleles	O
was	O
performed	O
by	O
pyrosequencing	O
.	O

In	O
SALL1	O
,	O
a	O
mutant	O
allele	O
causing	O
Townes	O
-	O
Brocks	O
syndrome	O
was	O
unexpectedly	O
resistant	O
to	O
NMD	O
,	O
whereas	O
a	O
different	O
mutation	O
causing	O
a	O
much	O
milder	O
phenotype	O
was	O
susceptible	O
to	O
NMD	O
.	O

In	O
GLI3	O
,	O
all	O
three	O
mutant	O
alleles	O
tested	O
were	O
susceptible	O
to	O
NMD	O
.	O

This	O
work	O
provides	O
novel	O
insights	O
into	O
the	O
molecular	O
pathophysiology	O
of	O
SALL1	O
and	O
GLI3	O
mutations	O
,	O
extends	O
the	O
phenotypic	O
spectrum	O
of	O
SALL1	O
mutations	O
,	O
and	O
provides	O
an	O
example	O
of	O
a	O
human	O
mutation	O
which	O
does	O
not	O
follow	O
the	O
usual	O
accepted	O
positional	O
rules	O
governing	O
mammalian	O
NMD	O
.	O

(	O
c	O
)	O
2007	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	O
syndrome	O
(	O
BOR	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
the	O
association	O
of	O
branchial	B-Phenotype
and	I-Phenotype
external	I-Phenotype
ear	I-Phenotype
malformations	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
renal	B-Phenotype
anomalies	E-Phenotype
.	O

The	O
phenotype	O
varies	O
from	O
ear	B-Phenotype
pits	E-Phenotype
to	O
profound	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
branchial	S-Phenotype
fistulae	O
,	O
and	O
kidney	B-Phenotype
agenesis	E-Phenotype
.	O

The	O
most	O
common	O
gene	O
mutated	O
in	O
BOR	O
families	O
is	O
EYA1	O
,	O
a	O
transcriptional	O
activator	O
.	O

Over	O
80	O
different	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
published	O
(	O
www.healthcare.uiowa.edu	O
/	O
labs	O
/	O
pendredandbor	O
/	O
,	O
last	O
accessed	O
20	O
November	O
2007	O
)	O
.	O

We	O
analyzed	O
the	O
EYA1	O
coding	O
region	O
(	O
16	O
exons	O
)	O
from	O
435	O
families	O
(	O
345	O
at	O
the	O
University	O
of	O
Iowa	O
[	O
UI	O
]	O
and	O
95	O
at	O
Boys	O
Town	O
National	O
Research	O
Hospital	O
[	O
BTNRH	O
]	O
,	O
including	O
five	O
at	O
both	O
)	O
and	O
found	O
70	O
different	O
EYA1	O
mutations	O
in	O
89	O
families	O
.	O

Most	O
of	O
the	O
mutations	O
(	O
56	O
/	O
70	O
)	O
were	O
private	O
.	O

EYA1	O
mutations	O
were	O
found	O
in	O
31	O
%	O
of	O
families	O
(	O
76	O
/	O
248	O
)	O
fitting	O
established	O
clinical	O
criteria	O
for	O
BOR	O
and	O
7	O
%	O
of	O
families	O
with	O
questionable	O
BOR	O
phenotype	O
(	O
13	O
/	O
187	O
)	O
.	O

Severity	O
of	O
the	O
phenotype	O
did	O
not	O
correlate	O
with	O
type	O
of	O
mutation	O
nor	O
with	O
the	O
domain	O
involved	O
.	O

These	O
results	O
add	O
considerably	O
to	O
the	O
spectrum	O
of	O
EYA1	O
mutations	O
associated	O
with	O
BOR	O
and	O
indicate	O
that	O
the	O
BOR	O
phenotype	O
is	O
an	O
indication	O
for	O
molecular	O
studies	O
to	O
diagnose	O
EYA1	O
-	O
associated	O
BOR	O
.	O

Growth	O
/	O
differentiation	O
factor	O
5	O
(	O
GDF5	O
)	O
is	O
a	O
secreted	O
growth	O
factor	O
that	O
plays	O
a	O
key	O
regulatory	O
role	O
in	O
embryonic	O
skeletal	O
and	O
joint	O
development	O
.	O

Mutations	O
in	O
the	O
GDF5	O
gene	O
can	O
cause	O
different	O
types	O
of	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
including	O
brachydactyly	S-Phenotype
type	O
C	O
(	O
BDC	S-Phenotype
)	O
and	O
proximal	B-Phenotype
symphalangism	E-Phenotype
(	O
SYM1	O
)	O
.	O

We	O
report	O
two	O
novel	O
mutations	O
in	O
the	O
GDF5	O
gene	O
in	O
Chinese	O
families	O
with	O
distinct	O
limb	B-Phenotype
malformations	E-Phenotype
.	O

In	O
one	O
family	O
affected	O
with	O
BDC	S-Phenotype
,	O
we	O
identified	O
a	O
novel	O
nonsense	O
mutation	O
,	O
c.1461T	O
>	O
G	O
(	O
p.Y487X	O
)	O
,	O
which	O
is	O
predicted	O
to	O
truncate	O
the	O
GDF5	O
precursor	O
protein	O
by	O
deleting	O
15	O
amino	O
acids	O
at	O
its	O
C	O
-	O
terminus	O
.	O

In	O
one	O
family	O
with	O
SYM1	O
,	O
we	O
found	O
a	O
novel	O
missense	O
mutation	O
,	O
c.1118T	O
>	O
G	O
(	O
p.L373R	O
)	O
,	O
which	O
changes	O
a	O
highly	O
conserved	O
amino	O
acid	O
in	O
the	O
prodomain	O
of	O
GDF5	O
.	O

We	O
transfected	O
COS	O
-	O
7	O
cells	O
with	O
retroviral	O
constructs	O
to	O
express	O
human	O
wild	O
-	O
type	O
or	O
mutant	O
GDF5	O
cDNAs	O
.	O

The	O
mature	O
GDF5	O
protein	O
was	O
detected	O
,	O
as	O
in	O
the	O
wild	O
-	O
type	O
,	O
in	O
supernatant	O
derived	O
from	O
the	O
p.L373R	O
mutant	O
GDF5	O
transfected	O
cells	O
,	O
but	O
not	O
in	O
the	O
supernatant	O
from	O
the	O
p.Y487X	O
mutant	O
transfected	O
cells	O
,	O
indicating	O
that	O
the	O
two	O
mutations	O
led	O
to	O
different	O
fates	O
of	O
the	O
mutant	O
GDF5	O
proteins	O
,	O
thereby	O
producing	O
distinct	O
limb	O
phenotypes	O
.	O

Naevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
is	O
a	O
pleiotropic	O
,	O
autosomal	O
dominant	O
disease	O
.	O

Growing	O
evidence	O
suggests	O
that	O
the	O
disorder	O
may	O
result	O
from	O
mutations	O
in	O
genes	O
of	O
the	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
signalling	O
pathway	O
.	O

To	O
investigate	O
the	O
pathogenic	O
gene	O
in	O
a	O
Chinese	O
Han	O
family	O
with	O
NBCCS	O
.	O

Mapping	O
and	O
mutation	O
screening	O
were	O
used	O
to	O
investigate	O
the	O
candidate	O
genes	O
SHH	O
,	O
PTCH	O
,	O
PTCH2	O
and	O
SMO	O
.	O

A	O
GLI1	O
reporter	O
gene	O
and	O
a	O
cell	O
growth	O
curve	O
were	O
used	O
to	O
examine	O
functional	O
consequences	O
of	O
the	O
detected	O
mutant	O
.	O

One	O
novel	O
mutation	O
,	O
a	O
G	O
-	O
-	O
>	O
A	O
transition	O
(	O
2157G	O
-	O
-	O
>	O
A	O
)	O
in	O
exon	O
15	O
of	O
the	O
PTCH2	O
gene	O
,	O
was	O
identified	O
in	O
this	O
family	O
with	O
NBCCS	O
by	O
direct	O
sequencing	O
and	O
digestion	O
with	O
the	O
AvaI	O
restriction	O
enzyme	O
.	O

The	O
mutation	O
was	O
not	O
found	O
in	O
normal	O
family	O
members	O
or	O
in	O
520	O
controls	O
.	O

The	O
mutation	O
led	O
to	O
an	O
R719Q	O
amino	O
acid	O
substitution	O
in	O
an	O
extracellular	O
loop	O
of	O
the	O
PTCH2	O
protein	O
.	O

Functional	O
studies	O
revealed	O
that	O
the	O
R719Q	O
mutation	O
resulted	O
in	O
inactivation	O
of	O
PTCH2	O
inhibitory	O
activities	O
.	O

In	O
contrast	O
to	O
wild	O
type	O
PTCH2	O
,	O
PTCH2	O
-	O
R719Q	O
could	O
not	O
inhibit	O
cell	O
proliferation	O
.	O

PTCH2	O
(	O
2157G	O
-	O
-	O
>	O
A	O
)	O
,	O
a	O
novel	O
missense	O
mutation	O
,	O
underlies	O
NBCCS	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
PTCH2	O
inhibitory	O
function	O
in	O
the	O
Shh	O
signalling	O
pathway	O
.	O

Branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
(	O
BOFS	O
)	O
is	O
a	O
rare	O
autosomal	O
-	O
dominant	O
cleft	B-Phenotype
palate	E-Phenotype
-	O
craniofacial	B-Phenotype
disorder	E-Phenotype
with	O
variable	O
expressivity	O
.	O

The	O
major	O
features	O
include	O
cutaneous	B-Phenotype
anomalies	E-Phenotype
(	O
cervical	O
,	O
infra	B-Phenotype
-	I-Phenotype
and	I-Phenotype
/	I-Phenotype
or	I-Phenotype
supra	I-Phenotype
-	I-Phenotype
auricular	I-Phenotype
defects	E-Phenotype
,	O
often	O
with	O
dermal	O
thymus	O
)	O
,	O
ocular	B-Phenotype
anomalies	E-Phenotype
,	O
characteristic	O
facial	B-Phenotype
appearance	E-Phenotype
(	O
malformed	B-Phenotype
pinnae	E-Phenotype
,	O
oral	B-Phenotype
clefts	E-Phenotype
)	O
,	O
and	O
,	O
less	O
commonly	O
,	O
renal	B-Phenotype
and	I-Phenotype
ectodermal	I-Phenotype
(	I-Phenotype
dental	I-Phenotype
and	I-Phenotype
hair	I-Phenotype
)	I-Phenotype
anomalies	E-Phenotype
.	O

The	O
molecular	O
basis	O
for	O
this	O
disorder	O
is	O
heretofore	O
unknown	O
.	O

We	O
detected	O
a	O
3.2	O
Mb	O
deletion	O
by	O
500K	O
SNP	O
microarray	O
in	O
an	O
affected	O
mother	O
and	O
son	O
with	O
BOFS	O
at	O
chromosome	O
6p24.3	O
.	O

Candidate	O
genes	O
in	O
this	O
region	O
were	O
selected	O
for	O
sequencing	O
on	O
the	O
basis	O
of	O
their	O
expression	O
patterns	O
and	O
involvement	O
in	O
developmental	O
pathways	O
associated	O
with	O
the	O
clinical	O
findings	O
of	O
BOFS	O
.	O

Four	O
additional	O
BOFS	O
patients	O
were	O
found	O
to	O
have	O
de	O
novo	O
missense	O
mutations	O
in	O
the	O
highly	O
conserved	O
exons	O
4	O
and	O
5	O
(	O
basic	O
region	O
of	O
the	O
DNA	O
binding	O
domain	O
)	O
of	O
the	O
TFAP2A	O
gene	O
in	O
the	O
candidate	O
deleted	O
region	O
.	O

We	O
conclude	O
BOFS	O
is	O
caused	O
by	O
mutations	O
involving	O
TFAP2A	O
.	O

More	O
patients	O
need	O
to	O
be	O
studied	O
to	O
determine	O
possible	O
genetic	O
heterogeneity	O
and	O
to	O
establish	O
whether	O
there	O
are	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
(	O
PPS	O
)	O
and	O
Van	O
der	O
Woude	O
syndrome	O
(	O
VWS	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
interferon	O
regulatory	O
factor	O
6	O
(	O
IRF6	O
)	O
.	O

Skeletal	B-Phenotype
,	I-Phenotype
genital	I-Phenotype
malformations	E-Phenotype
and	O
involvement	B-Phenotype
of	I-Phenotype
the	I-Phenotype
skin	E-Phenotype
occur	O
in	O
PPS	O
and	O
orofacial	B-Phenotype
clefting	E-Phenotype
and	O
lip	B-Phenotype
pits	E-Phenotype
occur	O
in	O
both	O
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
unilateral	B-Phenotype
cleft	I-Phenotype
lip	I-Phenotype
and	I-Phenotype
palate	E-Phenotype
,	O
ankyloblepharon	S-Phenotype
,	O
paramedian	B-Phenotype
lip	I-Phenotype
pits	E-Phenotype
,	O
unilateral	B-Phenotype
renal	I-Phenotype
aplasia	E-Phenotype
,	O
and	O
a	O
coronal	S-Phenotype
hypospadias	S-Phenotype
.	O

By	O
sequencing	O
IRF6	O
,	O
we	O
detected	O
a	O
novel	O
missense	O
mutation	O
(	O
Arg339Ile	O
)	O
.	O

The	O
other	O
family	O
members	O
were	O
unaffected	O
and	O
had	O
no	O
IRF6	O
mutations	O
,	O
including	O
the	O
patient	O
's	O
brother	O
who	O
was	O
also	O
born	O
with	O
hypospadias	S-Phenotype
.	O

The	O
patient	O
and	O
his	O
brother	O
were	O
both	O
conceived	O
by	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
.	O

It	O
is	O
discussed	O
whether	O
the	O
renal	B-Phenotype
malformation	E-Phenotype
in	O
the	O
patient	O
is	O
related	O
to	O
the	O
IVF	O
procedure	O
or	O
to	O
the	O
IRF6	O
mutation	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
A1	E-Phenotype
is	O
a	O
limb	B-Phenotype
malformation	E-Phenotype
characterized	O
by	O
a	O
uniform	O
shortening	B-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
phalanges	I-Phenotype
in	I-Phenotype
all	I-Phenotype
digits	E-Phenotype
.	O

Mutations	O
in	O
the	O
Indian	O
hedgehog	O
(	O
IHH	O
)	O
gene	O
were	O
shown	O
to	O
be	O
the	O
cause	O
of	O
this	O
autosomal	O
dominant	O
disorder	O
.	O

The	O
IHH	O
protein	O
is	O
known	O
to	O
be	O
an	O
important	O
signaling	O
molecule	O
involved	O
in	O
chondrocyte	O
formation	O
.	O

So	O
far	O
,	O
only	O
missense	O
mutations	O
in	O
IHH	O
have	O
been	O
reported	O
to	O
cause	O
BrachydactylyA1	O
.	O

We	O
report	O
here	O
on	O
the	O
first	O
deletion	O
in	O
IHH	O
,	O
p.delE95	O
,	O
causing	O
mild	O
BrachydactylyA1	O
in	O
a	O
small	O
Dutch	O
family	O
.	O

This	O
brings	O
the	O
total	O
number	O
of	O
different	O
mutations	O
found	O
to	O
cause	O
BDA1	O
to	O
7	O
.	O

Angelman	O
syndrome	O
is	O
a	O
neurological	B-Phenotype
disorder	E-Phenotype
whose	O
symptoms	O
include	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
loss	B-Phenotype
of	I-Phenotype
motor	I-Phenotype
coordination	E-Phenotype
,	O
and	O
sleep	B-Phenotype
disturbances	E-Phenotype
.	O

The	O
disease	O
is	O
caused	O
by	O
a	O
loss	O
of	O
function	O
of	O
UBE3A	O
,	O
which	O
encodes	O
a	O
HECT	O
-	O
domain	O
ubiquitin	O
ligase	O
.	O

Here	O
,	O
we	O
generate	O
a	O
Drosophila	O
model	O
for	O
the	O
disease	O
.	O

The	O
results	O
of	O
several	O
experiments	O
show	O
that	O
the	O
functions	O
of	O
human	O
UBE3A	O
and	O
its	O
fly	O
counterpart	O
,	O
dube3a	O
,	O
are	O
similar	O
.	O

First	O
,	O
expression	O
of	O
Dube3a	O
is	O
enriched	O
in	O
the	O
Drosophila	O
nervous	O
system	O
,	O
including	O
mushroom	O
bodies	O
,	O
the	O
seat	O
of	O
learning	O
and	O
memory	O
.	O

Second	O
,	O
we	O
have	O
generated	O
dube3a	O
null	O
mutants	O
,	O
and	O
they	O
appear	O
normal	O
externally	O
,	O
but	O
display	O
abnormal	O
locomotive	O
behavior	O
and	O
circadian	O
rhythms	O
,	O
and	O
defective	O
long	O
-	O
term	O
memory	O
.	O

Third	O
,	O
flies	O
that	O
overexpress	O
Dube3a	O
in	O
the	O
nervous	O
system	O
also	O
display	O
locomotion	O
defects	O
,	O
dependent	O
on	O
the	O
ubiquitin	O
ligase	O
activity	O
.	O

Finally	O
,	O
missense	O
mutations	O
in	O
UBE3A	O
alleles	O
of	O
Angelman	O
syndrome	O
patients	O
alter	O
amino	O
acid	O
residues	O
conserved	O
in	O
the	O
fly	O
protein	O
,	O
and	O
when	O
introduced	O
into	O
dube3a	O
,	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
.	O

The	O
simplest	O
model	O
for	O
Angelman	O
syndrome	O
is	O
that	O
in	O
the	O
absence	O
of	O
UBE3A	O
,	O
particular	O
substrates	O
fail	O
to	O
be	O
ubiquitinated	O
and	O
proteasomally	O
degraded	O
,	O
accumulate	O
in	O
the	O
brain	O
,	O
and	O
interfere	O
with	O
brain	O
function	O
.	O

We	O
have	O
generated	O
flies	O
useful	O
for	O
genetic	O
screens	O
to	O
identify	O
Dube3a	O
substrates	O
.	O

These	O
flies	O
overexpress	O
Dube3a	O
in	O
the	O
eye	O
or	O
wing	O
and	O
display	O
morphological	O
abnormalities	O
,	O
dependent	O
on	O
the	O
critical	O
catalytic	O
cysteine	O
.	O

We	O
conclude	O
that	O
dube3a	O
mutants	O
are	O
a	O
valid	O
model	O
for	O
Angelman	O
syndrome	O
,	O
with	O
great	O
potential	O
for	O
identifying	O
the	O
elusive	O
UBE3A	O
substrates	O
relevant	O
to	O
the	O
disease	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	O
syndrome	O
is	O
a	O
heterogeneous	O
disorder	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
,	O
characterized	O
by	O
branchial	B-Phenotype
arch	I-Phenotype
abnormalities	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
renal	B-Phenotype
abnormalities	E-Phenotype
,	O
with	O
mutations	O
in	O
EYA1	O
reported	O
in	O
30	O
-	O
70	O
%	O
of	O
patients	O
.	O

We	O
have	O
applied	O
a	O
molecular	O
testing	O
strategy	O
of	O
sequencing	O
of	O
the	O
complete	O
coding	O
region	O
/	O
flanking	O
intronic	O
regions	O
and	O
multiple	O
ligation	O
probe	O
amplification	O
analysis	O
of	O
EYA1	O
to	O
a	O
pediatric	O
branchio	O
-	O
oto	O
-	O
renal	O
proband	O
cohort	O
.	O

EYA1	O
mutations	O
were	O
identified	O
in	O
82	O
%	O
(	O
14	O
/	O
17	O
)	O
of	O
the	O
probands	O
.	O

We	O
also	O
describe	O
a	O
novel	O
recurrent	O
EYA1	O
mutation	O
c.867	O
+	O
5G	O
>	O
A	O
found	O
in	O
five	O
unrelated	O
affected	O
patients	O
.	O

RNA	O
analysis	O
showed	O
that	O
c.867	O
+	O
5G	O
>	O
A	O
affects	O
EYA1	O
splicing	O
,	O
producing	O
an	O
aberrant	O
mRNA	O
transcript	O
lacking	O
exon	O
8	O
and	O
resulting	O
in	O
premature	O
termination	O
in	O
exon	O
9	O
.	O

The	O
aberrant	O
transcript	O
was	O
present	O
at	O
approximately	O
50	O
%	O
level	O
of	O
wild	O
-	O
type	O
EYA1	O
mRNA	O
in	O
fibroblasts	O
,	O
and	O
is	O
predicted	O
to	O
encode	O
an	O
EYA1	O
protein	O
retaining	O
the	O
amino	O
terminal	O
transcriptional	O
coactivator	O
region	O
but	O
lacking	O
the	O
conserved	O
carboxy	O
terminal	O
Eya	O
phosphatase	O
domain	O
.	O

Patients	O
with	O
the	O
c.867	O
+	O
5G	O
>	O
A	O
mutation	O
were	O
found	O
to	O
have	O
more	O
severe	O
renal	B-Phenotype
abnormalities	E-Phenotype
than	O
probands	O
with	O
other	O
mutations	O
in	O
this	O
cohort	O
.	O

Analysis	O
of	O
the	O
c.867	O
+	O
5G	O
>	O
A	O
mutation	O
suggests	O
that	O
certain	O
transcripts	O
of	O
EYA1	O
escape	O
nonsense	O
-	O
mediated	O
decay	O
and	O
encode	O
truncated	O
EYA	O
proteins	O
that	O
may	O
be	O
capable	O
of	O
dominant	O
-	O
negative	O
interactions	O
producing	O
distinct	O
phenotypic	O
features	O
within	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
spectrum	O
.	O

We	O
have	O
investigated	O
the	O
incidence	O
of	O
Gorlin	O
syndrome	O
(	O
GS	O
)	O
in	O
patients	O
with	O
the	O
childhood	O
brain	B-Phenotype
tumour	E-Phenotype
,	O
medulloblastoma	S-Phenotype
.	O

One	O
hundred	O
and	O
seventy	O
-	O
three	O
consecutive	O
cases	O
of	O
medulloblastoma	S-Phenotype
in	O
the	O
North	O
-	O
West	O
Regional	O
Health	O
Authority	O
between	O
1954	O
and	O
1989	O
(	O
Manchester	O
Regional	O
Health	O
Board	O
before	O
1974	O
)	O
were	O
studied	O
.	O

After	O
review	O
of	O
case	O
notes	O
,	O
X	O
-	O
rays	O
and	O
health	O
surveys	O
only	O
2	O
/	O
173	O
cases	O
had	O
evidence	O
supporting	O
a	O
diagnosis	O
of	O
GS	O
.	O

A	O
further	O
case	O
at	O
50	O
%	O
risk	O
of	O
GS	O
died	O
of	O
a	O
brain	B-Phenotype
tumour	E-Phenotype
aged	O
4	O
years	O
.	O

The	O
incidence	O
of	O
GS	O
in	O
medulloblastoma	S-Phenotype
is	O
,	O
therefore	O
,	O
probably	O
between	O
1	O
-	O
2	O
%	O
.	O

A	O
population	O
based	O
study	O
of	O
GS	O
in	O
the	O
region	O
started	O
in	O
1983	O
was	O
used	O
to	O
assess	O
the	O
incidence	O
of	O
medulloblastoma	S-Phenotype
in	O
GS	O
,	O
which	O
was	O
found	O
to	O
be	O
between	O
3	O
-	O
5	O
%	O
.	O

This	O
figure	O
is	O
lower	O
than	O
previous	O
estimates	O
,	O
but	O
this	O
is	O
the	O
first	O
population	O
based	O
study	O
undertaken	O
.	O

In	O
view	O
of	O
the	O
early	O
age	O
of	O
onset	O
in	O
GS	O
(	O
mean	O
2	O
years	O
)	O
children	O
presenting	O
with	O
medulloblastoma	S-Phenotype
,	O
especially	O
under	O
5	O
years	O
,	O
should	O
be	O
examined	O
for	O
signs	O
of	O
the	O
syndrome	O
.	O

Those	O
at	O
high	O
risk	O
of	O
developing	O
multiple	O
invasive	O
basal	B-Phenotype
cell	I-Phenotype
carcinomata	E-Phenotype
will	O
then	O
be	O
identified	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
is	O
an	O
autosomal	O
-	O
dominant	O
multiple	B-Phenotype
neoplasia	E-Phenotype
syndrome	O
that	O
results	O
from	O
mutations	O
in	O
the	O
NF2	O
tumour	S-Phenotype
suppressor	O
gene	O
located	O
on	O
chromosome	O
22q	O
.	O

It	O
has	O
a	O
frequency	O
of	O
one	O
in	O
25,000	O
livebirths	O
and	O
nearly	O
100	O
%	O
penetrance	O
by	O
60	O
years	O
of	O
age	O
.	O

Half	O
of	O
patients	O
inherit	O
a	O
germline	O
mutation	O
from	O
an	O
affected	O
parent	O
and	O
the	O
remainder	O
acquire	O
a	O
de	O
novo	O
mutation	O
for	O
neurofibromatosis	S-Phenotype
type	O
2	O
.	O

Patients	O
develop	O
nervous	B-Phenotype
system	I-Phenotype
tumours	E-Phenotype
(	O
schwannomas	S-Phenotype
,	O
meningiomas	S-Phenotype
,	O
ependymomas	S-Phenotype
,	O
astrocytomas	S-Phenotype
,	O
and	O
neurofibromas	S-Phenotype
)	O
,	O
peripheral	B-Phenotype
neuropathy	E-Phenotype
,	O
ophthalmological	B-Phenotype
lesions	E-Phenotype
(	O
cataracts	S-Phenotype
,	O
epiretinal	B-Phenotype
membranes	E-Phenotype
,	O
and	O
retinal	B-Phenotype
hamartomas	E-Phenotype
)	O
,	O
and	O
cutaneous	B-Phenotype
lesions	E-Phenotype
(	O
skin	B-Phenotype
tumours	E-Phenotype
)	O
.	O

Optimum	O
treatment	O
is	O
multidisciplinary	O
because	O
of	O
the	O
complexities	O
associated	O
with	O
management	O
of	O
the	O
multiple	O
,	O
progressive	O
,	O
and	O
protean	O
lesions	O
associated	O
with	O
the	O
disorder	O
.	O

We	O
review	O
the	O
molecular	O
pathogenesis	O
,	O
genetics	O
,	O
clinical	O
findings	O
,	O
and	O
management	O
strategies	O
for	O
neurofibromatosis	S-Phenotype
type	O
2	O
.	O

We	O
report	O
on	O
2	O
children	O
with	O
Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
)	O
and	O
mental	B-Phenotype
retardation	E-Phenotype
.	O

One	O
child	O
had	O
mild	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
but	O
the	O
other	O
only	O
had	O
hearing	O
loss	O
at	O
8000	O
Hz	O
.	O

These	O
cases	O
suggest	O
that	O
there	O
may	O
be	O
an	O
increased	O
incidence	O
of	O
mental	B-Phenotype
retardation	E-Phenotype
in	O
individuals	O
with	O
TBS	O
.	O

Gorlin	O
syndrome	O
(	O
GS	O
)	O
is	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
with	O
high	O
-	O
penetrance	O
and	O
is	O
characterized	O
by	O
a	O
range	O
of	O
developmental	O
anomalies	O
and	O
increased	O
risk	O
of	O
developing	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
and	O
medulloblastoma	S-Phenotype
.	O

Between	O
50	O
%	O
and	O
85	O
%	O
of	O
patients	O
with	O
GS	O
harbor	O
germ	O
line	O
mutations	O
in	O
the	O
only	O
susceptibility	O
gene	O
identified	O
to	O
date	O
,	O
PTCH1	O
,	O
a	O
key	O
component	O
in	O
the	O
Sonic	O
Hedgehog	O
signaling	O
pathway	O
.	O

Another	O
component	O
in	O
this	O
pathway	O
,	O
SUFU	O
,	O
is	O
known	O
to	O
be	O
involved	O
in	O
susceptibility	O
to	O
medulloblastoma	S-Phenotype
but	O
has	O
never	O
been	O
reported	O
in	O
GS	O
patients	O
to	O
date	O
.	O

We	O
have	O
identified	O
the	O
known	O
c.1022	O
+	O
1G	O
>	O
A	O
SUFU	O
germ	O
line	O
splicing	O
mutation	O
in	O
a	O
family	O
that	O
was	O
PTCH1	O
-	O
negative	O
and	O
who	O
had	O
signs	O
and	O
symptoms	O
of	O
GS	O
,	O
including	O
medulloblastoma	S-Phenotype
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
germ	O
line	O
SUFU	O
mutation	O
associated	O
with	O
GS	O
.	O

Basal	B-Phenotype
cell	I-Phenotype
nevus	E-Phenotype
syndrome	O
(	O
BCNS	O
or	O
Gorlin	O
syndrome	O
,	O
OMIM	O
:	O
109400	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
with	O
high	O
penetrance	O
.	O

It	O
is	O
characterized	O
by	O
developmental	O
anomalies	O
and	O
predisposition	O
to	O
tumors	S-Phenotype
(	O
for	O
example	O
,	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
BCC	O
)	O
and	O
medulloblastoma	S-Phenotype
)	O
.	O

PTCH1	O
,	O
the	O
human	O
homolog	O
of	O
the	O
Drosophila	O
patched	O
gene	O
,	O
was	O
identified	O
as	O
a	O
gene	O
responsible	O
for	O
BCNS	O
.	O

The	O
PTCH1	O
protein	O
is	O
a	O
Hedgehog	O
(	O
Hh	O
)	O
protein	O
receptor	O
and	O
is	O
pivotal	O
for	O
early	O
development	O
,	O
stem	O
cell	O
maintenance	O
and	O
/	O
or	O
differentiation	O
.	O

We	O
analyzed	O
the	O
six	O
Japanese	O
families	O
with	O
BCNS	O
and	O
identified	O
six	O
germline	O
mutations	O
in	O
the	O
PTCH1	O
gene	O
.	O

One	O
family	O
had	O
a	O
nonsense	O
mutation	O
(	O
c.1196G	O
>	O
A	O
)	O
,	O
one	O
had	O
a	O
1	O
-	O
bp	O
deletion	O
(	O
c.2029delA	O
)	O
,	O
two	O
had	O
2	O
-	O
bp	O
deletions	O
(	O
c.239_240delGA	O
and	O
c.1670_1671delCA	O
)	O
and	O
one	O
had	O
a	O
58	O
-	O
bp	O
duplication	O
(	O
c.1138_1195dup	O
)	O
.	O

They	O
caused	O
premature	O
termination	O
,	O
resulting	O
in	O
the	O
truncation	O
of	O
the	O
PTCH1	O
protein	O
.	O

Analysis	O
of	O
a	O
high	O
-	O
density	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
mapping	O
array	O
showed	O
a	O
large	O
approximately	O
1.2	O
-	O
Mb	O
deletion	O
,	O
including	O
the	O
PTCH1	O
gene	O
in	O
one	O
allele	O
,	O
in	O
a	O
family	O
in	O
which	O
PTCH1	O
mutations	O
were	O
not	O
identified	O
at	O
the	O
sequence	O
level	O
.	O

These	O
data	O
indicated	O
that	O
all	O
the	O
six	O
families	O
who	O
were	O
diagnosed	O
with	O
BCNS	O
had	O
mutations	O
in	O
the	O
PTCH1	O
gene	O
and	O
that	O
a	O
single	O
copy	O
of	O
a	O
PTCH1	O
mutation	O
causes	O
BCNS	O
.	O

The	O
diagnosis	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
has	O
seldom	O
been	O
made	O
in	O
infants	O
because	O
the	O
previously	O
described	O
characteristic	O
manifestations	O
usually	O
are	O
not	O
apparent	O
until	O
after	O
age	O
2	O
years	O
.	O

We	O
describe	O
4	O
AS	O
patients	O
,	O
one	O
of	O
whom	O
has	O
oculocutaneous	S-Phenotype
albinism	S-Phenotype
,	O
who	O
were	O
less	O
than	O
2	O
years	O
old	O
when	O
first	O
evaluated	O
.	O

All	O
4	O
have	O
deletions	O
of	O
the	O
region	O
q11.2	O
-	O
q13	O
of	O
chromosome	O
15	O
.	O

In	O
the	O
3	O
cases	O
in	O
which	O
parents	O
were	O
available	O
for	O
study	O
the	O
deleted	O
chromosome	O
15	O
was	O
maternally	O
derived	O
,	O
as	O
determined	O
by	O
cytological	O
markers	O
.	O

All	O
of	O
the	O
patients	O
presented	O
with	O
severe	B-Phenotype
to	I-Phenotype
profound	I-Phenotype
global	I-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
and	O
postnatal	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
microcephaly	E-Phenotype
;	O
they	O
had	O
seizures	S-Phenotype
,	O
hypotonia	S-Phenotype
,	O
hyperreflexia	S-Phenotype
,	O
and	O
hyperkinesis	S-Phenotype
.	O

All	O
were	O
hypopigmented	S-Phenotype
as	O
compared	O
to	O
their	O
relatives	O
.	O

Each	O
had	O
eye	B-Phenotype
abnormalities	E-Phenotype
;	O
all	O
had	O
choroidal	B-Phenotype
pigment	I-Phenotype
hypoplasia	E-Phenotype
.	O

None	O
were	O
initially	O
described	O
as	O
having	O
an	O
abnormal	O
appearance	O
.	O

We	O
believe	O
that	O
AS	O
is	O
far	O
more	O
common	O
than	O
previously	O
thought	O
and	O
present	O
these	O
4	O
children	O
to	O
emphasize	O
the	O
manifestations	O
that	O
may	O
be	O
helpful	O
in	O
making	O
the	O
diagnosis	O
in	O
the	O
young	O
patient	O
.	O

We	O
also	O
emphasize	O
the	O
hypopigmentation	S-Phenotype
that	O
patients	O
with	O
AS	O
frequently	O
have	O
,	O
including	O
what	O
we	O
think	O
is	O
the	O
first	O
reported	O
case	O
of	O
albinism	S-Phenotype
and	O
AS	O
.	O

A	O
9	O
-	O
year	O
-	O
old	O
mentally	B-Phenotype
retarded	E-Phenotype
girl	O
with	O
multiple	O
congenital	O
anomalies	O
was	O
found	O
to	O
carry	O
a	O
balanced	O
13	O
/	O
14	O
Robertsonian	O
translocation	O
[	O
45	O
,	O
XX	O
,	O
t	O
(	O
13q14q	O
)	O
]	O
which	O
was	O
also	O
present	O
in	O
her	O
father	O
.	O

Her	O
mother	O
carried	O
a	O
balanced	O
reciprocal	O
translocation	O
between	O
chromosomes	O
1	O
and	O
14	O
[	O
46	O
,	O
XX	O
,	O
t	O
(	O
1	O
;	O
14	O
)	O
(	O
q32	O
;	O
q32	O
)	O
]	O
.	O

Both	O
of	O
her	O
parents	O
were	O
phenotypically	O
normal	O
.	O

Molecular	O
studies	O
were	O
carried	O
out	O
to	O
determine	O
the	O
parental	O
origin	O
of	O
chromosomes	O
1	O
,	O
13	O
,	O
and	O
14	O
in	O
the	O
patient	O
.	O

Using	O
probes	O
for	O
D14S13	O
and	O
D14S22	O
,	O
we	O
could	O
show	O
that	O
the	O
patient	O
inherited	O
both	O
chromosomes	O
14	O
from	O
her	O
father	O
and	O
none	O
from	O
her	O
mother	O
.	O

Similar	O
studies	O
using	O
probes	O
for	O
chromosomes	O
1	O
(	O
D1S76	O
)	O
and	O
13	O
(	O
D13S37	O
)	O
loci	O
showed	O
the	O
presence	O
of	O
both	O
maternal	O
and	O
paternal	O
alleles	O
in	O
the	O
patient	O
.	O

Our	O
findings	O
indicate	O
that	O
paternal	O
uniparental	O
heterodisomy	O
for	O
chromosome	O
14	O
most	O
likely	O
accounts	O
for	O
the	O
phenotypic	O
abnormalities	O
observed	O
in	O
our	O
patient	O
.	O

It	O
is	O
suggested	O
that	O
uniparental	O
disomy	O
may	O
be	O
the	O
basis	O
for	O
abnormal	B-Phenotype
development	E-Phenotype
in	O
at	O
least	O
some	O
phenotypically	O
abnormal	O
familial	O
balanced	O
-	O
translocation	O
carriers	O
.	O

Neurofibromatosis	S-Phenotype
2	O
or	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neurofibromatosis	E-Phenotype
(	O
NF2	O
)	O
is	O
a	O
severe	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
the	O
development	O
of	O
multiple	O
tumors	S-Phenotype
of	O
the	O
nervous	O
system	O
,	O
including	O
meningiomas	S-Phenotype
,	O
gliomas	S-Phenotype
,	O
neurofibromas	S-Phenotype
,	O
ependymomas	S-Phenotype
,	O
and	O
particularly	O
acoustic	B-Phenotype
neuromas	E-Phenotype
.	O

Polymorphic	O
DNA	O
markers	O
have	O
revealed	O
frequent	O
loss	O
of	O
one	O
copy	O
of	O
chromosome	O
22	O
in	O
the	O
tumor	S-Phenotype
types	O
associated	O
with	O
NF2	O
.	O

Family	O
studies	O
have	O
demonstrated	O
that	O
the	O
primary	O
defect	O
in	O
NF2	O
is	O
linked	O
to	O
DNA	O
markers	O
on	O
chromosome	O
22	O
,	O
suggesting	O
that	O
it	O
involves	O
inactivation	O
of	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
.	O

We	O
have	O
employed	O
a	O
combination	O
of	O
multipoint	O
linkage	O
analysis	O
and	O
examination	O
of	O
deletions	O
in	O
primary	O
tumor	S-Phenotype
specimens	O
to	O
precisely	O
map	O
the	O
NF2	O
locus	O
between	O
flanking	O
polymorphic	O
DNA	O
markers	O
on	O
chromosome	O
22	O
.	O

The	O
13	O
-	O
cM	O
region	O
bracketed	O
by	O
these	O
markers	O
corresponds	O
to	O
13	O
%	O
of	O
the	O
genetic	O
length	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
22	O
and	O
is	O
expected	O
to	O
contain	O
less	O
than	O
5	O
x	O
10	O
(	O
6	O
)	O
bp	O
of	O
DNA	O
.	O

The	O
delineation	O
of	O
flanking	O
markers	O
for	O
NF2	O
should	O
permit	O
accurate	O
presymptomatic	O
and	O
prenatal	O
diagnosis	O
for	O
the	O
disorder	O
and	O
greatly	O
facilitate	O
efforts	O
to	O
isolate	O
the	O
defective	O
gene	O
on	O
the	O
basis	O
of	O
its	O
location	O
.	O

This	O
paper	O
reports	O
on	O
a	O
family	O
with	O
popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
(	O
PPS	O
)	O
,	O
which	O
was	O
ascertained	O
through	O
a	O
baby	O
with	O
most	O
of	O
the	O
major	O
signs	O
of	O
the	O
syndrome	O
.	O

The	O
mother	O
,	O
who	O
had	O
a	O
repaired	O
cleft	B-Phenotype
palate	E-Phenotype
and	O
toe	S-Phenotype
syndactyly	S-Phenotype
,	O
had	O
been	O
aware	O
that	O
her	O
syndactyly	O
was	O
familial	O
,	O
but	O
her	O
unpreparedness	O
for	O
the	O
birth	O
of	O
a	O
child	O
with	O
PPS	O
led	O
to	O
interest	O
in	O
,	O
and	O
a	O
subsequent	O
review	O
of	O
,	O
the	O
differnetial	O
diagnosis	O
and	O
the	O
variable	O
expression	O
of	O
the	O
clinical	O
manifestations	O
of	O
this	O
syndrome	O
.	O

Upon	O
review	O
,	O
some	O
earlier	O
reported	O
cases	O
were	O
excluded	O
as	O
PPS	O
,	O
and	O
certain	O
ascertainment	O
and	O
reporting	O
biases	O
that	O
could	O
affect	O
such	O
an	O
analysis	O
were	O
considered	O
.	O

Clinical	O
and	O
genetic	O
data	O
of	O
10	O
patients	O
with	O
neurofibromatosis	S-Phenotype
2	O
(	O
NF	O
-	O
2	O
)	O
are	O
presented	O
.	O

Interestingly	O
,	O
no	O
family	O
history	O
of	O
neurofibromatosis	S-Phenotype
was	O
detectable	O
in	O
any	O
of	O
them	O
,	O
which	O
indicates	O
that	O
these	O
are	O
sporadic	O
cases	O
of	O
NF	O
-	O
2	O
,	O
most	O
likely	O
due	O
to	O
a	O
new	O
mutational	O
event	O
.	O

According	O
to	O
our	O
own	O
results	O
and	O
the	O
data	O
in	O
the	O
literature	O
,	O
sporadic	O
cases	O
of	O
NF	O
-	O
2	O
are	O
clinically	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
multiple	O
meningiomas	S-Phenotype
and	O
spinal	B-Phenotype
tumors	E-Phenotype
in	O
addition	O
to	O
the	O
bilateral	B-Phenotype
occurrence	I-Phenotype
of	I-Phenotype
acoustic	I-Phenotype
neurinomas	E-Phenotype
.	O

The	O
clinical	O
heterogeneity	O
of	O
NF	O
-	O
2	O
is	O
pointed	O
out	O
and	O
the	O
possible	O
existence	O
of	O
different	O
forms	O
of	O
this	O
disease	O
is	O
discussed	O
.	O

Six	O
patients	O
,	O
including	O
two	O
sibs	O
,	O
with	O
Angelman	O
syndrome	O
(	O
AS	O
;	O
three	O
females	O
and	O
three	O
males	O
,	O
aged	O
11	O
to	O
18	O
years	O
)	O
were	O
studied	O
cytogenetically	O
.	O

Molecular	O
analysis	O
was	O
also	O
performed	O
.	O

Using	O
high	O
-	O
resolution	O
banding	O
technique	O
,	O
we	O
detected	O
a	O
microdeletion	O
in	O
the	O
proximal	O
region	O
of	O
chromosome	O
15q	O
in	O
four	O
cases	O
.	O

The	O
deleted	O
segment	O
was	O
heterogenous	O
between	O
these	O
patients	O
,	O
and	O
the	O
common	O
deleted	O
region	O
appeared	O
to	O
be	O
15q11.2	O
.	O

Four	O
patients	O
with	O
deleted	O
15q	O
were	O
all	O
sporadic	O
cases	O
,	O
whereas	O
in	O
the	O
sib	O
cases	O
we	O
could	O
not	O
detect	O
a	O
visible	O
deletion	O
in	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
.	O

However	O
,	O
there	O
was	O
no	O
clinical	O
difference	O
between	O
sporadic	O
cases	O
and	O
sib	O
cases	O
.	O

Densitometric	O
analysis	O
of	O
autoradiographic	O
bands	O
of	O
Southern	O
hybridization	O
using	O
two	O
DNA	O
segments	O
,	O
pML34	O
and	O
pTD3	O
-	O
21	O
,	O
as	O
probes	O
demonstrated	O
that	O
two	O
patients	O
had	O
only	O
one	O
copy	O
for	O
each	O
of	O
the	O
probes	O
.	O

In	O
the	O
remaining	O
four	O
patients	O
,	O
including	O
the	O
sibs	O
,	O
two	O
copies	O
of	O
each	O
sequence	O
were	O
retained	O
.	O

The	O
probes	O
used	O
here	O
detect	O
a	O
molecular	O
deletion	O
in	O
most	O
Prader	O
-	O
Willi	O
syndrome	O
patients	O
.	O

Thus	O
the	O
segment	O
causing	O
AS	O
is	O
localized	O
adjacent	O
to	O
the	O
critical	O
segment	O
of	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

There	O
seemed	O
to	O
be	O
heterogeneity	O
for	O
the	O
molecular	O
deletion	O
within	O
AS	O
individuals	O
.	O

A	O
father	O
and	O
son	O
are	O
described	O
with	O
an	O
autosomal	O
dominant	O
branchial	B-Phenotype
cleft	E-Phenotype
syndrome	O
resembling	O
both	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
and	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
.	O

Both	O
syndromes	O
may	O
represent	O
variant	O
expressions	O
of	O
the	O
same	O
autosomal	O
dominant	O
gene	O
.	O

Thirty	O
six	O
children	O
with	O
typical	O
features	O
of	O
Angelman	O
's	O
syndrome	O
,	O
including	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
episodes	B-Phenotype
of	I-Phenotype
paroxysmal	I-Phenotype
laughter	E-Phenotype
,	O
seizures	S-Phenotype
,	O
and	O
microcephaly	S-Phenotype
were	O
studied	O
.	O

The	O
series	O
included	O
three	O
sibships	O
of	O
three	O
affected	O
sisters	O
,	O
two	O
affected	O
brothers	O
,	O
and	O
two	O
affected	O
sisters	O
,	O
respectively	O
.	O

The	O
facial	B-Phenotype
appearance	E-Phenotype
is	O
characterised	O
by	O
a	O
prominent	B-Phenotype
jaw	E-Phenotype
,	O
a	O
wide	B-Phenotype
mouth	E-Phenotype
,	O
and	O
a	O
pointed	B-Phenotype
chin	E-Phenotype
.	O

Tongue	B-Phenotype
thrusting	E-Phenotype
is	O
common	O
.	O

The	O
movement	B-Phenotype
disorder	E-Phenotype
consists	O
of	O
a	O
wide	B-Phenotype
based	I-Phenotype
,	I-Phenotype
ataxic	I-Phenotype
gait	E-Phenotype
with	O
frequent	O
jerky	B-Phenotype
limb	I-Phenotype
movements	E-Phenotype
and	O
flapping	B-Phenotype
of	I-Phenotype
the	I-Phenotype
hands	E-Phenotype
.	O

Tone	O
is	O
variable	O
in	O
the	O
limbs	O
with	O
normal	O
reflexes	O
,	O
and	O
the	O
plantar	O
responses	O
are	O
usually	O
flexor	O
.	O

The	O
syndrome	O
is	O
being	O
diagnosed	O
more	O
often	O
,	O
and	O
attention	O
is	O
drawn	O
to	O
its	O
diagnostic	O
aspects	O
.	O

A	O
pedigree	O
of	O
branchio	O
-	O
oto	O
-	O
renal	B-Phenotype
dysplasia	E-Phenotype
(	O
the	O
BOR	O
syndrome	O
)	O
is	O
reported	O
,	O
including	O
the	O
documentation	O
by	O
serial	O
audiometric	O
studies	O
of	O
the	O
onset	O
and	O
rapid	O
progression	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
the	O
twin	O
sister	O
of	O
an	O
affected	O
child	O
.	O

The	O
literature	O
on	O
this	O
syndrome	O
is	O
analyzed	O
to	O
derive	O
some	O
figures	O
for	O
use	O
in	O
genetic	O
counseling	O
of	O
such	O
families	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	B-Phenotype
dysplasia	E-Phenotype
is	O
an	O
autosomal	O
dominant	O
disorder	O
in	O
which	O
affected	O
individuals	O
may	O
have	O
preauricular	B-Phenotype
pits	E-Phenotype
,	O
lachrymal	B-Phenotype
duct	I-Phenotype
stenosis	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
branchial	S-Phenotype
fistulas	B-Phenotype
or	I-Phenotype
cysts	E-Phenotype
,	O
structural	B-Phenotype
defects	I-Phenotype
of	I-Phenotype
the	I-Phenotype
outer	I-Phenotype
,	I-Phenotype
middle	I-Phenotype
,	I-Phenotype
and	I-Phenotype
inner	I-Phenotype
ear	E-Phenotype
,	O
and	O
renal	B-Phenotype
anomalies	E-Phenotype
,	O
which	O
may	O
range	O
from	O
mild	O
hypoplasia	O
to	O
complete	O
absence	O
.	O

Not	O
all	O
features	O
of	O
the	O
syndrome	O
are	O
expressed	O
in	O
all	O
carriers	O
of	O
the	O
gene	O
,	O
but	O
few	O
carriers	O
lack	O
all	O
the	O
features	O
,	O
and	O
the	O
pits	S-Phenotype
,	O
branchial	B-Phenotype
clefts	E-Phenotype
,	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
are	O
frequently	O
expressed	O
.	O

Those	O
offspring	O
of	O
affected	O
persons	O
who	O
have	O
pits	S-Phenotype
or	O
fistulas	S-Phenotype
are	O
likely	O
(	O
about	O
80	O
%	O
)	O
to	O
have	O
hearing	B-Phenotype
loss	E-Phenotype
of	O
varying	O
degrees	O
of	O
severity	O
.	O

A	O
minority	O
of	O
heterozygotes	O
(	O
about	O
7	O
%	O
)	O
may	O
have	O
hearing	B-Phenotype
loss	E-Phenotype
without	O
pits	S-Phenotype
or	O
fistulas	S-Phenotype
.	O

The	O
risk	O
of	O
severe	O
renal	B-Phenotype
malformation	E-Phenotype
is	O
probably	O
fairly	O
low	O
.	O

Whether	O
families	O
that	O
show	O
dominant	O
inheritance	O
of	O
pits	S-Phenotype
,	O
clefts	S-Phenotype
,	O
and	O
deafness	S-Phenotype
without	O
renal	B-Phenotype
anomalies	E-Phenotype
represent	O
variants	O
of	O
the	O
BOR	O
syndrome	O
or	O
a	O
separate	O
entity	O
(	O
the	O
BO	O
syndrome	O
)	O
,	O
is	O
still	O
not	O
clear	O
.	O

At	O
present	O
,	O
any	O
individual	O
with	O
preauricular	B-Phenotype
pits	E-Phenotype
and	O
branchial	B-Phenotype
clefts	E-Phenotype
deserves	O
both	O
otologic	S-Phenotype
and	O
renal	B-Phenotype
investigation	E-Phenotype
.	O

The	O
authors	O
report	O
a	O
new	O
case	O
of	O
Townes	O
-	O
Brocks	O
syndrome	O
with	O
cardiac	B-Phenotype
defect	E-Phenotype
,	O
ossicular	B-Phenotype
anomalies	E-Phenotype
and	O
dominant	O
transmission	O
.	O

The	O
intrafamilial	O
variability	O
of	O
the	O
phenotype	O
and	O
the	O
difficulty	O
of	O
diagnosis	O
in	O
isolated	O
cases	O
are	O
underlined	O
.	O

This	O
study	O
of	O
47	O
patients	O
from	O
11	O
families	O
with	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF	O
2	O
)	O
confirms	O
our	O
previously	O
reported	O
association	O
between	O
posterior	B-Phenotype
capsular	I-Phenotype
cataract	E-Phenotype
and	O
NF	O
2	O
.	O

A	O
highly	O
significant	O
statistical	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
posterior	B-Phenotype
capsular	E-Phenotype
lens	B-Phenotype
opacities	E-Phenotype
and	O
the	O
presence	O
of	O
NF	O
2	O
as	O
determined	O
by	O
magnetic	O
resonance	O
imaging	O
or	O
pathologic	O
diagnosis	O
.	O

This	O
association	O
was	O
not	O
present	O
for	O
other	O
types	O
of	O
lens	B-Phenotype
opacities	E-Phenotype
that	O
could	O
be	O
the	O
result	O
of	O
age	O
-	O
related	O
or	O
nonspecific	O
changes	O
.	O

When	O
considering	O
the	O
diagnosis	O
of	O
NF	O
2	O
,	O
this	O
finding	O
now	O
makes	O
it	O
essential	O
to	O
use	O
a	O
careful	O
dilated	O
biomicroscopic	O
examination	O
of	O
the	O
lens	O
to	O
evaluate	O
known	O
,	O
suspected	O
,	O
or	O
at	O
-	O
risk	O
individuals	O
for	O
this	O
potentially	O
early	O
associated	O
manifestation	O
.	O

Bilateral	B-Phenotype
acoustic	E-Phenotype
neurofibromatosis	S-Phenotype
(	O
BANF	S-Phenotype
)	O
is	O
a	O
severe	O
autosomal	O
dominant	O
disorder	O
involving	O
development	O
of	O
multiple	O
tumours	S-Phenotype
of	O
the	O
nervous	O
system	O
including	O
meningiomas	S-Phenotype
,	O
gliomas	S-Phenotype
,	O
neurofibromas	S-Phenotype
and	O
particularly	O
bilateral	S-Phenotype
acoustic	B-Phenotype
neuromas	E-Phenotype
.	O

We	O
have	O
used	O
genetic	O
linkage	O
analysis	O
with	O
DNA	O
markers	O
to	O
establish	O
that	O
the	O
defective	O
gene	O
causing	O
BANF	S-Phenotype
is	O
on	O
chromosome	O
22	O
,	O
and	O
is	O
therefore	O
distinct	O
from	O
the	O
gene	O
for	O
the	O
von	O
Recklinghausen	O
form	O
of	O
neurofibromatosis	S-Phenotype
,	O
which	O
maps	O
to	O
chromosome	O
17	O
.	O

Linked	O
DNA	O
markers	O
will	O
be	O
particularly	O
valuable	O
in	O
BANF	S-Phenotype
,	O
facilitating	O
early	O
detection	O
of	O
tumours	S-Phenotype
and	O
thereby	O
permitting	O
more	O
effective	O
surgical	O
intervention	O
.	O

In	O
view	O
of	O
the	O
reported	O
loss	O
of	O
genes	O
on	O
chromosome	O
22	O
in	O
meningiomas	S-Phenotype
and	O
acoustic	B-Phenotype
neuromas	E-Phenotype
,	O
the	O
genetic	O
localization	O
of	O
the	O
primary	O
BANF	S-Phenotype
defect	O
strongly	O
supports	O
the	O
concept	O
that	O
the	O
disease	O
locus	O
encodes	O
a	O
'tumour	O
suppressor	O
'	O
gene	O
.	O

Isolation	O
of	O
this	O
gene	O
should	O
provide	O
insights	O
into	O
the	O
pathogenesis	O
of	O
acoustic	B-Phenotype
neuromas	E-Phenotype
and	O
other	O
nervous	B-Phenotype
system	I-Phenotype
tumours	E-Phenotype
,	O
as	O
well	O
as	O
into	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
of	O
neural	O
crest	O
cells	O
.	O

A	O
female	O
with	O
cystic	O
fibrosis	O
and	O
short	B-Phenotype
stature	E-Phenotype
was	O
investigated	O
for	O
molecular	O
or	O
cytogenetic	O
abnormalities	O
that	O
might	O
explain	O
the	O
combined	O
phenotype	O
.	O

Analysis	O
with	O
polymorphic	O
DNA	O
markers	O
indicated	O
that	O
the	O
father	O
did	O
not	O
contribute	O
alleles	O
to	O
the	O
propositus	O
for	O
markers	O
near	O
the	O
CF	O
locus	O
or	O
for	O
centromeric	O
markers	O
on	O
chromosome	O
7	O
.	O

High	O
-	O
resolution	O
cytogenetic	O
analysis	O
was	O
normal	O
,	O
and	O
the	O
result	O
could	O
not	O
be	O
explained	O
on	O
the	O
basis	O
of	O
nonpaternity	O
or	O
a	O
submicroscopic	O
deletion	O
.	O

All	O
of	O
the	O
data	O
indicate	O
that	O
the	O
propositus	O
inherited	O
two	O
identical	O
copies	O
of	O
maternal	O
sequences	O
for	O
much	O
or	O
all	O
of	O
chromosome	O
7	O
.	O

The	O
occurrence	O
of	O
uniparental	O
disomy	O
could	O
be	O
explained	O
by	O
models	O
postulating	O
postfertilization	O
error	O
,	O
gamete	O
complementation	O
,	O
monosomic	O
conception	O
with	O
subsequent	O
chromosome	O
gain	O
,	O
or	O
trisomic	O
conception	O
followed	O
by	O
chromosome	O
loss	O
.	O

Uniparental	O
disomy	O
in	O
an	O
individual	O
with	O
a	O
normal	O
chromosome	O
analysis	O
is	O
a	O
novel	O
mechanism	O
for	O
the	O
occurrence	O
of	O
human	O
genetic	O
disease	O
.	O

The	O
inheritance	O
of	O
Angelman	O
's	O
syndrome	O
,	O
a	O
disorder	O
characterised	O
by	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
a	O
happy	B-Phenotype
disposition	E-Phenotype
,	O
is	O
debated	O
because	O
affected	O
sibs	O
occur	O
less	O
frequently	O
than	O
expected	O
with	O
autosomal	O
recessive	O
inheritance	O
.	O

After	O
discovering	O
two	O
unrelated	O
patients	O
with	O
a	O
small	O
deletion	O
of	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
10	O
further	O
patients	O
with	O
Angelman	O
's	O
syndrome	O
were	O
reassessed	O
.	O

Five	O
had	O
apparently	O
normal	O
karyotypes	O
,	O
four	O
had	O
a	O
deletion	O
within	O
15q11	O
-	O
13	O
,	O
and	O
one	O
had	O
a	O
pericentric	O
inversion	O
,	O
inv	O
(	O
15	O
)	O
(	O
p11q13	O
)	O
involving	O
the	O
same	O
chromosomal	O
region	O
.	O

In	O
the	O
latter	O
case	O
,	O
the	O
healthy	O
mother	O
had	O
the	O
same	O
pericentric	O
inversion	O
,	O
indicating	O
that	O
the	O
patient	O
also	O
had	O
a	O
submicroscopic	O
mutation	O
on	O
his	O
other	O
chromosome	O
15	O
.	O

These	O
data	O
map	O
the	O
Angelman	O
locus	O
to	O
15q11	O
-	O
13	O
and	O
suggest	O
that	O
de	O
novo	O
visible	O
deletions	O
(	O
associated	O
with	O
a	O
low	O
recurrence	O
risk	O
)	O
and	O
autosomal	O
recessively	O
inherited	O
cases	O
combine	O
to	O
give	O
an	O
overall	O
sib	O
recurrence	O
risk	O
of	O
less	O
than	O
25	O
%	O
.	O

This	O
paper	O
is	O
based	O
on	O
our	O
experience	O
with	O
the	O
Gorlin	O
-	O
Goltz	O
syndrome	O
and	O
on	O
data	O
from	O
14	O
patients	O
of	O
the	O
Nordwestdeutsche	O
Kieferklinik	O
in	O
whom	O
this	O
disorder	O
was	O
detected	O
,	O
treated	O
and	O
followed	O
up	O
.	O

A	O
clinical	O
concept	O
has	O
been	O
produced	O
,	O
with	O
a	O
diagnostic	O
check	O
list	O
including	O
a	O
genetic	O
and	O
a	O
dermatological	O
routine	O
work	O
up	O
as	O
well	O
as	O
a	O
radiological	O
survey	O
of	O
the	O
jaws	O
and	O
skeleton	O
.	O

Whenever	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
plus	O
the	O
typical	O
jaw	B-Phenotype
lesions	E-Phenotype
are	O
found	O
in	O
a	O
patient	O
,	O
the	O
diagnosis	O
is	O
easy	O
.	O

A	O
minimum	O
diagnostic	O
criterion	O
is	O
the	O
combination	O
of	O
either	O
the	O
skin	B-Phenotype
tumours	E-Phenotype
or	O
multiple	O
odontogenic	B-Phenotype
keratocysts	E-Phenotype
plus	O
a	O
positive	O
family	O
history	O
for	O
this	O
disorder	O
,	O
bifid	B-Phenotype
ribs	E-Phenotype
,	O
lamellar	O
calcification	B-Phenotype
of	I-Phenotype
the	I-Phenotype
falx	I-Phenotype
cerebri	E-Phenotype
or	O
any	O
one	O
of	O
the	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
typical	O
of	O
this	O
syndrome	O
.	O

All	O
those	O
in	O
whom	O
this	O
disorder	O
is	O
diagnosed	O
or	O
suspected	O
should	O
be	O
followed	O
up	O
for	O
the	O
rest	O
of	O
their	O
lives	O
.	O

The	O
family	O
should	O
be	O
examined	O
and	O
genetic	O
counselling	O
should	O
be	O
offered	O
.	O

We	O
report	O
on	O
seven	O
children	O
with	O
Angelman	O
syndrome	O
presenting	O
with	O
psychomotor	B-Phenotype
retardation	E-Phenotype
during	O
the	O
1st	O
year	O
of	O
life	O
.	O

Seizures	S-Phenotype
developed	O
in	O
six	O
patients	O
,	O
and	O
computed	O
tomography	O
(	O
CT	O
)	O
scanning	O
showed	O
diffuse	B-Phenotype
atrophy	I-Phenotype
of	I-Phenotype
the	I-Phenotype
brain	E-Phenotype
in	O
five	O
patients	O
.	O

We	O
conclude	O
that	O
diagnosis	O
is	O
difficult	O
in	O
the	O
first	O
years	O
of	O
life	O
.	O

A	O
review	O
of	O
the	O
literature	O
is	O
given	O
.	O

The	O
application	O
of	O
recombinant	O
DNA	O
techniques	O
has	O
identified	O
two	O
fundamental	O
mechanisms	O
of	O
tumorigenesis	O
in	O
man	O
.	O

The	O
first	O
involves	O
a	O
qualitative	O
or	O
quantitative	O
change	O
in	O
an	O
oncogene	O
(	O
see	O
ref	O
.	O

1	O
for	O
review	O
)	O
.	O

In	O
the	O
second	O
,	O
discovered	O
in	O
embryonal	O
tumours	S-Phenotype
,	O
a	O
primary	O
mutation	O
occurs	O
which	O
is	O
recessive	O
at	O
the	O
cellular	O
level	O
to	O
the	O
normal	O
allele	O
.	O

The	O
growth	O
of	O
a	O
tumour	O
ensues	O
only	O
after	O
a	O
secondary	O
change	O
,	O
such	O
as	O
chromosome	O
loss	O
or	O
mitotic	O
recombination	O
,	O
eliminates	O
the	O
normal	O
allele	O
,	O
thereby	O
unmasking	O
the	O
altered	O
allele	O
.	O

Because	O
its	O
effect	O
is	O
recessive	O
,	O
the	O
primary	O
mutation	O
may	O
also	O
occur	O
and	O
be	O
transmitted	O
in	O
the	O
germ	O
line	O
,	O
resulting	O
in	O
a	O
familial	O
pattern	O
for	O
the	O
disease	O
.	O

In	O
familial	O
cases	O
,	O
independent	O
bilateral	O
tumours	S-Phenotype
are	O
common	O
,	O
since	O
the	O
tumours	O
result	O
from	O
a	O
single	O
event	O
-	O
-	O
loss	O
of	O
the	O
normal	O
genes	O
-	O
-	O
which	O
can	O
occur	O
in	O
any	O
cell	O
.	O

This	O
contrasts	O
with	O
non	O
-	O
familial	O
(	O
sporadic	O
)	O
cases	O
where	O
solitary	O
tumours	S-Phenotype
result	O
from	O
the	O
infrequent	O
occurrence	O
of	O
two	O
rare	O
events	O
within	O
the	O
same	O
cell	O
.	O

By	O
a	O
molecular	O
genetic	O
approach	O
we	O
have	O
now	O
shown	O
that	O
acoustic	B-Phenotype
neuroma	E-Phenotype
,	O
one	O
of	O
the	O
most	O
common	O
tumours	B-Phenotype
of	I-Phenotype
the	I-Phenotype
human	I-Phenotype
nervous	I-Phenotype
system	E-Phenotype
,	O
is	O
specifically	O
associated	O
with	O
loss	O
of	O
genes	O
on	O
human	O
chromosome	O
22	O
and	O
may	O
result	O
from	O
the	O
mechanism	O
of	O
tumorigenesis	O
discovered	O
in	O
embryonal	O
tumours	O
.	O

This	O
finding	O
might	O
provide	O
a	O
clue	O
to	O
the	O
chromosomal	O
location	O
of	O
the	O
defective	O
gene	O
in	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neurofibromatosis	E-Phenotype
,	O
an	O
autosomal	O
dominant	O
disorder	O
with	O
the	O
hallmark	O
of	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neuromas	E-Phenotype
.	O

In	O
view	O
of	O
the	O
frequent	O
occurrence	O
of	O
meningiomas	S-Phenotype
in	O
patients	O
with	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neurofibromatosis	E-Phenotype
and	O
the	O
association	O
of	O
meningioma	S-Phenotype
with	O
loss	O
of	O
chromosome	O
22	O
previously	O
reported	O
in	O
cytogenetic	O
studies	O
,	O
we	O
suggest	O
that	O
a	O
common	O
event	O
underlies	O
tumorigenesis	O
in	O
acoustic	B-Phenotype
neuroma	E-Phenotype
and	O
meningioma	O
.	O

Cell	O
cultures	O
grown	O
from	O
peripheral	O
neurofibromas	S-Phenotype
of	O
three	O
patients	O
suffering	O
from	O
sporadic	O
peripheral	O
neurofibromatosis	S-Phenotype
(	O
NF	O
)	O
were	O
analysed	O
cytogenetically	O
at	O
early	O
in	O
vitro	O
passages	O
.	O

The	O
NF	O
-	O
cultures	O
exhibited	O
a	O
6.7	O
-	O
fold	O
higher	O
frequency	O
of	O
aneuploid	O
mitoses	O
,	O
including	O
pseudodiploids	O
,	O
than	O
the	O
control	O
cultures	O
derived	O
from	O
the	O
skin	O
of	O
three	O
healthy	O
donors	O
.	O

The	O
predominant	O
numerical	O
anomaly	O
was	O
monosomy	O
22	O
.	O

Several	O
,	O
as	O
yet	O
unidentified	O
marker	O
chromosomes	O
occurred	O
in	O
the	O
NF	O
-	O
cultures	O
,	O
which	O
also	O
showed	O
a	O
much	O
higher	O
level	O
of	O
unstable	O
chromosomal	O
anomalies	O
.	O

The	O
role	O
of	O
monosomy	O
22	O
in	O
tumorigenesis	O
of	O
meningiomas	S-Phenotype
and	O
neurofibromas	S-Phenotype
is	O
discussed	O
.	O

In	O
situ	O
hybridization	O
with	O
a	O
c	O
-	O
sis	O
probe	O
was	O
performed	O
on	O
peripheral	O
lymphocytes	O
of	O
a	O
man	O
with	O
neurofibromatosis	S-Phenotype
and	O
a	O
ring	O
22	O
chromosome	O
.	O

Hybridization	O
was	O
observed	O
on	O
both	O
the	O
normal	O
#	O
22	O
and	O
the	O
ring	O
22	O
,	O
indicating	O
that	O
the	O
patient	O
is	O
not	O
constitutionally	O
hemizygous	O
for	O
c	O
-	O
sis	O
.	O

The	O
implications	O
of	O
a	O
ring	O
22	O
constitution	O
and	O
the	O
neurofibromatosis	S-Phenotype
phenotype	O
are	O
discussed	O
.	O

Bilateral	B-Phenotype
acoustic	I-Phenotype
neurofibromatosis	E-Phenotype
(	O
BANF	S-Phenotype
)	O
is	O
a	O
genetic	O
defect	O
associated	O
with	O
multiple	S-Phenotype
tumors	B-Phenotype
of	I-Phenotype
neural	I-Phenotype
crest	E-Phenotype
origin	O
.	O

Specific	O
loss	O
of	O
alleles	O
from	O
chromosome	O
22	O
was	O
detected	O
with	O
polymorphic	O
DNA	O
markers	O
in	O
two	O
acoustic	B-Phenotype
neuromas	E-Phenotype
,	O
two	O
neurofibromas	S-Phenotype
,	O
and	O
one	O
meningioma	S-Phenotype
from	O
BANF	S-Phenotype
patients	O
.	O

This	O
indicates	O
a	O
common	O
pathogenetic	O
mechanism	O
for	O
all	O
three	O
tumor	S-Phenotype
types	O
.	O

The	O
two	O
neurofibromas	S-Phenotype
were	O
among	O
three	O
taken	O
from	O
the	O
same	O
patient	O
,	O
and	O
both	O
showed	O
loss	O
of	O
identical	O
alleles	O
demonstrating	O
that	O
the	O
same	O
chromosome	O
suffered	O
deletion	O
in	O
both	O
tumors	S-Phenotype
.	O

The	O
third	O
neurofibroma	S-Phenotype
from	O
this	O
patient	O
showed	O
no	O
detectable	O
loss	O
of	O
heterozygosity	O
,	O
which	O
suggests	O
the	O
possibility	O
of	O
a	O
more	O
subtle	O
mutational	O
event	O
that	O
affects	O
chromosome	O
22	O
.	O

In	O
the	O
two	O
acoustic	B-Phenotype
neuromas	E-Phenotype
,	O
only	O
a	O
portion	O
of	O
chromosome	O
22	O
was	O
deleted	O
,	O
narrowing	O
the	O
possible	O
chromosomal	O
location	O
of	O
the	O
gene	O
that	O
causes	O
BANF	S-Phenotype
to	O
the	O
region	O
distal	O
to	O
the	O
D22S9	O
locus	O
in	O
band	O
22q11	O
.	O

The	O
identification	O
of	O
progressively	O
smaller	O
deletions	O
on	O
chromosome	O
22	O
in	O
these	O
tumor	S-Phenotype
types	O
may	O
well	O
provide	O
a	O
means	O
to	O
clone	O
and	O
characterize	O
the	O
defect	O
.	O

At	O
least	O
eight	O
provisional	O
categories	O
of	O
neurofibromatosis	S-Phenotype
have	O
been	O
proposed	O
.	O

Among	O
these	O
,	O
neurofibromatosis	S-Phenotype
1	O
(	O
von	O
Recklinghausen	O
's	O
disease	O
or	O
peripheral	O
neurofibromatosis	O
)	O
and	O
neurofibromatosis	O
2	O
(	O
central	O
or	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neurofibromatosis	E-Phenotype
)	O
have	O
been	O
established	O
as	O
distinct	O
disorders	O
.	O

We	O
studied	O
15	O
affected	O
male	O
and	O
8	O
affected	O
female	O
members	O
of	O
one	O
large	O
kindred	O
with	O
neurofibromatosis	S-Phenotype
2	O
.	O

None	O
of	O
the	O
patients	O
met	O
the	O
diagnostic	O
criteria	O
for	O
neurofibromatosis	S-Phenotype
1	O
.	O

Between	O
the	O
ages	O
of	O
15	O
and	O
53	O
years	O
,	O
the	O
patients	O
had	O
multiple	O
central	B-Phenotype
nervous	I-Phenotype
system	E-Phenotype
tumors	S-Phenotype
of	O
various	O
types	O
-	O
-	O
mainly	O
,	O
bilateral	S-Phenotype
acoustic	B-Phenotype
neuromas	E-Phenotype
.	O

Two	O
or	O
more	O
tumors	S-Phenotype
eventually	O
developed	O
in	O
20	O
of	O
the	O
patients	O
;	O
9	O
had	O
evidence	O
of	O
only	O
bilateral	S-Phenotype
acoustic	B-Phenotype
neuromas	E-Phenotype
.	O

Meningiomas	S-Phenotype
and	O
ependymomas	S-Phenotype
were	O
more	O
common	O
among	O
the	O
young	O
patients	O
;	O
those	O
who	O
initially	O
presented	O
with	O
acoustic	B-Phenotype
neuromas	E-Phenotype
were	O
nearly	O
a	O
decade	O
older	O
.	O

Intracranial	B-Phenotype
nontumoral	I-Phenotype
calcifications	E-Phenotype
were	O
present	O
in	O
most	O
patients	O
and	O
were	O
also	O
found	O
in	O
symptom	O
-	O
free	O
children	O
.	O

The	O
presence	O
of	O
such	O
lesions	O
is	O
probably	O
a	O
prodromic	O
feature	O
of	O
neurofibromatosis	S-Phenotype
2	O
.	O

Simultaneous	O
analysis	O
of	O
D22S1	O
and	O
IGLV	O
DNA	O
markers	O
for	O
coinheritance	O
with	O
neurofibromatosis	S-Phenotype
2	O
indicates	O
that	O
the	O
locus	O
for	O
the	O
disease	O
is	O
near	O
the	O
center	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
22	O
(	O
22q11.1	O
-	O
-	O
-	O
-	O
22q13.1	O
)	O
.	O

The	O
eventual	O
isolation	O
of	O
this	O
disease	O
gene	O
may	O
reveal	O
a	O
cause	O
of	O
the	O
most	O
common	O
intracranial	B-Phenotype
tumors	E-Phenotype
in	O
humans	O
.	O

We	O
describe	O
a	O
new	O
family	O
with	O
the	O
Townes	O
-	O
Brocks	O
syndrome	O
,	O
a	O
dominantly	O
inherited	O
syndrome	O
of	O
anal	B-Phenotype
,	I-Phenotype
urorenal	I-Phenotype
,	I-Phenotype
ear	I-Phenotype
and	I-Phenotype
limb	I-Phenotype
malformations	E-Phenotype
.	O

The	O
proband	O
shows	O
the	O
full	O
spectrum	O
of	O
anomalies	O
,	O
including	O
imperforate	B-Phenotype
anus	E-Phenotype
,	O
prominent	B-Phenotype
perineal	I-Phenotype
raphe	E-Phenotype
,	O
rectoperineal	B-Phenotype
fistula	E-Phenotype
,	O
triphalangeal	B-Phenotype
thumb	E-Phenotype
,	O
preaxial	B-Phenotype
hexadactyly	E-Phenotype
,	O
syndactyly	S-Phenotype
,	O
clinodactyly	S-Phenotype
,	O
preauricular	B-Phenotype
protuberances	E-Phenotype
,	O
hypoplastic	B-Phenotype
satyr	I-Phenotype
ears	E-Phenotype
,	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
and	O
urorenal	B-Phenotype
anomalies	E-Phenotype
.	O

In	O
contrast	O
,	O
the	O
father	O
shows	O
only	O
limb	B-Phenotype
anomalies	E-Phenotype
,	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
and	O
renal	B-Phenotype
anomalies	E-Phenotype
.	O

Anorectal	B-Phenotype
malformations	E-Phenotype
,	O
which	O
are	O
present	O
in	O
almost	O
every	O
patient	O
with	O
the	O
Townes	O
-	O
Brocks	O
syndrome	O
,	O
were	O
absent	O
in	O
the	O
father	O
.	O

This	O
case	O
report	O
illustrates	O
the	O
intrafamilial	O
variability	O
of	O
the	O
Townes	O
-	O
Brocks	O
syndrome	O
.	O

Consequently	O
,	O
careful	O
examination	O
of	O
relatives	O
of	O
patients	O
with	O
this	O
syndrome	O
is	O
necessary	O
for	O
the	O
differential	O
diagnosis	O
with	O
the	O
sporadically	O
inherited	O
VA	O
(	O
C	O
)	O
TER	O
(	O
L	O
)	O
association	O
.	O

The	O
diagnosis	O
,	O
size	O
and	O
operation	O
results	O
in	O
41	O
acoustic	B-Phenotype
neurinomas	E-Phenotype
(	O
26	O
females	O
and	O
15	O
males	O
)	O
are	O
presented	O
.	O

In	O
one	O
case	O
the	O
tumor	S-Phenotype
was	O
bilateral	O
.	O

Out	O
of	O
the	O
total	O
of	O
41	O
tumors	S-Phenotype
,	O
12.5	O
%	O
were	O
small	O
acoustic	B-Phenotype
neurinomas	E-Phenotype
.	O

As	O
a	O
rule	O
,	O
at	O
diagnosis	O
the	O
tumors	S-Phenotype
were	O
larger	O
in	O
females	O
than	O
in	O
males	O
.	O

Ten	O
of	O
the	O
small	O
and	O
medium	O
size	O
acoustic	B-Phenotype
neurinomas	E-Phenotype
had	O
no	O
brain	O
stem	O
and	O
cerebellar	B-Phenotype
symptoms	E-Phenotype
or	O
signs	O
at	O
all	O
,	O
only	O
the	O
8th	B-Phenotype
cranial	I-Phenotype
nerve	E-Phenotype
was	O
affected	O
.	O

All	O
large	O
tumors	S-Phenotype
already	O
had	O
brain	B-Phenotype
stem	I-Phenotype
symptoms	E-Phenotype
and	O
one	O
-	O
third	O
of	O
them	O
also	O
had	O
cerebellar	B-Phenotype
symptoms	E-Phenotype
,	O
lesions	B-Phenotype
of	I-Phenotype
further	I-Phenotype
cranial	I-Phenotype
nerves	E-Phenotype
and	O
increasing	B-Phenotype
intracranial	I-Phenotype
pressure	E-Phenotype
.	O

All	O
these	O
findings	O
were	O
always	O
present	O
in	O
giant	O
tumors	S-Phenotype
.	O

Neurootological	O
functional	O
laboratory	O
examinations	O
can	O
not	O
be	O
replaced	O
by	O
CT	O
because	O
of	O
the	O
possibility	O
of	O
false	O
negative	O
findings	O
in	O
the	O
smallest	O
acoustic	B-Phenotype
neurinomas	E-Phenotype
.	O

CT	O
and	O
functional	O
neurootological	O
laboratory	O
examinations	O
are	O
complementary	O
to	O
each	O
other	O
and	O
they	O
are	O
not	O
screening	O
procedures	O
at	O
all	O
.	O

As	O
regards	O
morbidity	O
and	O
mortality	O
,	O
the	O
surgical	O
results	O
are	O
comparable	O
with	O
those	O
of	O
other	O
authors	O
using	O
microsurgical	O
techniques	O
.	O

As	O
regards	O
the	O
preservation	O
of	O
hearing	O
,	O
the	O
results	O
are	O
among	O
the	O
best	O
particularly	O
in	O
tumors	S-Phenotype
that	O
were	O
diagnosed	O
as	O
small	O
or	O
medium	O
in	O
this	O
series	O
.	O

Thus	O
it	O
is	O
apparent	O
that	O
the	O
size	O
of	O
a	O
diagnosed	O
acoustic	B-Phenotype
neurinoma	E-Phenotype
is	O
more	O
important	O
for	O
surgical	O
results	O
than	O
the	O
chosen	O
approach	O
to	O
the	O
tumor	S-Phenotype
.	O

We	O
report	O
a	O
type	B-Phenotype
C	I-Phenotype
brachydactyly	E-Phenotype
transmitted	O
through	O
four	O
generations	O
,	O
with	O
incomplete	O
penetrance	O
and	O
feet	B-Phenotype
abnormalities	E-Phenotype
in	O
the	O
proposita	O
.	O

We	O
report	O
the	O
prenatal	O
diagnosis	O
of	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
I	O
by	O
ultrasound	O
at	O
18	O
wk	O
gestation	O
in	O
a	O
family	O
with	O
two	O
other	O
affected	O
members	O
(	O
mother	O
and	O
sister	O
of	O
the	O
fetus	O
)	O
.	O

The	O
pregnancy	O
was	O
followed	O
with	O
serial	O
ultrasounds	O
,	O
and	O
the	O
diagnosis	O
was	O
confirmed	O
after	O
birth	O
.	O

The	O
clinical	O
findings	O
in	O
all	O
affected	O
family	O
members	O
are	O
described	O
.	O

A	O
literature	O
survey	O
of	O
prenatally	O
diagnosed	O
cases	O
of	O
multiple	B-Phenotype
joint	I-Phenotype
contractures	E-Phenotype
is	O
presented	O
.	O

These	O
include	O
cases	O
with	O
many	O
different	O
diagnoses	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
prenatal	O
diagnosis	O
of	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
I	O
.	O

It	O
helps	O
to	O
illustrate	O
the	O
variability	O
and	O
prenatal	O
natural	O
history	O
of	O
the	O
condition	O
and	O
the	O
subtlety	O
of	O
the	O
prenatal	O
ultrasound	O
findings	O
.	O

We	O
report	O
on	O
two	O
sibs	O
with	O
Angelman	O
``	O
happy	B-Phenotype
puppet	E-Phenotype
''	O
syndrome	O
.	O

Out	O
of	O
48	O
families	O
reported	O
in	O
the	O
literature	O
,	O
this	O
is	O
only	O
the	O
fourth	O
family	O
with	O
affected	O
sibs	O
.	O

A	O
review	O
of	O
the	O
literature	O
shows	O
a	O
low	O
but	O
not	O
negligible	O
recurrence	O
risk	O
.	O

Different	O
explanations	O
for	O
this	O
are	O
discussed	O
.	O

We	O
observed	O
an	O
autosomal	O
dominant	O
disorder	O
of	O
abnormal	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
which	O
resembles	O
a	O
poorly	O
repaired	O
cleft	B-Phenotype
lip	E-Phenotype
,	O
malformed	B-Phenotype
nose	E-Phenotype
with	O
broad	B-Phenotype
bridge	E-Phenotype
and	O
flattened	B-Phenotype
tip	E-Phenotype
,	O
lacrimal	B-Phenotype
duct	I-Phenotype
obstruction	E-Phenotype
,	O
malformed	B-Phenotype
ears	E-Phenotype
,	O
and	O
branchial	B-Phenotype
cleft	I-Phenotype
sinuses	E-Phenotype
and	O
/	O
or	O
linear	B-Phenotype
skin	I-Phenotype
lesions	I-Phenotype
behind	I-Phenotype
the	I-Phenotype
ears	E-Phenotype
in	O
several	O
persons	O
in	O
3	O
families	O
.	O

In	O
each	O
of	O
the	O
3	O
families	O
,	O
an	O
affected	O
parent	O
had	O
at	O
least	O
one	O
affected	O
child	O
.	O

Father	O
-	O
to	O
-	O
son	O
transmission	O
in	O
one	O
of	O
these	O
families	O
ruled	O
out	O
X	O
-	O
linked	O
inheritance	O
.	O

Other	O
anomalies	O
include	O
coloboma	S-Phenotype
,	O
microphthalmia	S-Phenotype
,	O
auricular	B-Phenotype
pits	E-Phenotype
,	O
lip	B-Phenotype
pits	E-Phenotype
,	O
highly	B-Phenotype
arched	I-Phenotype
plate	E-Phenotype
,	O
dental	B-Phenotype
anomalies	E-Phenotype
,	O
and	O
subcutaneous	B-Phenotype
cysts	E-Phenotype
of	O
the	O
scalp	O
.	O

Premature	B-Phenotype
graying	I-Phenotype
of	I-Phenotype
hair	E-Phenotype
occurred	O
in	O
the	O
affected	O
adults	O
.	O

Growth	B-Phenotype
retardation	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
hand	B-Phenotype
anomalies	E-Phenotype
are	O
variable	O
components	O
of	O
the	O
syndrome	O
.	O

An	O
EEG	O
study	O
has	O
been	O
carried	O
out	O
on	O
19	O
children	O
(	O
including	O
siblings	O
in	O
3	O
families	O
)	O
with	O
clinical	O
features	O
of	O
Angelman	O
syndrome	O
.	O

The	O
age	O
at	O
time	O
of	O
the	O
first	O
EEG	O
ranged	O
from	O
11	O
months	O
to	O
11	O
years	O
with	O
the	O
majority	O
under	O
5	O
years	O
.	O

Six	O
children	O
had	O
no	O
history	O
of	O
seizures	S-Phenotype
at	O
the	O
time	O
of	O
the	O
first	O
EEG	O
.	O

One	O
or	O
more	O
of	O
the	O
following	O
EEG	B-Phenotype
abnormalities	E-Phenotype
were	O
seen	O
in	O
all	O
patients	O
:	O
1	O
.	O

Persistent	B-Phenotype
rhythmic	I-Phenotype
4	I-Phenotype
-	I-Phenotype
6	I-Phenotype
/	I-Phenotype
s	I-Phenotype
activities	E-Phenotype
reaching	O
more	O
than	O
200	O
microV	O
not	O
associated	O
with	O
drowsiness	S-Phenotype
.	O

2	O
.	O

Prolonged	O
runs	O
of	O
rhythmic	O
2	O
-	O
3	O
/	O
s	O
activity	O
(	O
200	O
-	O
500	O
microV	O
)	O
often	O
more	O
prominent	O
anteriorly	O
,	O
sometimes	O
associated	O
with	O
discharges	O
(	O
ill	O
-	O
defined	O
spike	O
/	O
wave	O
complexes	O
)	O
.	O

3	O
.	O

Spikes	O
mixed	O
with	O
3	O
-	O
4	O
/	O
s	O
components	O
usually	O
more	O
than	O
200	O
microV	O
mainly	O
posteriorly	O
and	O
facilitated	O
by	O
,	O
or	O
only	O
seen	O
with	O
,	O
eye	O
closure	O
.	O

Two	O
and	O
sometimes	O
three	O
of	O
these	O
EEG	O
features	O
could	O
be	O
present	O
in	O
the	O
same	O
record	O
particularly	O
at	O
a	O
young	O
age	O
.	O

The	O
appearance	O
of	O
discharges	O
mixed	O
with	O
slow	O
components	O
on	O
eye	O
closure	O
was	O
the	O
commonest	O
finding	O
seen	O
at	O
some	O
stage	O
in	O
17	O
patients	O
(	O
aged	O
from	O
11	O
months	O
to	O
over	O
12	O
years	O
)	O
.	O

The	O
EEG	O
features	O
of	O
Angelman	O
syndrome	O
appear	O
to	O
be	O
sufficiently	O
characteristic	O
to	O
help	O
identify	O
patients	O
at	O
an	O
early	O
age	O
before	O
the	O
clinical	O
features	O
become	O
obvious	O
and	O
at	O
a	O
time	O
when	O
genetic	O
counselling	O
may	O
be	O
particularly	O
important	O
.	O

The	O
nevoid	O
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
is	O
characterized	O
by	O
major	O
manifestations	O
,	O
such	O
as	O
multiple	O
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
carcinomata	E-Phenotype
,	O
cysts	B-Phenotype
of	I-Phenotype
the	I-Phenotype
jaws	E-Phenotype
,	O
and	O
skeletal	B-Phenotype
-	I-Phenotype
-	I-Phenotype
specifically	E-Phenotype
,	O
rib	B-Phenotype
-	I-Phenotype
-	I-Phenotype
abnormalities	E-Phenotype
.	O

Findings	O
in	O
53	O
patients	O
and	O
a	O
review	O
of	O
the	O
literature	O
document	O
both	O
major	O
and	O
lesser	O
-	O
known	O
manifestations	O
of	O
the	O
disorder	O
.	O

The	O
odontogenic	B-Phenotype
keratocyst	E-Phenotype
,	O
which	O
usually	O
appears	O
during	O
adolescence	O
,	O
has	O
a	O
marked	O
tendency	O
to	O
recur	O
.	O

In	O
addition	O
to	O
the	O
skin	B-Phenotype
tumors	E-Phenotype
,	O
milia	S-Phenotype
,	O
epidermoid	B-Phenotype
cysts	E-Phenotype
,	O
chalazia	S-Phenotype
,	O
comedones	S-Phenotype
,	O
and	O
palmar	B-Phenotype
and	I-Phenotype
plantar	I-Phenotype
pits	E-Phenotype
are	O
frequent	O
.	O

The	O
skin	B-Phenotype
tumors	E-Phenotype
,	O
originally	O
thought	O
to	O
be	O
independent	O
of	O
sun	O
exposure	O
,	O
are	O
more	O
common	O
in	O
sun	O
-	O
exposed	O
areas	O
and	O
are	O
far	O
less	O
frequent	O
and	O
occur	O
at	O
a	O
much	O
later	O
age	O
in	O
blacks	O
than	O
in	O
whites	O
.	O

There	O
is	O
some	O
evidence	O
that	O
radiation	O
of	O
the	O
skin	O
promotes	O
the	O
appearance	O
of	O
skin	B-Phenotype
cancers	E-Phenotype
in	O
this	O
disorder	O
.	O

Unilateral	O
linear	O
nevoid	O
basal	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
with	O
comedones	S-Phenotype
may	O
represent	O
postzygotic	O
somatic	O
mutation	O
.	O

A	O
proclivity	O
to	O
other	O
forms	O
of	O
neoplasia	S-Phenotype
exists	O
.	O

Patients	O
with	O
this	O
syndrome	O
have	O
had	O
medulloblastoma	S-Phenotype
,	O
meningioma	S-Phenotype
,	O
ovarian	B-Phenotype
fibroma	E-Phenotype
,	O
ovarian	S-Phenotype
fibrosarcoma	S-Phenotype
,	O
fibrosarcoma	O
of	O
the	O
jaws	O
,	O
cardiac	B-Phenotype
fibroma	E-Phenotype
,	O
fetal	O
rhabdomyoma	S-Phenotype
,	O
and	O
lymphatic	O
or	O
chylous	O
cysts	O
of	O
the	O
mesentery	O
.	O

In	O
addition	O
to	O
the	O
usual	O
modalities	O
of	O
treatment	O
,	O
topical	O
immunotherapy	O
and	O
topical	O
5	O
-	O
fluorouracil	O
have	O
been	O
used	O
with	O
success	O
.	O

Oral	O
synthetic	O
retinoids	O
,	O
such	O
as	O
13	O
-	O
cis	O
-	O
retinoic	O
acid	O
,	O
have	O
been	O
used	O
to	O
prevent	O
new	O
lesions	O
from	O
appearing	O
and	O
to	O
arrest	O
the	O
growth	O
of	O
older	O
lesions	O
by	O
inducing	O
differentiation	O
.	O

The	O
independent	O
observations	O
of	O
increased	O
prostaglandin	O
levels	O
associated	O
both	O
with	O
odontogenic	B-Phenotype
keratocyst	E-Phenotype
expansion	O
and	O
aggression	S-Phenotype
of	O
basal	B-Phenotype
cell	I-Phenotype
cancers	E-Phenotype
merit	O
further	O
investigation	O
both	O
as	O
a	O
fundamental	O
cellular	O
mechanism	O
and	O
as	O
a	O
possible	O
basis	O
for	O
treatment	O
(	O
e.g.	O
,	O
with	O
antiprostaglandins	O
)	O
.	O

The	O
key	O
to	O
pre	O
-	O
and	O
early	O
postnatal	O
diagnosis	O
of	O
the	O
disorder	O
-	O
-	O
as	O
well	O
as	O
to	O
an	O
understanding	O
of	O
the	O
basic	O
abnormality	O
-	O
-	O
lies	O
in	O
molecular	O
genetics	O
.	O

Prime	O
attention	O
should	O
be	O
given	O
to	O
finding	O
the	O
site	O
of	O
the	O
gene	O
through	O
the	O
use	O
of	O
DNA	O
and	O
other	O
markers	O
.	O

We	O
report	O
a	O
girl	O
aged	O
11	O
and	O
her	O
brother	O
aged	O
five	O
,	O
both	O
with	O
the	O
typical	O
features	O
of	O
Angelman	O
syndrome	O
,	O
and	O
three	O
isolated	O
cases	O
.	O

This	O
report	O
,	O
together	O
with	O
a	O
review	O
of	O
published	O
reports	O
and	O
contact	O
with	O
previous	O
authors	O
,	O
has	O
revealed	O
a	O
total	O
of	O
41	O
sibs	O
of	O
probands	O
,	O
although	O
only	O
nine	O
of	O
these	O
are	O
known	O
to	O
have	O
been	O
later	O
born	O
.	O

The	O
possible	O
effect	O
of	O
voluntary	O
restriction	O
of	O
family	O
size	O
after	O
the	O
birth	O
of	O
an	O
affected	O
child	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
possibility	O
of	O
autosomal	O
recessive	O
inheritance	O
,	O
but	O
a	O
recurrence	O
risk	O
of	O
5	O
%	O
is	O
appropriate	O
for	O
use	O
in	O
the	O
genetic	O
clinic	O
.	O

Deletions	O
,	O
duplications	O
,	O
and	O
rearrangements	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
are	O
frequently	O
associated	O
with	O
the	O
clinical	O
diagnosis	O
of	O
the	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

However	O
,	O
a	O
number	O
of	O
other	O
clinical	O
entities	O
have	O
also	O
been	O
associated	O
with	O
similar	O
,	O
if	O
not	O
identical	O
,	O
cytogenetic	O
defects	O
,	O
arguing	O
for	O
clinical	O
heterogeneity	O
associated	O
with	O
abnormalities	O
in	O
this	O
region	O
of	O
chromosome	O
15	O
.	O

We	O
present	O
3	O
patients	O
who	O
all	O
appear	O
to	O
have	O
deletions	O
in	O
15q11	O
-	O
15q12	O
,	O
such	O
as	O
described	O
for	O
many	O
patients	O
with	O
Prader	O
-	O
Willi	O
syndrome	O
;	O
however	O
,	O
none	O
of	O
these	O
patients	O
has	O
classical	O
clinical	O
features	O
of	O
the	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

The	O
first	O
patient	O
is	O
a	O
child	O
with	O
Williams	O
syndrome	O
,	O
the	O
second	O
,	O
Angelman	O
(	O
Happy	O
Puppet	O
)	O
syndrome	O
,	O
and	O
the	O
third	O
is	O
a	O
child	O
with	O
hypotonia	B-Phenotype
of	I-Phenotype
infancy	E-Phenotype
,	O
obesity	S-Phenotype
,	O
and	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
but	O
who	O
does	O
not	O
meet	O
specific	O
diagnostic	O
criteria	O
for	O
the	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

It	O
is	O
proposed	O
that	O
different	O
molecular	O
abnormalities	O
involving	O
specific	O
points	O
or	O
segments	O
along	O
the	O
long	O
arm	O
of	O
chromosome	O
15	O
might	O
account	O
for	O
the	O
clinical	O
diversity	O
seen	O
among	O
these	O
and	O
other	O
patients	O
.	O

Two	O
unrelated	O
females	O
,	O
age	O
15	O
and	O
5	O
years	O
respectively	O
,	O
were	O
studied	O
cytogenetically	O
because	O
of	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
seizures	S-Phenotype
and	O
ataxia	S-Phenotype
-	O
like	O
incoordination	S-Phenotype
.	O

A	O
similar	O
deletion	O
of	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
was	O
found	O
in	O
both	O
patients	O
.	O

Re	O
-	O
evaluation	O
showed	O
no	O
voracious	B-Phenotype
appetite	E-Phenotype
or	O
obesity	S-Phenotype
;	O
normal	O
size	O
of	O
hands	O
and	O
feet	O
,	O
minimal	O
to	O
no	O
hypotonia	S-Phenotype
by	O
history	O
or	O
examination	O
and	O
facial	O
features	O
not	O
typical	O
of	O
the	O
Prader	O
-	O
Willi	O
syndrome	O
.	O

However	O
,	O
the	O
facial	B-Phenotype
appearance	E-Phenotype
of	O
the	O
girls	O
was	O
similar	O
to	O
each	O
other	O
with	O
mild	O
hypertelorism	S-Phenotype
.	O

The	O
similarity	O
of	O
these	O
girls	O
and	O
dissimilarity	O
to	O
Prader	O
-	O
Willi	O
syndrome	O
suggest	O
a	O
different	O
syndrome	O
,	O
perhaps	O
the	O
result	O
of	O
deletion	O
of	O
a	O
different	O
segment	O
of	O
15q	O
.	O

The	O
findings	O
of	O
ataxic	B-Phenotype
-	I-Phenotype
like	I-Phenotype
movements	E-Phenotype
,	O
frequent	B-Phenotype
,	I-Phenotype
unprovoked	I-Phenotype
and	I-Phenotype
prolonged	I-Phenotype
bouts	I-Phenotype
of	I-Phenotype
laughter	E-Phenotype
and	O
facial	B-Phenotype
appearance	E-Phenotype
are	O
more	O
compatible	O
with	O
the	O
diagnosis	O
of	O
Angelman	O
syndrome	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	B-Phenotype
dysplasia	E-Phenotype
,	O
often	O
called	O
the	O
BOR	O
syndrome	O
,	O
in	O
its	O
full	O
expression	O
consists	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
of	O
conductive	O
,	O
sensorineural	O
,	O
or	O
mixed	O
type	O
;	O
preauricular	B-Phenotype
pits	E-Phenotype
;	O
auricular	O
deformities	O
;	O
lateral	B-Phenotype
cervical	I-Phenotype
sinuses	E-Phenotype
,	O
cysts	O
,	O
or	O
fistulas	S-Phenotype
;	O
and	O
renal	B-Phenotype
malformations	E-Phenotype
.	O

The	O
condition	O
is	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
mode	O
.	O

The	O
findings	O
in	O
three	O
affected	O
families	O
are	O
described	O
,	O
and	O
pertinent	O
genetic	O
and	O
clinical	O
aspects	O
are	O
discussed	O
.	O

The	O
potential	O
seriousness	O
of	O
the	O
renal	O
and	O
aural	O
malformations	O
stresses	O
the	O
importance	O
of	O
early	O
recognition	O
of	O
this	O
syndrome	O
.	O

Short	B-Phenotype
stature	E-Phenotype
may	O
be	O
a	O
component	O
of	O
the	O
brachydactyly	B-Phenotype
C	E-Phenotype
syndrome	O
.	O

A	O
family	O
is	O
presented	O
in	O
which	O
the	O
propositus	O
has	O
brachydactyly	B-Phenotype
C	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
and	O
hip	B-Phenotype
dysplasia	E-Phenotype
.	O

Branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
is	O
a	O
developmental	O
complex	O
presenting	O
with	O
various	O
combinations	O
of	O
ear	B-Phenotype
pits	E-Phenotype
,	O
branchial	B-Phenotype
cleft	E-Phenotype
cysts	O
,	O
deafness	S-Phenotype
and	O
renal	B-Phenotype
anomalies	E-Phenotype
,	O
which	O
is	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

This	O
report	O
describes	O
a	O
father	O
and	O
2	O
children	O
with	O
BOR	O
syndrome	O
in	O
which	O
gustatory	B-Phenotype
lacrimation	E-Phenotype
(	O
GL	O
)	O
was	O
also	O
present	O
in	O
2	O
of	O
them	O
.	O

GL	O
is	O
considered	O
to	O
be	O
a	O
rare	O
,	O
non	O
-	O
hereditary	O
type	O
of	O
anomalous	O
,	O
cranial	B-Phenotype
nerve	I-Phenotype
-	I-Phenotype
end	I-Phenotype
organ	I-Phenotype
innervation	E-Phenotype
.	O

Since	O
lacrimal	B-Phenotype
stenosis	E-Phenotype
,	O
which	O
can	O
clinically	O
mimic	O
GL	O
,	O
is	O
also	O
a	O
feature	O
of	O
the	O
BOR	O
syndrome	O
,	O
future	O
reports	O
require	O
lacrimal	O
reflex	O
testing	O
and	O
duct	O
patency	O
evaluation	O
to	O
define	O
this	O
variation	O
in	O
the	O
BOR	O
phenotype	O
.	O

We	O
have	O
reviewed	O
a	O
series	O
of	O
36	O
patients	O
with	O
the	O
basal	B-Phenotype
cell	I-Phenotype
nevus	E-Phenotype
syndrome	O
seen	O
at	O
Roswell	O
Park	O
Memorial	O
Institute	O
from	O
1950	O
to	O
1978	O
.	O

Among	O
these	O
patients	O
a	O
number	O
of	O
disastrous	O
complications	O
occurred	O
.	O

These	O
include	O
extensive	O
uncontrolled	O
basal	B-Phenotype
cell	I-Phenotype
epithelioma	E-Phenotype
of	O
the	O
face	O
resulting	O
in	O
one	O
death	O
from	O
direct	O
cerebral	O
invasion	O
via	O
the	O
orbit	O
,	O
one	O
facial	B-Phenotype
nerve	I-Phenotype
palsy	E-Phenotype
,	O
two	O
bilateral	O
and	O
two	O
unilateral	O
eye	B-Phenotype
enucleations	E-Phenotype
,	O
and	O
several	O
severe	O
facial	B-Phenotype
mutilations	E-Phenotype
in	O
young	O
patients	O
.	O

There	O
were	O
three	O
patients	O
who	O
developed	O
severe	O
bradycardia	S-Phenotype
and	O
hypotension	S-Phenotype
during	O
induction	O
of	O
general	O
anesthesia	O
required	O
postponement	O
of	O
the	O
intended	O
operation	O
,	O
and	O
one	O
patient	O
with	O
congenital	B-Phenotype
hemiparesis	E-Phenotype
who	O
on	O
investigation	O
was	O
found	O
to	O
have	O
an	O
absent	B-Phenotype
internal	I-Phenotype
carotid	I-Phenotype
artery	E-Phenotype
.	O

A	O
review	O
of	O
the	O
syndrome	O
complex	O
is	O
presented	O
with	O
a	O
plan	O
for	O
recognition	O
and	O
management	O
.	O

A	O
17	O
-	O
year	O
-	O
old	O
girl	O
presented	O
with	O
an	O
enlarged	B-Phenotype
cardiac	I-Phenotype
silhouette	E-Phenotype
on	O
routine	O
chest	O
roentgenogram	O
.	O

After	O
clinical	O
evaluation	O
,	O
echocardiography	O
,	O
and	O
pericardiocentesis	O
failed	O
to	O
provide	O
a	O
diagnosis	O
,	O
exploratory	O
thoracotomy	O
and	O
biopsy	O
revealed	O
an	O
unresectable	O
left	B-Phenotype
ventricular	I-Phenotype
fibroma	E-Phenotype
.	O

The	O
tumor	S-Phenotype
continued	O
to	O
enlarge	O
and	O
began	O
causing	O
ventricular	B-Phenotype
arrhythmia	E-Phenotype
.	O

Therefore	O
,	O
she	O
underwent	O
cardiac	O
transplantation	O
2	O
years	O
after	O
the	O
initial	O
diagnosis	O
was	O
made	O
.	O

She	O
is	O
now	O
alive	O
nd	O
well	O
18	O
months	O
following	O
transplantation	O
.	O

Three	O
families	O
are	O
presented	O
,	O
one	O
with	O
branchio	O
-	O
oto	O
-	O
renal	B-Phenotype
dysplasia	E-Phenotype
(	O
BOR	O
)	O
and	O
two	O
with	O
branchio	O
-	O
oto	O
dysplasia	O
(	O
BO	O
)	O
.	O

The	O
former	O
syndrome	O
is	O
characterized	O
by	O
external	B-Phenotype
ear	I-Phenotype
malformations	E-Phenotype
,	O
cervical	B-Phenotype
fistulae	E-Phenotype
,	O
mixed	S-Phenotype
hearing	B-Phenotype
loss	E-Phenotype
and	O
renal	B-Phenotype
anomalies	E-Phenotype
of	O
varying	O
severity	O
.	O

The	O
latter	O
syndrome	O
differs	O
in	O
that	O
there	O
are	O
no	O
renal	B-Phenotype
anomalies	E-Phenotype
and	O
that	O
the	O
sensorineural	O
component	O
of	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
may	O
be	O
absent	O
.	O

The	O
external	B-Phenotype
ear	I-Phenotype
malformations	E-Phenotype
are	O
quite	O
variable	O
in	O
both	O
syndromes	O
.	O

Evidence	O
is	O
presented	O
which	O
supports	O
the	O
idea	O
that	O
these	O
two	O
syndromes	O
are	O
not	O
phenotypic	O
variants	O
of	O
the	O
same	O
autosomal	O
dominant	O
mutation	O
but	O
distinct	O
disease	O
entities	O
.	O

The	O
BOR	O
syndrome	O
appears	O
to	O
belong	O
to	O
a	O
larger	O
group	O
of	O
hereditary	O
ear	B-Phenotype
dysplasia	E-Phenotype
-	O
renal	B-Phenotype
adysplasia	E-Phenotype
syndromes	O
that	O
must	O
be	O
carefully	O
ruled	O
out	O
in	O
all	O
patients	O
with	O
familial	O
branchial	B-Phenotype
arch	I-Phenotype
malformations	E-Phenotype
as	O
well	O
as	O
in	O
the	O
parents	O
and	O
siblings	O
of	O
infants	O
with	O
``	O
Potter	B-Phenotype
facies	E-Phenotype
''	O
in	O
the	O
presence	O
of	O
auricular	B-Phenotype
malformation	E-Phenotype
and	O
renal	O
adysplasia	O
.	O

A	O
young	O
girl	O
12	O
old	O
,	O
sent	O
to	O
us	O
for	O
obesity	S-Phenotype
,	O
and	O
coxa	B-Phenotype
-	I-Phenotype
epiphysiolysis	E-Phenotype
showed	O
signs	O
of	O
mental	S-Phenotype
retardation	S-Phenotype
and	O
bilateral	O
thumb	B-Phenotype
ankylosis	E-Phenotype
.	O

The	O
fact	O
that	O
the	O
mother	O
was	O
also	O
affected	O
by	O
both	O
of	O
these	O
signs	O
,	O
led	O
to	O
a	O
more	O
detailed	O
genetic	O
research	O
.	O

The	O
latter	O
revealed	O
that	O
not	O
only	O
the	O
daughter	O
,	O
the	O
mother	O
,	O
but	O
also	O
their	O
own	O
mother	O
and	O
may	O
be	O
,	O
the	O
sister	O
,	O
the	O
grand	O
-	O
mother	O
and	O
the	O
great	O
-	O
aunt	O
of	O
the	O
patient	O
had	O
a	O
retardation	S-Phenotype
,	O
a	O
slight	B-Phenotype
dysmorphia	E-Phenotype
,	O
a	O
type	B-Phenotype
A	I-Phenotype
brachydactylia	I-Phenotype
,	E-Phenotype
signs	O
of	O
obesity	S-Phenotype
and	O
an	O
identical	O
ankylosis	B-Phenotype
of	I-Phenotype
both	I-Phenotype
thumbs	E-Phenotype
.	O

This	O
vertical	O
inheritance	O
,	O
affecting	O
apparently	O
females	O
only	O
,	O
but	O
not	O
associated	O
with	O
a	O
high	O
rate	O
of	O
miscarriage	O
,	O
has	O
,	O
it	O
seems	O
,	O
never	O
been	O
reported	O
.	O

The	O
characteristics	O
of	O
this	O
family	O
are	O
being	O
considered	O
and	O
discussed	O
.	O

This	O
is	O
a	O
report	O
on	O
a	O
child	O
with	O
sensorineural	B-Phenotype
deafness	E-Phenotype
,	O
imperforate	B-Phenotype
anus	E-Phenotype
with	O
rectovaginal	B-Phenotype
fistula	E-Phenotype
,	O
hypoplastic	B-Phenotype
thumb	E-Phenotype
,	O
and	O
congenital	B-Phenotype
heart	I-Phenotype
defect	E-Phenotype
.	O

This	O
pattern	O
of	O
congenital	O
anomalies	O
is	O
similar	O
to	O
that	O
described	O
in	O
patients	O
with	O
the	O
Townes	O
-	O
Brocks	O
syndrome	O
,	O
although	O
the	O
present	O
patient	O
has	O
characteristics	O
that	O
have	O
not	O
been	O
reported	O
previously	O
in	O
this	O
syndrome	O
.	O

It	O
is	O
proposed	O
that	O
the	O
clinical	O
spectrum	O
of	O
the	O
Townes	O
-	O
Brocks	O
syndrome	O
must	O
be	O
extended	O
to	O
include	O
congenital	B-Phenotype
heart	I-Phenotype
defect	E-Phenotype
,	O
auricular	B-Phenotype
changes	E-Phenotype
differing	O
from	O
those	O
previously	O
described	O
,	O
and	O
anomalies	O
of	O
other	O
internal	O
organs	O
.	O

The	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
trait	O
.	O

The	O
present	O
case	O
may	O
represent	O
a	O
de	O
novo	O
mutation	O
.	O

Neurofibromatosis	S-Phenotype
includes	O
the	O
common	O
``	O
peripheral	O
''	O
form	O
and	O
a	O
recently	O
documented	O
``	O
central	O
''	O
form	O
.	O

We	O
describe	O
the	O
central	O
form	O
in	O
130	O
cases	O
from	O
9	O
kindreds	O
personally	O
studied	O
and	O
15	O
reported	O
kindreds	O
.	O

Central	O
neurofibromatosis	S-Phenotype
with	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neuroma	E-Phenotype
is	O
an	O
autosomal	O
dominant	O
disorder	O
beginning	O
about	O
20	O
years	O
of	O
age	O
,	O
accompanied	O
by	O
mild	O
skin	B-Phenotype
changes	E-Phenotype
.	O

In	O
three	O
kindreds	O
with	O
central	O
neurofibromatosis	S-Phenotype
,	O
we	O
measured	O
nerve	O
growth	O
factor	O
in	O
serum	O
by	O
radioimmunoassay	O
and	O
radioreceptor	O
assay	O
.	O

Only	O
the	O
antigenic	O
activity	O
of	O
nerve	O
growth	O
factor	O
was	O
increased	O
.	O

In	O
contrast	O
,	O
in	O
peripheral	O
neurofibromatosis	S-Phenotype
,	O
only	O
the	O
functional	O
activity	O
of	O
nerve	O
growth	O
factor	O
has	O
been	O
reported	O
increased	O
.	O

Central	O
and	O
peripheral	O
forms	O
of	O
neurofibromatosis	S-Phenotype
are	O
closely	O
related	O
but	O
discrete	O
diseases	O
which	O
appear	O
to	O
have	O
separate	O
alterations	O
in	O
nerve	O
growth	O
factor	O
activity	O
.	O

We	O
report	O
a	O
man	O
who	O
had	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
with	O
crossed	O
renal	B-Phenotype
ectopia	E-Phenotype
.	O

His	O
three	O
children	O
were	O
born	O
with	O
bilateral	B-Phenotype
renal	I-Phenotype
agenesis	E-Phenotype
and	O
the	O
so	O
-	O
called	O
Potter	B-Phenotype
syndrome	E-Phenotype
.	O

This	O
case	O
illustrates	O
the	O
potential	O
severity	O
of	O
the	O
renal	B-Phenotype
anomalies	E-Phenotype
in	O
the	O
BOR	O
syndrome	O
and	O
the	O
inadequacy	O
of	O
oligohydramnios	S-Phenotype
and	O
maternal	O
serum	O
alpha	O
-	O
fetoprotein	O
as	O
screening	O
methods	O
for	O
renal	B-Phenotype
agenesis	E-Phenotype
.	O

This	O
case	O
also	O
implies	O
strongly	O
the	O
necessity	O
for	O
meticulous	O
search	O
for	O
renal	B-Phenotype
anomalies	E-Phenotype
in	O
individuals	O
with	O
the	O
BOR	O
syndrome	O
and	O
proper	O
counseling	O
regarding	O
the	O
possibility	O
of	O
lethal	O
bilateral	B-Phenotype
renal	I-Phenotype
agenesis	E-Phenotype
.	O

We	O
report	O
two	O
families	O
in	O
which	O
propositi	O
had	O
severe	O
bilateral	B-Phenotype
sensorineural	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
a	O
preauricular	B-Phenotype
pit	I-Phenotype
or	I-Phenotype
tag	E-Phenotype
,	O
and	O
duplication	B-Phenotype
of	I-Phenotype
the	I-Phenotype
ureters	E-Phenotype
or	O
bifid	B-Phenotype
renal	I-Phenotype
pelvices	E-Phenotype
.	O

Other	O
relatives	O
had	O
one	O
or	O
more	O
of	O
these	O
anomalies	O
in	O
a	O
pattern	O
suggesting	O
autosomal	O
dominant	O
inheritance	O
with	O
reduced	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

We	O
suggest	O
the	O
term	O
``	O
branchio	O
-	O
oto	O
-	O
ureteral	O
syndrome	O
''	O
to	O
designate	O
this	O
condition	O
.	O

We	O
report	O
9	O
subjects	O
from	O
2	O
families	O
with	O
the	O
syndrome	O
of	O
cerebral	B-Phenotype
gigantism	E-Phenotype
,	O
seven	O
of	O
the	O
patients	O
also	O
had	O
jaw	B-Phenotype
cyst	E-Phenotype
basal	B-Phenotype
cell	I-Phenotype
naevoid	E-Phenotype
syndrome	O
.	O

Neurological	O
,	O
radiological	O
,	O
somatic	O
and	O
biochemical	O
features	O
of	O
this	O
hitherto	O
unreported	O
association	O
are	O
described	O
.	O

Neurological	O
symptoms	O
included	O
mild	O
hydrocephalus	S-Phenotype
,	O
ventricular	B-Phenotype
malformation	E-Phenotype
,	O
cerebellar	B-Phenotype
syndrome	E-Phenotype
,	O
intracranial	B-Phenotype
calcification	E-Phenotype
,	O
oculomotor	B-Phenotype
disturbances	E-Phenotype
,	O
EEG	B-Phenotype
abnormalities	E-Phenotype
and	O
rarely	O
,	O
mild	O
peripheral	B-Phenotype
nervous	I-Phenotype
disorders	E-Phenotype
.	O

A	O
disturbance	O
of	O
calcium	B-Phenotype
metabolism	E-Phenotype
appears	O
to	O
be	O
a	O
prominent	O
feature	O
of	O
the	O
genetically	O
determined	O
nonprogressive	O
syndrome	O
.	O

A	O
family	O
with	O
the	O
Popliteal	B-Phenotype
Pterygium	E-Phenotype
Syndrome	O
is	O
presented	O
.	O

The	O
father	O
was	O
born	O
with	O
a	O
cleft	B-Phenotype
of	I-Phenotype
the	I-Phenotype
palate	E-Phenotype
and	O
lower	B-Phenotype
lip	I-Phenotype
pits	E-Phenotype
.	O

Two	O
of	O
the	O
three	O
offspring	O
showed	O
extensive	O
involvement	B-Phenotype
of	I-Phenotype
the	I-Phenotype
palate	I-Phenotype
,	I-Phenotype
gums	I-Phenotype
,	I-Phenotype
and	I-Phenotype
lips	E-Phenotype
with	O
minimal	O
involvement	B-Phenotype
of	I-Phenotype
the	I-Phenotype
lower	I-Phenotype
limbs	E-Phenotype
,	O
genitalia	O
,	O
and	O
nails	O
.	O

Several	O
pedigrees	O
with	O
19	O
new	O
cases	O
of	O
the	O
earpits	S-Phenotype
-	O
deafness	S-Phenotype
syndrome	O
(	O
McK	O
+12510	O
)	O
[	O
28	O
]	O
are	O
presented	O
.	O

Mention	O
is	O
made	O
of	O
clinical	O
findings	O
obtained	O
in	O
audiometric	O
and	O
vestibular	O
studies	O
,	O
studies	O
of	O
renal	O
function	O
and	O
configuration	O
and	O
polytomographic	O
studies	O
of	O
the	O
labyrinth	O
,	O
and	O
results	O
of	O
exploratory	O
tympanotomies	O
are	O
discussed	O
.	O

The	O
literature	O
is	O
reviewed	O
and	O
the	O
features	O
found	O
in	O
138	O
cases	O
and	O
in	O
our	O
19	O
cases	O
are	O
presented	O
.	O

The	O
earpits	S-Phenotype
-	O
deafness	S-Phenotype
syndrome	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
in	O
which	O
affected	O
individuals	O
may	O
have	O
sensorineural	B-Phenotype
,	I-Phenotype
conductive	I-Phenotype
or	I-Phenotype
mixed	E-Phenotype
hearing	B-Phenotype
loss	E-Phenotype
,	O
preauricular	B-Phenotype
pits	E-Phenotype
,	O
structural	O
defects	B-Phenotype
of	I-Phenotype
the	I-Phenotype
outer	I-Phenotype
,	I-Phenotype
middle	I-Phenotype
and	I-Phenotype
inner	I-Phenotype
ear	E-Phenotype
,	O
lacrimal	B-Phenotype
duct	I-Phenotype
stenosis	E-Phenotype
,	O
branchial	S-Phenotype
fistulas	O
or	O
cysts	O
of	O
the	O
second	O
branchial	O
arch	O
,	O
and	O
renal	B-Phenotype
anomalies	E-Phenotype
ranging	O
from	O
mild	O
hypoplasia	O
to	O
complete	O
absence	O
.	O

Not	O
all	O
the	O
features	O
of	O
the	O
syndrome	O
are	O
expressed	O
in	O
all	O
carriers	O
of	O
the	O
gene	O
.	O

Pits	S-Phenotype
,	O
branchial	B-Phenotype
clefts	E-Phenotype
and	O
hearing	B-Phenotype
loss	E-Phenotype
are	O
frequently	O
expressed	O
.	O

The	O
incidence	O
of	O
renal	B-Phenotype
malformation	E-Phenotype
is	O
higher	O
,	O
as	O
mentioned	O
earlier	O
in	O
the	O
literature	O
.	O

The	O
poor	O
results	O
of	O
exploratory	O
tympanotomies	O
are	O
discussed	O
.	O

On	O
the	O
basis	O
of	O
personal	O
observations	O
as	O
well	O
as	O
in	O
view	O
of	O
data	O
from	O
the	O
literature	O
it	O
is	O
maintained	O
that	O
the	O
BOR	O
(	O
branchio	O
-	O
oto	O
-	O
renal	B-Phenotype
dysplasia	E-Phenotype
)	O
syndrome	O
[	O
12,30	O
-	O
32	O
]	O
and	O
the	O
BO	O
(	O
branchio	O
-	O
oto	O
dysplasia	O
)	O
syndrome	O
are	O
in	O
fact	O
the	O
same	O
affection	O
.	O

It	O
is	O
also	O
maintained	O
that	O
no	O
separate	O
syndromes	O
can	O
be	O
distinguished	O
on	O
the	O
basis	O
of	O
the	O
type	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

The	O
present	O
knowledge	O
of	O
the	O
syndrome	O
is	O
summarized	O
in	O
terms	O
of	O
the	O
information	O
available	O
for	O
genetic	O
counselling	O
.	O

The	O
results	O
of	O
a	O
systematic	O
study	O
of	O
the	O
otological	O
aspects	O
in	O
13	O
cases	O
of	O
earpit	S-Phenotype
-	O
deafness	S-Phenotype
syndrome	O
are	O
reported	O
.	O

The	O
audiometric	O
,	O
radiological	O
and	O
vestibular	O
findings	O
as	O
well	O
as	O
the	O
results	O
of	O
exploratory	O
tympanotomies	O
with	O
and	O
without	O
stapedectomies	O
are	O
discussed	O
together	O
with	O
the	O
results	O
reported	O
in	O
the	O
literature	O
.	O

A	O
convincing	O
explanation	O
of	O
the	O
poor	O
results	O
of	O
exploratory	O
tympanotomies	O
in	O
cases	O
with	O
mixed	S-Phenotype
hearing	B-Phenotype
loss	E-Phenotype
is	O
not	O
furnished	O
.	O

If	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
is	O
confined	O
to	O
conduction	S-Phenotype
and	O
ankylosis	B-Phenotype
of	I-Phenotype
the	I-Phenotype
stapes	E-Phenotype
or	O
a	O
disconnection	B-Phenotype
of	I-Phenotype
the	I-Phenotype
ossicular	I-Phenotype
chain	E-Phenotype
is	O
suspected	O
,	O
exploratory	O
tympanotomy	O
can	O
be	O
expected	O
to	O
be	O
successful	O
.	O

We	O
report	O
on	O
44	O
patients	O
(	O
18	O
with	O
additional	O
affected	O
family	O
members	O
)	O
,	O
with	O
congenital	B-Phenotype
distal	I-Phenotype
limb	I-Phenotype
contractures	E-Phenotype
identified	O
from	O
a	O
large	O
study	O
of	O
over	O
350	O
patients	O
with	O
congenital	B-Phenotype
joint	I-Phenotype
contractures	E-Phenotype
.	O

Fourteen	O
propositi	O
(	O
seven	O
familial	O
cases	O
,	O
seven	O
isolated	O
cases	O
)	O
had	O
a	O
newly	O
recognized	O
form	O
of	O
arthrogryposis	S-Phenotype
,	O
which	O
we	O
have	O
designated	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
1	O
,	O
with	O
the	O
predominant	O
manifestations	O
of	O
autosomal	O
dominant	O
inheritance	O
;	O
tightly	B-Phenotype
clenched	I-Phenotype
fists	E-Phenotype
at	O
birth	O
,	O
with	O
medially	B-Phenotype
overlapping	I-Phenotype
fingers	E-Phenotype
,	O
ulnar	B-Phenotype
deviation	E-Phenotype
,	O
and	O
camptodactyly	S-Phenotype
in	O
adults	O
;	O
and	O
positional	B-Phenotype
foot	I-Phenotype
deformities	E-Phenotype
.	O

Contractures	S-Phenotype
at	O
other	O
major	O
joints	O
are	O
variable	O
.	O

There	O
are	O
no	O
associated	O
visceral	B-Phenotype
anomalies	E-Phenotype
;	O
intelligence	O
is	O
normal	O
.	O

There	O
can	O
be	O
marked	O
intrafamilial	O
and	O
interfamilial	O
variability	O
.	O

Twenty	O
-	O
two	O
propositi	O
with	O
similar	O
distal	B-Phenotype
contractures	E-Phenotype
had	O
additional	O
findings	O
and	O
were	O
classified	O
into	O
five	O
subcategories	O
of	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
(	O
type	O
IIA	O
-	O
E	O
)	O
.	O

Among	O
type	O
II	O
patients	O
cleft	B-Phenotype
palate	E-Phenotype
,	O
cleft	B-Phenotype
lip	E-Phenotype
,	O
small	B-Phenotype
tongue	E-Phenotype
,	O
trismus	S-Phenotype
,	O
ptosis	S-Phenotype
,	O
epicanthal	B-Phenotype
folds	E-Phenotype
,	O
keratoconus	S-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
scoliosis	S-Phenotype
,	O
a	O
unique	B-Phenotype
hand	I-Phenotype
position	E-Phenotype
,	O
and	O
dull	O
normal	O
intelligence	O
were	O
seen	O
.	O

These	O
characteristics	O
were	O
seen	O
in	O
various	O
combinations	O
and	O
patterns	O
and	O
allowed	O
sorting	O
into	O
groups	O
that	O
were	O
the	O
basis	O
for	O
the	O
categorization	O
.	O

The	O
remaining	O
eight	O
propositi	O
were	O
recognized	O
to	O
have	O
previously	O
described	O
conditions	O
with	O
distal	B-Phenotype
contractures	E-Phenotype
and	O
autosomal	O
dominant	O
inheritance	O
,	O
ie	O
,	O
the	O
Freeman	O
-	O
Sheldon	O
syndrome	O
,	O
trismus	S-Phenotype
-	O
pseudo	O
-	O
camptodactyly	S-Phenotype
syndrome	O
,	O
congenital	O
contractural	B-Phenotype
arachnodactyly	E-Phenotype
,	O
and	O
familial	O
camptodactyly	O
.	O

Pathogenetically	O
we	O
postulate	O
similar	O
underlying	O
defects	O
of	O
abnormal	O
tendon	O
attachments	O
,	O
attenuation	O
,	O
and	O
absence	O
;	O
careful	O
nosologic	O
comparisons	O
are	O
important	O
for	O
prognostic	O
counseling	O
and	O
habilitative	O
management	O
.	O

Fifteen	O
patients	O
with	O
bilateral	B-Phenotype
acoustic	I-Phenotype
neuromas	E-Phenotype
are	O
presented	O
.	O

Ten	O
patients	O
became	O
symptomatic	O
before	O
age	O
21	O
,	O
and	O
9	O
of	O
these	O
patients	O
developed	O
additional	O
central	B-Phenotype
nervous	I-Phenotype
system	E-Phenotype
tumors	S-Phenotype
.	O

Cutaneous	B-Phenotype
manifestations	E-Phenotype
of	O
neurofibromatosis	S-Phenotype
and	O
a	O
positive	O
family	O
history	O
of	O
this	O
disorder	O
were	O
absent	O
in	O
many	O
of	O
the	O
patients	O
.	O

Most	O
patients	O
required	O
multiple	O
surgical	O
procedures	O
,	O
and	O
the	O
timing	O
,	O
techniques	O
,	O
and	O
results	O
of	O
these	O
operations	O
are	O
reported	O
.	O

The	O
pathogenesis	O
of	O
these	O
tumors	S-Phenotype
,	O
the	O
genetic	O
aspects	O
of	O
this	O
disorder	O
,	O
and	O
potential	O
treatment	O
alternatives	O
are	O
discussed	O
.	O

We	O
report	O
studies	O
of	O
six	O
patients	O
with	O
the	O
Angelman	O
``	O
Happy	B-Phenotype
Puppet	E-Phenotype
''	O
syndrome	O
and	O
compare	O
the	O
data	O
with	O
those	O
from	O
previous	O
reports	O
.	O

The	O
results	O
confirm	O
the	O
classic	O
findings	O
of	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
``	B-Phenotype
puppet	I-Phenotype
-	I-Phenotype
like	I-Phenotype
''	I-Phenotype
gait	E-Phenotype
,	O
characteristic	O
craniofacial	B-Phenotype
abnormalities	E-Phenotype
,	O
and	O
frequent	B-Phenotype
episodes	I-Phenotype
of	I-Phenotype
laughter	E-Phenotype
and	O
suggest	O
that	O
this	O
syndrome	O
is	O
more	O
common	O
than	O
previously	O
thought	O
.	O

Computerized	O
axial	O
tomographs	O
of	O
the	O
brain	O
demonstrating	O
unilateral	B-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype
in	O
one	O
patient	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
cerebellar	B-Phenotype
abnormalities	E-Phenotype
in	O
this	O
syndrome	O
.	O

A	O
mother	O
and	O
son	O
with	O
bilateral	B-Phenotype
branchial	I-Phenotype
sinuses	E-Phenotype
,	O
intrauterine	B-Phenotype
and	I-Phenotype
postnatal	E-Phenotype
growth	B-Phenotype
retardation	E-Phenotype
,	O
unusual	B-Phenotype
facial	I-Phenotype
appearance	E-Phenotype
,	O
and	O
premature	B-Phenotype
aging	E-Phenotype
in	O
the	O
mother	O
are	O
reported	O
.	O

No	O
other	O
members	O
of	O
the	O
family	O
are	O
similarly	O
affected	O
.	O

No	O
hormonal	O
or	O
systemic	O
cause	O
of	O
growth	B-Phenotype
retardation	E-Phenotype
was	O
identified	O
.	O

Chromosomal	O
studies	O
with	O
G	O
-	O
banding	O
were	O
normal	O
.	O

It	O
is	O
suggested	O
that	O
this	O
syndrome	O
is	O
a	O
dominant	O
trait	O
,	O
the	O
mother	O
being	O
the	O
initial	O
mutant	O
.	O

Five	O
new	O
cases	O
are	O
presented	O
of	O
a	O
syndrome	O
characterized	O
mainly	O
by	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
puppet	B-Phenotype
-	I-Phenotype
like	I-Phenotype
ataxic	I-Phenotype
movements	E-Phenotype
,	O
microbrachycephaly	S-Phenotype
,	O
prognathism	S-Phenotype
,	O
tongue	B-Phenotype
protrusion	E-Phenotype
,	O
and	O
inappropriate	B-Phenotype
paroxysms	I-Phenotype
of	I-Phenotype
laughter	E-Phenotype
.	O

The	O
cases	O
are	O
analyzed	O
with	O
reference	O
to	O
personal	O
and	O
family	O
histories	O
,	O
clinical	O
findings	O
,	O
and	O
results	O
of	O
special	O
investigations	O
(	O
biochemical	O
,	O
chromosomal	O
,	O
dermatoglyphic	O
,	O
EEG	O
,	O
and	O
radiologic	O
)	O
.	O

The	O
findings	O
are	O
compared	O
with	O
those	O
in	O
the	O
22	O
patients	O
described	O
previously	O
.	O

Though	O
clinically	O
distinctive	O
,	O
there	O
is	O
as	O
yet	O
no	O
clear	O
-	O
cut	O
evidence	O
as	O
to	O
cause	O
.	O

The	O
basal	B-Phenotype
cell	I-Phenotype
nevus	I-Phenotype
syndrome	E-Phenotype
is	O
characterized	O
by	O
multiple	B-Phenotype
basal	I-Phenotype
cell	I-Phenotype
nevi	E-Phenotype
and	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
cysts	B-Phenotype
of	I-Phenotype
the	I-Phenotype
jaw	E-Phenotype
,	O
anomalies	B-Phenotype
of	I-Phenotype
ribs	E-Phenotype
and	O
spine	O
,	O
abnormal	B-Phenotype
calcifications	E-Phenotype
,	O
and	O
additional	O
anomalies	B-Phenotype
of	I-Phenotype
the	I-Phenotype
facial	E-Phenotype
skull	O
.	O

A	O
German	O
family	O
is	O
described	O
with	O
manifestations	O
of	O
the	O
syndrome	O
in	O
the	O
mother	O
and	O
her	O
three	O
daughters	O
.	O

Expressivity	O
was	O
variable	O
,	O
in	O
part	O
due	O
to	O
age	O
effects	O
.	O

The	O
observation	O
conforms	O
to	O
the	O
assumed	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
with	O
high	O
penetrance	O
.	O

Nine	O
children	O
with	O
the	O
``	O
happy	B-Phenotype
puppet	E-Phenotype
''	O
syndrome	O
are	O
presented	O
here	O
and	O
19	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O

A	O
characteristic	O
psychological	O
profile	O
is	O
suggested	O
by	O
the	O
children	O
's	O
``	B-Phenotype
unfocused	I-Phenotype
''	I-Phenotype
activities	E-Phenotype
and	O
inconsistent	O
responsiveness	O
to	O
their	O
surroundings	O
.	O

Behavioral	B-Phenotype
characteristics	E-Phenotype
are	O
atypical	O
for	O
mental	O
age	O
and	O
do	O
not	O
appear	O
to	O
represent	O
unusual	O
seizure	S-Phenotype
equivalents	O
.	O

Recognition	O
of	O
such	O
non	B-Phenotype
-	I-Phenotype
adaptive	I-Phenotype
behavior	E-Phenotype
may	O
be	O
of	O
importance	O
in	O
selecting	O
specific	O
treatment	O
and	O
management	O
techniques	O
to	O
modify	O
the	O
characteristics	O
of	O
this	O
syndrome	O
at	O
an	O
early	O
age	O
.	O

We	O
report	O
on	O
a	O
32	O
-	O
year	O
-	O
old	O
Italian	O
man	O
,	O
his	O
5	O
-	O
year	O
-	O
old	O
daughter	O
,	O
and	O
his	O
3	O
1	O
/	O
2	O
-	O
year	O
-	O
old	O
son	O
,	O
all	O
of	O
whom	O
had	O
congenital	B-Phenotype
joint	I-Phenotype
contractures	E-Phenotype
.	O

Each	O
has	O
severe	O
ulnar	B-Phenotype
deviation	I-Phenotype
of	I-Phenotype
fingers	E-Phenotype
and	O
soft	O
-	O
tissue	O
contractures	B-Phenotype
of	I-Phenotype
both	I-Phenotype
hands	E-Phenotype
;	O
and	O
each	O
had	O
bilateral	B-Phenotype
clubfeet	E-Phenotype
at	O
birth	O
.	O

The	O
father	O
is	O
short	B-Phenotype
in	I-Phenotype
stature	E-Phenotype
,	O
as	O
are	O
the	O
children	O
,	O
who	O
also	O
have	O
delayed	B-Phenotype
carpal	I-Phenotype
ossification	E-Phenotype
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
autosomal	O
-	O
dominant	O
inheritance	O
of	O
the	O
condition	O
.	O

The	O
clinical	O
features	O
are	O
consistent	O
with	O
the	O
condition	O
currently	O
referred	O
to	O
as	O
``	B-Phenotype
distal	I-Phenotype
''	I-Phenotype
arthrogryposis	E-Phenotype
.	O

Two	O
siblings	O
with	O
the	O
``	O
happy	B-Phenotype
puppet	E-Phenotype
''	O
syndrome	O
are	O
presented	O
.	O

Their	O
clinical	O
features	O
are	O
quite	O
similar	O
and	O
closely	O
resemble	O
those	O
of	O
previously	O
reported	O
cases	O
.	O

These	O
features	O
include	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
epileptic	B-Phenotype
seizures	E-Phenotype
,	O
easily	B-Phenotype
provoked	I-Phenotype
and	I-Phenotype
prolonged	I-Phenotype
paroxysms	I-Phenotype
of	I-Phenotype
laughter	E-Phenotype
,	O
atactic	B-Phenotype
jerky	I-Phenotype
movements	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
large	O
mandible	B-Phenotype
with	I-Phenotype
prognathia	E-Phenotype
,	O
and	O
2	B-Phenotype
-	I-Phenotype
3	I-Phenotype
cps	I-Phenotype
spike	I-Phenotype
and	I-Phenotype
wave	I-Phenotype
activity	I-Phenotype
in	I-Phenotype
the	I-Phenotype
EEG	E-Phenotype
.	O

The	O
occurrence	O
of	O
this	O
syndrome	O
in	O
the	O
two	O
siblings	O
suggests	O
a	O
genetic	O
etiology	O
possible	O
as	O
an	O
autosomal	O
recessive	O
trait	O
.	O

Nineteen	O
of	O
421	O
white	O
children	O
in	O
Montreal	O
schools	O
for	O
the	O
deaf	S-Phenotype
had	O
preauricular	B-Phenotype
pits	E-Phenotype
.	O

The	O
branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
syndrome	O
was	O
identified	O
in	O
four	O
of	O
the	O
nine	O
families	O
who	O
agreed	O
to	O
family	O
investigation	O
,	O
including	O
audiograms	O
and	O
intravenous	O
pyelograms	O
(	O
IVPs	O
)	O
and	O
may	O
have	O
been	O
present	O
in	O
several	O
others	O
.	O

The	O
penetrance	O
of	O
this	O
autosomal	O
dominant	O
syndrome	O
appears	O
to	O
be	O
high	O
.	O

It	O
is	O
estimated	O
that	O
severe	O
renal	B-Phenotype
dysplasia	E-Phenotype
occurs	O
in	O
about	O
6	O
%	O
of	O
heterozygotes	O
.	O

The	O
presence	O
of	O
a	O
preauricular	B-Phenotype
pit	E-Phenotype
at	O
birth	O
suggests	O
that	O
the	O
child	O
has	O
at	O
least	O
one	O
chance	O
in	O
200	O
of	O
severe	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
this	O
warrants	O
a	O
careful	O
family	O
history	O
,	O
as	O
well	O
as	O
alertness	O
for	O
any	O
signs	O
of	O
hearing	B-Phenotype
impairment	E-Phenotype
.	O

Offspring	O
of	O
affected	O
individuals	O
are	O
eligible	O
for	O
parental	O
diagnosis	O
of	O
renal	B-Phenotype
dysplasia	E-Phenotype
.	O

We	O
describe	O
47	O
patients	O
with	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
from	O
Belgium	O
and	O
the	O
Netherlands	O
,	O
including	O
the	O
anamnestic	O
data	O
,	O
the	O
clinical	O
and	O
the	O
behavioral	O
attributes	O
at	O
different	O
ages	O
.	O

The	O
clinical	O
picture	O
of	O
AS	O
is	O
most	O
distinct	O
between	O
the	O
ages	O
of	O
2	O
-	O
16	O
years	O
.	O

Most	O
patients	O
of	O
this	O
age	O
group	O
show	O
at	O
least	O
8	O
of	O
the	O
major	O
characteristics	O
(	O
bursts	B-Phenotype
of	I-Phenotype
laughter	E-Phenotype
,	O
happy	B-Phenotype
disposition	E-Phenotype
,	O
hyperactive	B-Phenotype
behaviour	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
brachycephaly	S-Phenotype
,	O
macrostomia	S-Phenotype
,	O
tongue	B-Phenotype
protrusion	E-Phenotype
,	O
mandibular	B-Phenotype
prognathism	E-Phenotype
,	O
widely	B-Phenotype
spaced	I-Phenotype
teeth	E-Phenotype
,	O
stiff	O
and	O
puppetlike	B-Phenotype
movements	E-Phenotype
,	O
typical	O
stature	O
,	O
wide	B-Phenotype
based	I-Phenotype
gait	E-Phenotype
)	O
beside	O
the	O
mental	B-Phenotype
retardation	E-Phenotype
and	O
(	O
almost	O
)	O
absence	B-Phenotype
of	I-Phenotype
speech	E-Phenotype
,	O
which	O
is	O
a	O
universal	O
trait	O
.	O

The	O
diagnosis	O
in	O
infants	O
is	O
based	O
on	O
only	O
a	O
limited	O
number	O
of	O
clinical	O
characteristics	O
or	O
on	O
anamnestic	O
data	O
.	O

However	O
,	O
if	O
these	O
occur	O
in	O
combination	O
,	O
they	O
are	O
indicative	O
of	O
AS	O
.	O

In	O
older	O
patients	O
,	O
the	O
diagnosis	O
may	O
be	O
hampered	O
in	O
part	O
because	O
of	O
the	O
changing	O
behavioral	B-Phenotype
characteristics	E-Phenotype
and	O
the	O
decreasing	O
frequency	O
of	O
fits	O
.	O

Other	O
manifestations	O
,	O
such	O
as	O
scoliosis	S-Phenotype
,	O
may	O
become	O
more	O
pronounced	O
with	O
age	O
.	O

Three	O
successive	O
generations	O
in	O
two	O
families	O
affected	O
with	O
the	O
popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
are	O
reported	O
.	O

While	O
expression	O
of	O
the	O
syndrome	O
was	O
relatively	O
mild	O
in	O
the	O
first	O
and	O
second	O
generation	O
,	O
the	O
patients	O
in	O
the	O
third	O
generation	O
showed	O
the	O
full	O
-	O
blown	O
syndrome	O
.	O

Differential	O
diagnosis	O
between	O
mildly	O
affected	O
patients	O
with	O
the	O
popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
and	O
those	O
with	O
Van	O
der	O
Woude	O
syndrome	O
is	O
difficult	O
and	O
may	O
even	O
be	O
impossible	O
.	O

The	O
present	O
observations	O
further	O
support	O
the	O
hypothesis	O
that	O
both	O
syndromes	O
may	O
in	O
fact	O
represent	O
variants	O
of	O
the	O
same	O
condition	O
.	O

To	O
determine	O
the	O
spectrum	O
of	O
manifestations	O
in	O
neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
and	O
to	O
assess	O
possible	O
heterogeneity	O
,	O
we	O
evaluated	O
63	O
affected	O
individuals	O
from	O
32	O
families	O
.	O

Work	O
-	O
up	O
included	O
skin	O
and	O
neurologic	O
examinations	O
,	O
audiometry	O
,	O
a	O
complete	O
ophthalmology	O
examination	O
with	O
slit	O
-	O
lamp	O
biomicroscopy	O
of	O
the	O
lens	O
and	O
fundus	O
,	O
and	O
gadolinium	O
-	O
enhanced	O
MRI	O
of	O
the	O
brain	O
and	O
,	O
in	O
some	O
,	O
of	O
the	O
spine	O
.	O

Mean	O
age	O
-	O
at	O
-	O
onset	O
in	O
58	O
individuals	O
was	O
20.3	O
years	O
;	O
initial	O
symptoms	O
resulted	O
from	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
(	O
44.4	O
%	O
)	O
,	O
other	O
CNS	B-Phenotype
tumors	E-Phenotype
(	O
22.2	O
%	O
)	O
,	O
skin	B-Phenotype
tumors	E-Phenotype
(	O
12.7	O
%	O
)	O
,	O
and	O
ocular	B-Phenotype
manifestations	E-Phenotype
including	O
cataracts	S-Phenotype
and	O
retinal	B-Phenotype
hamartomas	E-Phenotype
(	O
12.7	O
%	O
)	O
.	O

Five	O
asymptomatic	O
individuals	O
were	O
diagnosed	O
through	O
screening	O
.	O

Vestibular	B-Phenotype
schwannomas	E-Phenotype
were	O
documented	O
in	O
62	O
individuals	O
(	O
98.4	O
%	O
)	O
;	O
other	O
findings	O
included	O
cataracts	S-Phenotype
(	O
81.0	O
%	O
)	O
,	O
skin	B-Phenotype
tumors	E-Phenotype
(	O
67.7	O
%	O
)	O
,	O
spinal	B-Phenotype
tumors	E-Phenotype
(	O
67.4	O
%	O
)	O
,	O
and	O
meningiomas	S-Phenotype
(	O
49.2	O
%	O
)	O
.	O

Usually	O
,	O
clinical	O
manifestations	O
and	O
course	O
were	O
similar	O
within	O
families	O
but	O
differed	O
among	O
families	O
.	O

To	O
assess	O
possible	O
heterogeneity	O
,	O
we	O
assigned	O
affected	O
individuals	O
to	O
three	O
proposed	O
subtypes	O
(	O
representing	O
mild	O
,	O
intermediate	O
,	O
and	O
severe	O
NF2	O
)	O
based	O
on	O
age	O
-	O
at	O
-	O
onset	O
,	O
presence	O
or	O
absence	O
of	O
CNS	B-Phenotype
tumors	E-Phenotype
other	O
than	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
,	O
and	O
presence	O
or	O
absence	O
of	O
retinal	B-Phenotype
hamartomas	E-Phenotype
.	O

Comparisons	O
among	O
the	O
three	O
subtypes	O
for	O
many	O
clinical	O
parameters	O
demonstrated	O
that	O
patients	O
in	O
the	O
mild	O
subtype	O
differed	O
from	O
those	O
in	O
the	O
other	O
two	O
subtypes	O
for	O
most	O
parameters	O
,	O
but	O
that	O
none	O
of	O
the	O
parameters	O
distinguished	O
patients	O
in	O
the	O
intermediate	O
subtype	O
from	O
those	O
in	O
the	O
severe	O
subtype	O
.	O

Thus	O
,	O
there	O
are	O
likely	O
two	O
rather	O
than	O
three	O
subtypes	O
of	O
NF2	O
.	O

Classification	O
of	O
patients	O
to	O
subtype	O
may	O
aid	O
in	O
counseling	O
about	O
long	O
-	O
term	O
prognosis	O
and	O
in	O
formulating	O
individualized	O
guidelines	O
for	O
medical	O
surveillance	O
.	O

We	O
review	O
43	O
patients	O
(	O
15	O
new	O
,	O
28	O
literature	O
)	O
with	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
(	O
BOF	O
)	O
syndrome	O
,	O
which	O
has	O
a	O
distinctive	O
phenotype	O
ranging	O
from	O
mild	O
to	O
severe	O
forms	O
,	O
consisting	O
of	O
eye	B-Phenotype
,	I-Phenotype
ear	I-Phenotype
,	I-Phenotype
oral	I-Phenotype
,	I-Phenotype
and	I-Phenotype
craniofacial	I-Phenotype
anomalies	E-Phenotype
.	O

Virtually	O
ubiquitous	O
and	O
possibly	O
pathognomonic	O
are	O
the	O
cervical	B-Phenotype
/	I-Phenotype
infra	I-Phenotype
-	I-Phenotype
auricular	I-Phenotype
skin	I-Phenotype
defects	E-Phenotype
.	O

Much	O
less	O
common	O
are	O
supra	B-Phenotype
-	I-Phenotype
auricular	I-Phenotype
defects	E-Phenotype
occurring	O
as	O
isolated	O
anomalies	O
or	O
with	O
cervical	O
defects	O
.	O

Regardless	O
of	O
location	O
,	O
these	O
lesions	O
may	O
have	O
aplastic	O
,	O
``	O
hemangiomatous	O
,	O
''	O
or	O
otherwise	O
abnormal	B-Phenotype
overlying	I-Phenotype
skin	E-Phenotype
,	O
and	O
draining	B-Phenotype
sinus	I-Phenotype
fistulae	E-Phenotype
.	O

Renal	B-Phenotype
malformations	E-Phenotype
are	O
frequent	O
,	O
but	O
congenital	B-Phenotype
heart	I-Phenotype
and	I-Phenotype
central	I-Phenotype
nervous	I-Phenotype
system	I-Phenotype
defects	E-Phenotype
are	O
rare	O
.	O

Psychomotor	O
performance	O
is	O
usually	O
normal	O
,	O
but	O
development	B-Phenotype
delays	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
and	O
visual	B-Phenotype
,	I-Phenotype
hearing	I-Phenotype
,	I-Phenotype
and	I-Phenotype
speech	I-Phenotype
problems	E-Phenotype
are	O
common	O
.	O

Autosomal	O
dominant	O
inheritance	O
seems	O
likely	O
.	O

Overlap	O
between	O
the	O
BOF	O
and	O
branchio	O
-	O
otorenal	O
syndromes	O
has	O
been	O
observed	O
,	O
but	O
elucidation	O
of	O
its	O
molecular	O
basis	O
is	O
not	O
yet	O
available	O
.	O

This	O
article	O
also	O
discusses	O
5	O
patients	O
with	O
atypical	O
manifestations	O
considered	O
to	O
be	O
possibly	O
affected	O
or	O
probably	O
unaffected	O
,	O
who	O
are	O
sufficiently	O
unusual	O
to	O
be	O
excluded	O
from	O
the	O
final	O
data	O
analysis	O
.	O

The	O
index	O
case	O
was	O
a	O
Maori	O
bushman	O
who	O
presented	O
with	O
severe	O
congenital	O
spinal	B-Phenotype
stenosis	E-Phenotype
and	O
manifestations	O
of	O
distal	S-Phenotype
arthrogryposis	S-Phenotype
.	O

His	O
offspring	O
and	O
8	O
of	O
his	O
9	O
sibs	O
and	O
most	O
of	O
their	O
offspring	O
were	O
interviewed	O
and	O
examined	O
.	O

Of	O
those	O
examined	O
7	O
individuals	O
with	O
definite	O
and	O
2	O
with	O
probable	O
distal	S-Phenotype
arthrogryposis	S-Phenotype
were	O
identified	O
in	O
4	O
of	O
the	O
families	O
.	O

A	O
tenth	O
relative	O
with	O
distal	S-Phenotype
arthrogryposis	S-Phenotype
and	O
contractural	B-Phenotype
arachnodactyly	E-Phenotype
had	O
died	O
.	O

There	O
was	O
marked	O
variability	O
in	O
the	O
severity	O
and	O
nature	O
of	O
manifestations	O
with	O
2	O
having	O
severe	O
hand	B-Phenotype
and	I-Phenotype
foot	I-Phenotype
involvement	E-Phenotype
in	O
addition	O
to	O
craniofacial	B-Phenotype
changes	E-Phenotype
compatible	O
with	O
a	O
diagnosis	O
of	O
Freeman	O
-	O
Sheldon	O
syndrome	O
.	O

Other	O
apparently	O
unrelated	O
hereditary	O
disorders	O
in	O
the	O
family	O
included	O
ectrodactyly	S-Phenotype
,	O
biliary	B-Phenotype
atresia	E-Phenotype
,	O
and	O
Brachmann	O
-	O
de	O
Lange	O
syndrome	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
arthrogryposis	S-Phenotype
in	O
a	O
Maori	O
family	O
.	O

Four	O
disease	O
genes	O
(	O
NBCCS	O
,	O
ESS1	O
,	O
XPAC	O
,	O
FACC	O
)	O
map	O
to	O
9q22.3	O
-	O
q31	O
.	O

A	O
fine	O
map	O
of	O
this	O
region	O
was	O
produced	O
by	O
linkage	O
and	O
haplotype	O
analysis	O
using	O
12	O
DNA	O
markers	O
.	O

The	O
gene	O
for	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
,	O
Gorlin	O
)	O
has	O
an	O
important	O
role	O
in	O
congenital	O
malformations	O
and	O
carcinogenesis	O
.	O

Phase	O
-	O
known	O
recombinants	O
in	O
a	O
study	O
of	O
133	O
meioses	O
place	O
NBCCS	O
between	O
(	O
D9S12	O
/	O
D9S151	O
)	O
and	O
D9S176	O
.	O

Haplotype	O
analysis	O
in	O
a	O
two	O
-	O
generation	O
family	O
suggests	O
that	O
NBCCS	O
lies	O
in	O
a	O
smaller	O
interval	O
of	O
2.6	O
cM	O
centromeric	O
to	O
D9S287	O
.	O

These	O
flanking	O
markers	O
will	O
be	O
useful	O
clinically	O
for	O
gene	O
tracking	O
.	O

Recombinants	O
also	O
map	O
FACC	O
(	O
Fanconi	O
anemia	O
,	O
group	O
C	O
)	O
to	O
the	O
same	O
region	O
,	O
between	O
(	O
D9S196	O
/	O
D9S197	O
)	O
and	O
D9S287	O
.	O

The	O
recombination	O
rate	O
between	O
(	O
D9S12	O
/	O
D9S151	O
)	O
and	O
D9S53	O
in	O
males	O
is	O
8.3	O
%	O
and	O
13.2	O
%	O
in	O
females	O
,	O
giving	O
a	O
sex	O
-	O
specific	O
male	O
:	O
female	O
ratio	O
of	O
1:1.6	O
and	O
a	O
sex	O
-	O
averaged	O
map	O
distance	O
of	O
10.4	O
cM	O
.	O

No	O
double	O
recombinants	O
were	O
detected	O
,	O
in	O
agreement	O
with	O
the	O
apparently	O
complete	O
level	O
of	O
interference	O
predicted	O
from	O
the	O
male	O
chiasmata	O
map	O
.	O

The	O
analysis	O
of	O
a	O
de	O
novo	O
8q12.2	O
-	O
q21.2	O
deletion	O
led	O
to	O
the	O
identification	O
of	O
a	O
proposed	O
previously	O
undescribed	O
contiguous	O
gene	O
syndrome	O
consisting	O
of	O
Branchio	O
-	O
Oto	O
-	O
Renal	O
(	O
BOR	O
)	O
syndrome	O
,	O
Duane	B-Phenotype
syndrome	E-Phenotype
,	O
hydrocephalus	S-Phenotype
and	O
trapeze	B-Phenotype
aplasia	E-Phenotype
.	O

This	O
is	O
the	O
first	O
reported	O
localization	O
of	O
the	O
genes	O
responsible	O
for	O
Duane	B-Phenotype
syndrome	E-Phenotype
and	O
this	O
dominant	O
form	O
of	O
hydrocephalus	S-Phenotype
.	O

In	O
contrast	O
,	O
we	O
report	O
a	O
new	O
localization	O
for	O
the	O
gene	O
responsible	O
for	O
BOR	O
syndrome	O
which	O
is	O
more	O
telomeric	O
to	O
an	O
initial	O
placement	O
.	O

Linkage	O
analysis	O
of	O
affected	O
families	O
consistently	O
mapped	O
the	O
gene	O
responsible	O
for	O
BOR	O
and	O
Branchio	O
-	O
Oto	O
(	O
BO	O
)	O
syndromes	O
to	O
within	O
the	O
deletion	O
.	O

Using	O
new	O
algorithms	O
,	O
a	O
YAC	O
contig	O
was	O
constructed	O
and	O
used	O
to	O
localize	O
the	O
breakpoint	O
of	O
another	O
chromosomal	O
rearrangement	O
associated	O
with	O
BO	O
syndrome	O
to	O
a	O
500	O
kb	O
interval	O
within	O
the	O
deletion	O
.	O

The	O
8q12.2	O
-	O
q21.2	O
deletion	O
suggests	O
that	O
reduced	O
dosage	O
of	O
the	O
relevant	O
genes	O
is	O
sufficient	O
to	O
cause	O
Duane	B-Phenotype
syndrome	E-Phenotype
,	O
BOR	O
syndrome	O
and	O
this	O
dominant	O
form	O
of	O
hydrocephalus	S-Phenotype
.	O

Club	B-Phenotype
foot	E-Phenotype
is	O
one	O
of	O
the	O
most	O
common	O
human	O
congenital	O
malformations	O
.	O

Distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
I	O
(	O
DA	O
-	O
1	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
dominantly	O
inherited	O
club	B-Phenotype
foot	E-Phenotype
.	O

Performing	O
a	O
genomewide	O
search	O
using	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
polymorphisms	O
,	O
we	O
have	O
mapped	O
a	O
DA	O
-	O
1	O
gene	O
to	O
the	O
pericentromeric	O
region	O
of	O
chromosome	O
9	O
in	O
a	O
large	O
kindred	O
.	O

Linkage	O
analysis	O
has	O
generated	O
a	O
positive	O
lod	O
score	O
of	O
5.90	O
at	O
theta	O
=	O
0	O
,	O
with	O
the	O
marker	O
GS	O
-	O
4	O
.	O

Multiple	O
recombinants	O
bracketing	O
the	O
region	O
have	O
been	O
identified	O
.	O

Analysis	O
of	O
an	O
additional	O
family	O
demonstrated	O
no	O
linkage	O
to	O
the	O
same	O
locus	O
,	O
indicating	O
likely	O
locus	O
heterogeneity	O
.	O

Of	O
the	O
autosomal	O
congenital	B-Phenotype
contracture	E-Phenotype
disorders	O
causing	O
positional	B-Phenotype
foot	I-Phenotype
deformities	E-Phenotype
,	O
this	O
is	O
the	O
first	O
to	O
be	O
mapped	O
.	O

Nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
,	O
or	O
Gorlin	O
syndrome	O
)	O
is	O
a	O
cancer	S-Phenotype
predisposition	O
syndrome	O
characterized	O
by	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
diverse	O
developmental	B-Phenotype
defects	E-Phenotype
.	O

The	O
gene	O
responsible	O
for	O
NBCCS	O
,	O
which	O
is	O
most	O
likely	O
to	O
be	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
has	O
previously	O
been	O
mapped	O
to	O
9q22.3	O
-	O
q31	O
in	O
a	O
12	O
-	O
cM	O
interval	O
between	O
the	O
microsatellite	O
marker	O
loci	O
D9S12.1	O
and	O
D9S109	O
.	O

Combined	O
multipoint	O
and	O
haplotype	O
analyses	O
of	O
additional	O
polymorphisms	O
in	O
this	O
region	O
in	O
our	O
collection	O
of	O
Australasian	O
pedigrees	O
have	O
further	O
refined	O
the	O
localization	O
of	O
the	O
gene	O
to	O
between	O
the	O
markers	O
D9S196	O
and	O
D9S180	O
,	O
an	O
interval	O
reported	O
to	O
be	O
approximately	O
2	O
cM	O
.	O

The	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCC	O
)	O
is	O
an	O
autosomal	O
dominant	O
multisystem	O
disorder	O
with	O
variable	O
expressivity	O
.	O

We	O
present	O
the	O
clinical	O
findings	O
on	O
11	O
African	O
-	O
American	O
NBCC	O
cases	O
from	O
2	O
families	O
and	O
a	O
review	O
of	O
the	O
literature	O
of	O
NBCC	O
in	O
African	O
-	O
Americans	O
.	O

The	O
2	O
new	O
families	O
,	O
as	O
well	O
as	O
those	O
previously	O
reported	O
,	O
suggest	O
minimal	O
expression	O
of	O
the	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
full	O
expression	O
of	O
the	O
other	O
components	O
of	O
the	O
syndrome	O
.	O

The	O
3	O
most	O
common	O
findings	O
in	O
the	O
11	O
cases	O
were	O
jaw	B-Phenotype
cysts	E-Phenotype
,	O
palmar	B-Phenotype
and	I-Phenotype
/	I-Phenotype
or	I-Phenotype
plantar	I-Phenotype
pits	E-Phenotype
,	O
and	O
calcification	B-Phenotype
of	I-Phenotype
the	I-Phenotype
falx	I-Phenotype
cerebri	E-Phenotype
.	O

Only	O
44	O
%	O
(	O
4	O
/	O
11	O
)	O
of	O
these	O
cases	O
had	O
one	O
or	O
more	O
confirmed	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
.	O

This	O
frequency	O
is	O
substantially	O
less	O
than	O
that	O
observed	O
in	O
whites	O
(	O
90	O
%	O
with	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
)	O
.	O

The	O
relative	O
lack	O
of	O
these	O
skin	B-Phenotype
tumors	E-Phenotype
in	O
African	O
-	O
Americans	O
partly	O
reflects	O
ultraviolet	O
radiation	O
protection	O
resulting	O
from	O
increased	B-Phenotype
skin	I-Phenotype
pigmentation	E-Phenotype
.	O

Future	O
research	O
should	O
help	O
identify	O
the	O
specific	O
mutation	O
(	O
s	O
)	O
in	O
blacks	O
as	O
well	O
as	O
other	O
modifying	O
genes	O
and	O
environmental	O
exposures	O
that	O
may	O
contribute	O
to	O
the	O
varied	O
manifestations	O
of	O
the	O
syndrome	O
.	O

One	O
hundred	O
eighteen	O
cases	O
of	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
,	O
Gorlin	O
's	O
syndrome	O
or	O
basal	B-Phenotype
cell	I-Phenotype
nevus	E-Phenotype
syndrome	O
)	O
are	O
presented	O
in	O
this	O
study	O
.	O

In	O
aiming	O
to	O
ascertain	O
all	O
the	O
affected	O
families	O
in	O
Australia	O
,	O
we	O
have	O
examined	O
the	O
largest	O
series	O
to	O
date	O
.	O

Relative	O
frequencies	O
of	O
associated	O
complications	O
are	O
presented	O
and	O
compared	O
with	O
those	O
of	O
the	O
recent	O
English	O
survey	O
by	O
Evans	O
et	O
al	O
.	O

[	O
J	O
Med	O
Genet	O
30:460	O
-	O
464	O
,	O
1993	O
]	O
.	O

The	O
frequencies	O
of	O
most	O
manifestations	O
are	O
similar	O
.	O

However	O
,	O
one	O
major	O
difference	O
is	O
that	O
the	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
are	O
manifest	O
from	O
an	O
earlier	O
age	O
in	O
the	O
Australian	O
population	O
,	O
which	O
probably	O
reflects	O
greater	O
exposure	O
to	O
ultraviolet	O
radiation	O
.	O

Of	O
the	O
64	O
families	O
ascertained	O
,	O
37	O
represented	O
simplex	O
cases	O
,	O
and	O
,	O
accordingly	O
,	O
the	O
apparent	O
new	O
mutation	O
rate	O
is	O
surprisingly	O
high	O
(	O
14	O
-	O
81	O
%	O
)	O
given	O
the	O
lack	O
of	O
impact	O
of	O
NBCCS	O
on	O
reproductive	O
capabilities	O
.	O

There	O
is	O
some	O
evidence	O
to	O
suggest	O
that	O
this	O
may	O
be	O
attributable	O
to	O
anticipation	O
.	O

Branchio	O
-	O
oto	O
-	O
renal	O
(	O
BOR	O
)	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
condition	O
of	O
branchial	B-Phenotype
arch	I-Phenotype
anomalies	E-Phenotype
,	O
deafness	S-Phenotype
and	O
renal	B-Phenotype
dysplasia	E-Phenotype
.	O

Clinical	O
manifestations	O
tend	O
to	O
have	O
considerable	O
intrafamilial	O
and	O
interfamilial	O
variability	O
.	O

Previous	O
linkage	O
studies	O
had	O
localized	O
the	O
gene	O
responsible	O
for	O
BOR	O
syndrome	O
to	O
a	O
broad	O
region	O
of	O
chromosome	O
8q	O
.	O

Using	O
10	O
microsatellite	O
markers	O
,	O
we	O
have	O
further	O
refined	O
the	O
localization	O
of	O
this	O
disorder	O
by	O
establishing	O
tight	O
linkage	O
to	O
two	O
markers	O
,	O
D8S279	O
and	O
D8S530	O
(	O
Zmax	O
=	O
3.91	O
and	O
Zmax	O
=	O
2.83	O
respectively	O
at	O
theta	O
=	O
0.00	O
)	O
.	O

These	O
markers	O
are	O
within	O
1	O
cM	O
of	O
one	O
another	O
.	O

Multipoint	O
analysis	O
,	O
involving	O
7	O
loci	O
,	O
placed	O
the	O
gene	O
between	O
these	O
markers	O
,	O
with	O
a	O
lod	O
-	O
1	O
confidence	O
interval	O
0.7	O
cM	O
proximal	O
to	O
D8S530	O
and	O
0.6	O
cM	O
distal	O
to	O
D8S279	O
.	O

Branchiootorenal	O
(	O
BOR	O
)	O
syndrome	O
is	O
a	O
common	O
autosomal	O
dominant	O
form	O
of	O
hearing	B-Phenotype
impairment	E-Phenotype
previously	O
mapped	O
to	O
8q	O
.	O

This	O
report	O
refines	O
the	O
localization	O
of	O
the	O
BOR	O
syndrome	O
gene	O
by	O
haplotype	O
analysis	O
to	O
the	O
interval	O
flanked	O
by	O
markers	O
D8S553	O
and	O
D8S286	O
.	O

By	O
multipoint	O
linkage	O
analysis	O
,	O
the	O
disease	O
locus	O
most	O
likely	O
is	O
flanked	O
by	O
markers	O
D8S530	O
and	O
D8S279	O
.	O

RFLP	O
typing	O
of	O
members	O
of	O
a	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
family	O
suggested	O
that	O
affected	O
individuals	O
were	O
hemizygous	O
at	O
the	O
neurofilament	O
heavy	O
chain	O
(	O
NEFH	O
)	O
locus	O
,	O
possibly	O
as	O
a	O
result	O
of	O
a	O
disease	O
-	O
associated	O
deletion	O
.	O

Conventional	O
karyotyping	O
revealed	O
no	O
evidence	O
for	O
a	O
deletion	O
and	O
all	O
or	O
a	O
majority	O
of	O
the	O
affected	O
family	O
members	O
were	O
heterozygous	O
for	O
closely	O
linked	O
markers	O
which	O
mapped	O
proximal	O
to	O
the	O
NEFH	O
locus	O
(	O
D22S1	O
and	O
D22S56	O
)	O
and	O
for	O
the	O
distal	O
marker	O
D22S32	O
.	O

FISH	O
analysis	O
confirmed	O
a	O
disease	O
-	O
associated	O
germinal	O
deletion	O
on	O
22q	O
which	O
encompassed	O
the	O
NEFH	O
locus	O
,	O
which	O
is	O
known	O
to	O
be	O
very	O
closely	O
linked	O
to	O
NF2	O
,	O
but	O
did	O
not	O
extend	O
as	O
far	O
as	O
the	O
proximal	O
Ewing	O
sarcoma	S-Phenotype
region	O
or	O
the	O
distal	O
leukaemia	O
factor	O
(	O
LIF	O
)	O
locus	O
.	O

PFGE	O
analysis	O
with	O
a	O
LIF	O
cosmid	O
subclone	O
identified	O
patient	O
-	O
specific	O
NotI	O
and	O
MluI	O
fragments	O
and	O
suggested	O
that	O
the	O
deletion	O
is	O
about	O
700	O
kb	O
in	O
length	O
.	O

Although	O
this	O
large	O
deletion	O
could	O
be	O
expected	O
to	O
eliminate	O
a	O
considerable	O
fraction	O
,	O
and	O
possibly	O
all	O
of	O
the	O
NF2	O
gene	O
,	O
the	O
resulting	O
phenotype	O
is	O
the	O
mild	O
,	O
so	O
-	O
called	O
Gardner	O
subtype	O
of	O
NF2	O
.	O

The	O
deletion	O
should	O
provide	O
a	O
useful	O
mapping	O
resource	O
for	O
characterising	O
the	O
chromosomal	O
region	O
containing	O
the	O
NF2	O
locus	O
.	O

Robertsonian	O
translocations	O
,	O
occurring	O
with	O
a	O
frequency	O
of	O
about	O
1	O
in	O
10,000	O
livebirths	O
,	O
may	O
be	O
an	O
important	O
cause	O
of	O
uniparental	O
disomy	O
as	O
demonstrated	O
for	O
13	O
/	O
15	O
,	O
13	O
/	O
14	O
,	O
14	O
/	O
14	O
,	O
and	O
22	O
/	O
22	O
translocations	O
.	O

Dysmorphogenesis	S-Phenotype
and	O
/	O
or	O
mental	B-Phenotype
retardation	E-Phenotype
provide	O
clinical	O
clues	O
for	O
uniparental	O
disomy	O
in	O
apparently	O
balanced	O
offspring	O
of	O
translocation	O
carriers	O
.	O

Research	O
strategies	O
for	O
assessing	O
frequency	O
and	O
implications	O
of	O
uniparental	O
disomy	O
in	O
translocation	O
carriers	O
include	O
a	O
genetic	O
register	O
approach	O
,	O
study	O
of	O
abortuses	O
from	O
balanced	O
translocation	O
carriers	O
,	O
and	O
parent	O
-	O
of	O
-	O
origin	O
studies	O
on	O
de	O
novo	O
homologous	O
Robertsonian	O
translocations	O
.	O

We	O
present	O
3	O
individuals	O
,	O
a	O
mother	O
,	O
her	O
son	O
,	O
and	O
an	O
unrelated	O
child	O
,	O
with	O
a	O
number	O
of	O
manifestations	O
reported	O
in	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
(	O
BOFS	O
)	O
.	O

The	O
former	O
2	O
individuals	O
lacked	O
the	O
ocular	O
and	O
branchial	O
abnormalities	O
normally	O
encountered	O
in	O
this	O
syndrome	O
.	O

However	O
,	O
unilateral	B-Phenotype
renal	I-Phenotype
agenesis	E-Phenotype
was	O
present	O
in	O
the	O
first	O
child	O
,	O
a	O
defect	O
infrequently	O
found	O
in	O
the	O
BOF	O
syndrome	O
.	O

Both	O
the	O
mother	O
and	O
her	O
son	O
also	O
had	O
bilateral	B-Phenotype
supra	I-Phenotype
-	I-Phenotype
auricular	I-Phenotype
sinuses	E-Phenotype
.	O

These	O
defects	O
may	O
represent	O
persistence	O
of	O
the	O
otic	O
vesicle	O
sinus	O
tract	O
.	O

The	O
second	O
child	O
has	O
a	O
mild	O
expression	O
of	O
this	O
condition	O
,	O
among	O
the	O
mildest	O
reported	O
in	O
the	O
literature	O
.	O

The	O
BOFS	O
appears	O
to	O
represent	O
a	O
spectrum	O
involving	O
the	O
development	B-Phenotype
of	I-Phenotype
the	I-Phenotype
optic	I-Phenotype
vesicles	E-Phenotype
,	O
branchial	B-Phenotype
arches	E-Phenotype
,	O
eyes	O
,	O
face	O
,	O
lips	O
,	O
and	O
kidneys	O
.	O

The	O
variations	O
seen	O
in	O
this	O
disorder	O
and	O
the	O
overlap	O
between	O
this	O
condition	O
and	O
the	O
branchio	O
-	O
oto	O
-	O
renal	O
syndrome	O
may	O
represent	O
different	O
mutations	O
within	O
a	O
single	O
gene	O
or	O
may	O
be	O
a	O
contiguous	O
gene	O
deletion	O
syndrome	O
.	O

Familial	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
can	O
result	O
from	O
mutations	O
in	O
chromosome	O
15q11q13	O
that	O
,	O
when	O
transmitted	O
from	O
father	O
to	O
child	O
,	O
result	O
in	O
no	O
phenotypic	O
abnormality	O
but	O
,	O
when	O
transmitted	O
from	O
mother	O
to	O
child	O
,	O
cause	O
AS	O
.	O

These	O
mutations	O
therefore	O
behave	O
neither	O
as	O
dominant	O
nor	O
as	O
recessive	O
mutations	O
but	O
,	O
rather	O
,	O
show	O
an	O
imprinted	O
mode	O
of	O
inheritance	O
.	O

We	O
have	O
analyzed	O
two	O
sibling	O
pairs	O
with	O
AS	O
and	O
a	O
larger	O
family	O
with	O
four	O
AS	O
offspring	O
of	O
three	O
sisters	O
with	O
several	O
recently	O
described	O
microsatellite	O
polymorphisms	O
in	O
the	O
AS	O
region	O
.	O

AS	O
siblings	O
inherited	O
the	O
same	O
maternal	O
alleles	O
at	O
the	O
GABRB3	O
and	O
GABRA5	O
loci	O
,	O
and	O
the	O
unaffected	O
siblings	O
of	O
AS	O
individuals	O
inherited	O
the	O
other	O
maternal	O
alleles	O
at	O
these	O
loci	O
.	O

In	O
one	O
of	O
the	O
AS	O
sibling	O
pairs	O
,	O
analysis	O
of	O
a	O
recombination	O
event	O
indicates	O
that	O
the	O
mutation	O
responsible	O
for	O
AS	O
is	O
distal	O
to	O
locus	O
D15S63	O
.	O

This	O
result	O
is	O
consistent	O
with	O
a	O
previously	O
described	O
imprinted	O
submicroscopic	O
deletion	O
causing	O
AS	O
,	O
a	O
deletion	O
that	O
includes	O
loci	O
D15S10	O
,	O
D15S113	O
,	O
and	O
GABRB3	O
,	O
all	O
distal	O
to	O
D15S63	O
.	O

The	O
analysis	O
of	O
the	O
larger	O
AS	O
family	O
provides	O
the	O
first	O
clear	O
demonstration	O
of	O
a	O
new	O
mutation	O
in	O
nondeletion	O
AS	O
.	O

Analysis	O
of	O
linkage	O
of	O
AS	O
to	O
GABRB3	O
in	O
these	O
three	O
families	O
,	O
on	O
the	O
assumption	O
of	O
imprinted	O
inheritance	O
(	O
i.e.	O
,	O
penetrance	O
of	O
an	O
AS	O
mutation	O
is	O
1	O
if	O
transmitted	O
maternally	O
and	O
is	O
0	O
if	O
transmitted	O
paternally	O
)	O
,	O
indicates	O
a	O
maximum	O
lod	O
score	O
of	O
3.52	O
at	O
theta	O
=	O
0	O
.	O

This	O
prospective	O
study	O
of	O
96	O
individuals	O
from	O
29	O
families	O
with	O
neurofibromatosis	S-Phenotype
2	O
,	O
49	O
of	O
whom	O
were	O
affected	O
,	O
confirms	O
in	O
an	O
extended	O
series	O
the	O
previously	O
reported	O
association	O
between	O
posterior	B-Phenotype
subcapsular	I-Phenotype
/	I-Phenotype
capsular	I-Phenotype
cataract	E-Phenotype
and	O
neurofibromatosis	O
2	O
.	O

Posterior	B-Phenotype
subcapsular	I-Phenotype
/	I-Phenotype
capsular	I-Phenotype
cataracts	E-Phenotype
were	O
found	O
in	O
36	O
(	O
80	O
%	O
)	O
of	O
the	O
45	O
affected	O
individuals	O
(	O
four	O
individuals	O
were	O
excluded	O
from	O
statistical	O
analyses	O
)	O
.	O

In	O
addition	O
,	O
the	O
association	O
of	O
peripheral	B-Phenotype
cortical	I-Phenotype
lens	I-Phenotype
opacities	E-Phenotype
with	O
neurofibromatosis	S-Phenotype
2	O
was	O
found	O
to	O
be	O
statistically	O
significant	O
.	O

Seventeen	O
of	O
the	O
patients	O
with	O
neurofibromatosis	S-Phenotype
2	O
(	O
37.8	O
%	O
)	O
had	O
peripheral	B-Phenotype
cortical	I-Phenotype
cataracts	E-Phenotype
in	O
comparison	O
with	O
none	O
of	O
the	O
unaffected	O
family	O
members	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
three	O
patients	O
peripheral	B-Phenotype
cortical	I-Phenotype
opacities	E-Phenotype
were	O
present	O
despite	O
the	O
absence	O
of	O
posterior	B-Phenotype
subcapsular	I-Phenotype
/	I-Phenotype
capsular	I-Phenotype
cataracts	E-Phenotype
.	O

These	O
findings	O
support	O
the	O
inclusion	O
of	O
cortical	B-Phenotype
cataracts	I-Phenotype
of	I-Phenotype
early	I-Phenotype
onset	E-Phenotype
,	O
in	O
addition	O
to	O
posterior	B-Phenotype
subcapsular	I-Phenotype
/	I-Phenotype
capsular	I-Phenotype
cataracts	E-Phenotype
,	O
in	O
the	O
diagnostic	O
criteria	O
of	O
neurofibromatosis	S-Phenotype
2	O
.	O

There	O
are	O
many	O
potential	O
complications	O
which	O
have	O
been	O
reported	O
in	O
association	O
with	O
the	O
naevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
.	O

We	O
have	O
been	O
able	O
to	O
show	O
the	O
relative	O
frequencies	O
of	O
these	O
problems	O
in	O
a	O
population	O
based	O
study	O
of	O
84	O
cases	O
in	O
the	O
north	O
west	O
of	O
England	O
.	O

The	O
major	O
complications	O
of	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
jaw	B-Phenotype
cysts	E-Phenotype
occur	O
in	O
over	O
90	O
%	O
of	O
patients	O
by	O
40	O
years	O
of	O
age	O
,	O
but	O
may	O
both	O
occur	O
before	O
10	O
years	O
of	O
age	O
.	O

Less	O
well	O
described	O
complications	O
are	O
ovarian	B-Phenotype
calcification	E-Phenotype
or	O
fibroma	O
(	O
24	O
%	O
)	O
,	O
medulloblastoma	S-Phenotype
(	O
5	O
%	O
)	O
,	O
cardiac	B-Phenotype
fibroma	E-Phenotype
(	O
3	O
%	O
)	O
,	O
cleft	B-Phenotype
palate	E-Phenotype
(	O
5	O
%	O
)	O
,	O
and	O
ophthalmic	B-Phenotype
abnormalities	E-Phenotype
such	O
as	O
squint	S-Phenotype
or	O
cataract	S-Phenotype
(	O
26	O
%	O
)	O
.	O

This	O
study	O
more	O
clearly	O
defines	O
the	O
possible	O
complications	O
of	O
the	O
syndrome	O
and	O
gives	O
clearer	O
guidelines	O
for	O
counselling	O
and	O
screening	O
affected	O
and	O
at	O
risk	O
persons	O
.	O

Neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
is	O
a	O
monogenic	O
dominantly	O
inherited	O
disease	O
predisposing	O
carriers	O
to	O
develop	O
nervous	B-Phenotype
system	E-Phenotype
tumours	S-Phenotype
.	O

To	O
identify	O
the	O
genetic	O
defect	O
,	O
the	O
region	O
between	O
two	O
flanking	O
polymorphic	O
markers	O
on	O
chromosome	O
22	O
was	O
cloned	O
and	O
several	O
genes	O
identified	O
.	O

One	O
is	O
the	O
site	O
of	O
germ	O
-	O
line	O
mutations	O
in	O
NF2	O
patients	O
and	O
of	O
somatic	O
mutations	O
in	O
NF2	O
-	O
related	O
tumours	S-Phenotype
.	O

Its	O
deduced	O
product	O
has	O
homology	O
with	O
proteins	O
at	O
the	O
plasma	O
membrane	O
and	O
cytoskeleton	O
interface	O
,	O
a	O
previously	O
unknown	O
site	O
of	O
action	O
of	O
tumour	S-Phenotype
suppressor	O
genes	O
in	O
humans	O
.	O

Neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
is	O
a	O
dominantly	O
inherited	O
disorder	O
characterized	O
by	O
multiple	O
tumors	S-Phenotype
of	O
the	O
central	O
nervous	O
system	O
,	O
predominantly	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
.	O

The	O
gene	O
for	O
NF2	O
is	O
located	O
in	O
the	O
chromosomal	O
region	O
22q12	O
between	O
the	O
loci	O
D22S1	O
and	O
D22S28	O
.	O

We	O
have	O
performed	O
genetic	O
linkage	O
analysis	O
on	O
13	O
NF2	O
families	O
with	O
a	O
total	O
of	O
nine	O
polymorphic	O
DNA	O
markers	O
,	O
including	O
five	O
which	O
we	O
have	O
recently	O
mapped	O
to	O
this	O
region	O
.	O

Two	O
loci	O
,	O
D22S32	O
and	O
NEFH	O
,	O
are	O
linked	O
to	O
the	O
NF2	O
locus	O
at	O
0	O
%	O
recombination	O
(	O
lod	O
scores	O
of	O
6.03	O
and	O
4.28	O
,	O
respectively	O
)	O
.	O

By	O
multipoint	O
linkage	O
analysis	O
,	O
we	O
assign	O
the	O
NF2	O
gene	O
to	O
an	O
interval	O
of	O
7	O
cM	O
,	O
between	O
the	O
loci	O
D22S212	O
and	O
D22S28	O
.	O

We	O
have	O
used	O
this	O
set	O
of	O
nine	O
markers	O
to	O
construct	O
chromosome	O
22	O
haplotypes	O
for	O
the	O
82	O
at	O
-	O
risk	O
individuals	O
in	O
this	O
pedigree	O
set	O
.	O

It	O
has	O
been	O
possible	O
to	O
determine	O
,	O
with	O
a	O
high	O
degree	O
of	O
certainty	O
,	O
the	O
carrier	O
status	O
of	O
70	O
(	O
85	O
%	O
)	O
of	O
these	O
at	O
-	O
risk	O
individuals	O
.	O

Risk	O
prediction	O
was	O
possible	O
in	O
every	O
case	O
where	O
DNA	O
was	O
available	O
from	O
both	O
parents	O
.	O

Fifty	O
-	O
three	O
of	O
the	O
70	O
(	O
76	O
%	O
)	O
informative	O
individuals	O
were	O
assigned	O
decreased	O
risks	O
of	O
being	O
carriers	O
.	O

The	O
use	O
of	O
chromosome	O
22	O
probes	O
for	O
risk	O
assessment	O
should	O
result	O
in	O
a	O
greatly	O
reduced	O
number	O
of	O
individuals	O
who	O
require	O
periodic	O
screening	O
for	O
NF2	O
.	O

Chromosome	O
region	O
15q	O
is	O
thought	O
to	O
contain	O
one	O
or	O
more	O
genes	O
that	O
are	O
important	O
for	O
melanin	B-Phenotype
pigment	I-Phenotype
synthesis	I-Phenotype
in	I-Phenotype
the	I-Phenotype
hair	I-Phenotype
,	I-Phenotype
skin	I-Phenotype
,	I-Phenotype
and	I-Phenotype
eyes	E-Phenotype
.	O

Hypopigmentation	S-Phenotype
has	O
been	O
identified	O
in	O
the	O
Prader	O
-	O
Willi	O
(	O
PWS	O
)	O
and	O
Angelman	O
(	O
AS	O
)	O
syndromes	O
.	O

We	O
have	O
examined	O
6	O
individuals	O
with	O
AS	O
to	O
further	O
characterize	O
the	O
pigment	O
pattern	O
in	O
this	O
condition	O
.	O

The	O
age	O
of	O
the	O
5	O
girls	O
and	O
one	O
boy	O
ranged	O
from	O
2.4	O
to	O
7.0	O
years	O
.	O

None	O
had	O
obvious	O
albinism	S-Phenotype
.	O

Hair	O
color	O
ranged	O
from	O
light	O
blond	O
to	O
brown	O
.	O

Skin	O
was	O
type	O
I	O
in	O
3	O
and	O
type	O
II	O
in	O
3	O
.	O

Eye	O
changes	O
included	O
nystagmus	S-Phenotype
in	O
2	O
,	O
strabismus	S-Phenotype
in	O
4	O
,	O
and	O
reduced	B-Phenotype
retinal	I-Phenotype
pigment	E-Phenotype
in	O
5	O
.	O

The	O
mean	O
hairbulb	O
tyrosinase	O
activity	O
was	O
0.37	O
+	O
/	O
-	O
0.44	O
pmol	O
/	O
hb	O
/	O
120	O
min	O
for	O
the	O
individuals	O
with	O
AS	O
,	O
with	O
a	O
range	O
of	O
0.00	O
to	O
1.13	O
(	O
normal	O
brown	O
control	O
1.49	O
+	O
/	O
-	O
0.79	O
,	O
normal	O
blond	O
control	O
1.50	O
+	O
/	O
-	O
0.85	O
)	O
.	O

Electron	O
microscopic	O
examination	O
of	O
hairbulb	O
melanocytes	O
showed	O
normal	O
melanosome	O
and	O
melanocyte	O
architecture	O
and	O
number	O
,	O
but	O
reduced	O
melanin	O
formation	O
,	O
with	O
many	O
stage	O
II	O
and	O
III	O
premelanosomes	O
but	O
few	O
stage	O
IV	O
fully	O
melanized	O
melanosomes	O
.	O

Hypopigmentation	S-Phenotype
characterized	O
by	O
light	O
skin	O
,	O
reduced	B-Phenotype
retinal	I-Phenotype
pigment	E-Phenotype
,	O
low	O
hairbulb	O
tyrosinase	O
activity	O
,	O
and	O
incomplete	O
melanization	O
of	O
melanosomes	O
is	O
part	O
of	O
the	O
phenotype	O
of	O
AS	O
,	O
and	O
is	O
similar	O
to	O
that	O
found	O
in	O
PWS	O
.	O

Branchiootorenal	O
(	O
BOR	O
)	O
syndrome	O
is	O
a	O
variable	O
,	O
autosomal	O
-	O
dominant	O
disorder	O
of	O
the	O
first	O
and	O
second	O
embryonic	O
branchial	B-Phenotype
arches	E-Phenotype
,	O
kidneys	O
,	O
and	O
urinary	O
tract	O
.	O

We	O
describe	O
the	O
phenotype	O
in	O
45	O
individuals	O
,	O
highlighting	O
differences	O
and	O
similarities	O
reported	O
in	O
other	O
studies	O
.	O

Characteristic	O
temporal	B-Phenotype
bone	I-Phenotype
findings	E-Phenotype
include	O
cochlear	B-Phenotype
hypoplasia	E-Phenotype
(	O
4	O
/	O
5	O
of	O
normal	O
size	O
with	O
only	O
2	O
turns	O
)	O
,	O
dilation	B-Phenotype
of	I-Phenotype
the	I-Phenotype
vestibular	I-Phenotype
aqueduct	E-Phenotype
,	O
bulbous	B-Phenotype
internal	I-Phenotype
auditory	I-Phenotype
canals	E-Phenotype
,	O
deep	B-Phenotype
posterior	I-Phenotype
fossae	E-Phenotype
,	O
and	O
acutely	B-Phenotype
-	I-Phenotype
angled	I-Phenotype
promontories	E-Phenotype
.	O

We	O
studied	O
the	O
seizure	S-Phenotype
and	O
polygraphic	O
patterns	O
of	O
18	O
patients	O
with	O
Angelman	O
's	O
syndrome	O
.	O

All	O
patients	O
showed	O
movement	B-Phenotype
problems	E-Phenotype
.	O

Eleven	O
patients	O
were	O
also	O
reported	O
to	O
have	O
long	O
-	O
lasting	O
periods	O
of	O
jerky	B-Phenotype
movements	E-Phenotype
.	O

The	O
polygraphic	O
recording	O
showed	O
a	O
myoclonic	S-Phenotype
status	B-Phenotype
epilepticus	E-Phenotype
in	O
nine	O
of	O
them	O
.	O

Seven	O
patients	O
had	O
partial	S-Phenotype
seizures	S-Phenotype
with	O
eye	B-Phenotype
deviation	E-Phenotype
and	O
vomiting	S-Phenotype
,	O
similar	O
to	O
those	O
of	O
childhood	O
occipital	O
epilepsies	S-Phenotype
.	O

These	O
seizures	S-Phenotype
and	O
electroencephalographic	B-Phenotype
patterns	E-Phenotype
suggest	O
that	O
Angelman	O
's	O
syndrome	O
occurs	O
in	O
most	O
of	O
the	O
patients	O
as	O
a	O
nonprogressive	B-Phenotype
,	I-Phenotype
age	I-Phenotype
-	I-Phenotype
dependent	E-Phenotype
myoclonic	B-Phenotype
encephalopathy	E-Phenotype
with	O
a	O
prominent	O
occipital	O
involvement	O
.	O

These	O
findings	O
indicate	O
that	O
,	O
whereas	O
ataxia	S-Phenotype
is	O
a	O
constant	O
symptom	O
in	O
Angelman	O
's	O
syndrome	O
,	O
the	O
occurrence	O
of	O
a	O
transient	O
myoclonic	S-Phenotype
status	B-Phenotype
epilepticus	E-Phenotype
may	O
account	O
for	O
the	O
recurrence	O
of	O
different	O
abnormal	B-Phenotype
movements	E-Phenotype
,	O
namely	O
the	O
jerky	O
ones	O
.	O

Type	B-Phenotype
A1	I-Phenotype
brachydactyly	E-Phenotype
in	O
humans	O
is	O
a	O
recognisable	O
syndrome	O
characterised	O
by	O
shortening	B-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
phalanx	I-Phenotype
of	I-Phenotype
all	I-Phenotype
digits	E-Phenotype
with	O
occasional	O
fusion	B-Phenotype
of	I-Phenotype
the	I-Phenotype
middle	I-Phenotype
and	I-Phenotype
terminal	I-Phenotype
phalanges	E-Phenotype
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
candidate	O
genes	O
for	O
type	B-Phenotype
A1	I-Phenotype
brachydactyly	E-Phenotype
in	O
two	O
families	O
with	O
multiple	O
affected	O
members	O
.	O

Several	O
classes	O
of	O
genes	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
distal	O
limb	O
development	O
including	O
homeobox	O
containing	O
genes	O
(	O
MSX1	O
,	O
MSX2	O
)	O
some	O
members	O
of	O
the	O
homeobox	O
gene	O
family	O
,	O
and	O
genes	O
encoding	O
growth	O
factors	O
of	O
the	O
FGF	O
,	O
TGF	O
,	O
and	O
PDGF	O
families	O
.	O

Homeobox	O
(	O
Hox	O
)	O
genes	O
are	O
a	O
family	O
of	O
developmental	O
control	O
genes	O
activated	O
early	O
in	O
embryogenesis	O
that	O
encode	O
positional	O
information	O
along	O
the	O
anterior	O
-	O
posterior	O
body	O
axis	O
and	O
specify	O
distinct	O
spatial	O
domains	O
within	O
developing	O
limbs	O
.	O

Growth	O
factor	O
genes	O
can	O
regulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
embryonic	O
structures	O
including	O
limb	O
buds	O
and	O
have	O
been	O
shown	O
to	O
influence	O
Hox	O
gene	O
expression	O
.	O

Candidate	O
genes	O
HOXD	O
,	O
MSX1	O
,	O
MSX2	O
,	O
FGF	O
-	O
1	O
,	O
and	O
FGF	O
-	O
2	O
were	O
excluded	O
in	O
one	O
family	O
.	O

The	O
brachydactyly	B-Phenotype
type	I-Phenotype
A1	E-Phenotype
gene	O
or	O
locus	O
was	O
not	O
found	O
in	O
either	O
of	O
the	O
two	O
families	O
studied	O
.	O

The	O
basal	B-Phenotype
cell	I-Phenotype
nevus	I-Phenotype
syndrome	E-Phenotype
(	O
BCNS	O
)	O
is	O
characterized	O
by	O
developmental	B-Phenotype
abnormalities	E-Phenotype
and	O
by	O
the	O
postnatal	O
occurrence	O
of	O
cancers	O
,	O
especially	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
BCCs	O
)	O
,	O
the	O
most	O
common	O
human	O
cancer	S-Phenotype
.	O

Heritable	O
mutations	O
in	O
BCNS	O
patients	O
and	O
a	O
somatic	O
mutation	O
in	O
a	O
sporadic	O
BCC	O
were	O
identified	O
in	O
a	O
human	O
homolog	O
of	O
the	O
Drosophila	O
patched	O
(	O
ptc	O
)	O
gene	O
.	O

The	O
ptc	O
gene	O
encodes	O
a	O
transmembrane	O
protein	O
that	O
in	O
Drosophila	O
acts	O
in	O
opposition	O
to	O
the	O
Hedgehog	O
signaling	O
protein	O
,	O
controlling	O
cell	O
fates	O
,	O
patterning	O
,	O
and	O
growth	O
in	O
numerous	O
tissues	O
.	O

The	O
human	O
PTC	O
gene	O
appears	O
to	O
be	O
crucial	O
for	O
proper	O
embryonic	O
development	O
and	O
for	O
tumor	S-Phenotype
suppression	O
.	O

The	O
Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
)	O
is	O
comprised	O
of	O
a	O
triad	O
including	O
characteristic	O
anal	B-Phenotype
,	I-Phenotype
thumb	I-Phenotype
,	I-Phenotype
and	I-Phenotype
ear	I-Phenotype
anomalies	E-Phenotype
.	O

There	O
are	O
many	O
other	O
organ	O
system	O
abnormalities	O
which	O
may	O
be	O
present	O
.	O

However	O
,	O
the	O
literature	O
does	O
not	O
emphasize	O
craniofacial	B-Phenotype
findings	E-Phenotype
except	O
with	O
reference	O
to	O
the	O
typical	B-Phenotype
ear	I-Phenotype
configuration	E-Phenotype
.	O

A	O
three	O
-	O
generation	O
family	O
is	O
described	O
in	O
which	O
craniofacial	B-Phenotype
manifestations	E-Phenotype
were	O
prominent	O
and	O
a	O
Goldenhar	O
-	O
like	O
condition	O
was	O
considered	O
as	O
the	O
most	O
likely	O
diagnosis	O
.	O

However	O
,	O
with	O
the	O
recent	O
birth	O
of	O
an	O
affected	O
male	O
who	O
had	O
an	O
imperforate	B-Phenotype
anus	E-Phenotype
,	O
the	O
diagnosis	O
of	O
TBS	O
was	O
also	O
considered	O
.	O

The	O
family	O
manifests	O
a	O
variety	O
of	O
Goldenhar	O
-	O
like	O
findings	O
,	O
including	O
epibulbar	B-Phenotype
dermoids	E-Phenotype
,	O
hemifacial	B-Phenotype
microsomia	E-Phenotype
,	O
preauricular	B-Phenotype
tags	E-Phenotype
,	O
macrostomia	S-Phenotype
,	O
and	O
micrognathia	S-Phenotype
in	O
addition	O
to	O
classical	O
ear	B-Phenotype
,	I-Phenotype
radial	I-Phenotype
,	I-Phenotype
and	I-Phenotype
anal	I-Phenotype
findings	E-Phenotype
of	O
TBS	O
.	O

We	O
report	O
on	O
this	O
family	O
to	O
point	O
out	O
a	O
possible	O
biological	O
relationship	O
of	O
these	O
two	O
conditions	O
.	O

The	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
BCCs	O
)	O
,	O
pits	S-Phenotype
of	O
the	O
palms	O
and	O
soles	O
,	O
jaw	B-Phenotype
keratocysts	E-Phenotype
,	O
a	O
variety	O
of	O
other	S-Phenotype
tumors	S-Phenotype
,	O
and	O
developmental	B-Phenotype
abnormalities	E-Phenotype
.	O

NBCCS	O
maps	O
to	O
chromosome	O
9q22.3	O
.	O

Familial	O
and	O
sporadic	O
BCCs	O
display	O
loss	O
of	O
heterozygosity	O
in	O
this	O
region	O
,	O
consistent	O
with	O
the	O
gene	O
being	O
a	O
tumor	S-Phenotype
suppressor	O
.	O

A	O
human	O
sequence	O
(	O
PTC	O
)	O
with	O
strong	O
homology	O
to	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
,	O
patched	O
,	O
was	O
isolated	O
from	O
a	O
YAC	O
and	O
cosmid	O
contig	O
of	O
the	O
NBCCS	O
region	O
.	O

Mutation	O
analysis	O
revealed	O
alterations	O
of	O
PTC	O
in	O
NBCCS	O
patients	O
and	O
in	O
related	O
tumors	S-Phenotype
.	O

We	O
propose	O
that	O
a	O
reduction	O
in	O
expression	O
of	O
the	O
patched	O
gene	O
can	O
lead	O
to	O
the	O
developmental	B-Phenotype
abnormalities	E-Phenotype
observed	O
in	O
the	O
syndrome	O
and	O
that	O
complete	O
loss	O
of	O
patched	O
function	O
contributes	O
to	O
transformation	O
of	O
certain	O
cell	O
types	O
.	O

Neurofibromatosis	S-Phenotype
2	O
(	O
NF2	O
)	O
features	O
bilateral	S-Phenotype
vestibular	B-Phenotype
schwannomas	E-Phenotype
,	O
other	O
benign	O
neural	S-Phenotype
tumors	S-Phenotype
,	O
and	O
cataracts	S-Phenotype
.	O

Patients	O
in	O
some	O
families	O
develop	O
many	S-Phenotype
tumors	S-Phenotype
at	O
an	O
early	O
age	O
and	O
have	O
rapid	O
clinical	O
progression	O
,	O
whereas	O
in	O
other	O
families	O
,	O
patients	O
may	O
not	O
have	O
symptoms	O
until	O
much	O
later	O
and	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
may	O
be	O
the	O
only	O
tumors	O
.	O

The	O
NF2	O
gene	O
has	O
been	O
cloned	O
from	O
chromosome	O
22q	O
;	O
most	O
identified	O
germ	O
-	O
line	O
mutations	O
result	O
in	O
a	O
truncated	O
protein	O
and	O
severe	O
NF2	O
.	O

To	O
look	O
for	O
additional	O
mutations	O
and	O
clinical	O
correlations	O
,	O
we	O
used	O
SSCP	O
analysis	O
to	O
screen	O
DNA	O
from	O
32	O
unrelated	O
patients	O
.	O

We	O
identified	O
20	O
different	O
mutations	O
in	O
21	O
patients	O
(	O
66	O
%	O
)	O
:	O
10	O
nonsense	O
mutations	O
,	O
2	O
frameshifts	O
,	O
7	O
splice	O
-	O
site	O
mutations	O
,	O
and	O
1	O
large	O
in	O
-	O
frame	O
deletion	O
.	O

Clinical	O
information	O
on	O
47	O
patients	O
from	O
the	O
21	O
families	O
included	O
ages	O
at	O
onset	O
and	O
at	O
diagnosis	O
,	O
numbers	O
of	O
meningiomas	S-Phenotype
,	O
spinal	O
and	O
skin	S-Phenotype
tumors	S-Phenotype
,	O
and	O
presence	O
of	O
cataracts	S-Phenotype
and	O
retinal	O
abnormalities	O
.	O

We	O
compared	O
clinical	O
findings	O
in	O
patients	O
with	O
nonsense	O
or	O
frameshift	O
mutations	O
to	O
those	O
with	O
splice	O
-	O
site	O
mutations	O
.	O

When	O
each	O
patient	O
was	O
considered	O
as	O
an	O
independent	O
random	O
event	O
,	O
the	O
two	O
groups	O
differed	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
for	O
nearly	O
every	O
variable	O
.	O

Patients	O
with	O
nonsense	O
or	O
frameshift	O
mutations	O
were	O
younger	O
at	O
onset	O
and	O
at	O
diagnosis	O
and	O
had	O
a	O
higher	O
frequency	O
and	O
mean	O
number	O
of	O
tumors	S-Phenotype
,	O
supporting	O
the	O
correlation	O
between	O
nonsense	O
and	O
frameshift	O
mutations	O
and	O
severe	O
NF2	O
.	O

When	O
each	O
family	O
was	O
considered	O
as	O
an	O
independent	O
random	O
event	O
,	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
only	O
for	O
mean	O
ages	O
at	O
onset	O
and	O
at	O
diagnosis	O
.	O

A	O
larger	O
data	O
set	O
is	O
needed	O
to	O
resolve	O
these	O
discrepancies	O
.	O

We	O
observed	O
retinal	B-Phenotype
hamartomas	E-Phenotype
and	O
/	O
or	O
epiretinal	B-Phenotype
membranes	E-Phenotype
in	O
nine	O
patients	O
from	O
five	O
families	O
with	O
four	O
different	O
nonsense	O
mutations	O
.	O

This	O
finding	O
,	O
which	O
may	O
represent	O
a	O
new	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
merits	O
further	O
study	O
.	O

The	O
gene	O
predisposing	O
to	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
on	O
human	O
chromosome	O
22	O
has	O
revealed	O
a	O
wide	O
variety	O
of	O
different	O
mutations	O
in	O
NF2	O
individuals	O
.	O

These	O
patients	O
display	O
a	O
marked	O
variability	O
in	O
clinical	O
presentation	O
,	O
ranging	O
from	O
very	O
severe	O
disease	O
with	O
numerous	S-Phenotype
tumors	S-Phenotype
at	O
a	O
young	O
age	O
to	O
a	O
relatively	O
mild	O
condition	O
much	O
later	O
in	O
life	O
.	O

To	O
investigate	O
whether	O
this	O
phenotypic	O
heterogeneity	O
is	O
determined	O
by	O
the	O
type	O
of	O
mutation	O
in	O
NF2	O
,	O
we	O
have	O
collected	O
clinical	O
information	O
on	O
111	O
NF2	O
cases	O
from	O
73	O
different	O
families	O
on	O
whom	O
we	O
have	O
performed	O
mutation	O
screening	O
in	O
this	O
gene	O
.	O

Sixty	O
-	O
seven	O
individuals	O
(	O
56.2	O
%	O
)	O
from	O
41	O
of	O
these	O
kindreds	O
revealed	O
36	O
different	O
putative	O
disease	O
-	O
causing	O
mutations	O
.	O

These	O
include	O
26	O
proposed	O
protein	O
-	O
truncating	O
alterations	O
(	O
frameshift	O
deletions	O
/	O
insertions	O
and	O
nonsense	O
mutations	O
)	O
,	O
6	O
splice	O
-	O
site	O
mutations	O
,	O
2	O
missense	O
mutations	O
,	O
1	O
base	O
substitution	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
NF2	O
cDNA	O
,	O
and	O
a	O
single	O
3	O
-	O
bp	O
in	O
-	O
frame	O
insertion	O
.	O

Seventeen	O
of	O
these	O
mutations	O
are	O
novel	O
,	O
whereas	O
the	O
remaining	O
19	O
have	O
been	O
described	O
previously	O
in	O
other	O
NF2	O
individuals	O
or	O
sporadic	O
tumors	S-Phenotype
.	O

When	O
individuals	O
harboring	O
protein	O
-	O
truncating	O
mutations	O
are	O
compared	O
with	O
cases	O
with	O
single	O
codon	O
alterations	O
,	O
a	O
significant	O
correlation	O
(	O
P	O
<	O
.001	O
)	O
with	O
clinical	O
outcome	O
is	O
observed	O
.	O

Twenty	O
-	O
four	O
of	O
28	O
patients	O
with	O
mutations	O
that	O
cause	O
premature	O
truncation	O
of	O
the	O
NF2	O
protein	O
,	O
schwannomin	O
,	O
present	O
with	O
severe	O
phenotypes	O
.	O

In	O
contrast	O
,	O
all	O
16	O
cases	O
from	O
three	O
families	O
with	O
mutations	O
that	O
affect	O
only	O
a	O
single	O
amino	O
acid	O
have	O
mild	O
NF2	O
.	O

These	O
data	O
provide	O
conclusive	O
evidence	O
that	O
a	O
phenotype	O
/	O
genotype	O
correlation	O
exists	O
for	O
certain	O
NF2	O
mutations	O
.	O

Gorlin	O
syndrome	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
medulloblastomas	S-Phenotype
,	O
ovarian	B-Phenotype
fibromas	E-Phenotype
,	O
and	O
a	O
variety	O
of	O
developmental	B-Phenotype
defects	E-Phenotype
.	O

All	O
affected	O
individuals	O
share	O
certain	O
key	O
features	O
,	O
but	O
there	O
is	O
significant	O
phenotypic	O
variability	O
within	O
and	O
among	O
kindreds	O
with	O
respect	O
to	O
malformations	O
.	O

The	O
gene	O
(	O
NBCCS	O
)	O
maps	O
to	O
chromosome	O
9q22	O
,	O
and	O
allelic	O
loss	O
at	O
this	O
location	O
is	O
common	O
in	O
tumors	S-Phenotype
from	O
Gorlin	O
syndrome	O
patients	O
.	O

Two	O
recessive	O
cancer	S-Phenotype
-	O
predisposition	O
syndromes	O
,	O
xeroderma	O
pigmentosum	O
group	O
A	O
(	O
XPAC	O
)	O
and	O
Fanconi	O
anemia	O
group	O
C	O
(	O
FACC	O
)	O
,	O
map	O
to	O
the	O
NBCCS	O
region	O
;	O
and	O
unusual	O
,	O
dominant	O
mutations	O
in	O
these	O
genes	O
have	O
been	O
proposed	O
as	O
the	O
cause	O
of	O
Gorlin	O
syndrome	O
.	O

This	O
study	O
presents	O
cytogenetic	O
and	O
molecular	O
characterization	O
of	O
germ	O
-	O
line	O
deletions	O
in	O
one	O
patient	O
with	O
a	O
chromosome	O
9q22	O
deletion	O
and	O
in	O
a	O
second	O
patient	O
with	O
a	O
deletion	O
of	O
9q22	O
-	O
q3l	O
.	O

Both	O
have	O
typical	O
features	O
of	O
Gorlin	O
syndrome	O
plus	O
additional	O
findings	O
,	O
including	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
conductive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
and	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
.	O

That	O
Gorlin	O
syndrome	O
can	O
be	O
caused	O
by	O
null	O
mutations	O
(	O
deletions	O
)	O
rather	O
than	O
by	O
activating	O
mutations	O
has	O
several	O
implications	O
.	O

First	O
,	O
in	O
conjunction	O
with	O
previous	O
analyses	O
of	O
allelic	O
loss	O
in	O
tumors	S-Phenotype
,	O
this	O
study	O
provides	O
evidence	O
that	O
associated	O
neoplasms	S-Phenotype
arise	O
with	O
homozygous	O
inactivation	O
of	O
the	O
gene	O
.	O

In	O
addition	O
,	O
dominant	O
mutations	O
of	O
the	O
XPAC	O
and	O
FACC1	O
genes	O
can	O
be	O
ruled	O
out	O
as	O
the	O
cause	O
of	O
Gorlin	O
syndrome	O
,	O
since	O
the	O
two	O
patients	O
described	O
have	O
null	O
mutations	O
.	O

Finally	O
,	O
phenotypic	O
features	O
that	O
show	O
variable	O
expression	O
must	O
be	O
influenced	O
by	O
genetic	O
background	O
,	O
epigenetic	O
effects	O
,	O
somatic	O
mutations	O
,	O
or	O
environmental	O
factors	O
,	O
since	O
these	O
two	O
patients	O
with	O
identical	O
alterations	O
(	O
deletions	O
)	O
of	O
the	O
Gorlin	O
syndrome	O
gene	O
have	O
somewhat	O
different	O
manifestations	O
of	O
Gorlin	O
syndrome	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
is	O
characterized	O
by	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
absent	B-Phenotype
speech	E-Phenotype
,	O
puppet	B-Phenotype
-	I-Phenotype
like	I-Phenotype
movements	E-Phenotype
,	O
inappropriate	B-Phenotype
laughter	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
and	O
abnormal	B-Phenotype
electroencephalogram	E-Phenotype
.	O

The	O
majority	O
of	O
AS	O
patients	O
(	O
approximately	O
65	O
%	O
)	O
have	O
a	O
maternal	O
deficiency	O
within	O
chromosomal	O
region	O
15q11	O
-	O
q13	O
,	O
caused	O
by	O
maternal	O
deletion	O
or	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
.	O

Approximately	O
35	O
%	O
of	O
AS	O
patients	O
exhibit	O
neither	O
detectable	O
deletion	O
nor	O
UPD	O
,	O
but	O
a	O
subset	O
of	O
these	O
patients	O
have	O
abnormal	O
methylation	O
at	O
several	O
loci	O
in	O
the	O
15q11	O
-	O
q13	O
region	O
.	O

We	O
describe	O
here	O
three	O
patients	O
with	O
Angelman	O
syndrome	O
belonging	O
to	O
an	O
extended	O
inbred	O
family	O
.	O

High	O
resolution	O
chromosome	O
analysis	O
combined	O
with	O
DNA	O
analysis	O
using	O
14	O
marker	O
loci	O
from	O
the	O
15ql1	O
-	O
q13	O
region	O
failed	O
to	O
detect	O
a	O
deletion	O
in	O
any	O
of	O
the	O
three	O
patients	O
.	O

Paternal	O
UPD	O
of	O
chromosome	O
15	O
was	O
detected	O
in	O
one	O
case	O
,	O
while	O
the	O
other	O
two	O
patients	O
have	O
abnormal	O
methylation	O
at	O
D15S9	O
,	O
D15S63	O
,	O
and	O
SNRPN	O
.	O

Although	O
the	O
three	O
patients	O
are	O
distantly	O
related	O
,	O
the	O
chromosome	O
15q11	O
-	O
q13	O
haplotypes	O
are	O
different	O
,	O
suggesting	O
that	O
independent	O
mutations	O
gave	O
rise	O
to	O
AS	O
in	O
this	O
family	O
.	O

A	O
young	O
male	O
infant	O
was	O
noted	O
at	O
birth	O
to	O
have	O
bilateral	B-Phenotype
cleft	I-Phenotype
lip	E-Phenotype
and	O
palate	O
,	O
bilateral	B-Phenotype
microphthalmos	E-Phenotype
and	O
ocular	B-Phenotype
colobomata	E-Phenotype
,	O
and	O
a	O
dysplastic	B-Phenotype
left	I-Phenotype
kidney	E-Phenotype
.	O

His	O
mother	O
had	O
similar	O
ophthalmological	B-Phenotype
findings	E-Phenotype
and	O
milder	B-Phenotype
facial	I-Phenotype
anomalies	E-Phenotype
which	O
included	O
abnormality	B-Phenotype
of	I-Phenotype
the	I-Phenotype
philtrum	E-Phenotype
and	O
bilateral	B-Phenotype
congenital	I-Phenotype
nasolacrimal	I-Phenotype
duct	I-Phenotype
obstruction	E-Phenotype
.	O

His	O
maternal	O
grandmother	O
had	O
mild	B-Phenotype
facial	I-Phenotype
anomalies	E-Phenotype
including	O
a	O
short	B-Phenotype
philtrum	E-Phenotype
and	O
bilateral	B-Phenotype
congenital	I-Phenotype
nasolacrimal	I-Phenotype
duct	I-Phenotype
obstruction	E-Phenotype
but	O
had	O
no	O
evidence	O
of	O
any	O
ocular	B-Phenotype
abnormalities	E-Phenotype
.	O

The	O
spectrum	O
of	O
abnormalities	O
seen	O
in	O
this	O
family	O
are	O
similar	O
to	O
those	O
described	O
in	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
,	O
a	O
rare	O
dominantly	O
inherited	O
syndrome	O
in	O
which	O
there	O
are	O
a	O
number	O
of	O
developmental	B-Phenotype
abnormalities	E-Phenotype
of	O
the	O
eye	O
,	O
face	O
,	O
and	O
kidney	O
.	O

Although	O
the	O
precise	O
cause	O
of	O
this	O
syndrome	O
is	O
unknown	O
,	O
it	O
is	O
likely	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
responsible	O
for	O
the	O
ordered	O
closure	O
of	O
the	O
foetal	O
fissure	O
and	O
fusion	O
of	O
facial	O
structures	O
.	O

Since	O
the	O
group	O
of	O
disorders	O
known	O
as	O
the	O
distal	B-Phenotype
arthrogryposes	E-Phenotype
(	O
DAs	O
)	O
were	O
defined	O
,	O
additional	O
disorders	O
characterized	O
by	O
multiple	B-Phenotype
congenital	I-Phenotype
contractures	E-Phenotype
of	O
the	O
distal	O
limbs	O
were	O
described	O
,	O
and	O
the	O
distribution	O
of	O
phenotypic	O
findings	O
in	O
the	O
DAs	O
has	O
been	O
expanded	O
.	O

The	O
breadth	O
of	O
disorders	O
labeled	O
as	O
DAs	O
has	O
diminished	O
the	O
usefulness	O
of	O
the	O
DA	O
classification	O
.	O

We	O
propose	O
a	O
strict	O
definition	O
of	O
DA	O
and	O
diagnostic	O
criteria	O
for	O
DA	O
disorders	O
.	O

Subsequently	O
,	O
we	O
use	O
these	O
standards	O
and	O
propose	O
a	O
revised	O
classification	O
of	O
discrete	O
conditions	O
that	O
should	O
be	O
labeled	O
DAs	O
.	O

Optimally	O
,	O
this	O
serves	O
as	O
a	O
framework	O
for	O
a	O
DA	O
classification	O
based	O
on	O
underlying	O
molecular	O
and	O
physiologic	O
abnormalities	O
.	O

We	O
describe	O
the	O
clinical	O
findings	O
of	O
15	O
individuals	O
in	O
a	O
large	O
kindred	O
affected	O
with	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
1A	O
(	O
DA1A	O
)	O
.	O

The	O
most	O
consistent	O
findings	O
among	O
individuals	O
were	O
overlapping	B-Phenotype
fingers	I-Phenotype
at	I-Phenotype
birth	E-Phenotype
,	O
abnormal	B-Phenotype
digital	I-Phenotype
flexion	I-Phenotype
creases	E-Phenotype
,	O
and	O
foot	B-Phenotype
deformities	E-Phenotype
,	O
including	O
talipes	S-Phenotype
equinovarus	O
and	O
vertical	B-Phenotype
talus	E-Phenotype
.	O

There	O
was	O
marked	O
intrafamilial	O
variation	O
in	O
the	O
expression	O
of	O
DA1A	O
.	O

Linkage	O
mapping	O
of	O
the	O
locus	O
for	O
DA1A	O
suggests	O
that	O
the	O
use	O
of	O
strict	O
diagnostic	O
criteria	O
excludes	O
unaffected	O
individuals	O
rigorously	O
,	O
but	O
can	O
produce	O
incomplete	O
ascertainment	O
of	O
affected	O
individuals	O
.	O

In	O
the	O
context	O
of	O
an	O
affected	O
family	O
,	O
the	O
range	O
of	O
phenotypes	O
consistent	O
with	O
a	O
diagnosis	O
of	O
DA1A	O
needs	O
to	O
be	O
expanded	O
.	O

We	O
report	O
the	O
clinical	O
features	O
in	O
27	O
Australasian	O
patients	O
with	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
,	O
all	O
with	O
a	O
DNA	O
deletion	O
involving	O
chromosome	O
15	O
(	O
q11	O
-	O
13	O
)	O
,	O
spanning	O
markers	O
from	O
D15S9	O
to	O
D15S12	O
,	O
about	O
3	O
center	O
dot	O
5	O
Mb	O
of	O
DNA	O
.	O

There	O
were	O
nine	O
males	O
and	O
18	O
females	O
.	O

All	O
cases	O
were	O
sporadic	O
.	O

The	O
mean	O
age	O
at	O
last	O
review	O
(	O
end	O
of	O
1994	O
)	O
was	O
11	O
center	O
dot	O
2	O
years	O
(	O
range	O
3	O
to	O
34	O
years	O
)	O
.	O

All	O
patients	O
were	O
ataxic	S-Phenotype
,	O
severely	B-Phenotype
retarded	E-Phenotype
,	O
and	O
lacking	B-Phenotype
recognisable	I-Phenotype
speech	I-Phenotype
.	E-Phenotype

In	O
all	O
patients	O
,	O
head	O
circumference	O
(	O
HC	O
)	O
at	O
birth	O
was	O
normal	O
but	O
skewed	O
in	O
distribution	O
,	O
with	O
62	O
center	O
dot	O
5	O
%	O
at	O
the	O
10th	O
centile	O
.	O

At	O
last	O
review	O
HC	O
was	O
around	O
the	O
50th	O
centile	O
in	O
three	O
patients	O
(	O
12	O
center	O
dot	O
5	O
%	O
)	O
while	O
15	O
had	O
poor	B-Phenotype
postnatal	I-Phenotype
head	I-Phenotype
growth	E-Phenotype
.	O

Short	B-Phenotype
stature	E-Phenotype
was	O
not	O
invariable	O
,	O
5	O
/	O
26	O
(	O
19	O
%	O
)	O
were	O
on	O
or	O
above	O
the	O
50th	O
centile	O
.	O

Hypotonia	S-Phenotype
at	O
birth	O
was	O
recorded	O
in	O
15	O
/	O
24	O
(	O
63	O
%	O
)	O
and	O
neonatal	B-Phenotype
feeding	I-Phenotype
difficulties	E-Phenotype
were	O
recorded	O
in	O
20	O
/	O
26	O
(	O
77	O
%	O
)	O
.	O

Epilepsy	S-Phenotype
was	O
present	O
in	O
26	O
/	O
27	O
(	O
96	O
%	O
)	O
with	O
onset	O
by	O
the	O
third	O
year	O
of	O
life	O
in	O
20	O
patients	O
(	O
83	O
%	O
)	O
.	O

Improvement	O
in	O
epilepsy	S-Phenotype
was	O
reported	O
in	O
11	O
/	O
16	O
patients	O
(	O
69	O
%	O
)	O
with	O
age	O
.	O

An	O
abnormal	B-Phenotype
EEG	E-Phenotype
was	O
reported	O
in	O
25	O
/	O
25	O
patients	O
.	O

Hypopigmentation	S-Phenotype
was	O
present	O
in	O
19	O
/	O
26	O
(	O
73	O
%	O
)	O
.	O

One	O
patient	O
had	O
oculocutaneous	B-Phenotype
albinism	E-Phenotype
.	O

Five	O
patients	O
could	B-Phenotype
not	I-Phenotype
walk	I-Phenotype
independently	E-Phenotype
.	O

Of	O
the	O
remaining	O
22	O
who	O
could	O
walk	O
,	O
age	O
of	O
onset	O
of	O
walking	O
ranged	O
from	O
2	O
to	O
8	O
years	O
.	O

Disrupted	B-Phenotype
sleep	I-Phenotype
patterns	E-Phenotype
were	O
present	O
in	O
18	O
/	O
21	O
patients	O
(	O
86	O
%	O
)	O
,	O
with	O
improvement	O
in	O
9	O
/	O
12	O
patients	O
(	O
75	O
%	O
)	O
over	O
10	O
years	O
of	O
age	O
.	O

The	O
clinical	O
features	O
in	O
this	O
group	O
of	O
deletional	O
AS	O
patients	O
were	O
similar	O
to	O
previous	O
reports	O
,	O
but	O
these	O
have	O
not	O
separated	O
patients	O
into	O
subgroups	O
based	O
on	O
DNA	O
studies	O
.	O

In	O
our	O
group	O
of	O
deletional	O
cases	O
,	O
100	O
%	O
showed	O
severe	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
,	O
ataxic	B-Phenotype
movements	E-Phenotype
,	O
absent	B-Phenotype
language	E-Phenotype
,	O
abnormal	B-Phenotype
EEG	E-Phenotype
,	O
happy	B-Phenotype
disposition	E-Phenotype
(	O
noted	O
in	O
infancy	O
in	O
95	O
%	O
)	O
,	O
normal	O
birth	O
weight	O
and	O
head	O
circumference	O
at	O
birth	O
,	O
and	O
a	O
large	O
,	O
wide	B-Phenotype
mouth	E-Phenotype
.	O

These	O
features	O
occurred	O
with	O
a	O
higher	O
frequency	O
than	O
in	O
AS	O
patients	O
as	O
a	O
whole	O
.	O

Our	O
study	O
also	O
provided	O
information	O
on	O
the	O
evolution	O
of	O
the	O
phenotype	O
.	O

The	O
data	O
can	O
act	O
as	O
a	O
benchmark	O
for	O
comparisons	O
of	O
AS	O
resulting	O
from	O
other	O
genetic	O
mechanisms	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
abnormal	B-Phenotype
segmentation	I-Phenotype
of	I-Phenotype
the	I-Phenotype
index	I-Phenotype
and	I-Phenotype
middle	I-Phenotype
fingers	E-Phenotype
segregating	O
with	O
a	O
high	O
degree	O
of	O
variable	O
expression	O
in	O
members	O
of	O
the	O
same	O
family	O
.	O

We	O
have	O
followed	O
up	O
and	O
studied	O
members	O
of	O
the	O
large	O
kindred	O
segregating	O
with	O
the	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
phenotype	O
described	O
by	O
Virgil	O
Haws	O
in	O
1963	O
,	O
and	O
using	O
genetic	O
linkage	O
analysis	O
,	O
we	O
localized	O
the	O
susceptibility	O
gene	O
to	O
human	O
chromosome	O
12q24	O
.	O

The	O
human	O
homologue	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
patched	O
is	O
implicated	O
in	O
the	O
development	O
of	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
and	O
in	O
the	O
genesis	O
of	O
sporadic	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
.	O

In	O
order	O
to	O
examine	O
the	O
phenotypic	O
variability	O
in	O
NBCCS	O
and	O
to	O
highlight	O
functionally	O
important	O
domains	O
of	O
the	O
PTCH	O
protein	O
,	O
we	O
have	O
now	O
screened	O
71	O
unrelated	O
NBCCS	O
individuals	O
for	O
mutations	O
in	O
the	O
PTCH	O
exons	O
.	O

We	O
identified	O
28	O
mutations	O
that	O
are	O
distributed	O
throughout	O
the	O
entire	O
gene	O
,	O
and	O
most	O
(	O
86	O
%	O
)	O
cause	O
protein	O
truncation	O
.	O

As	O
part	O
of	O
this	O
analysis	O
,	O
we	O
demonstrate	O
that	O
failure	O
of	O
one	O
NBCCS	O
family	O
to	O
show	O
clear	O
linkage	O
to	O
chromosome	O
9q22.3	O
-	O
31	O
is	O
most	O
likely	O
due	O
to	O
germinal	O
mosaicism	O
.	O

We	O
have	O
identified	O
three	O
families	O
bearing	O
identical	O
mutations	O
with	O
variable	O
phenotypes	O
,	O
suggesting	O
phenotypic	O
variability	O
in	O
NBCCS	O
is	O
a	O
complex	O
genetic	O
event	O
.	O

No	O
phenotype	O
genotype	O
correlation	O
between	O
the	O
position	O
of	O
truncation	O
mutations	O
and	O
major	O
clinical	O
features	O
was	O
evident	O
.	O

Two	O
missense	O
mutations	O
have	O
been	O
identified	O
,	O
and	O
their	O
location	O
within	O
transmembrane	O
domains	O
supports	O
the	O
notion	O
that	O
PTCH	O
may	O
have	O
a	O
transport	O
function	O
.	O

The	O
preponderance	O
of	O
truncation	O
mutants	O
in	O
the	O
germ	O
line	O
of	O
NBCCS	O
patients	O
suggests	O
that	O
the	O
developmental	B-Phenotype
defects	E-Phenotype
associated	O
with	O
the	O
disorder	O
are	O
most	O
likely	O
due	O
to	O
haploinsufficiency	O
.	O

Angelman	O
syndrome	O
(	O
AS	O
)	O
,	O
characterized	O
by	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
seizures	S-Phenotype
,	O
frequent	B-Phenotype
smiling	I-Phenotype
and	I-Phenotype
laughter	E-Phenotype
,	O
and	O
abnormal	B-Phenotype
gait	E-Phenotype
,	O
is	O
one	O
of	O
the	O
best	O
examples	O
of	O
human	O
disease	O
in	O
which	O
genetic	O
imprinting	O
plays	O
a	O
role	O
.	O

In	O
about	O
70	O
%	O
of	O
cases	O
,	O
AS	O
is	O
caused	O
by	O
de	O
novo	O
maternal	O
deletions	O
at	O
15q11	O
-	O
q13	O
(	O
ref	O
.	O

2	O
)	O
.	O

Approximately	O
2	O
%	O
of	O
AS	O
cases	O
are	O
caused	O
by	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
of	O
chromosome	O
15	O
(	O
ref	O
.	O

3	O
)	O
and	O
2	O
-	O
3	O
%	O
are	O
caused	O
by	O
``	O
imprinting	O
mutations	O
'	O
.	O

In	O
the	O
remaining	O
25	O
%	O
of	O
AS	O
cases	O
,	O
no	O
deletion	O
,	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
,	O
or	O
methylation	O
abnormality	O
is	O
detectable	O
,	O
and	O
these	O
cases	O
,	O
unlike	O
deletions	O
or	O
UPD	O
,	O
can	O
be	O
familial	O
.	O

These	O
cases	O
are	O
likely	O
to	O
result	O
from	O
mutations	O
in	O
a	O
gene	O
that	O
is	O
expressed	O
either	O
exclusively	O
or	O
preferentially	O
from	O
the	O
maternal	O
chromosome	O
15	O
.	O

We	O
have	O
found	O
that	O
a	O
15q	O
inversion	O
inherited	O
by	O
an	O
AS	O
child	O
from	O
her	O
normal	O
mother	O
disrupts	O
the	O
5	O
'	O
end	O
of	O
the	O
UBE3A	O
(	O
E6	O
-	O
AP	O
)	O
gene	O
,	O
the	O
product	O
of	O
which	O
functions	O
in	O
protein	O
ubiquitination	O
.	O

We	O
have	O
looked	O
for	O
novel	O
UBE3A	O
mutations	O
in	O
nondeletion	O
/	O
non	O
-	O
UPD	O
/	O
non	O
-	O
imprinting	O
mutation	O
(	O
NDUI	O
)	O
AS	O
patients	O
and	O
have	O
found	O
one	O
patient	O
who	O
is	O
heterozygous	O
for	O
a	O
5	O
-	O
bp	O
de	O
novo	O
tandem	O
duplication	O
.	O

We	O
have	O
also	O
found	O
in	O
two	O
brothers	O
a	O
heterozygous	O
mutation	O
,	O
an	O
A	O
to	O
G	O
transition	O
that	O
creates	O
a	O
new	O
3	O
'	O
splice	O
junction	O
7	O
bp	O
upstream	O
from	O
the	O
normal	O
splice	O
junction	O
.	O

Both	O
mutations	O
are	O
predicted	O
to	O
cause	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
translation	O
.	O

Our	O
results	O
demonstrate	O
that	O
UBE3A	O
mutations	O
are	O
one	O
cause	O
of	O
AS	O
and	O
indicate	O
a	O
possible	O
abnormality	O
in	O
ubiquitin	O
-	O
mediated	O
protein	O
degradation	O
during	O
brain	O
development	O
in	O
this	O
disease	O
.	O

Distal	B-Phenotype
arthrogryposis	E-Phenotype
type	O
1	O
(	O
DA1	O
)	O
and	O
Freeman	O
-	O
Sheldon	O
syndrome	O
(	O
FSS	O
)	O
are	O
the	O
two	O
most	O
common	O
known	O
causes	O
of	O
inherited	O
multiple	B-Phenotype
congenital	I-Phenotype
contractures	E-Phenotype
.	O

We	O
recently	O
have	O
characterized	O
a	O
new	O
disorder	O
(	O
DA2B	O
)	O
with	O
a	O
phenotype	O
intermediate	O
between	O
DA1	O
and	O
FSS	O
.	O

We	O
report	O
the	O
mapping	O
of	O
a	O
gene	O
that	O
causes	O
DA2B	O
to	O
chromosome	O
11p15.5	O
-	O
pter	O
.	O

Linkage	O
analysis	O
in	O
a	O
single	O
kindred	O
generated	O
a	O
positive	O
LOD	O
score	O
of	O
5.31	O
at	O
theta	O
=	O
0	O
with	O
the	O
marker	O
D11S922	O
,	O
and	O
recombinants	O
localize	O
the	O
gene	O
to	O
an	O
approximately	O
3.5	O
-	O
6.5	O
-	O
cM	O
region	O
between	O
the	O
marker	O
TH	O
and	O
the	O
telomere	O
.	O

Analysis	O
of	O
additional	O
families	O
improves	O
the	O
LOD	O
score	O
to	O
6.45	O
at	O
theta	O
=	O
0	O
and	O
suggests	O
linkage	O
homogeneity	O
for	O
DA2B	O
.	O

Brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
is	O
characterized	O
by	O
shortness	B-Phenotype
of	I-Phenotype
the	I-Phenotype
second	I-Phenotype
and	I-Phenotype
fifth	I-Phenotype
middle	I-Phenotype
phalanges	E-Phenotype
and	O
the	O
first	O
metacarpal	O
.	O

It	O
is	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
,	O
and	O
is	O
noted	O
for	O
its	O
widely	O
variable	O
clinical	O
phenotype	O
both	O
within	O
and	O
between	O
families	O
.	O

In	O
most	O
families	O
involvement	O
is	O
limited	O
to	O
the	O
hands	O
.	O

However	O
,	O
in	O
some	O
families	O
additional	O
skeletal	B-Phenotype
and	I-Phenotype
non	I-Phenotype
-	I-Phenotype
skeletal	I-Phenotype
findings	E-Phenotype
have	O
been	O
reported	O
.	O

We	O
report	O
on	O
12	O
affected	O
members	O
from	O
a	O
5	O
generation	O
kindred	O
that	O
segregates	O
a	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
phenotype	O
.	O

All	O
affected	O
individuals	O
had	O
shortness	B-Phenotype
principally	I-Phenotype
affecting	I-Phenotype
the	I-Phenotype
second	I-Phenotype
and	I-Phenotype
fifth	I-Phenotype
phalanges	I-Phenotype
and	I-Phenotype
first	I-Phenotype
metacarpal	E-Phenotype
.	O

However	O
,	O
the	O
metacarpal	O
-	O
phalangeal	O
profile	O
indicated	O
that	O
other	O
digital	O
elements	O
were	O
short	O
as	O
well	O
.	O

In	O
addition	O
,	O
one	O
affected	O
individual	O
had	O
a	O
bilateral	B-Phenotype
Madelung	I-Phenotype
deformity	E-Phenotype
,	O
but	O
none	O
had	O
foot	B-Phenotype
involvement	E-Phenotype
.	O

No	O
other	O
non	O
-	O
skeletal	O
findings	O
cosegregated	O
with	O
brachydactyly	S-Phenotype
in	O
this	O
family	O
.	O

Recently	O
,	O
a	O
gene	O
for	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
has	O
been	O
localized	O
to	O
12q24	O
.	O

This	O
was	O
done	O
by	O
studying	O
a	O
large	O
kindred	O
first	O
reported	O
by	O
Haws	O
[	O
1963	O
]	O
,	O
which	O
manifests	O
both	O
hand	B-Phenotype
and	I-Phenotype
foot	I-Phenotype
anomalies	E-Phenotype
.	O

Here	O
we	O
present	O
linkage	O
data	O
which	O
excludes	O
the	O
12q24	O
locus	O
in	O
our	O
kindred	O
,	O
indicating	O
locus	O
heterogeneity	O
as	O
one	O
explanation	O
for	O
the	O
interfamilial	O
variability	O
described	O
in	O
brachydactyly	B-Phenotype
type	I-Phenotype
C	E-Phenotype
.	O

Nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCC	O
;	O
Gorlin	O
syndrome	O
)	O
,	O
an	O
autosomal	O
dominant	O
disorder	O
linked	O
to	O
9q22.3	O
-	O
q31	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
PTC	O
,	O
the	O
human	O
homologue	O
of	O
the	O
Drosophila	O
patched	O
gene	O
,	O
comprises	O
multiple	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
keratocysts	B-Phenotype
of	I-Phenotype
the	I-Phenotype
jaw	E-Phenotype
,	O
palmar	B-Phenotype
/	E-Phenotype
plantar	B-Phenotype
pits	E-Phenotype
,	O
spine	B-Phenotype
and	I-Phenotype
rib	I-Phenotype
anomalies	E-Phenotype
and	O
calcification	B-Phenotype
of	I-Phenotype
the	I-Phenotype
falx	I-Phenotype
cerebri	E-Phenotype
.	O

We	O
reviewed	O
the	O
findings	O
on	O
105	O
affected	O
individuals	O
examined	O
at	O
the	O
NIH	O
since	O
1985	O
.	O

The	O
data	O
included	O
48	O
males	O
and	O
57	O
females	O
ranging	O
in	O
age	O
from	O
4	O
months	O
to	O
87	O
years	O
.	O

Eighty	O
percent	O
of	O
whites	O
(	O
71	O
/	O
90	O
)	O
and	O
38	O
%	O
(	O
5	O
/	O
13	O
)	O
of	O
African	O
-	O
Americans	O
had	O
at	O
least	O
one	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
BCC	O
)	O
,	O
with	O
the	O
first	O
tumor	S-Phenotype
occurring	O
at	O
a	O
mean	O
age	O
of	O
23	O
(	O
median	O
20	O
)	O
years	O
and	O
21	O
(	O
median	O
20	O
)	O
years	O
,	O
respectively	O
.	O

Excluding	O
individuals	O
exposed	O
to	O
radiation	O
therapy	O
,	O
the	O
number	O
of	O
BCCs	O
ranged	O
from	O
1	O
to	O
>	O
1,000	O
(	O
median	O
8	O
)	O
and	O
1	O
to	O
3	O
(	O
median	O
2	O
)	O
,	O
respectively	O
,	O
in	O
the	O
2	O
groups	O
.	O

Jaw	B-Phenotype
cysts	E-Phenotype
occurred	O
in	O
78	O
/	O
105	O
(	O
74	O
%	O
)	O
with	O
the	O
first	O
tumor	S-Phenotype
occurring	O
in	O
80	O
%	O
by	O
the	O
age	O
of	O
20	O
years	O
.	O

The	O
number	O
of	O
total	O
jaw	B-Phenotype
cysts	E-Phenotype
ranged	O
from	O
1	O
to	O
28	O
(	O
median	O
3	O
)	O
.	O

Palmar	B-Phenotype
pits	E-Phenotype
and	O
plantar	B-Phenotype
pits	E-Phenotype
were	O
seen	O
in	O
87	O
%	O
.	O

Ovarian	B-Phenotype
fibromas	E-Phenotype
were	O
diagnosed	O
by	O
ultrasound	O
in	O
9	O
/	O
52	O
(	O
17	O
%	O
)	O
at	O
a	O
mean	O
age	O
of	O
30	O
years	O
.	O

Medulloblastoma	S-Phenotype
occurred	O
in	O
4	O
patients	O
at	O
a	O
mean	O
age	O
of	O
2.3	O
years	O
.	O

Three	O
patients	O
had	O
cleft	B-Phenotype
lip	I-Phenotype
or	I-Phenotype
palate	E-Phenotype
.	O

Physical	O
findings	O
include	O
``	O
coarse	B-Phenotype
face	E-Phenotype
''	O
in	O
54	O
%	O
,	O
relative	B-Phenotype
macrocephaly	E-Phenotype
in	O
50	O
%	O
,	O
hypertelorism	S-Phenotype
in	O
42	O
%	O
,	O
frontal	B-Phenotype
bossing	E-Phenotype
in	O
27	O
%	O
,	O
pectus	B-Phenotype
deformity	E-Phenotype
in	O
13	O
%	O
,	O
and	O
Sprengel	B-Phenotype
deformity	E-Phenotype
in	O
11	O
%	O
.	O

Important	O
radiological	O
signs	O
included	O
calcification	B-Phenotype
of	I-Phenotype
the	I-Phenotype
falx	I-Phenotype
cerebri	E-Phenotype
in	O
65	O
%	O
,	O
of	O
the	O
tentorium	O
cerebelli	O
in	O
20	O
%	O
,	O
bridged	B-Phenotype
sella	E-Phenotype
in	O
68	O
%	O
,	O
bifid	B-Phenotype
ribs	E-Phenotype
in	O
26	O
%	O
,	O
hemivertebrae	S-Phenotype
in	O
15	O
%	O
,	O
fusion	B-Phenotype
of	I-Phenotype
the	I-Phenotype
vertebral	I-Phenotype
bodies	E-Phenotype
in	O
10	O
%	O
,	O
and	O
flame	O
shaped	O
lucencies	O
of	O
the	O
phalanges	O
,	O
metacarpal	O
,	O
and	O
carpal	O
bones	O
of	O
the	O
hands	O
in	O
30	O
%	O
.	O

Several	O
traits	O
previously	O
considered	O
components	O
of	O
the	O
syndrome	O
(	O
including	O
short	B-Phenotype
fourth	I-Phenotype
metacarpal	E-Phenotype
,	O
scoliosis	S-Phenotype
,	O
cervical	B-Phenotype
ribs	E-Phenotype
and	O
spina	B-Phenotype
bifida	I-Phenotype
occulta	E-Phenotype
)	O
were	O
not	O
found	O
to	O
be	O
significantly	O
increased	O
in	O
the	O
affected	O
individuals	O
.	O

This	O
study	O
delineates	O
the	O
frequency	O
of	O
the	O
clinical	O
and	O
radiological	O
anomalies	O
in	O
NBCC	O
in	O
a	O
large	O
population	O
of	O
US	O
patients	O
and	O
discusses	O
guidelines	O
for	O
diagnosis	O
and	O
management	O
.	O

We	O
present	O
an	O
8	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
boy	O
with	O
medulloblastoma	S-Phenotype
and	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
who	O
exhibited	O
the	O
radiosensitive	B-Phenotype
response	E-Phenotype
of	O
basal	O
cell	O
carcinoma	O
(	O
BCC	O
)	O
formation	O
in	O
the	O
area	O
irradiated	O
for	O
medulloblastoma	O
.	O

Such	O
a	O
response	O
is	O
well	O
-	O
documented	O
in	O
Caucasian	O
NBCCS	O
patients	O
with	O
medulloblastoma	S-Phenotype
.	O

The	O
propositus	O
was	O
diagnosed	O
with	O
medulloblastoma	S-Phenotype
at	O
the	O
age	O
of	O
2	O
years	O
and	O
underwent	O
surgery	O
,	O
chemotherapy	O
,	O
and	O
craniospinal	O
irradiation	O
.	O

At	O
the	O
age	O
of	O
6	O
years	O
,	O
he	O
was	O
diagnosed	O
with	O
NBCCS	O
following	O
his	O
presentation	O
with	O
a	O
large	O
odontogenic	B-Phenotype
keratocyst	I-Phenotype
of	I-Phenotype
the	I-Phenotype
mandible	E-Phenotype
,	O
pits	B-Phenotype
of	I-Phenotype
the	I-Phenotype
palms	E-Phenotype
and	O
soles	O
and	O
numerous	O
BCCs	O
in	O
the	O
area	O
of	O
the	O
back	O
and	O
neck	O
that	O
had	O
been	O
irradiated	O
previously	O
for	O
medulloblastoma	S-Phenotype
.	O

Examination	O
of	O
other	O
relatives	O
showed	O
that	O
the	O
propositus	O
'	O
mother	O
also	O
had	O
NBCCS	O
but	O
was	O
more	O
mildly	O
affected	O
;	O
in	O
particular	O
,	O
she	O
had	O
no	O
BCCs	O
.	O

This	O
case	O
illustrates	O
complex	O
gene	O
-	O
environment	O
interaction	O
,	O
in	O
that	O
increased	B-Phenotype
skin	I-Phenotype
pigmentation	E-Phenotype
in	O
African	O
-	O
Americans	O
is	O
presumably	O
protective	O
against	O
ultraviolet	O
,	O
but	O
not	O
ionizing	O
,	O
radiation	O
.	O

This	O
case	O
and	O
other	O
similar	O
cases	O
in	O
the	O
literature	O
show	O
the	O
importance	O
of	O
considering	O
NBCCS	O
in	O
the	O
differential	O
diagnosis	O
of	O
any	O
patient	O
who	O
presents	O
with	O
a	O
medulloblastoma	S-Phenotype
,	O
especially	O
before	O
the	O
age	O
of	O
5	O
years	O
,	O
and	O
of	O
examining	O
other	O
close	O
relatives	O
for	O
signs	O
of	O
NBCCS	O
to	O
determine	O
the	O
patient	O
's	O
at	O
-	O
risk	O
status	O
.	O

Finally	O
,	O
for	O
individuals	O
who	O
are	O
radiosensitive	S-Phenotype
,	O
protocols	O
that	O
utilize	O
chemotherapy	O
in	O
lieu	O
of	O
radiotherapy	O
should	O
be	O
considered	O
.	O

Undiagnosed	O
institutionalised	O
patients	O
were	O
reviewed	O
in	O
an	O
attempt	O
to	O
identify	O
those	O
with	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
.	O

The	O
aim	O
was	O
to	O
test	O
these	O
patients	O
for	O
deletion	O
of	O
chromosome	O
15	O
(	O
q11	O
-	O
13	O
)	O
and	O
to	O
describe	O
the	O
adult	O
phenotype	O
.	O

The	O
selection	O
criteria	O
included	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
ataxic	S-Phenotype
or	O
hypermotoric	B-Phenotype
limb	I-Phenotype
movements	E-Phenotype
,	O
lack	B-Phenotype
of	I-Phenotype
speech	E-Phenotype
,	O
a	O
``	B-Phenotype
happy	I-Phenotype
''	I-Phenotype
demeanour	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
and	O
facial	B-Phenotype
appearance	E-Phenotype
consistent	O
with	O
the	O
diagnosis	O
.	O

Patients	O
were	O
examined	O
,	O
medical	O
records	O
perused	O
,	O
and	O
patients	O
'	O
doctors	O
contacted	O
as	O
required	O
.	O

Genetic	O
tests	O
performed	O
included	O
routine	O
cytogenetics	O
,	O
DNA	O
methylation	O
analysis	O
(	O
with	O
probe	O
PW71B	O
)	O
,	O
and	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
with	O
probes	O
D15S10	O
,	O
GABRbeta3	O
,	O
or	O
SNRPN	O
)	O
.	O

A	O
deletion	O
in	O
the	O
AS	O
region	O
was	O
detected	O
in	O
11	O
patients	O
(	O
9	O
males	O
and	O
2	O
females	O
)	O
of	O
22	O
tested	O
.	O

The	O
mean	O
age	O
at	O
last	O
review	O
(	O
March	O
1996	O
)	O
was	O
31.5	O
years	O
(	O
range	O
24	O
to	O
36	O
years	O
)	O
.	O

Clinical	O
assessment	O
documented	O
findings	O
of	O
large	B-Phenotype
mouth	I-Phenotype
and	I-Phenotype
jaw	E-Phenotype
with	O
deep	B-Phenotype
set	I-Phenotype
eyes	E-Phenotype
,	O
and	O
microcephaly	S-Phenotype
in	O
nine	O
patients	O
(	O
two	O
having	O
a	O
large	B-Phenotype
head	E-Phenotype
size	O
for	O
height	O
)	O
.	O

No	O
patient	O
was	O
hypopigmented	S-Phenotype
;	O
1	O
/	O
11	O
patients	O
was	O
fair	O
.	O

Outbursts	B-Phenotype
of	I-Phenotype
laughter	E-Phenotype
occurred	O
in	O
all	O
patients	O
but	O
infrequently	O
in	O
7	O
/	O
11	O
(	O
64	O
%	O
)	O
and	O
a	O
constant	B-Phenotype
happy	I-Phenotype
demeanour	E-Phenotype
was	O
present	O
in	O
5	O
/	O
11	O
(	O
46	O
%	O
)	O
.	O

All	O
had	O
epilepsy	S-Phenotype
,	O
with	O
improvement	O
in	O
5	O
/	O
11	O
(	O
46	O
%	O
)	O
,	O
no	O
change	O
in	O
4	O
(	O
36	O
%	O
)	O
,	O
and	O
deterioration	O
in	O
2	O
(	O
18	O
%	O
)	O
.	O

The	O
EEG	O
was	O
abnormal	O
in	O
10	O
/	O
10	O
patients	O
.	O

Ocular	B-Phenotype
abnormalities	E-Phenotype
were	O
reported	O
in	O
3	O
/	O
8	O
patients	O
(	O
37.5	O
%	O
)	O
and	O
4	O
/	O
11	O
(	O
36	O
%	O
)	O
had	O
developed	O
kyphosis	S-Phenotype
.	O

Two	O
had	O
never	B-Phenotype
walked	E-Phenotype
.	O

All	O
nine	O
who	O
walked	O
were	O
ataxic	S-Phenotype
with	O
an	O
awkward	O
,	O
clumsy	O
,	O
heavy	O
,	O
and	O
/	O
or	O
lilting	O
gait	O
.	O

No	O
patient	O
had	O
a	O
single	O
word	O
of	O
speech	O
but	O
one	O
patient	O
could	O
use	O
sign	O
language	O
for	O
two	O
needs	O
(	O
food	O
and	O
drink	O
)	O
.	O

Our	O
data	O
support	O
the	O
concept	O
that	O
AS	O
resulting	O
from	O
deletion	O
is	O
a	O
severe	O
neurological	O
syndrome	O
in	O
adulthood	O
.	O

The	O
diagnosis	O
in	O
adults	O
may	O
not	O
be	O
straightforward	O
as	O
some	O
manifestations	O
change	O
with	O
age	O
.	O

Kyphosis	S-Phenotype
and	O
keratoconus	S-Phenotype
are	O
two	O
problems	O
of	O
older	O
patients	O
.	O

Neurofibromatosis	S-Phenotype
1	O
and	O
neurofibromatosis	S-Phenotype
2	O
are	O
autosomal	O
dominant	O
genetic	O
disorders	O
in	O
which	O
affected	O
individuals	O
develop	O
both	O
benign	O
and	O
malignant	O
tumors	S-Phenotype
at	O
an	O
increased	O
frequency	O
.	O

Since	O
the	O
original	O
National	O
Institutes	O
of	O
Health	O
Consensus	O
Development	O
Conference	O
in	O
1987	O
,	O
there	O
has	O
been	O
significant	O
progress	O
toward	O
a	O
more	O
complete	O
understanding	O
of	O
the	O
molecular	O
bases	O
for	O
neurofibromatosis	S-Phenotype
1	O
and	O
neurofibromatosis	O
2	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
the	O
diagnostic	O
criteria	O
for	O
neurofibromatosis	S-Phenotype
1	O
and	O
neurofibromatosis	O
2	O
,	O
recommendations	O
for	O
the	O
care	O
of	O
patients	O
and	O
their	O
families	O
at	O
diagnosis	O
and	O
during	O
routine	O
follow	O
-	O
up	O
,	O
and	O
the	O
role	O
of	O
DNA	O
diagnostic	O
testing	O
in	O
the	O
evaluation	O
of	O
these	O
disorders	O
.	O

Published	O
reports	O
from	O
1966	O
through	O
1996	O
obtained	O
by	O
MEDLINE	O
search	O
and	O
studies	O
presented	O
at	O
national	O
and	O
international	O
meetings	O
.	O

All	O
studies	O
were	O
reviewed	O
and	O
analyzed	O
by	O
consensus	O
from	O
multiple	O
authors	O
.	O

Peer	O
-	O
reviewed	O
published	O
data	O
were	O
critically	O
evaluated	O
by	O
independent	O
extraction	O
by	O
multiple	O
authors	O
.	O

The	O
main	O
results	O
of	O
the	O
review	O
were	O
qualitative	O
and	O
were	O
reviewed	O
by	O
neurofibromatosis	S-Phenotype
clinical	O
directors	O
worldwide	O
through	O
an	O
Internet	O
Web	O
site	O
.	O

On	O
the	O
basis	O
of	O
the	O
information	O
presented	O
in	O
this	O
review	O
,	O
we	O
propose	O
a	O
comprehensive	O
approach	O
to	O
the	O
diagnosis	O
and	O
treatment	O
of	O
individuals	O
with	O
neurofibromatosis	S-Phenotype
1	O
and	O
neurofibromatosis	O
2	O
.	O

The	O
case	O
of	O
a	O
seriously	O
disabled	O
and	O
retarded	S-Phenotype
female	O
patient	O
with	O
neurofibromatosis	S-Phenotype
type	O
2	O
(	O
NF2	O
)	O
is	O
reported	O
.	O

She	O
suffered	O
from	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
,	O
multiple	B-Phenotype
intracranial	I-Phenotype
meningiomas	E-Phenotype
and	O
neurinomas	S-Phenotype
.	O

The	O
constitutional	O
karyotype	O
of	O
the	O
patient	O
was	O
46	O
,	O
XX	O
,	O
r	O
(	O
22	O
)	O
/	O
45	O
,	O
XX	O
,	O
-	O
22	O
.	O

A	O
constitutional	O
G	O
to	O
A	O
transition	O
in	O
the	O
proximal	O
3	O
'	O
untranslated	O
region	O
of	O
isoforms	O
1	O
and	O
2	O
was	O
identified	O
in	O
the	O
patient	O
's	O
NF2	O
gene	O
and	O
shown	O
not	O
to	O
affect	O
differential	O
splicing	O
or	O
mRNA	O
stability	O
.	O

The	O
instability	O
of	O
the	O
ring	O
chromosome	O
22	O
with	O
the	O
associated	O
loss	O
of	O
tumor	S-Phenotype
suppressor	O
genes	O
on	O
chromosome	O
22	O
,	O
in	O
particular	O
the	O
loss	O
of	O
the	O
NF2	O
gene	O
,	O
are	O
assumed	O
to	O
have	O
caused	O
multiple	B-Phenotype
tumorigenesis	E-Phenotype
in	O
this	O
patient	O
.	O

DNA	O
mapping	O
studies	O
in	O
two	O
families	O
provide	O
further	O
information	O
on	O
the	O
Angelman	O
syndrome	O
critical	O
region	O
,	O
which	O
has	O
recently	O
been	O
defined	O
by	O
the	O
gene	O
UBE3A	O
.	O

The	O
first	O
family	O
has	O
probable	O
familial	O
Angelman	O
syndrome	O
with	O
a	O
maternally	O
imprinted	O
inheritance	O
pattern	O
.	O

A	O
5	O
year	O
old	O
girl	O
with	O
this	O
disorder	O
has	O
a	O
14	O
year	O
old	O
brother	O
and	O
an	O
11	O
year	O
old	O
male	O
cousin	O
who	O
have	O
less	O
typical	O
clinical	O
features	O
.	O

DNA	O
microsatellite	O
analysis	O
has	O
shown	O
that	O
the	O
three	O
share	O
a	O
common	O
segment	O
of	O
the	O
same	O
grandpaternal	O
chromosome	O
15q11	O
-	O
q13	O
that	O
overlaps	O
with	O
UBE3A	O
.	O

The	O
child	O
with	O
typical	O
Angelman	O
syndrome	O
has	O
an	O
additional	O
maternal	O
recombination	O
5	O
'	O
to	O
UBE3A	O
.	O

The	O
second	O
family	O
is	O
a	O
mother	O
and	O
son	O
both	O
of	O
whom	O
have	O
mental	B-Phenotype
retardation	E-Phenotype
but	O
no	O
other	O
features	O
of	O
Angelman	O
syndrome	O
despite	O
an	O
extensive	O
DNA	O
deletion	O
on	O
the	O
telomeric	O
side	O
of	O
UBE3A	O
.	O

Together	O
,	O
the	O
two	O
families	O
identify	O
a	O
region	O
between	O
loci	O
D15S210	O
and	O
D15S986	O
which	O
forms	O
part	O
of	O
the	O
Angelman	O
syndrome	O
critical	O
region	O
.	O

A	O
new	O
microsatellite	O
(	O
D15S1234	O
)	O
is	O
described	O
which	O
can	O
be	O
used	O
in	O
place	O
of	O
the	O
LS6	O
-	O
1	O
marker	O
at	O
locus	O
D15S113	O
.	O

Townes	O
-	O
Brocks	O
syndrome	O
(	O
TBS	O
,	O
OMIM	O
#	O
107480	O
)	O
is	O
a	O
rare	O
autosomal	O
-	O
dominant	O
malformation	O
syndrome	O
with	O
a	O
combination	O
of	O
anal	B-Phenotype
,	I-Phenotype
renal	I-Phenotype
,	I-Phenotype
limb	I-Phenotype
and	I-Phenotype
ear	I-Phenotype
anomalies	E-Phenotype
.	O

Cytogenetic	O
findings	O
suggested	O
that	O
the	O
gene	O
mutated	O
in	O
TBS	O
maps	O
to	O
chromosome	O
16q12.1	O
,	O
where	O
SALL1	O
(	O
previously	O
known	O
as	O
HSAL1	O
)	O
,	O
a	O
human	O
homologue	O
of	O
spalt	O
(	O
sal	O
)	O
,	O
is	O
located	O
.	O

SAL	O
is	O
a	O
developmental	O
regulator	O
in	O
Drosophila	O
melanogaster	O
and	O
is	O
conserved	O
throughout	O
evolution	O
.	O

No	O
phenotype	O
has	O
yet	O
been	O
attributed	O
to	O
mutations	O
in	O
vertebrate	O
sal	O
-	O
like	O
genes	O
.	O

The	O
expression	O
patterns	O
of	O
sal	O
-	O
like	O
genes	O
in	O
mouse	O
,	O
Xenopus	O
and	O
the	O
fish	O
Medaka	O
,	O
and	O
the	O
finding	O
that	O
Medaka	O
sal	O
is	O
regulated	O
by	O
Sonic	O
hedgehog	O
(	O
Shh	O
;	O
ref	O
.	O

11	O
)	O
,	O
prompted	O
us	O
to	O
examine	O
SALL1	O
as	O
a	O
TBS	O
candidate	O
gene	O
.	O

Here	O
we	O
demonstrate	O
that	O
SALL1	O
mutations	O
cause	O
TBS	O
in	O
a	O
family	O
with	O
vertical	O
transmission	O
of	O
TBS	O
and	O
in	O
an	O
unrelated	O
family	O
with	O
a	O
sporadic	O
case	O
of	O
TBS	O
.	O

Both	O
mutations	O
are	O
predicted	O
to	O
result	O
in	O
a	O
prematurely	O
terminated	O
SALL1	O
protein	O
lacking	O
all	O
putative	O
DNA	O
binding	O
domains	O
.	O

TBS	O
therefore	O
represents	O
another	O
human	O
developmental	O
disorder	O
caused	O
by	O
mutations	O
in	O
a	O
putative	O
C2H2	O
zinc	O
-	O
finger	O
transcription	O
factor	O
.	O

Nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
is	O
rare	O
in	O
black	O
persons	O
.	O

We	O
describe	O
an	O
11	O
-	O
year	O
-	O
old	O
black	O
boy	O
with	O
NBCCS	O
who	O
presented	O
with	O
exotropia	S-Phenotype
and	O
a	O
painful	O
,	O
expanding	O
,	O
cystic	B-Phenotype
mass	I-Phenotype
in	I-Phenotype
the	I-Phenotype
left	I-Phenotype
posterior	I-Phenotype
alveolar	I-Phenotype
ridge	E-Phenotype
.	O

Further	O
examination	O
revealed	O
odontogenic	B-Phenotype
keratocysts	E-Phenotype
with	O
palmar	B-Phenotype
and	I-Phenotype
plantar	I-Phenotype
pitting	E-Phenotype
.	O

Less	O
than	O
5	O
%	O
of	O
reported	O
patients	O
with	O
NBCCS	O
are	O
black	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
black	O
patient	O
with	O
NBCCS	O
presenting	O
with	O
exotropia	S-Phenotype
and	O
an	O
impacted	O
molar	O
displaced	O
into	O
the	O
orbit	O
by	O
an	O
odontogenic	B-Phenotype
keratocyst	E-Phenotype
.	O

We	O
compared	O
epilepsy	S-Phenotype
phenotypes	O
with	O
genotypes	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
,	O
including	O
chromosome	O
15q11	O
-	O
13	O
deletions	O
(	O
class	O
I	O
)	O
,	O
uniparental	O
disomy	O
(	O
class	O
II	O
)	O
,	O
methylation	O
imprinting	O
abnormalities	O
(	O
class	O
III	O
)	O
,	O
and	O
mutation	O
in	O
the	O
UBE3A	O
gene	O
(	O
class	O
IV	O
)	O
.	O

Twenty	O
patients	O
were	O
prospectively	O
selected	O
based	O
on	O
clinical	O
cytogenetic	O
and	O
molecular	O
diagnosis	O
of	O
AS	O
.	O

All	O
patients	O
had	O
6	O
to	O
72	O
hours	O
of	O
closed	O
-	O
circuit	O
television	O
videotaping	O
and	O
digitized	O
electroencephalogrpahic	O
(	O
EEG	O
)	O
telemetry	O
.	O

Patients	O
from	O
all	O
genotypic	O
classes	O
had	O
characteristic	B-Phenotype
EEGs	E-Phenotype
with	O
diffuse	O
bifrontally	O
dominant	O
high	O
-	O
amplitude	O
1	O
-	O
to	O
3	O
-	O
Hz	O
notched	O
or	O
triphasic	O
or	O
polyphasic	O
slow	O
waves	O
,	O
or	O
slow	O
and	O
sharp	O
waves	O
.	O

Class	O
I	O
patients	O
had	O
severe	O
intractable	S-Phenotype
epilepsy	S-Phenotype
,	O
most	O
frequently	O
with	O
atypical	B-Phenotype
absences	E-Phenotype
and	O
myoclonias	S-Phenotype
and	O
less	O
frequently	O
with	O
generalized	B-Phenotype
extensor	I-Phenotype
tonic	I-Phenotype
seizures	E-Phenotype
or	O
flexor	B-Phenotype
spasms	E-Phenotype
.	O

Epileptic	B-Phenotype
spasms	E-Phenotype
were	O
recorded	O
in	O
AS	O
patients	O
as	O
old	O
as	O
41	O
years	O
.	O

Aged	O
-	O
matched	O
class	O
II	O
,	O
III	O
,	O
and	O
IV	O
patients	O
had	O
either	O
no	O
epilepsy	S-Phenotype
or	O
drug	O
-	O
responsive	O
mild	O
epilepsy	O
with	O
relatively	O
infrequent	O
atypical	B-Phenotype
absences	E-Phenotype
,	O
myoclonias	S-Phenotype
,	O
or	O
atonic	B-Phenotype
seizures	E-Phenotype
.	O

In	O
conclusion	O
,	O
maternally	O
inherited	O
chromosome	O
15q11	O
-	O
13	O
deletions	O
produce	O
severe	O
epilepsy	S-Phenotype
.	O

Loss	O
-	O
of	O
-	O
function	O
UBE3A	O
mutations	O
,	O
uniparental	O
disomy	O
,	O
or	O
methylation	O
imprint	O
abnormalities	O
in	O
AS	O
are	O
associated	O
with	O
relatively	O
mild	O
epilepsy	S-Phenotype
.	O

Involvement	O
of	O
other	O
genes	O
in	O
the	O
chromosome	O
15q11	O
-	O
13	O
deletion	O
,	O
such	O
as	O
GABRB3	O
,	O
may	O
explain	O
severe	O
epilepsy	S-Phenotype
in	O
AS	O
.	O

Prader	O
-	O
Willi	O
and	O
Angelman	O
syndromes	O
are	O
2	O
clinically	O
distinct	O
disorders	O
associated	O
with	O
multiple	O
anomalies	O
and	O
mental	B-Phenotype
retardation	E-Phenotype
.	O

They	O
are	O
only	O
discussed	O
together	O
because	O
they	O
share	O
a	O
similar	O
and	O
uncommon	O
genetic	O
basis	O
:	O
they	O
involve	O
genes	O
that	O
are	O
located	O
in	O
the	O
same	O
region	O
in	O
the	O
genome	O
and	O
are	O
characterized	O
by	O
genetic	O
imprinting	O
.	O

This	O
normal	O
process	O
has	O
contributed	O
to	O
these	O
2	O
complex	O
and	O
severe	O
conditions	O
through	O
inactivation	O
of	O
1	O
copy	O
of	O
the	O
genes	O
relevant	O
to	O
each	O
disorder	O
:	O
the	O
maternally	O
derived	O
copy	O
of	O
genes	O
for	O
Prader	O
-	O
Willi	O
syndrome	O
in	O
proximal	O
15q	O
are	O
normally	O
silent	O
,	O
and	O
a	O
paternally	O
derived	O
copy	O
of	O
1	O
gene	O
for	O
Angelman	O
syndrome	O
in	O
15q	O
is	O
normally	O
silent	O
.	O

For	O
both	O
disorders	O
,	O
when	O
the	O
normally	O
active	O
copy	O
of	O
the	O
gene	O
or	O
genes	O
is	O
missing	O
,	O
abnormality	O
results	O
.	O

Since	O
the	O
genes	O
for	O
these	O
2	O
disorders	O
are	O
located	O
very	O
close	O
together	O
,	O
and	O
since	O
the	O
center	O
involved	O
in	O
inactivating	O
the	O
genes	O
involved	O
in	O
imprinting	O
may	O
be	O
the	O
same	O
,	O
both	O
these	O
disorders	O
usually	O
result	O
from	O
the	O
same	O
chromosomal	O
deletion	O
;	O
which	O
disorder	O
results	O
depends	O
on	O
the	O
parent	O
of	O
origin	O
of	O
the	O
chromosome	O
15	O
that	O
becomes	O
deleted	O
.	O

Both	O
Prader	O
-	O
Willi	O
and	O
Angelman	O
syndrome	O
can	O
also	O
occur	O
as	O
a	O
result	O
of	O
having	O
both	O
members	O
of	O
the	O
chromosome	O
15	O
pair	O
derived	O
from	O
1	O
parent	O
,	O
a	O
condition	O
known	O
as	O
uniparental	O
disomy	O
.	O

Both	O
can	O
also	O
result	O
from	O
a	O
structural	O
abnormality	O
of	O
the	O
imprinting	O
center	O
,	O
known	O
as	O
an	O
imprinting	O
mutation	O
.	O

In	O
addition	O
,	O
Angelman	O
syndrome	O
can	O
be	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
that	O
causes	O
it	O
;	O
a	O
comparable	O
cause	O
is	O
not	O
present	O
in	O
Prader	O
-	O
Willi	O
syndrome	O
since	O
it	O
results	O
from	O
abnormality	O
in	O
more	O
than	O
1	O
gene	O
.	O

Finally	O
,	O
despite	O
the	O
complexity	O
of	O
possible	O
causes	O
,	O
all	O
but	O
the	O
single	O
gene	O
mutation	O
of	O
the	O
Angelman	O
syndrome	O
gene	O
can	O
be	O
detected	O
through	O
methylation	O
-	O
sensitive	O
DNA	O
probes	O
,	O
since	O
DNA	O
methylation	O
is	O
the	O
process	O
by	O
which	O
the	O
genes	O
for	O
these	O
2	O
disorders	O
are	O
imprinted	O
.	O

This	O
unusual	O
property	O
of	O
specific	O
areas	O
of	O
the	O
DNA	O
holds	O
promise	O
for	O
future	O
treatment	O
of	O
these	O
and	O
other	O
disorders	O
related	O
to	O
imprinting	O
through	O
reversal	O
of	O
the	O
imprinting	O
process	O
.	O

The	O
causal	O
heterogeneity	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
makes	O
providing	O
information	O
regarding	O
recurrence	O
risk	O
both	O
important	O
and	O
challenging	O
,	O
and	O
may	O
have	O
a	O
dramatic	O
impact	O
on	O
reproductive	O
decision	O
-	O
making	O
for	O
the	O
nuclear	O
and	O
extended	O
family	O
.	O

Most	O
cases	O
of	O
AS	O
result	O
from	O
typical	O
large	O
de	O
novo	O
deletions	O
of	O
15q11	O
-	O
q13	O
,	O
and	O
are	O
expected	O
to	O
have	O
a	O
low	O
(	O
<	O
1	O
%	O
)	O
risk	O
of	O
recurrence	O
.	O

AS	O
due	O
to	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
,	O
which	O
occurs	O
in	O
the	O
absence	O
of	O
a	O
parental	O
translocation	O
,	O
is	O
likewise	O
expected	O
to	O
have	O
a	O
<	O
1	O
%	O
risk	O
of	O
recurrence	O
.	O

Parental	O
transmission	O
of	O
a	O
structurally	O
or	O
functionally	O
unbalanced	O
chromosome	O
complement	O
can	O
lead	O
to	O
15q11	O
-	O
q13	O
deletions	O
or	O
to	O
UPD	O
and	O
will	O
result	O
in	O
case	O
-	O
specific	O
recurrence	O
risks	O
.	O

In	O
instances	O
where	O
there	O
is	O
no	O
identifiable	O
large	O
deletion	O
or	O
UPD	O
,	O
the	O
risk	O
for	O
recurrence	O
may	O
be	O
as	O
high	O
as	O
50	O
%	O
as	O
the	O
result	O
of	O
either	O
a	O
maternally	O
inherited	O
imprinting	O
center	O
(	O
IC	O
)	O
mutation	O
or	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
(	O
UBE3A	O
)	O
gene	O
mutation	O
.	O

Individuals	O
with	O
AS	O
who	O
have	O
none	O
of	O
the	O
above	O
abnormalities	O
comprise	O
a	O
significant	O
proportion	O
of	O
cases	O
,	O
and	O
some	O
may	O
be	O
at	O
a	O
50	O
%	O
recurrence	O
risk	O
.	O

Misdiagnoses	O
,	O
as	O
well	O
,	O
can	O
be	O
represented	O
in	O
this	O
group	O
.	O

In	O
light	O
of	O
the	O
many	O
conditions	O
which	O
are	O
clinically	O
similar	O
to	O
AS	O
,	O
it	O
is	O
essential	O
to	O
address	O
the	O
possibility	O
of	O
diagnostic	O
uncertainty	O
and	O
potential	O
misdiagnosis	O
prior	O
to	O
the	O
provision	O
of	O
genetic	O
counseling	O
.	O

Summaries	O
of	O
the	O
different	O
causal	O
classes	O
of	O
AS	O
as	O
an	O
algorithm	O
for	O
determination	O
of	O
recurrence	O
risks	O
are	O
presented	O
.	O

Six	O
cases	O
of	O
this	O
syndrome	O
previously	O
reported	O
in	O
Great	O
Britain	O
and	O
in	O
Canada	O
are	O
reviewed	O
in	O
relation	O
to	O
a	O
personal	O
case	O
,	O
a	O
17	O
-	O
month	O
-	O
old	O
boy	O
.	O

The	O
syndrome	O
's	O
main	O
features	O
are	O
microbrachycephaly	S-Phenotype
and	O
peculiar	B-Phenotype
face	E-Phenotype
,	O
mental	B-Phenotype
deficiency	E-Phenotype
with	O
euphoria	S-Phenotype
and	O
laughter	S-Phenotype
,	O
ataxia	S-Phenotype
and	O
epilepsy	S-Phenotype
consisting	O
in	O
infantile	B-Phenotype
spasms	E-Phenotype
and	O
grand	B-Phenotype
-	I-Phenotype
mal	I-Phenotype
attacks	E-Phenotype
.	O

Though	O
its	O
precise	O
nature	O
and	O
cause	O
still	O
remain	O
unknown	O
,	O
the	O
syndrome	O
seems	O
neither	O
familial	O
nor	O
progressive	O
.	O

Blood	O
samples	O
from	O
125	O
unrelated	O
families	O
with	O
classical	O
type	O
2	O
neurofibromatosis	S-Phenotype
(	O
NF2	O
)	O
with	O
bilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
have	O
been	O
analysed	O
for	O
mutations	O
in	O
the	O
NF2	O
gene	O
.	O

A	O
further	O
17	O
families	O
fulfilling	O
modified	O
criteria	O
for	O
NF2	O
have	O
also	O
been	O
analysed	O
.	O

Causative	O
mutations	O
have	O
been	O
identified	O
in	O
54	O
(	O
43	O
%	O
)	O
classical	O
families	O
and	O
six	O
(	O
35	O
%	O
)	O
of	O
those	O
fulfilling	O
modified	O
criteria	O
.	O

Forty	O
-	O
two	O
cases	O
from	O
38	O
families	O
with	O
truncating	O
mutations	O
had	O
an	O
average	O
age	O
at	O
onset	O
of	O
symptoms	O
of	O
19	O
years	O
and	O
diagnosis	O
at	O
22.4	O
years	O
.	O

Fifty	O
-	O
one	O
cases	O
from	O
16	O
families	O
with	O
splice	O
site	O
mutations	O
(	O
15	O
from	O
six	O
)	O
,	O
missense	O
mutations	O
(	O
18	O
from	O
six	O
)	O
,	O
and	O
large	O
deletions	O
(	O
18	O
from	O
five	O
)	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
27.8	O
years	O
and	O
at	O
diagnosis	O
of	O
33.4	O
years	O
.	O

Subjects	O
with	O
truncating	O
mutations	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
symptoms	O
before	O
20	O
years	O
of	O
age	O
(	O
p	O
<	O
0.001	O
)	O
and	O
to	O
develop	O
at	O
least	O
two	O
symptomatic	O
CNS	B-Phenotype
tumours	E-Phenotype
in	O
addition	O
to	O
vestibular	B-Phenotype
schwannoma	E-Phenotype
before	O
30	O
years	O
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
were	O
also	O
significantly	O
fewer	O
multigenerational	O
families	O
with	O
truncating	O
mutations	O
.	O

Four	O
further	O
truncating	O
mutations	O
were	O
in	O
mosaic	O
form	O
and	O
were	O
associated	O
with	O
milder	O
disease	O
than	O
other	O
similar	O
mutations	O
.	O

This	O
large	O
study	O
has	O
confirmed	O
the	O
previous	O
impression	O
that	O
truncating	O
mutations	O
are	O
associated	O
with	O
severe	O
disease	O
,	O
but	O
caution	O
has	O
to	O
be	O
exercised	O
in	O
using	O
mutation	O
type	O
to	O
predict	O
disease	O
course	O
.	O

The	O
E6	O
-	O
AP	O
ubiquitin	O
ligase	O
(	O
human	O
/	O
mouse	O
gene	O
UBE3A	O
/	O
Ube3a	O
)	O
promotes	O
the	O
degradation	O
of	O
p53	O
in	O
association	O
with	O
papilloma	S-Phenotype
E6	O
protein	O
,	O
and	O
maternal	O
deficiency	O
causes	O
human	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
.	O

Ube3a	O
is	O
imprinted	O
with	O
silencing	O
of	O
the	O
paternal	O
allele	O
in	O
hippocampus	O
and	O
cerebellum	O
in	O
mice	O
.	O

We	O
found	O
that	O
the	O
phenotype	O
of	O
mice	O
with	O
maternal	O
deficiency	O
(	O
m	O
-	O
/	O
p+	O
)	O
for	O
Ube3a	O
resembles	O
human	O
AS	O
with	O
motor	B-Phenotype
dysfunction	E-Phenotype
,	O
inducible	O
seizures	S-Phenotype
,	O
and	O
a	O
context	O
-	O
dependent	O
learning	B-Phenotype
deficit	E-Phenotype
.	O

Long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
was	O
severely	O
impaired	O
in	O
m	O
-	O
/	O
p+	O
mice	O
despite	O
normal	O
baseline	O
synaptic	O
transmission	O
and	O
neuroanatomy	O
,	O
indicating	O
that	O
ubiquitination	O
may	O
play	O
a	O
role	O
in	O
mammalian	O
LTP	O
and	O
that	O
LTP	O
may	O
be	O
abnormal	O
in	O
AS	O
.	O

The	O
cytoplasmic	O
abundance	O
of	O
p53	O
was	O
increased	O
in	O
postmitotic	O
neurons	O
in	O
m	O
-	O
/	O
p+	O
mice	O
and	O
in	O
AS	O
,	O
providing	O
a	O
potential	O
biochemical	O
basis	O
for	O
the	O
phenotype	O
through	O
failure	O
to	O
ubiquitinate	O
and	O
degrade	O
various	O
effectors	O
.	O

Stereotactic	O
radiosurgery	O
is	O
the	O
principal	O
alternative	O
to	O
microsurgical	O
resection	O
for	O
acoustic	B-Phenotype
neuromas	E-Phenotype
(	O
vestibular	B-Phenotype
schwannomas	E-Phenotype
)	O
.	O

The	O
goals	O
of	O
radiosurgery	O
are	O
the	O
long	O
-	O
term	O
prevention	O
of	O
tumor	S-Phenotype
growth	O
,	O
maintenance	O
of	O
neurologic	O
function	O
,	O
and	O
prevention	O
of	O
new	O
neurologic	B-Phenotype
deficits	E-Phenotype
.	O

Although	O
acceptable	O
short	O
-	O
term	O
outcomes	O
have	O
been	O
reported	O
,	O
long	O
-	O
term	O
outcomes	O
have	O
not	O
been	O
well	O
documented	O
.	O

We	O
evaluated	O
162	O
consecutive	O
patients	O
who	O
underwent	O
radiosurgery	O
for	O
acoustic	B-Phenotype
neuromas	E-Phenotype
between	O
1987	O
and	O
1992	O
by	O
means	O
of	O
serial	O
imaging	O
tests	O
,	O
clinical	O
evaluations	O
,	O
and	O
a	O
survey	O
between	O
5	O
and	O
10	O
years	O
after	O
the	O
procedure	O
.	O

The	O
average	O
dose	O
of	O
radiation	O
to	O
the	O
tumor	S-Phenotype
margin	O
was	O
16	O
Gy	O
,	O
and	O
the	O
mean	O
transverse	O
diameter	O
of	O
the	O
tumor	O
was	O
22	O
mm	O
(	O
range	O
,	O
8	O
to	O
39	O
)	O
.	O

Resection	O
had	O
been	O
performed	O
previously	O
in	O
42	O
patients	O
(	O
26	O
percent	O
)	O
;	O
in	O
13	O
patients	O
the	O
tumor	S-Phenotype
represented	O
a	O
recurrence	O
of	O
disease	O
after	O
a	O
previous	O
total	O
resection	O
.	O

Facial	O
function	O
was	O
normal	O
in	O
76	O
percent	O
of	O
the	O
patients	O
before	O
radiosurgery	O
,	O
and	O
20	O
percent	O
had	O
useful	O
hearing	O
.	O

The	O
rate	O
of	O
tumor	S-Phenotype
control	O
(	O
with	O
no	O
resection	O
required	O
)	O
was	O
98	O
percent	O
.	O

One	O
hundred	O
tumors	S-Phenotype
(	O
62	O
percent	O
)	O
became	O
smaller	O
,	O
53	O
(	O
33	O
percent	O
)	O
remained	O
unchanged	O
in	O
size	O
,	O
and	O
9	O
(	O
6	O
percent	O
)	O
became	O
slightly	O
larger	O
.	O

Resection	O
was	O
performed	O
in	O
four	O
patients	O
(	O
2	O
percent	O
)	O
within	O
four	O
years	O
after	O
radiosurgery	O
.	O

Normal	O
facial	O
function	O
was	O
preserved	O
in	O
79	O
percent	O
of	O
the	O
patients	O
after	O
five	O
years	O
(	O
House	O
-	O
Brackmann	O
grade	O
1	O
)	O
,	O
and	O
normal	O
trigeminal	O
function	O
was	O
preserved	O
in	O
73	O
percent	O
.	O

Fifty	O
-	O
one	O
percent	O
of	O
the	O
patients	O
had	O
no	O
change	O
in	O
hearing	O
ability	O
.	O

No	O
new	O
neurologic	B-Phenotype
deficits	E-Phenotype
appeared	O
more	O
than	O
28	O
months	O
after	O
radiosurgery	O
.	O

An	O
outcomes	O
questionnaire	O
was	O
returned	O
by	O
115	O
patients	O
(	O
77	O
percent	O
of	O
the	O
149	O
patients	O
still	O
living	O
)	O
.	O

Fifty	O
-	O
four	O
of	O
these	O
patients	O
(	O
47	O
percent	O
)	O
were	O
employed	O
at	O
the	O
time	O
of	O
radiosurgery	O
,	O
and	O
37	O
(	O
69	O
percent	O
)	O
remained	O
so	O
.	O

Radiosurgery	O
was	O
believed	O
to	O
have	O
been	O
successful	O
by	O
all	O
30	O
patients	O
who	O
had	O
undergone	O
surgery	O
previously	O
and	O
by	O
81	O
(	O
95	O
percent	O
)	O
of	O
the	O
85	O
who	O
had	O
not	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
115	O
patients	O
(	O
31	O
percent	O
)	O
described	O
at	O
least	O
one	O
complication	O
,	O
which	O
resolved	O
in	O
56	O
percent	O
of	O
those	O
cases	O
.	O

Radiosurgery	O
can	O
provide	O
long	O
-	O
term	O
control	O
of	O
acoustic	B-Phenotype
neuromas	E-Phenotype
while	O
preserving	O
neurologic	O
function	O
.	O

We	O
had	O
previously	O
described	O
a	O
patient	O
with	O
an	O
overgrowth	S-Phenotype
syndrome	O
and	O
the	O
chromosome	O
constitution	O
45	O
,	O
XY	O
,	O
t	O
(	O
15q15q	O
)	O
(	O
Wajntal	O
et	O
al.	O
,	O
DNA	O
Cell	O
Biol	O
1993	O
:	O
12	O
:	O
227	O
-	O
231	O
)	O
.	O

Clinical	O
reassessment	O
and	O
the	O
use	O
of	O
molecular	O
studies	O
,	O
including	O
methylation	O
analysis	O
with	O
an	O
SNRPN	O
probe	O
,	O
microsatellite	O
analyses	O
of	O
D15S11	O
,	O
GABRB3	O
and	O
D15S113	O
loci	O
,	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
using	O
the	O
SNRPN	O
and	O
GABRB3	O
probes	O
,	O
are	O
consistent	O
with	O
a	O
diagnosis	O
of	O
Angelman	O
syndrome	O
(	O
AS	O
)	O
due	O
to	O
paternal	O
isodisomy	O
.	O

This	O
is	O
the	O
fourth	O
report	O
case	O
of	O
a	O
translocation	O
15q15q	O
with	O
paternal	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
some	O
patients	O
with	O
clinical	O
features	O
of	O
AS	O
have	O
hyperphagia	S-Phenotype
and	O
obesity	S-Phenotype
with	O
overgrowth	S-Phenotype
,	O
and	O
that	O
these	O
features	O
should	O
not	O
rule	O
out	O
a	O
diagnosis	O
of	O
AS	O
.	O

Patients	O
who	O
present	O
with	O
unilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
either	O
at	O
a	O
young	O
age	O
or	O
with	O
additional	O
features	O
of	O
type	O
2	O
neurofibromatosis	S-Phenotype
(	O
NF2	O
)	O
are	O
at	O
risk	O
of	O
developing	O
bilateral	B-Phenotype
disease	E-Phenotype
and	O
transmitting	O
a	O
risk	O
of	O
neurogenic	S-Phenotype
tumours	S-Phenotype
to	O
their	O
offspring	O
.	O

We	O
have	O
identified	O
15	O
patients	O
from	O
a	O
series	O
of	O
537	O
with	O
unilateral	B-Phenotype
vestibular	I-Phenotype
schwannomas	E-Phenotype
who	O
also	O
had	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
other	O
tumours	S-Phenotype
(	O
10	O
/	O
15	O
)	O
,	O
features	O
of	O
NF2	O
(	O
3	O
/	O
15	O
)	O
,	O
or	O
a	O
family	O
history	O
of	O
neurogenic	B-Phenotype
tumours	E-Phenotype
(	O
5	O
/	O
15	O
)	O
.	O

No	O
germline	O
NF2	O
mutations	O
were	O
detected	O
and	O
in	O
7	O
/	O
9	O
cases	O
where	O
tumour	S-Phenotype
material	O
was	O
available	O
for	O
analysis	O
a	O
germline	O
mutation	O
in	O
the	O
NF2	O
gene	O
has	O
been	O
excluded	O
.	O

Although	O
a	O
possibility	O
of	O
gonosomal	O
mosaicism	O
still	O
exists	O
,	O
exclusion	O
tests	O
for	O
the	O
offspring	O
are	O
now	O
possible	O
.	O

We	O
suggest	O
a	O
general	O
strategy	O
,	O
based	O
on	O
analysis	O
of	O
tumour	S-Phenotype
DNA	O
,	O
for	O
distinguishing	O
sporadic	O
and	O
familial	O
cases	O
of	O
tumours	S-Phenotype
caused	O
by	O
two	O
hit	O
mechanisms	O
.	O

Application	O
of	O
this	O
strategy	O
suggests	O
that	O
most	O
instances	O
of	O
unilateral	B-Phenotype
vestibular	I-Phenotype
schwannoma	E-Phenotype
which	O
do	O
not	O
fulfil	O
criteria	O
for	O
NF2	O
represent	O
chance	O
occurrences	O
.	O

Mutations	O
of	O
the	O
human	O
Patched	O
gene	O
(	O
PTCH	O
)	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
the	O
nevoid	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	O
)	O
as	O
well	O
as	O
in	O
sporadic	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
medulloblastomas	S-Phenotype
.	O

We	O
have	O
isolated	O
a	O
homologue	O
of	O
this	O
tumour	O
suppressor	O
gene	O
and	O
localized	O
it	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
1p32.1	O
-	O
32.3	O
)	O
.	O

Patched	O
2	O
(	O
PTCH2	O
)	O
comprises	O
22	O
coding	O
exons	O
and	O
spans	O
approximately	O
15	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
gene	O
encodes	O
a	O
1203	O
amino	O
acid	O
putative	O
transmembrane	O
protein	O
which	O
is	O
highly	O
homologous	O
to	O
the	O
PTCH	O
product	O
.	O

We	O
have	O
characterized	O
the	O
genomic	O
structure	O
of	O
PTCH2	O
and	O
have	O
used	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
analysis	O
to	O
search	O
for	O
mutations	O
in	O
PTCH2	O
in	O
NBCCS	O
patients	O
,	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
in	O
medulloblastomas	S-Phenotype
.	O

To	O
date	O
,	O
we	O
have	O
identified	O
one	O
truncating	O
mutation	O
in	O
a	O
medulloblastoma	S-Phenotype
and	O
a	O
change	O
in	O
a	O
splice	O
donor	O
site	O
in	O
a	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
suggesting	O
that	O
the	O
gene	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
some	O
tumours	S-Phenotype
.	O

Transcribed	O
,	O
low	O
-	O
copy	O
repeat	O
elements	O
are	O
associated	O
with	O
the	O
breakpoint	O
regions	O
of	O
common	O
deletions	O
in	O
Prader	O
-	O
Willi	O
and	O
Angelman	O
syndromes	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
the	O
ancestral	O
gene	O
(	O
HERC2	O
)	O
and	O
a	O
family	O
of	O
duplicated	O
,	O
truncated	O
copies	O
that	O
comprise	O
these	O
low	O
-	O
copy	O
repeats	O
.	O

This	O
gene	O
encodes	O
a	O
highly	O
conserved	O
giant	O
protein	O
,	O
HERC2	O
,	O
that	O
is	O
distantly	O
related	O
to	O
p532	O
(	O
HERC1	O
)	O
,	O
a	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	O
GEF	O
)	O
implicated	O
in	O
vesicular	O
trafficking	O
.	O

The	O
mouse	O
genome	O
contains	O
a	O
single	O
Herc2	O
locus	O
,	O
located	O
in	O
the	O
jdf2	O
(	O
juvenile	O
development	O
and	O
fertility	O
-	O
2	O
)	O
interval	O
of	O
chromosome	O
7C	O
.	O

We	O
have	O
identified	O
single	O
nucleotide	O
splice	O
junction	O
mutations	O
in	O
Herc2	O
in	O
three	O
independent	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
induced	O
jdf2	O
mutant	O
alleles	O
,	O
each	O
leading	O
to	O
exon	O
skipping	O
with	O
premature	O
termination	O
of	O
translation	O
and	O
/	O
or	O
deletion	O
of	O
conserved	O
amino	O
acids	O
.	O

Therefore	O
,	O
mutations	O
in	O
Herc2	O
lead	O
to	O
the	O
neuromuscular	O
secretory	O
vesicle	O
and	O
sperm	O
acrosome	O
defects	O
,	O
other	O
developmental	B-Phenotype
abnormalities	E-Phenotype
and	O
juvenile	O
lethality	O
of	O
jdf2	O
mice	O
.	O

Combined	O
,	O
these	O
findings	O
suggest	O
that	O
HERC2	O
is	O
an	O
important	O
gene	O
encoding	O
a	O
GEF	O
involved	O
in	O
protein	O
trafficking	O
and	O
degradation	O
pathways	O
in	O
the	O
cell	O
.	O

A	O
woman	O
with	O
the	O
autosomal	O
dominant	O
syndrome	O
of	O
preauricular	B-Phenotype
pits	E-Phenotype
,	O
cervical	B-Phenotype
fistulae	E-Phenotype
,	O
and	O
partial	B-Phenotype
deafness	E-Phenotype
gave	O
birth	O
to	O
two	O
children	O
with	O
preauricular	O
pits	O
and	O
severe	B-Phenotype
renal	I-Phenotype
dysgenesis	E-Phenotype
.	O

The	O
facies	O
had	O
some	O
features	O
of	O
the	O
Potter	B-Phenotype
facies	E-Phenotype
of	O
renal	B-Phenotype
agenesis	E-Phenotype
.	O

One	O
child	O
died	O
soon	O
after	O
birth	O
because	O
of	O
pneumothorax	S-Phenotype
and	O
immature	B-Phenotype
development	I-Phenotype
of	I-Phenotype
the	I-Phenotype
lungs	E-Phenotype
.	O

We	O
suggest	O
that	O
all	O
infants	O
with	O
renal	B-Phenotype
agenesis	I-Phenotype
or	I-Phenotype
dysgenesis	E-Phenotype
be	O
examined	O
for	O
preauricular	B-Phenotype
pits	E-Phenotype
because	O
of	O
the	O
high	O
recurrence	O
risk	O
of	O
renal	B-Phenotype
anomalies	E-Phenotype
in	O
families	O
with	O
this	O
syndrome	O
.	O